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Abstract 
In the last decades, the endocannabinoid system (ECS) has emerged as a promising therapeutic 
target. The identification of the cannabinoid receptors CB1R and CB2R and their endogenous lipid 
ligands has triggered an exponential growth of studies exploring the role of the ECS in physiological 
and pathological processes. The potential of cannabinoids has been preclinically explored in the 
treatment of a wide variety of diseases such as cancer, bone-related disorders, neurodegenerative 
diseases, or metabolic syndromes among others. So far, however, the clinical use of synthetic and 
phyto-cannabinoids has been limited to pain, emesis and appetite due to their undesirable 
psychoactive properties. Thus, emerging strategies for exploiting cannabinoids as medicines need to 
be developed to overcome these side-effects. The dissertation focusses on three of these strategies: 
a) selective CB2R ligands; b) multitarget cannabinoids for cancer therapy; c) compounds acting on a 
new additional therapeutic target of the ECS.  
In this context, we propose to explore the chromenopyrazole scaffold for the development of novel 
modulators of the ECS.
a) Structural modifications of the chromenopyrazole scaffold led to the synthesis of new 
cannabinoids allowing fine-tuning of cannabinoid receptor affinity and activity. Structural features 
required for CB1R/CB2R affinity and selectivity were studied by molecular modeling. In addition, 
bivalent chromenopyrazoles were prepared in order to explore the CB2R dimerization process.  
b) Multifunctional chromenopyrazoles have been designed and synthesized for cancer therapy. This 
approach involved the antitumor properties of cannabinoids and the redox properties characterizing 
quinones.  The antiproliferative activity of these new compounds was successfully explored in vitro
and in vivo in breast and prostate cancer models.  
c) Finally, the chromenopyrazole scaffold as modulator of the new target GPR55 has been explored. 
The design of two series of compounds followed by their synthesis was reported. Their ability to 
Abstract
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activate GPR55 was measured through an innovative label-free cell impedance assay allowing the 
discovery of novel GPR55 partial agonists and antagonists. 
To sum up, exploration of the chromenopyrazole as a versatile scaffold led to the identification of 
CB2R selective ligands and bivalent ligands, multifunctional antitumor agents, and GPR55 
modulators. These compounds represent promising pharmacological tools and drugs for further 
development. 
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Summary*
The endocannabinoid system (ECS) has shown to be of great importance in the regulation of 
numerous physiological and pathological processes. To date, two cannabinoid receptors, CB1R and 
CB2R, have been discovered and are found predominantly in the central nervous system (CB1R) or 
the immune system (CB2R) among other organs and tissues. Endogenous cannabinoid receptor 
ligands (endocannabinoids) and the enzymes involved in their synthesis, cell uptake and degradation 
have also been identified and are part of the ECS. Other G-coupled protein receptors such as 
GPR55 have also been proposed as potential member of the ECS. However, this categorization 
instigates strong debate due to the lack of pharmacological tools to fully determine GPR55 
biological functions. 
The potential of cannabinoid receptor ligands has been preclinically explored in the treatment of 
diverse symptoms and diseases such as pain, inflammation, metabolic syndromes, cancer, 
hypertension, bone-related disorders or neurodegenerative processes. The only cannabinoids on 
clinical use today are the phytocannabinoids tetrahydrocannabinol (Δ9-THC) and cannabidiol 
(CBD), and the THC synthetic derivative nabilone, which are approved for pain, emesis and appetite 
disorders. Taking into account the fact that these compounds lack of CB1R/CB2R selectivity, 
identifying new synthetic cannabinoids is of great interest. These novel entities should be exempt of 
the undesirable psychotropic effects related to the activation of brain CB1R to have greater 
opportunity to be explored as cannabinoid-based medicines.  
In this context, we aimed to explore the chromenopyrazole scaffold (figure 1) as a privileged 
structure in drug discovery targeting the ECS. From that perspective, this research work has been 
structured in three different chapters regarding biological and chemical outcomes.  
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Figure 1. Chromenopyrazole scaffold general structure.
Chapter 1 
Chromenopyrazoles were first identified in our research group as non-psychoactive CB1R agonists 
with peripheral antinociceptive properties. However, CB2Rs, mainly located in peripheral tissues, 
represent another promising drug target for the treatment of numerous diseases avoiding the 
psychotropic side effects characteristic of targeting CB1R in the brain. Consequently, the main goal 
of this chapter was to optimize the structure modifications on the chromenopyrazole core in order 
to obtain CB2R selective ligands. Thus, focusing on the pyrazole and the phenol substituents, novel 
series of chromenopyrazoles were synthesized in moderate to high yields using a route of four to six 
steps (figure 2). The affinity of these new compounds for the cannabinoid receptors CB1R and CB2R 
was evaluated measuring their ability to displace the radioligand [3H]CP55940 from both receptors 
respectively transfected into HEK293 EBNA cells. Then, functional activity of the compounds with 
better CB2R affinity profiles was tested by cAMP accumulation experiments, GTPγS binding assays 
and by an in vitro assay on BV-2 microglial cells. Docking studies using the active CB1R* and CB2R* 
models provided structural information related to ligand-receptor interactions and validating the 
experimental structure-activity relationships.  
Among the series of chromenopyrazoles reported in this chapter, novel CB2R selective and potent 
agonists have been identified, as well as CB2R antagonists, and potent CB1R/CB2R agonists. 
Moreover, predicted pharmacokinetic properties of these newly synthesized CB2R ligands calculated 
in silico using QikProp from Maestro Software clearly suggested their favorable druggability profiles.    
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Figure 2. Fine-tuning of affinity and selectivity of chromenopyrazoles towards CB2R was achieved by 
structural modifications at R-positions of the scaffold.
In order to explore the CB2R homodimer process, the design of bivalent ligands was proposed 
(figure 3). In the last years growing evidence suggests that numerous GPCRs, cannabinoid receptors 
among them, may form hetero- and homodimers. This oligomerization interferes with the receptor 
function, activation and signal transduction. In this scenario, bivalent ligands, which consist of two 
pharmacophores connected by a spacer, have emerged in the last years as promising 
pharmacological entities and potential tools for the biological study of their respective dimeric 
receptors. Thus, a series of homobivalent chromenopyrazoles containing alkyl chains as spacers and 
their respective univalent 9-alkoxychromenopyrazole analogs were synthesized. Different alkyl 
chains (ten to sixteen methylenes) were introduced in order to investigate the influence of the spacer 
length on affinity and potency. Their ability to bind to the cannabinoid receptors was measured 
through radioligand assays. They show significant CB2R affinity with full CB2R selectivity over 
CB1R. It is worthy to note that their corresponding univalent ligands did not display any affinity for 
neither CB1R nor CB2R, suggesting a possible interaction of both pharmacophores of the bivalent 
entities with CB2R. Furthermore, these ligands showed agonism through cAMP functional assays
using HEK293 cells stably expressing CB2R for which the presence of CB2R dimers has been 
confirmed. To our knowledge, this is the first time that fully CB2R selective bivalent ligands are 
described.  
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Figure 3. Homobivalent chromenopyrazoles. DMH: 1,1 Dimethylheptyl. 
In summary, within the first chapter, new selective CB2R agonists and antagonists, as well as, the 
first fully CB2R selective bivalent ligands have been identified. 
Chapter 2 
This chapter focused on a multitarget strategy applied to cancer therapy. Based on increasing 
evidence of cannabinoids antitumor properties and the well-known redox properties of quinones, 
we designed compounds with a structure that include both features. Thus, structural modification of 
the chromenopyrazole scaffold has been oriented towards this new approach. Para and ortho-
chromenopyrazolediones were synthesized by regioselective oxidation of chromenopyrazoles. Their 
antitumor properties were evaluated in vitro and in vivo in different models of human cancers. 
a) Ortho-chromenopyrazolediones (figure 4) showed affinity and selectivity for the CB2R eliminating 
possible side psychotropic effect derived from the activity at the CB1R in the brain. Concerning their 
antitumor activity, they decreased cell proliferation in human triple-negative breast cancer cell line 
(MDA-MB-231) using MTT assays. An additional important fact is their lack of significant 
cytotoxicity against normal human mammary epithelial cells (HMEC). Further mechanistic studies 
allowed us to determine that these antitumor effects were mediated through activation of CB2R and 
through induction of oxidative stress. As confirmed by western blot analysis using active caspase-3 
as biomarker, these compounds induced apoptosis in the aforementioned breast cancer cell line. The 
antiproliferative effect of the most potent derivative was reproduced in vivo. This cannabinoid-
quinone induced significant reduction of tumor xenograft growth (MDA-MB-231) in nude mice. 
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Moreover, the lack of toxicity in different vital organs was further confirmed in vivo by 
histopathological analysis. 
 b) Para-chromenopyrazolediones (figure 4) exhibited CB1R/CB2R affinity in the submicromolar 
range. Some of these compounds were efficient against two prostate cancer cell lines, LNCaP and 
PC-3. This antiproliferative activity has been shown to involve oxidative stress, PPARγ activation, 
and CB1R activation. In in vivo mice experiments, one of the compounds totally blocked the growth 
of the aggressive androgen-sensitive prostate cancer tumor.  
Figure 4. Para and ortho-chromenopyrazolediones.
In summary, within the second chapter, the discovery of a new class of anticancer cannabinoid-
quinones with potential for the development of anticancer agents against hormone-sensitive prostate 
tumors and triple negative breast cancer has been reported. 
Chapter 3 
In the last chapter of this dissertation we focused our efforts in the identification of novel ligands of 
the putative cannabinoid receptor GPR55. The validity of the categorization of GPR55 as a 
cannabinoid member is still under debate mainly due to the lack of potent and selective agonists and 
antagonists. In this scenario, we designed and synthesized two different series of new 
chromenopyrazole derivatives (figure 5) on the basis of the structural features recently identified for 
GPR55 ligands.
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Figure 5. Phenylpiperazinyl-acetamidomethyl-chromenopyrazoles and acyl-piperazinyl-chromenopyrazoles. 
Appraisal of GPR55 activity of the new synthesized compounds was accomplished by using an 
innovative cell-impedance, label-free based assay with HEK293 cells stably expressing human 
GPR55. The real-time impedance responses provide an integrative assessment of the cellular 
consequence to GPR55 stimulation taking into account the different possible signaling pathways.  
Analysis of data obtained allowed potent GPR55 partial agonists to be identified (EC50 values in 
nanomolar range). Upon antagonist treatment, four of these GPR55 partial agonists significantly 
inhibited GPR55-mediated responses to lysophosphatidylinositol (LPI). In contrast to LPI, these 
compounds did not show off-target effects at concentrations up to 10 µM in this assay. Due to the 
relation of GPR55 with the endocannabinoid system, selectivity towards the classical cannabinoid 
receptors was investigated through CB1R and CB2R radioligand binding experiments. Some of the 
compounds exhibited GPR55 full selectivity. Additionally, one of the series displayed high affinity 
for CB2R. It is worthy to note that none of the compounds bind to the CB1R. Moreover, their 
predicted physicochemical parameters suggested a clear pharmacokinetic improvement compared to 
LPI.
In summary, within the third chapter, we have discovered a novel GPR55 chemotype that may serve 
to develop appropriate pharmacological tools or novel drugs to continue with the challenging goal 
of the validation of this receptor. 
Summary
xv 
To conclude, medicinal chemistry efforts directed toward distinct strategies to obtain compounds 
acting on the endocannabinoid system (ECS) led to the discovery of a privileged scaffold, the 
chromenopyrazole. 
*P.M. performed: i) the synthesis and characterization of the novel compounds and their in silico
pharmacokinetic properties at Instituto de Química Médica (CSIC); ii) the binding studies, hosted by 
Prof. Javier Fernández-Ruiz, Facultad de Medicina, Universidad Complutense de Madrid (UCM); iii) the 
triple-negative breast cancer antiproliferative studies in vitro and in vivo, hosted by Prof. Cristina Sánchez, 
Facultad de Biología, UCM; iv) the molecular modeling, hosted by Prof Patricia Reggio, Department of 
Chemistry and Biochemistry, University of North Carolina at Greensboro (UNCG); v) the GPR55 cell-
impedance assays, hosted by Prof. Ruth Ross, Department of Pharmacology and Toxicology, University 
of Toronto (UofT).  
Other assays (SPR, electrochemistry, cAMP, GTPγS binding, BV-2 microglial cells, and all the antitumor 
evaluation in prostate cancer) have been performed by collaborators.
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Resumen*
El sistema endocannabinoide ha mostrado tener gran relevancia en la regulación de numerosos 
procesos fisiológicos y patológicos. Hasta el momento se han identificado dos tipos de receptores 
cannabinoides: tipo 1 (CB1), predominantes en el sistema nervioso central, y tipo 2 (CB2), ubicados 
principalmente en el sistema inmune entre otros órganos y tejidos. Asimismo, se han identificado los 
ligandos endógenos de estos receptores y las enzimas implicadas en su síntesis, recaptación y 
degradación. Otros receptores acoplados a proteínas G, como GPR55, también se han propuesto 
como posibles miembros del sistema endocannabinoide. Sin embargo, esta categorización aún no ha 
sido confirmada debido a la falta de herramientas farmacológicas que permitan caracterizar 
apropiadamente las funciones biológicas de GPR55. 
El potencial terapéutico de los ligandos cannabinoides ha sido evaluado a nivel preclínico para el 
tratamiento de numerosas enfermedades y síntomas como el dolor, la inflamación, el cáncer y la 
hipertensión, así como patologías metabólicas y neurodegenerativas. El problema fundamental 
asociado al tratamiento con cannabinoides radica en la imposibilidad actual de separar los efectos 
terapéuticos de la acción psicoactiva. Hoy en día, los únicos cannabinoides utilizados en la clínica 
son el tetrahidrocannabinol, su análogo sintético nabilona y el cannabidiol; se emplean para el 
tratamiento del dolor, la emesis y la mejora del apetito. Estos compuestos actúan sobre ambos 
receptores CB1 y CB2 provocando efectos psicoactivos asociados a la modulación del receptor CB1
en el cerebro. Por tanto, es de gran interés la identificación de nuevos cannabinoides sintéticos con 
efectos secundarios reducidos.  
En este contexto, nos propusimos explorar el potencial del esqueleto de cromenopirazol (figura 1) 
en el desarrollo de nuevas moléculas capaces de modular el sistema endocannabinoide. Para ello, 
este proyecto se ha estructurado en tres capítulos atendiendo a criterios químicos y farmacológicos.
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Figura 1. Estructura general del esqueleto de cromenopirazol.
Capítulo 1 
Por analogía a fitocannabinoides como el cannabinol, en nuestro grupo de trabajo se diseñó y 
sintetizó previamente una familia de compuestos, denominados cromenopirazoles. Estas estructuras 
fueron caracterizadas como ligandos agonistas del receptor CB1 y mostraron propiedades 
antinociceptivas en un modelo de analgesia periférica sin presentar psicoactividad.  
El receptor CB2, cuya activación no desencadena efectos psicotrópicos, representa una prometedora 
diana terapéutica para el tratamiento de diversas patologías. Por ello, este capítulo se centra en la 
optimización del esqueleto de cromenopirazol con el fin de desarrollar ligandos selectivos y potentes 
para este receptor. Con este objetivo se sintetizó una nueva serie de derivados modificando los 
sustituyentes del pirazol y el fenol (figura 2). La afinidad de los nuevos compuestos por los 
receptores CB1 y CB2 fue evaluada mediante ensayos de desplazamiento de radioligando. La 
funcionalidad de los compuestos que presentaron mejor perfil de afinidad y/o selectividad por el 
receptor CB2 fue evaluada mediante ensayos de acumulación de AMP cíclico intracelular, GTPγS o 
experimentos en células BV-2 microgliales. A continuación, se llevaron a cabo estudios de 
modelización molecular usando modelos computacionales de receptores cannabinoides CB1 y CB2
activados (CB1* y CB2*). Estos estudios proporcionaron información estructural sobre las 
interacciones del complejo ligando-receptor, permitiendo validar las relaciones estructura-actividad 
obtenidas experimentalmente.
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En este estudio se identificaron nuevos agonistas CB2 potentes y selectivos. Asimismo, algunos de 
los compuestos de esta serie mostraron ser antagonistas CB2 o potentes agonistas CB1/CB2. Por 
otro lado, estudios in silico llevados a cabo mediante el programa QikProp (Maestro) sugirieron un 
perfil farmacocinético favorable para los cromenopirazoles desarrollados en este capítulo. 
Figura 2. Modificaciones estructurales en las posiciones destacadas dieron lugar a derivados de 
cromenopirazol con afinidad por el receptor CB2.
En los últimos años numerosos estudios han demostrado que determinados receptores acoplados a 
proteínas G, CB1 y CB2 entre ellos, existen como heterodímeros y homodímeros en condiciones 
fisiológicas y patológicas. Esta oligomerización puede modificar tanto la función del receptor como 
su activación por determinados compuestos. Con el fin de explorar la homodimerización del 
receptor CB2, se propuso el diseño de ligandos bivalentes siguiendo el patrón estructural mostrado 
en la figura 3. Este tipo de ligandos están formados por dos unidades farmacofóricas unidas por un 
espaciador de una longitud determinada. En este contexto, se sintetizó una familia de 
cromenopirazoles bivalentes y sus respectivos análogos monovalentes 9-alcoxicromenopirazoles. En 
lo que se refiere al espaciador, se introdujeron cadenas alquílicas de distinta longitud (de diez a 
dieciséis metilenos) con el fin de estudiar la influencia del espaciador sobre la potencia y afinidad de 
las nuevas moléculas. Los compuestos bivalentes y sus análogos monovalentes fueron evaluados 
mediante ensayos de desplazamiento de radioligando para determinar sus afinidades por los 
receptores CB1 y CB2. Los derivados bivalentes mostraron ser ligandos selectivos del receptor CB2 
con afinidad en el rango submicromolar. Sin embargo, sus análogos monovalentes no presentaron 
afinidad por estos receptores. Estos resultados sugieren una posible interacción del segundo 
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farmacóforo con el receptor. Determinados ligandos bivalentes mostraron agonismo en ensayos de 
funcionalidad basados en la determinación de acumulación de AMPc en células HEK293 
transfectadas con CB2 y en la cuales se confirmó la extistencia de homodimeros CB2.  
Figure 3. Estructura general de cromenopirazoles homobivalentes. DMH: 1,1 dimetilheptilo. 
En resumen, a lo largo del primer capítulo de esta tesis doctoral se han identificado tanto agonistas 
CB2 potentes como ligandos bivalentes selectivos para dicho receptor, todos ellos basados en la 
estrutura de cromenopirazol. 
Capítulo 2 
Existen múltiples procesos biológicos involucrados en la patogénesis del cáncer. Para abordar su 
tratamiento se suelen utilizar terapias combinadas. En este ámbito, resulta de especial interés el 
desarrollo de ligandos capaces de actuar sobre varias dianas terapéuticas implicadas en procesos 
neoplásicos. Debido al potencial antitumoral de las quinonas y a las propiedades anticancerosas de 
los cannabinoides, se llevó a cabo el diseño y la síntesis de nuevos compuestos basados en ambos 
motivos estructurales. En el segundo capítulo se presenta la síntesis de para y orto-
cromenopirazoldionas mediante oxidación regioselectiva del esqueleto de partida. Su interacción con 
los receptores cannabinoides fue evaluada mediante ensayos de desplazamiento de radioligando. Por 
otro lado, las propiedades antitumorales de estas nuevas moléculas fueron evaluadas in vitro e in vivo
en distintos modelos de cáncer. 
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a) Orto-cromenopirazoldionas (figura 4, izquierda): Estos compuestos mostraron afinidad y 
selectividad por el receptor CB2 descartando así posibles efectos psicoactivos asociados a la 
activación de CB1. Con respecto a su actividad antitumoral, las orto-cromenopirazoldionas fueron 
capaces de disminuir la proliferación de células humanas de cáncer de mama triple negativo (MDA-
MB-231). Además, estos compuestos no presentaron citotoxicidad en células mamarias epiteliales 
normales (HMEC). Mediante distintos estudios in vitro se intentó profundizar en la determinación 
del mecanismo de acción antitumoral de estos compuestos. Estas moléculas actúan a través de la 
activación de receptores CB2 y la generación de estrés oxidativo. El análisis mediante western blot de la 
activación de caspasa 3 permitió determinar que estos compuestos son capaces de inducir apoptosis 
en la mencionada línea celular MDA-MB-231. El derivado más potente de esta serie fue evaluado en 
un modelo in vivo de cáncer de mama triple negativo. Dicha quinona-cannabinoide fue capaz de 
reducir significativamente el crecimiento del tumor en ratones inmunodeprimidos. Además, 
mediante análisis histopatológicos de órganos vitales, se demostró que el compuesto no induce 
toxicidad en este modelo de la enfermedad. 
b) Para-cromenopirazoldionas (figura 4, derecha): Estas nuevas moléculas presentaron afinidad por 
ambos receptores cannabinoides en el rango submicromolar. Asimismo, presentaron un marcado 
efecto antiproliferativo en líneas celulares derivadas de tumores humanos de próstata LNCaP y PC-
3, dependiente e independiente de andrógenos respectivamente. En esta actividad antitumoral se 
demostró la implicación de los receptores CB1, los receptores PPARγ y la generación de estrés 
oxidativo. Finalmente, se realizaron ensayos in vivo con una de las para-cromenopirazoldionas
mostrando su capacidad para bloquear casi totalmente el crecimiento tumoral LNCaP y reducir 
significativamente el crecimiento de tumores PC-3. 
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Figura 4. Para y orto-cromenopirazoldionas.
En resumen, en este segundo capítulo se ha descubierto un nuevo prototipo para el desarrollo de 
fármacos antitumorales con potencial aplicación para el tratamiento del cáncer de mama triple 
negativo y el cáncer de próstata.  
Capítulo 3 
En el último capítulo de esta tesis doctoral se aborda la búsqueda de nuevos ligandos del receptor 
GPR55. La falta de agonistas y antagonistas selectivos para este receptor ha dificultado su validación 
como miembro del sistema endocannabinoide. Por ello, se diseñaron y sintetizaron dos series de 
cromenopirazoles (figura 5) en base a requisitos estructurales recientemente identificados para 
ligandos de GPR55. 
Figura 5. Fenilpiperazinil-acetamidometil-cromenopirazoles y acil-piperazinil-cromenopirazoles. 
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La actividad de los nuevos compuestos en el receptor GPR55 fue determinada mediante un 
novedoso estudio de impedancia celular en células HEK293 que expresan el receptor GPR55 de 
manera estable. Estos ensayos permiten obtener la respuesta celular integrada tras la estimulación del 
receptor en tiempo real, evitando así los problemas derivados del análisis de una sola vía de 
señalización. Estos estudios permitieron identificar potentes agonistas parciales de GPR55 (con 
concentraciones efectivas medias en el rango nanomolar). Del mismo modo, algunos de los 
compuestos de esta serie mostraron capacidad para inhibir el efecto del agonista endógeno 
lisofosfatidilinositol (LPI). Al contrario que LPI, los derivados de cromenopirazol no presentan 
efectos en células HEK293 normales a altas concentraciones.  
Debido a la estrecha relación entre GPR55 y los receptores cannabinoides clásicos, se evaluó la 
unión de los nuevos compuestos a los receptores CB1 y CB2 mediante ensayos de desplazamiento de 
radioligando. Algunos de estos derivados no mostraron afinidad por CB1 ni CB2 siendo ligandos 
selectivos de GPR55 frente a receptores cannabinoides clásicos. Sin embargo, aunque ninguno de 
los compuestos se une al receptor CB1, algunos sí presentaron afinidad por CB2.  
En resumen, en el tercer capítulo de esta tesis doctoral se ha descubierto un prototipo para el 
desarrollo de nuevos ligandos y herramientas farmacológicas del receptor GPR55. 
A lo largo de esta tesis doctoral se ha identificado un nuevo esqueleto privilegiado para el desarrollo 
de moléculas capaces de modular el sistema endocannabinoide. 
* La doctoranda (P.M.) ha llevado a cabo las siguientes tareas: i) síntesis y caracterización estructural de 
los nuevos compuestos y predicción in silico de sus propiedades farmacocinéticas en el Instituto de 
Química Médica (CSIC); ii) ensayos de unión a receptores CB1 y CB2 de los nuevos compuestos en el 
laboratorio del Prof. Javier Fernández-Ruiz, Facultad de Medicina, Universidad Complutense de Madrid 
(UCM); iii) ensayos in vitro e in vivo en cáncer de mama triple negativo en el laboratorio de la Prof. 
Cristina Sánchez, Facultad de Biología, UCM; iv) estudios de modelización molecular en el laboratorio de 
la Prof. Patricia Reggio, Department of Chemistry and Biochemistry, University of North Carolina at Greensboro
(UNCG); v) ensayos de impedancia celular evaluando la capacidad de los nuevos compuestos para 
modular GPR55 en el laboratorio de la Prof. Ruth Ross, Department of Pharmacology and Toxicology, University 
of Toronto (UofT).  
El resto de ensayos (SPR, electroquímica, funcionalidad mediante AMPc, GTPγS, células microgliales 
BV-2, así como la evaluación antitumoral en cáncer de próstata) han sido realizados por grupos de 
investigación colaboradores.
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1. Introduction  
Cannabis sativa has been extensively employed by mankind throughout the history. The earliest 
recorded use of cannabis can be traced back to ancient China nearly five thousand years ago. It was 
used as a source of textiles and food, as well as for medicinal, religious and recreational purposes. 
From China, the use of cannabis spread across Asia and to the Middle East but it did not reach 
Europe until centuries later. Medicinally, cannabis was used in many cultures to treat diverse 
complaints including pain, convulsions, inflammation, asthma and lack of appetite.1
The decline of medicinal cannabis began in the early twentieth century mainly due to its spread 
consumption as a recreational psychoactive drug. This fact limited the research of cannabis 
therapeutic applications until the 1960s. The isolation and structural characterization of the main 
active constituent of Cannabis sativa, ∆9–tetrahydrocannabinol (∆9–THC, figure 5), was reported in 
1964 by Gaoni and Mechoulam.2 Subsequent studies demonstrated the existence of a number of 
structurally related cannabinoids in the plant.  
During the last decades, research in this field has remarkably accelerated. The discovery of specific 
receptors in the body and an entire endogenous cannabinoid system has led to the development of 
numerous synthetic cannabimimetic drugs and a better understanding of their physiological effects.  
1.1  Endocannabinoid system (ECS) 
Although cannabinoids have been used for medicinal purposes for centuries, their mechanism of 
action remained unclear until a couple of decades ago. In 1988, Devane et al.3 identified specific 
binding sites in the brain (cannabinoid receptors, CBRs) that were activated by different 
phytocannabinoids. This discovery was followed by the cloning and expression of a complementary 
DNA that encodes for this receptor, which was consequently named as cannabinoid receptor type 1 
(CB1R).4 In 1993, Munro et al.5 isolated and cloned the second cannabinoid receptor, cannabinoid 
receptor type 2 (CB2R), from the human promyelocytic cell line HL60. Furthermore, as 
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phytocannabinoids themselves do not exist in the brain, the existence of these receptors prompted 
research to identify the endogenous molecules able to activate them. Accordingly, Devane et al.6
reported the isolation of anandamide [N-arachidonoylethanolamine (AEA), figure 3], a lipid 
neurotransmitter considered the first endocannabinoid identified. Later, 2-Arachidonoylglycerol (2-
AG, figure 3) and several other endogenous molecules acting on CBRs have been discovered.7,8
In addition to the cannabinoid receptors and their endogenous ligands, the proteins responsible for 
the biosynthesis, inactivation and transport of endocannabinoids are also part of the ECS. The 
metabolizing enzymes fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL) as 
well the anandamide transporter (AT) have been extensively studied.9–13
Whether additional cannabinoid receptors are part of the ECS still instigates strong debate. Recent 
studies have shown that several cannabinoid ligands bind to the receptor GPR5514 supporting the 
idea that it plays an important role in the ECS (this receptor will be extensively described in the third 
chapter of this dissertation). Furthermore, GPR1815 (N-arachidonoyl glycine) and GPR11916 have 
been suggested as putative cannabinoid receptors in different investigations. Moreover, there is 
extensive evidence indicating that ECS also interacts with a number of established non-CB1, non-
CB2 GPCRs, ligand-gated ion channels, ion channels, and nuclear receptors.17,18
Cannabinoid receptors 
CBRs belong to the superfamily of G-protein coupled receptors (GPCRs) and are single 
polypeptides with seven transmembrane α-helices, an extracellular, glycosylated N-terminus and an 
intracellular C-terminus.19 CB1R and CB2R types possess 68% amino acid identity within their 
transmembrane regions but only 44% identity throughout the entire peptide. Despite this structural 
difference, many cannabinoid compounds display nearly equal affinity for both receptors. 
CB1R and CB2R are membrane-bound proteins and therefore are extremely difficult to purify and 
crystalize. The lack of CBRs high-resolution crystal structure has hampered the progress in 
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understanding their three-dimensional structure; however, computational homology models have 
been developed to enable drug design.  
Signaling pathways
The complexity of signaling pathways of GPCRs is extended to CBRs. Both CB1R and CB2R share 
some common signaling mechanisms that are schematically represented in figure 1. They are 
coupled to Gi/o proteins, negatively to adenylyl cyclase (AC) and positively to mitogen-activated 
protein kinase (MAPK). Consequently, activation of these receptors causes inhibition of AC, thus 
inhibiting the conversion of ATP to cyclic AMP (cAMP). Reduction of cAMP levels affects 
phosphorylation by protein kinase A, which triggers modulation of ion channels and other second 
messengers such as intracellular calcium. Whereas AC inactivation is mediated by the α subunit of 
the Gi/o protein,4 the βγ subunit of this G-protein complex causes activation of extracellular signal-
regulated kinase (ERK).20 This enzyme in conjunction with other MAPKs such as c-Jun N-terminal 
kinase (JNK) and p38 are regulated by activation of CBRs. In spite of their common features, CB1R 
and CB2R differ in signaling mechanisms and tissue distribution (figure 2). For instance, modulation 
of voltage-dependent ion channels has been related to CB1R activation.17,21
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Figure 1. General overview of signaling pathways associated with CBRs activation by agonists. Extracted 
from Di Marzo et al.22
CB1 Receptors  
The CB1R is among the most abundant and widely distributed GPCRs in the brain. CB1Rs are 
mainly found on nerve cells in the brain, spinal cord and peripheral nervous system, but are also 
present in certain peripheral organs and tissues, among them endocrine glands, spleen, leukocytes, 
heart and parts of the reproductive, urinary and gastrointestinal tracts. CB1R plays an important role 
in the physiology of the nervous system.17 These receptors are highly expressed in regions of the 
brain, which are responsible for movement (basal ganglia, cerebellum), memory processing 
(hippocampus, cerebral cortex) and pain modulation (certain parts of the spinal cords, 
periaqueductal grey).4,17,23 CB1R modulates synaptic transmission by inhibiting calcium channels and 
possibly activating potassium channels on presynaptic terminals.24 Based on these findings, it has 
been suggested that CB1R agonists suppress neuronal excitability and play a role in regulating 
neurotransmitter release.21,25
CB2 Receptors  
The CB2R is predominantly expressed within the immune system, however, its expression was 
further confirmed in the brain on microglia,26 blood vessels,26 and on some neurons.27,28 Since CB2Rs 
CBR
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are mainly located in immune cells, among them leukocytes, one of their main functions is the 
modulation of release of cytokines, which are responsible of inflammation and regulation of the 
immune system. Moreover, CB2R regulates immune responses by regulating immune cell migration29
and antigen presentation.30
Even though CB2R has been widely studied for its immunomodulatory properties, it exhibits a 
valuable role in the CNS through microglial cells.31 Interestingly, its activation does not trigger 
psychoactive effects, while activation of CB1R clearly does. Thus, CB2R represents a very promising 
target for the management of neurological disorders. 
Figure 2. Tissue distribution of the human CB1R and CB2R receptors in the body. Extracted from 
Fundación Canna.32
Oligomerization of Cannabinoid Receptors 
Recent studies have shown that GPCRs, can exist and function as dimers or higher order 
multimers.33–35 Regarding CBRs, the presence of homodimers and heteromers in different tissues has 
been convincingly demonstrated over these last years.  
For the CB1R, heteromers have been shown to exist with serotonin,36,37 angiotensin,38 opioid,39,40
GPR55,41,42 orexin,43,44 dopamine45 and adenosine46 receptors among others. Although CB2R has 
Introduction
8 
been less investigated, very recent research revealed that it forms heterodimers with CB1R,47 with the 
orphan receptor GPR5548,49 and with HER2 (human epidermal growth factor receptor 2) receptors 
in cancer cells.50 All these data concerning CBR heteromerization suggest that the ECS interacts in a 
significant manner with several other endogenous systems.  
In what concerns cannabinoids receptor homodimerization, more data have been published on 
CB1R homodimers than CB2R counterparts. The presence of CB1R homodimers has been 
confirmed in different biological tissues in vivo and in vitro.51–55 Even if their functional role has not 
been properly determined, diverse pharmacological approaches have already been explored.56–58 On 
the other hand, CB2R homodimers have been evidenced59–61 but not fully evaluated and their 
pharmacological potential has not been explored yet.  
It is certain that homo- and heterodimerization affects the manner in which the CBRs respond to 
ligands.  However, it remains a challenge to clearly identify what biological functions are impacted 
by these dimers and to develop drugs targeting them.    
1.2  Cannabinoid ligands 
Cannabinoid modulators can be classified attending to diverse criteria such as their biological 
activity, their nature or their chemical structure. Herein, cannabinergic ligands will be briefly 
categorized attending to the last criterion: 
1.2.1 Endocannabinoids and related compounds  
As aforementioned, the identification of cannabinoid receptors was followed by the detection of 
their endogenous ligands. These molecules, named endocannabinoids, are lipid neurotransmitters 
that mediate retrograde signal from postsynaptic neurons to presynaptic ones targeting CBRs.62
Endocannabinoids comprise a family of polyunsaturated fatty acids that structurally differ from 
phytocannabinoids. Among the endocannabinoids identified so far are anandamide (N-
arachidonoylethanolamide, AEA), 2-arachidonoylglycerol (2-AG), 2-arachidonylglyceryl ether 
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(noladin ether, 2-AGE), O-arachidonoyl ethanolamine (virodhamine), and N-arachidonoyl-
dopamine (NADA) (figure 3).  
Figure 3. Structure of endocannabinoids: AEA, 2-AG, 2-AGE, virodhamine and NADA.
The first two discovered endocannabinoids, AEA and 2-AG, are more widely spread and have been 
more intensively evaluated.25 AEA is a CB1R/CB2R partial agonist while 2-AG exhibit full agonism 
towards both receptors. In contrast to other brain chemical signals, which are stored in the nerve 
cells, endocannabinoids are synthesized “on demand” from membrane phospholipid precursors 
upon stimulation.63,64 After release, they are rapidly deactivated by uptake into cells and metabolized 
by enzymatic hydrolysis by FAAH and MAGL.13,65
There is no doubt that this endogenous machinery presents a promising therapeutic potential, 
consequently, different drug discovery strategies have been explored. One of them considers 
amplifying the ECS tone by inhibiting the enzymes FAAH or MAGL, or the transporter AT. 
Another emerging strategy is based on positive allosteric modulation of CBRs that would enhance 
cannabimimetic activity of endocannabinoids. Development of synthetic endocannabinoid 
analogues that activate CBRs but are weak substrates for the metabolic enzymes has also been 
proposed as a promising approach.66 Subsequently, diverse synthetic eicosanoids have been 
described in the last years. Structural modifications of AEA and 2-AG have reported on the polar 
head, the lipophilic pentyl tail and the arachidonoyl backbone. For instance, molecules such as 
ACEA (arachidonyl-2'-chloroethylamide) or ACPA (arachidonylcyclopropylamide)67 (figure 4), AEA 
analogues with modified polar groups, led to compounds with increased CB1R affinity. (R)-(+)-
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Methanandamide (Met-AEA), another anandamide analogue alkylated at position 1, retains activity 
while providing a better enzymatic stability.  
Figure 4. Structure of synthetic endocannabinoids derivatives ACEA, ACPA and (R)-methanandamide.
1.2.2 Phytocannabinoids and derivatives 
To date over 80 cannabinoids, the so-called phytocannabinoids, have been isolated from the 
cannabis plant. Contrary to other naturally occurring drugs, such as opioids, nicotine, cocaine or 
caffeine, they do not contain nitrogen, and hence are not alkaloids. Most phytocannabinoids share 
common structural features that include a dibenzopyran ring and a hydrophobic alkyl chain. The 
most abundant cannabinoids in the plant are ∆9-tetrahydrocannabinol (∆9-THC), cannabidiol (CBD), 
cannabinol (CBN), cannabigerol (CBG), and cannabichromene (CBC) (figure 5).
Phytocannabinoids show different affinity for CB1R and CB2R. ∆9-THC binds to both receptors 
with similar potencies. This compound is largely responsible of the pharmacological properties as 
well as of the psychoactive effects associated with marijuana use. Other phytocannabinoids also 
contribute to the therapeutic effects of the plant, especially CBD, a non-psychoactive compound 
that demonstrated anti-inflammatory, analgesic, anti-anxiety and anti-tumor properties among 
others.68
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Figure 5. Structure of some plant cannabinoid ligands.
Numerous phytocannabinoid analogues and related derivatives have been synthesized. 
Consequently, SAR (structure-activity relationship) studies have helped to elucidate the structural 
requirements for cannabinoid activity. From a pharmacophoric point of view, different features of 
phytocannabinoid structures such as the alkyl lipophilic chain, the phenolic and the pyran ring have 
been explored leading to potent synthetic cannabinoid ligands. Some relevant and well-studied 
phytocannabinoid analogues are CP55,940, HU210, JWH133 and HU308 (figure 6). CP55,940, a 
very potent full agonist at both CB1R and CB2R, is currently used as a valuable experimental tool. 
Replacement of the methyl of ∆9-THC by a hydroxymethyl group allowed the discovery of HU210, 
a very potent CB1R/CB2R agonist. In contrast, the deoxy and the methoxy-∆9-THC derivatives 
JWH133 and HU308 are CB2R agonists with significant selectivity over CB1R.69 The only structural 
modification of Δ9-THC that led to an approved drug is nabilone (figure 6). Its therapeutic potential 
will be discussed further in this dissertation
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Figure 6. Structure of some phytocannabinoid synthetic derivatives.
1.2.3 Synthetic cannabinoids 
The interest gained by the ECS as valuable target for drug discovery led to the synthesis of 
numerous cannabinoid ligands in the last years. Approaches for the development of novel 
cannabinergic drugs include selective activation or blockage of CB1R or CB2R.70 These compounds 
are designed trying to improve the poor drug-like properties and to reduce the undesirable effects of 
phytocannabinoids. Other approaches include the inhibition of FAAH, MAGL or AT, as well as the 
design of ligands capable of modulating the ECS by binding to allosteric sites.71,72 From a structural 
point of view, diverse cannabinoid scaffolds have been identified in the last decades, some of them 
will be briefly mentioned herein: 
Aminoalkylindoles 
In the early 1990´s aminoalkyindoles were identified as cannabinoid ligands.73 These compounds are 
derivatives of pravadoline and were initially developed as non-steroidal anti-inflammatory drugs. 
Since they are not structurally related to phyto- or endocannabinoids, their identification was 
considered as a breakthrough in the field. Particularly, that of R-(+)-WIN55,212 (figure 7), a very 
potent CB1R/CB2R agonist which has been extensively used to investigate the endocannabinoid 
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system. SAR studies on the aminoalkylindole scaffold revealed that the morpholine and/or the 
benzomorpholino ring are not necessary to retain CBR activity. Remarkable members of this family 
are the naphthoylindole JWH01574 (figure 7), a CB1R/CB2R agonist that displays certain selectivity 
towards CB2R, and the iodoindole derivative AM63075 (figure 7), a CB2R inverse agonist and weak 
CB1R partial agonist.  
Figure 7. Aminoalkylindole cannabinoid ligands WIN55212, JWH015 and AM630.
Arylpyrazoles 
The arylpyrazole scaffold was identified in 1994 by Sanofi with the discovery of SR141716A 
(rimonabant, figure 8). This compound is a potent CB1R antagonist/inverse agonist which 
therapeutic potential has been deeply investigated and will be further discuss in this dissertation.76
Arylpyrazoles have been widely explored in the cannabinoid system becoming very relevant in the 
design of CB1R or CB2R inverse agonists or antagonists. SAR studies have revealed that for CB1R 
binding affinity the pyrazole ring should be substituted at positions 1 and 5 with substituted phenyl 
moieties. Cannabinoids AM25177 and AM28178 (figure 8) are two representative CB1R inverse 
agonists of this class. Moreover, a potent antiobesity derivative of SR141716A, the triazole LH21 
(figure 8), was discovered in our research group.79 Sanofi also discovered the first CB2R antagonist, 
SR14452880 (figure 8), an arylpyrazole that has been used as pharmacological tool in numerous in 
vitro and in vivo models. 
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Figure 8. Arylpyrazoles SR141716A, AM251, AM281, SR144528, and LH21.
Indole-2-carboxamides 
In the last years, allosteric modulation has emerged as a very attractive pharmacological approach in 
the cannabinoid field.72 Allosteric modulators can provide mechanisms for fine-tuning the receptor 
response while reducing side effects.81 From this perspective, 5-chloro-3-ethyl-N-(4-(piperidin-1-yl)-
phenethyl)-1H-indole-2-carboxamide (ORG27569, figure 9) was identified as the prototypical 
allosteric modulator for the CB1R.82 ORG27569 is able to increase orthosteric CP55,940 binding 
affinity but decreases CP55,940 agonist efficacy in CB1R Gα-mediated pathways assays.83 SAR 
analysis of indole-2-carboxamides revealed the wide potential of this scaffold for developing CB1R 
allosteric modulators.84–87 For instance, a derivative developed by Kendall and coworkers72,86,87
(LDK1258) exhibits an improved CB1R allosteric profile.  
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Figure 9. Indole-2-carboxamides ORG27569 and its derivative LDK1258.
Other cannabinergic ligands 
Other classes of ligands that exhibit interesting cannabinoid activity have been identified in the last 
years. These compounds do not fall into the structural categories previously mentioned. For 
example, the company Eli Lilly developed the diarylbenzofuran88 scaffold describing the ability of 
the novel compounds to act as selective CB1R inverse agonists. Diarylmethyleneazetidine analogues 
have been reported by Aventis Pharma as CB1R receptor antagonists. Furthermore, Bayer 
Healthcare identified the cannabinoid potential of the biaryl ether core reporting a potent 
CB1R/CB2R agonist (BAY38-7271)89 and a CB1R partial agonist (BAY59-3074).90
Recently, the CB2R have centered much attention leading to the development of scaffolds such as 
1,8-naphthyridine-3-carboxamides,91,92 quinoline-2,4(1H,3H)-diones,93 or triazolopyrimidine94
derivatives which were described as CB2R agonists displaying weak affinity towards CB1R. 
Moreover, the pharmaceutical company Shionogi discovered the potential of the 3-carbamoyl-2-
pyridone scaffold targeting the ECS.95 In fact, the CB1R/CB2R dual agonist S-44482396 and the CB2R
agonist S-77746997 were characterized as antipruritic agents and were tested in late stage clinical trials 
for treating atopic dermatitis. Figure 10 illustrates different hit compounds commented herein.
However, these are only representative examples of the research that is being done in this drug 
discovery field. Nonetheless, more efforts need to be done to identify better chemotypes especially
with improved selectivity and druggability profile.
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Figure 10. Representative ligands from novel cannabinergic scaffolds: diarylbenzofuran, 
diarylmethyleneazetidine, biaryl ethers (BAY38-7271 and BAY59-3074), 1,8-naphthyridin-2(1H)‑one-3-
carboxamide, quinoline-2,4(1H,3H)-dione, triazolopyrimidine and 3-carbamoyl-2-pyridones (S-777469 and S-
444823).
1.3  Therapeutic perspectives 
It is widely demonstrated that compounds targeting the ECS, particularly CB1R and/or CB2R, have 
therapeutic potential for the clinical management of an ever growing number of disorders.98 These 
include inflammatory and neuropathic pain, neurological pathologies or cancer among others. 
However, just a few of these diseases can be treated with cannabinoid-based medicines nowadays. 
Marinol® (dronabinol, synthetic Δ9-THC) and Cesamet® (nabilone, a THC synthetic analogue, figure 
6) can be prescribed in several countries as antiemetic drugs for chemotherapy-induced nausea and 
vomiting,99,100 and for anorexia101 treatment in patients with AIDS. Sativex® (nabiximols, a 
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combination of Δ9-THC and CBD, 1:1 ratio) is used for the symptomatic relief of neuropathic pain 
in adults suffering multiple sclerosis, and as an adjunctive analgesic treatment for adult cancer 
patients. Rimonabant (SR141716A, figure 8), a CB1R antagonist/inverse agonist, was 
commercialized in 2006 as Acomplia® for the management of obesity.102 Unfortunately, the 
beneficial effects were accompanied by a significantly increase of depression, anxiety, headache, and 
suicidal thoughts which forced its withdrawal from the market few years later.  
Even though CB1R/CB2R agonists are currently in the forefront of clinical research103 for different 
applications such as cancer and neuroprotection, there is an increasing interest in exploiting novel 
pharmacological strategies.72 CB2R selective agonists or peripherally restricted CB1R/CB2R agonists 
exhibit a promising therapeutic potential for treating various pathologies while avoiding the adverse 
psychotropic effects related to the modulation of CB1R in the brain.104 CB1R and/or CB2R 
antagonists or inverse agonist as well allosteric cannabinoid ligands are also emerging and may be 
useful in the treatment of certain diseases.70,72 Nonetheless, more preclinical and specially clinical 
research needs to be done in this field.  
Pain 
The analgesic effects of phytocannabinoids have been known for centuries. Antinociceptive 
properties of cannabinoids are not surprising since CBRs are largely expressed in CNS areas which 
control pain modulation such as spinal dorsal horn and the dorsal root ganglion.105 Consequently, 
the ECS represents a very interesting target for pain treatment.106
As already mentioned, CB1R/CB2R agonists are already in the clinic in certain countries for the 
treatment of neuropathic pain related to multiple sclerosis or cancer treatment. However, 
psychotropic effects due to central CB1R activation are major limitations for advancing therapies. 
From this perspective, CB2R selective agonists are potential candidates in the management of pain as 
revealed in a wide variety of in vitro and in vivo models of inflammatory, post-operative or 
neuropathic pain.107 Furthermore, pharmacological strategies that enhance levels of 
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endocannabinoids by inhibiting enzymes controling endocannabinoid deactivation also exert 
antinociceptive activity.106
Cancer 
Besides their well-established palliative effects on some cancer-associated symptoms, 
cannabimimetics have recently shown to produce antitumor activity in different models of cancer. In 
vitro and in vivo data revealed their ability to reduce tumor growth, and to inhibit angiogenesis, 
migration and metastasis.100,108,109 Potential pharmacological approaches for cancer treatment 
involving the ECS will be further described in the second chapter of this dissertation.  
Emesis, obesity and metabolic disorders 
The ECS has widely demonstrated an important role in the regulation of metabolic physiological 
processes, specially in food intake, energy balance, glucose and lipid metabolism.110,111 As previuosly 
mentioned, dronabinol and nabilone, are currently on the market for antiemetic purposes. 
Based on the role of the endocannabinoids as orexigenic mediators, inhibition of CB1R has been 
considered a new promising pharmacological approach for he treatment of obesity and metabolic 
syndrome.  However, when the psychiatric side effects of rimonabant forced its withdrawal from the 
clinic, the development of CB1R antagonist and inverse agonists significantly diminished.112,113
Compounds acting preferentially through CB2R have shown their efficacy in a rat model of alcoholic 
hepatic steatosis by decreasing the liver/body weight ratio and hepatic triglyceride content.114,115
Consequently, CB2R ligands represent a potential new alternative for treatment of some metabolic 
disorders. 
Neurodegenerative diseases 
The wide expression of CBRs in the CNS suggests the involvement of the ECS in 
neurophysiological processes.116 For this reason, this system was widely validated as an outstanding 
target for the treatment of numerous brain-related pathologies such as motor disorders,117 adult and 
neonatal ischemia,118 brain trauma,119,120 epilepsy,121–123 memory-related disorders,124 or 
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neurodegeneration.125,126 Cannabinoids exhibit neuroprotective effects, they participate in the 
regulation of neuronal homeostasis and survival what confers them the ability to inhibit events 
related to the progression of neurodegeneration such as excitotoxicity, oxidative stress, or 
neuroinflammation.116,127 Different pharmacological studies provide evidence of their potential in the 
management of neurodegenerative diseases such as Parkinson´s disease,128 Alzheimer´s disease,129,130
amyotrophic lateral sclerosis,131 Huntington’s disease,31,132 or multiple sclerosis.133,134
Although, CB1R is the main receptor of the CNS, the presence of CB2R in microglia and neuronal 
cells as well as its role in the immune system,26–28 suggest the possibility to use CB2R agonists to treat 
certain neurological conditions without psychotropic unwanted effects.135,136 Alternative 
pharmacological approaches to achieve neuroprotection may be to enhance the endogenous 
cannabinoid tone or allosteric modulation of CBRs.66,137 The non-psychoactive compound CBD 
have also attracted much attention in this field. Indeed, its anti-convulsive properties have recently 
encouraged different clinical trials in severe pediatric epilepsies such as Dravet syndrome and 
Lennox-Gastaut syndrome.121
Other applications 
Aside from neurology, cancer and metabolism there seems to be a diverse range of possibilities for 
the therapeutic use of cannabinoids. The role of the ECS has been extensively studied in 
pathophysiological conditions such as gastrointestinal disorders,138 atherosclerosis and certain other 
cardiovascular diseases.139 Cannabinoids have also shown a promising potential in the management 
of bone-related diseases,140 immune disorders,141 drug addiction142 or cerebral malaria.143
Preclinical evidence thoroughly confirmed that CBRs are outstanding targets for developing useful 
medications for numerous ailments. Nonetheless, a deeper  understanding of its pharmacology as 
well as novel drugs and therapeutic approaches are needed to overcome their limitations. 
Additionally, there is a clear need for human clinical research to confirm their effectiveness in 
patients.  
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2. Background and aims 
The separation of the therapeutic effects of cannabinoids from their psychotropic effects has been 
long pursued in the development of ECS modulators. In this sense, CB2R, represents a promising 
target for the treatment of numerous disorders without serious undesired CNS side effects. In this 
context, the main purpose of this chapter is the synthesis, optimization and evaluation of selective 
CB2R ligands. 
Previous work in our research group led to the identification of a novel cannabinoid scaffold: the 
chromenopyrazole (figure 11, left). This new tricyclic structure was designed in analogy to the 
classical cannabinoid cannabinol, bearing a benzopyran moiety but exploring for the first time the 
contribution of a pyrazole ring in place of the CBN´s phenyl group. In this study, a series of 
chromenopyrazoles were described as non-psychoactive and selective CB1R agonists with peripheral 
antinociceptive properties.144 Different lipophilic side chains were studied at the pharmacophoric 
position 7 obtaining the best results for the 1,1-dimethylheptyl derivatives. 
Figure 11. Structural modifications on the chromenopyrazole scaffold. On the left, results obtained in 
2012;144 on the right novel substitution patterns.    
In an attempt to target the CB2R, we proposed different structural modifications on the 
chromenopyrazole scaffold (figure 11, right) retaining the mentioned aliphatic chain. We decided to 
explore the conversion of the phenolic hydroxyl, a pharmacophoric moiety of classical cannabinoids, 
to different alkoxy groups in order to study the importance of this position in our heterocyclic core. 
Moreover, different pyrazole substituents as well as bioisosteric replacement of the pyrazole by an 
isoxazole have been explored for further fine-tuning of CBRs affinity and selectivity. 
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With these considerations in mind, the first part of this chapter is devoted to the identification of 
CB2R ligands by exploring pharmacophoric features in the chromenopyrazole scaffold. Specifically, 
the aims of section 3.1 are: 
- Synthesis and structural characterization of novel 7-(1,1-dimethylheptyl)-chromenopyrazole 
derivatives.a
- Evaluation of their affinity and activity at CB1R and CB2R.b,c
- Prediction of their pharmacokinetical profile by in silico approaches.a
- Molecular modeling investigation on the structural features required for CB1R/CB2R affinity 
and selectivity.d
Regarding the recent cannabinoid literature and the identification of different cannabinoid homo- 
and heterodimers in different tissues and cell lines, we proposed the synthesis of chromenopyrazole 
bivalent ligands as potential tools for the study of CB2 homodimers. Previous findings in section 3.1 
led to design these new structures. Accordingly, the specific aims of section 3.2 are as follows: 
- Synthesis of homobivalent chromenopyrazoles and their corresponding monovalent 
analogues. a
- Evaluation of their affinity for CB1R and CB2R by radioligand binding assays.b
- Appraisal of their functionality in a cAMP screening.c
a) Performed by PM at Instituto de Química Médica (CSIC). 
b) Performed in collaboration with Prof. Javier Fernández-Ruiz (Facultad de Medicina, UCM).
c) Performed in collaboration with Prof. Rafael Franco (Facultad de Farmacia, UB). 
d) Performed by PM hosted by Prof. Patricia Reggio (Chemistry Department, University of North Carolina at 
Greensboro). 
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3. Results  
3.1 From CB1R towards CB2R selectivity 
3.1.1 Synthesis 
Compounds 1.41.38 were synthesized following the synthetic route shown in scheme 1. Firstly, 
demethylation of the commercially available 5-(1,1-dimethylheptyl)-1,3-dimethoxybenzene with 
boron tribromide provided the desired resorcinol 1.1. Chromanone 1.2 was obtained upon treatment 
of 5-(1,1-dimethylheptyl)-1,3-dihydroxybenzene (1.1) with 3,3-dimethylacrylic acid in presence of 
phosphorus pentoxide using methanesulfonic acid as solvent at 70 ºC. In order to deepen the study 
of this reaction, the influence of different 5-alkyl-substituted resorcinols on the formation of 2,2-
dimethyl-chroman-4-ones was examined experimentally and theoretically. These data are reported in 
Appendix 1 of this dissertation.  
Following with our synthetic route (scheme 1), 7-(1,1-dimethylheptyl)-5-hydroxy-3-
(hydroxymethylen)-2,2-dimethylchroman-4-one (1.3) was obtained by α–formylation of 1.2 under 
microwave conditions using an excess of sodium hydride followed by the addition of ethyl formate. 
Then, condensation of the β-ketoaldehyde 1.3 with the appropriate hydrazine gave the 
corresponding 7-alkyl-1(2),4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-oles 1.41.13. Two 
regioisomers can be form, N1- and N2-substituted pyrazoles. As expected, with alkylhydrazines, 
both (N1/N2) regioisomers (1.5a, 1.5b, 1.6a, 1.6b, 1.9a, and 1.9b) were isolated with different 
relative ratios. N2-Isomer was formed as the major compound with methylhydrazine, whereas, an 
approximate relative ratio of 1:1 was obtained for ethyl and hydroxyethyl regioisomers. In the case 
of the arylhydrazines, reaction with β-ketoaldehyde 1.3 resulted in the isolation of one isomer, 
corresponding to the N1-aryl-chromenopyrazole (1.7, 1.8, 1.11 and 1.12). This may be due to the fact 
that the substituted nitrogen of arylhydrazines is less nucleophilic.  
Compound 1.10 was prepared by condensation of chromenopyrazole 1.4 with formaldehyde to 
obtain the hydroxymethylpyrazole derivative following the procedure previously reported.145,146
Results
23 
Although HPLC-MS analysis of the crude displayed both regioisomers, only the major one (N2-
pyrazole) was properly isolated and characterized. 
The synthesis of compounds 1.14l.38 was achieved by alkylation of the phenolic oxygen of 
chromenopyrazoles 1.41.8 with the corresponding alkyl halide. Alkylation of 1.4 led to N-alkylated, 
and N-/O- alkylated subproducts that decreased the yield of the desired O-alkylated compounds. 
To increase structural diversity at this position and expand the SAR study, derivatives with different 
R2 substituents such as methyl, benzyl, hydroxypropoxy or bromopropoxy were synthesized.  
Scheme 1. Synthesis of chromenopyrazoles 1.14l.38. Reaction conditions: (i) BBr3, CH2Cl2, overnight, 0 ºC-
r.t., 92%; (ii) 3,3-dimethylacrylic acid, methanesulfonic acid, P2O5, 8 h, 70 ºC, 81%; (iii) a) NaH, THF, MW, 
25 min, 45 ºC; b) ethyl formate, MW, 25 min, 45 ºC, 76%; (iv) corresponding hydrazine, EtOH, 1-4 h, 40 ºC, 
2-82%; (v) a) NaH, THF, 10 min, b) 1-bromo or iodoalkane, 1-12 h, reflux, 22-96%. *Compound 1.10 was 
synthesized by reaction of 1.4 with formaldehyde in EtOH, 5 h, reflux, 69%.
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To explore the SAR of the phenol substitution, we decided to prepare two conformationally 
restricted etherified derivatives by incorporating a fourth ring. For that purpose, the pyrano-
chromenopyrazoles 1.39 and 1.40 were synthesized as depicted in scheme 2. 
Alkoxychromenopyrazoles 1.29 and 1.30 were obtained by O-alkylation of 1.6a and 1.6b with 3-
bromopropanol as previously detailed. Subsequent cyclodehydration with phosphorus pentoxide 
yielded the desired condensed cyclic ethers.  
Scheme 2. Synthesis of pyrano-chromenopyrazoles 1.39 and 1.40. Reaction conditions: (i) P2O5, toluene, 1
h, reflux, 52-87%.  
 
Further exploration of our scaffold led us to the bioisosteric replacement of the pyrazole by an 
isoxazole moiety. For this purpose, condensation of β-diketone 1.3 to isoxazole 1.41 was efficiently 
achieved upon reaction with hydroxylamine hydrochloride under ethanol refluxing conditions. 
Phenolic alkylation of chromenoisoxazole 1.41 yielded methoxy (1.42) and hydroxypropoxy (1.43) 
derivatives. This reaction was performed following the procedure described for 
alkoxychromenopyrazoles. 
Scheme 3. Synthesis of chromenoisoxazoles 1.411.43. Reaction conditions: (i) Hydroxylamine 
hydrochloride, ethanol, 45 min, reflux, 91%; (ii) a) NaH, THF, 10 min, 0 ºC; b) 1-bromo or iodoalkane, 1-3 
h, reflux, 22-61%.
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3.1.2 Cannabinoid binding studies 
The synthesized compounds were evaluated in vitro for their ability to displace the radioligand 
[3H]CP55,940 from human CB1R (hCB1R) and CB2R (hCB2R). As source of these receptors, 
commercial membrane preparations of HEK293 EBNA cells stably expressing each receptor type 
were used. Initially, compounds were screened at 40 µM. A complete dose–response curve was 
generated for compounds that displaced the radioligand over 70% in the preliminary screening. 
Table 1 lists the experimental binding affinities (Ki values) from the respective displacement curves 
for hCB1R and hCB2R. 
As previously reported by us,144 chromenopyrazoles 1.4 to 1.8 showed significant to high affinity and 
selectivity for CB1R (Ki: 4.5–28.5 nM). These CB1R chromenopyrazoles were characterized by a free 
phenol group. N-Methyl, or ethyl substitution of the pyrazole ring did not drastically changed CB1R 
binding and selectivity. With respect to the novel substitutions that have been introduced on the 
pyrazole ring (1.91.13), the presence of hydroxyalkyl groups (1.9a, 1.9b and 1.10) resulted in loss of 
selectivity but with high to moderate affinity constants for both CBRs. The nature of the N-
substituents clearly influenced the CBRs binding. Aromatic substituents such as 3,5-difluorophenyl 
or 4-methoxyphenyl (1.11 and 1.12) led to loss of affinity while the N1-cyclohexyl derivative 1.13
exhibited CB2R selectivity. 
Regarding the O-alkylated chromenopyrazoles, different features could be highlighted from our 
results. In general, the loss of the free phenolic group led to compounds displaying high to moderate 
CB2R affinity with low or lack of CB1R activity. Among the phenolic substituents (R2), alkyl groups, 
in particular propanol, gave the best CB2 selectivity ratios whereas bencyloxy-chromenopyrazoles 
caused a significant decrease in this percentage. It is interesting to note that the condensation of a 
2,4H-pyran to the chromenopyrazoles structure (1.39 and 1.40) which was done for restricted 
conformational issues, elicited excellent CB2R selectivity. 
The pyrazole substitution also contributes to determine affinity and selectivity issues. As depicted in 
table 1, unsubstituted pyrazoles (1.14, 1.21, 1.27 and 1.33) revealed high affinity towards both 
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receptors regardless the nature of the phenol substitution. N-Aryl substitution (1.18, 1.19, 1.25, 1.26, 
1.31 and 1.32) led to inactive derivatives while N-methyl or ethyl substituents (1.151.17, 1.221.24,
1.281.30 and 1.341.38) resulted in high to moderate CB2R affinity and selectivity independently of 
the nature of the phenol substituent. These results suggest that CB2Rs do not tolerate bulky aromatic 
substituents in the pyrazole ring. 
In an effort to explore the chromenopyrazoles scaffold for cannabinoid activity, we proposed the 
bioisosteric replacement of the pyrazole by an isoxazole. This structural modification on the initial 
scaffold led to very potent cannabinoid ligands. Compound 1.41 exhibits high affinity for both CB1R 
and CB2R with Ki values in the low nanomolar range (CB1R Ki: 15.4 nM; CB2R Ki: 5.3 nM). The 
results obtained for O-alkylated chromenopyrazoles prompted us develop the alkoxy derivatives of 
chromenoisoxazole 1.41. Replacement of the phenolic hydroxyl group with either a methoxy (1.42) 
or a hydroxypropoxy (1.43) group led to CB2R selectivity. Chromenoisoxazole 1.42 is the most 
potent and selective ligand of our series, being over 3000-fold selective for CB2R with an affinity 
constant of 12.8 nM. 
Table 1. Binding affinity of chromenopyrazoles 1.41.43 and the reference cannabinoids SR141716, 
WIN55,212-2 for hCB1R and hCB2R. 
Compd R1 R2 CB1R Ki (nM)a
CB2R Ki 
(nM)a
CB1R
Selectivityb
CB2R
Selectivityc
1.4 H H 28.5 ± 23.7 >40000 >1428 -
1.5b N2-Me H 14.2 ± 2.9 >40000 >2816 -
1.6a N1-Et H 4.5 ± 0.6 >40000 >8888 -
1.6b N2-Et H 18.6 ± 2.9 >40000 >2150 -
1.7 N1-3,4-diClPh H 514 ± 205 270 - 1.9
1.8 N1-2,4-diClPh H 5.2 ± 4.3 >40000 >7692 -
1.9a N1-(CH2)2OH H 19.1 ± 8.9 366 ± 169 19.1 -
1.9b N2-(CH2)2OH H 54.4 ± 8.1 39.6 ± 7.1 - 1.4
1.10 N2-CH2OH H 218.1 ± 40.5 59.4 ± 31.2 - 3.7
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1.11 N1-3,5-diFPh H >40000 >40000 - -
1.12 N1-3-OMePh H 6440 ± 655 562.0 ± 13.2 - 11.5
1.13 N1-Cy H 1140 ± 190 53.7 ± 11.8 - 21.5
1.14 H Me 272 ± 75 87.1 ± 10.6 - 3.1
1.15 N2-Me Me 4159 ± 542 66.4 ± 13.29 - 62.6
1.16 N1-Et Me 5040 ± 670 159.5 ± 31.2 - 31.6
1.17 N2-Et Me 2930 ± 470 92.6 ± 17.1 - 31.8
1.18 N1-3,4-diClPh Me 2324 ± 327 2256 ± 499 - -
1.19 N1-2,4-diClPh Me 1693 ± 239 1493 ± 272 - -
1.20 N1-3,4-diClPh Et >40000 3545 ± 89 - >11.3
1.21 H Bn 22.4 ± 4.1 93.3 ± 29.5 4.2 -
1.22 N2-Me Bn 702.4 ± 98.6 208.8 ± 39.5 - 3.3
1.23 N1-Et Bn 613.7 ± 206.9 295.9 ± 53.6 - 2.0
1.24 N2-Et Bn 671.3 ± 166.1 212.2 ± 49.4 - 3.1
1.25 N1-3,4-diClPh Bn >40000 3740  ± 297 - >10.7
1.26 N1-2,4-diClPh Bn >40000 >40000 - -
1.27 H (CH2)3OH 450.4 ± 9.9 26.0 ± 7.1 - 17.3
1.28 N2-Me (CH2)3OH >40000 364.0 ± 68.9 - >109.9
1.29 N1-Et (CH2)3OH 1613 ± 284 440 ± 145 - 3.6
1.30 N2-Et (CH2)3OH >40000 97.4 ± 9.9 - >410.7
1.31 N1-3,4-diClPh (CH2)3OH >40000 >40000 - -
1.32 N1-2,4-diClPh (CH2)3OH >40000 >40000 - -
1.33 H (CH2)2OH 64.8 ± 18.0 3.6 ± 0.7 - 18
1.34 N2-Me (CH2)2OH 1086 ± 198 39.8 ± 24.9 - 27.2
1.35 N2-Et (CH2)2OH 6512 ± 714 210.6 ± 93.2 - 31.0
1.36 N2-Me (CH2)3Br 1482 ± 221 77.3 ± 0.87 - 19.1
1.37 N2-Et (CH2)3Br 657 ± 159 87.1 ± 14.2 - 7.5
1.38 N1-Et (CH2)2Br 1331 ± 320 78.7 ± 11.3 - 16.9
1.39 N1-Et - >10000 563.8 ± 13.1 - >17.7
1.40 N2-Et - >40000 121.6 ± 43.5 - >330.5
1.41 - H 15.4 ± 12.2 5.3 ± 0.8 - 2.9
1.42 - Me >40000 12.8 ± 2.4 - >3125
1.43 - (CH2)3OH 332.6 ± 143.9 65.5  ± 21.8 - 5.1
SR141716 - - 7.3 ± 0.9 >40000 - -
WIN55,212-2 - - 45.6 ± 8.6 3.7 ± 0.2 - -
aValues obtained from competition curves using [3H]CP55940 as radioligand for hCB1R and hCB2R and are expressed as the 
mean ± SEM of at least three experiments. bKi(CB1R)/Ki(CB2R) selectivity ratio. cKi(CB2R)/Ki(CB1R) selectivity ratio. 
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Following the first aims of this chapter concerning the SARs of the chromenopyrazoles as 
cannabinoids, that were the exploration of the substitution on i) the phenol, ii) the pyrazole, and iii) 
replacement of pyrazole by isoxazole, some general conclusions can be featured.  
i) The phenol substitution seems to play a crucial role in selectivity. CB1R selective 
chromenopyrazoles bear a free hydroxyl phenolic group, whereas high CB2R selectivity was achieved 
when the phenol was alkylated. 
ii) The nature of the pyrazole substituent influences the affinity for CBRs. In general, alkyl 
groups showed better affinity for CB1R and/or CB2R compared to aryl substituents. 
iii) The bioisosteric replacement of the pyrazole by an isoxazole resulted in cannabinoid 
ligands with affinity in the nanomolar range.  
3.1.3 Functional assays 
Although radioligand binding assays are widely used to determine the affinities of ligands for a 
receptor, they do not reveal information about how ligands modulate receptor activity. Thus, 
functional receptor assays are required in order to evaluate the properties of a ligand. Cannabinoid 
activity of certain chromenopyrazoles derivatives was evaluated through different functional 
experiments. Compounds were selected according to high CB2 selectivity and/or affinity criteria.  
Activity at CB2R was appraised through cAMP accumulation experiments. To further assess 
functionality through a different outcome, GTPγS binding assays were performed. In addition, 
selected CB2R ligands were evaluated using an in vitro assay on BV-2 microglial cells. 
cAMP accumulation assay at CB2R. 
Adenosine 3’,5’-cyclic monophosphate (cAMP) is the main second messenger in the signalling 
pathway for Gi protein-coupled receptors. The Gi activation induces the inhibition of the effector 
activity (adenylate cyclase), resulting in a decrease of intracellular cAMP concentration. Detection of 
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this reduction in cAMP production depends on the basal level of cAMP present within the cells. 
Using forskolin (Fk) to activate adenylate cyclase allows an easier detection of this inhibitory effect. 
Functional properties of our new molecules were investigated in cAMP assays using HEK293 cells 
stably expressing the human CB2 receptor subtype.  
Agonism. Effects of tested compounds on forskolin-stimulated cAMP levels were determined in a 
preliminary screening at two concentrations (at 200 nM and 1 μM). As CB2 is a Gi/o-coupled 
receptor, its activation by agonists leads to inhibition of forskolin-stimulated cAMP accumulation, 
whereas inverse agonists may facilitate cAMP production and antagonists do not trigger changes in 
forskolin-stimulated cAMP levels. 
Results obtained from this cAMP screening are depicted in figure 12. Molecules displaying high 
inhibition of forskolin-stimulated cAMP accumulation (1.33 and 1.40−1.43) or not showing effect 
(1.15, 1.30 and 1.34) were selected for further pharmacological characterization. Compounds 
exhibiting slight inhibitory effect at both concentrations (1.16, 1.17, 1.21, 1.27, 1.36 and 1.38) were 
considered as potential partial or weak agonists in our screening. 
Figure 12. cAMP screening in HEK293 cells stably expressing the human CB2R type. Results are expressed 
as percent of forskolin-stimulated cAMP accumulation at a concentration of 200 nM and 1 μM of our 
compounds and the reference cannabinoid CP55,940. All data result from at least three independent 
experiments, performed in triplicates. 
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The tested compounds were also screened in normal HEK293 cells at the same concentrations. As 
displayed in figure 13, the compounds, as well as the reference agonist CP55,940, did not exert 
effect in this cell line. These results confirm that the ability of certain chromenopyrazoles and 
chromenoisoxazoles to inhibit forskolin-stimulated cAMP accumulation was effectively mediated by 
CB2R. 
Figure 13. cAMP screening in normal HEK293 cells. Results are expressed as percent of forskolin-stimulated 
cAMP accumulation at a concentration of 200 nM and 1 μM of test compounds. All data result from at least 
three independent experiments, performed in triplicates. 
For compounds with a good inhibitory effect in the aforementioned cAMP screening (1.33 and
1.40−1.43), full concentration−response curves were measured and EC50 and Emax values were 
determined. CB2R-activation by 1.33 and 1.40−1.43 led to a dose-dependent inhibition of forskolin-
stimulated cAMP increase. All these ligands are potent CB2R agonists showing EC50 values in the 
nanomolar range (table 2). Results obtained for the well-known potent CB1R/CB2R agonist 
CP55,940 and the CB2R selective agonist JWH133 are consistent with previously published data.19 It 
is noteworthy that the most potent and efficacious ligand of our series is the chromenoisoxazole 
1.42 (EC50 = 4.2 nM), which displays more CB2R selectivity and potency than the reference 
cannabinoid agonists. This data highlight 1.42 as a potential lead compound for additional 
pharmacological development.
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Table 2. Functional potencies of compounds 1.33, 1.40−1.43 and the reference cannabinoids CP55,940 and 
JWH133 at CB2 receptor determined by measuring the decrease in forskolin-stimulated cAMP levels in 
HEK293-CB2R cells.
Compd R1 R2 CB2R cAMP assays
aEC50 (nM) bEmax (%)
1.33 H (CH2)2OH 21.6 ± 1.5 95 ± 6
1.40 N2-Et - 25.5 ± 2.0 98 ± 11
1.41 - H 134.0 ± 2.3 98 ± 9
1.42 - Me 4.2 ± 1.5 101 ± 10
1.43 - (CH2)3OH 14.0 ± 1.9 91± 10
CP55,940 - - 8.3 ± 1.5 106 ± 9
JWH133 - - 81.8 ± 1.7 98 ± 11
aEC50 values were calculated using nonlinear regression analysis. Data are expressed as the mean ± SEM of at least three 
independent experiments performed in triplicates. bForskolin stimulated cAMP levels were normalized to 100%. Emax is the 
maximum inhibition of forskolin stimulated cAMP levels.
Antagonism. Compounds exhibiting no inhibition of forskolin-stimulated cAMP accumulation in the 
preliminary screening (1.15, 1.30 and 1.34, figure 12), were subjected to further cAMP studies in
HEK293 cells stably expressing CB2R in order to confirm their functionality. Their effect on 
CP55,940-induced inhibition of cAMP accumulation was evaluated (figure 14).  
 
(B)(A)
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Figure 14. Effect of compounds 1.15, 1.30 and 1.34 on CP55,940-induced inhibition of cAMP accumulation in 
HEK293-CB2R cells. (A) Compound 1.15 at 200 nM; (B) Compound 1.34 at 200 nM; (C) Compound 1.30 at 200 
nM; (D) Compound 1.30 at 1 µM. All data result from at least three independent experiments, performed in 
triplicates. Data were assessed by one-way analysis of variance (F(5,43)=20.57, p<0.0001 for compound 1.16; 
F(5,42)=17.92, p<0.0001 for compound 1.34; F(5,33)=27.16, p<0.0001 for compound 1.30 (C); F(5,33)=22.03, 
p<0.0001 for compound 1.30 (D); *p<0.05, **p<0.01,***p<0.005 compounds alone versus control (forskolin 
cAMP accumulation); &p<0.05, &&p<0.01, &&&p<0.005 CB2 agonist versus CB2 agonist + 1.15, 1.30 or 1.34).
As shown in figure 14, in the presence of 1.15 at 200 nM, the inhibitory activity of the reference CB2 
agonist was significantly decreased (at 100 nM and 1 µM). Likewise, 200 nM of 1.34 was found to 
antagonize the effect of CP55,940 (figure 14, B). At the same concentration, 1.30 did not show this 
capacity (figure 14, C), however, its administration at 1 µM was able to significantly reverse 
CP55,940-induced inhibition of cAMP. These data indicate that 1.15, 1.30 and 1.34 are CB2R
antagonists through this functional readout being 1.15 and 1.34 more potent than 1.30.
GTPγS binding assays: CB1R and CB2R 
Activity of selected compounds was carried out by evaluating the coupling of CBR/G-protein, by 
using the radioligand [35S]-GTPγS (guanosine 5′-O-[gamma-thio]triphosphate). When a GPCR is 
activated by agonist binding in the presence of GTPγS, it displaces GDP and the G protein is 
persistently activated. The extent of receptor activation is determined by the difference between 
basal [35S]-GTPγS binding and binding in the presence of the compound.147
Functionality at CB1R. Even though our main aim is to develop CB2R selective ligands, the evaluation 
of compounds with good affinity towards CB1R (1.9b, 1.21 and 1.41) was considered of interest. 
GTPγS experiments have been performed in membranes extracted from HEK293 cells stably
(C) (D)
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expressing CB1 receptors. Tested compounds present ability to stimulate CB1R activation acting as 
agonists of this receptor with EC50 values in the nanomolar range (table 3). As reported by us in 
2012,144 the functional activity of CB1 selective chromenopyrazoles 1.4, 1.6a and 1.6b was evaluated 
on mouse vas deferens. These compounds inhibited the electrically evoked contractile response of this 
tissue exhibiting a full agonist profile. Therefore, all the CB1R ligands from this series demonstrated 
ability to activate CB1 regardless the functional outcome. Activity of 1.33 at CB1R remains to be 
determined. 
Table 2. [35S]-GTPγS binding of compounds 1.9b, 1.21 and 1.41 and the reference cannabinoid WIN55,212-2 
for hCB1R. 
Compd R1 R2 CB1R GTPγS assays
aEC50 (nM) bEmax (%)
1.9b N1-(CH2)2OH H 298.8 ± 54.2 97 ± 52
1.21 H Bn 191.0 ± 90.8 234 ± 79
1.41 - H 15.8 ± 8.6 196 ± 111
WIN55,212 - - 44 ± 30 153 ± 70
aEC50 values were calculated using nonlinear regression analysis. Data are expressed as the mean ± SEM of at least three 
independent experiments, each one run in triplicates. bEmax: Maximal agonist effect, determined using nonlinear regression 
analysis.
Functionality at CB2R. Functional properties of compounds 1.33, 1.41−1.43 at CB2R was further 
appraised through [35S]-GTPγS binding assays in commercial CB2R-containing membranes (see 
experimental section). Dose-response analyses of these new derivatives indicate that they act as full 
CB2 agonists through this outcome (table 4). Even though, EC50 values are in the nanomolar range, 
potencies slightly vary from those obtained in cAMP experiments. As in the previous functional
readout, chromenoisoxazole 1.42 stands out in GTPγS binding assays being the most potent and 
selective CB2R ligand of this series. 
Table 4. [35S]-GTPγS binding of compounds 1.33, 1.41−1.43 and the reference cannabinoid HU308 for 
hCB2R. 
 
Compd R1 R2 CB2R GTPγS assays
aEC50 (nM) bEmax (%)
1.33 H (CH2)2OH 95.1 ± 7.2 110 ± 17
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1.41 - H 50.2 ± 24.9 114 ± 37
1.42 - Me 38.6 ± 6.7 98 ± 8
1.43 - (CH2)3OH 539.6 ± 208.1 96 ± 15
HU308 - - 64.5 ± 1.6 91 ± 7
aEC50 values were calculated using nonlinear regression analysis. Data are expressed as the mean ± SEM of at least three 
independent experiments, each one run in triplicates. bEmax: Maximal agonist effect, determined using nonlinear regression 
analysis.
Bioassay for CB2R functionality on cultured cells.  
In the course of our studies, activity of CB2R chromenopyrazoles 1.15, 1.30 and 1.34 have been also 
studied in a BV-2 murine microglial cell line. This cell line has been used extensively in research 
related to neurodegenerative disorders. However, in the present study, we used this cell line for 
evaluating the functionality of new compounds. The ability of our compounds to reduce 
lipopolysaccharide (LPS)-induced inflammatory responses in cultures was determined. CB2R are 
highly expressed in this microglial cell line so the activation of this receptor results in a decrease of 
the intensity of the proinflammatory response.148–150 This response is quantified by measuring the 
concentration of prostaglandin E2 (PGE2) using an ELISA immunoassay. CB2R agonists will reduce 
the inflammatory response (by attenuating LPS-induced PGE2 release), whereas antagonists or 
inverse agonists of CB2R reverse agonistic effects and may even increase the inflammatory response 
produced by LPS. Two well-known CB2R ligands, the non-selective agonist WIN55,212-2, and the 
CB2R selective antagonist/inverse agonist SR144528 were evaluated as reference. As depicted in 
figure 15, stimulation of BV-2 cells with LPS produced a great increase in PGE2 release which was 
completely reversed by co-incubation with WIN55,212-2. In addition, the effect of this agonist was 
completely blocked by SR144528 supporting the fact that PGE2 release is mediated through CB2R 
activation. 
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Figure 15. Effects of control ligands WIN55,212-2 (WIN) and SR144528 (SR2) on the LPS-induced release 
of PGE2 in cultured BV-2 cells. Data were assessed by one-way analysis of variance (F(3,27) = 11.93, 
p<0.0001; *p<0.05, **p<0.01,***p<0.005 versus control (DMSO-exposed); #p<0.05, ##p<0.01, ###p<0.005 
versus LPS; @p<0.05, @@p<0.01, @@@p<0.005 versus LPS+WIN).  
Chromenopyrazoles 1.30 and 1.34 did not reverse LPS-induced response (figure 15 D and F), 
however they were able to reverse the effect of WIN55,212-2 suggesting neutral antagonism at CB2R 
(figure 16 C and E). In addition, 1.15 showed elevated PGE2 levels when combined with LPS (figure 
16 B) suggesting inverse agonistic properties. These data are in agreement with the results obtained 
in the cAMP assays for compounds 1.30 and 1.34 (figure 14). Results obtained for 1.15 in the LPS-
induced PGE2 and cAMP assays differ since 1.15 acted as inverse agonist/antagonist in the LPS 
assays whereas no inverse agonist was detected in cAMP tests. This variation can be attributed to 
different sources of CB2R (BV-2 murine microglial cells and CB2R-HEK293 EBNA cells). 
Compd 1.15
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Figure 16. Effects of compounds 1.15, 1.30 or 1.34, combined with WIN55,212-2 and/or SR144528, on the LPS-
induced release of PGE2 in cultured BV-2 cells. (A) Compound 1.15 and WIN; (B) Compound 1.15 and SR2; (C) 
Compound 1.30 and WIN; (D) Compound 1.30 and SR2; (E) Compound 1.34 and WIN; (F) Compound 1.34 and 
SR2. Data were assessed by one-way analysis of variance (F(3,26)=8.03, p=0.0008 for (A); F(3,27)=104.20, 
p<0.0001 for (B); F(3,27)=7.94, p=0.0008 for (C); F(3,27)=18.15, p<0.0001 for (D); F(3,27)=8.43, p=0.0005 for 
(E); F(3,27)=30.81, p<0.0001 for (F); *p<0.05, **p<0.01,***p<0.005 versus controls (DMSO-exposed); #p<0.05, 
##p<0.01, ###p<0.005 versus LPS; @p<0.05, @@p<0.01, @@@p<0.005 versus WIN+LPS or compounds 1.15, 1.30
or 1.34+LPS)
To sum up, all these functional data indicate that we have discovered novel selective and potent 
agonists of the cannabinoid receptor CB2R. This behaviour was demonstrated through different 
biochemical assays, including ligand-mediated GTPγS binding, forskolin-stimulated cAMP and 
competition binding experiments. Among this series CB2R antagonists and potent CB1R/CB2R 
agonists were also identified.  
Compd 1.30
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3.1.4 Molecular modeling 
As already mentioned, significant CBR affinity differences were observed among the 
chromenopyrazoles and isoxazoles described in this chapter. These data offered us the opportunity 
to explore the structural features required for CB1R/CB2R selectivity using molecular modeling 
approaches. Cannabinoid selectivity and structural patterns led us to select molecules 1.4, 1.6b, 1.17
and 1.41 for docking studies. The CB1R chromenopyrazole 1.4 was compared with its isoxazole 
analog 1.41, a potent non-selective CB1R/CB2R ligand. On the other hand, the CB1R selective 
chromenopyrazole 1.6b was studied in relation to its methoxy derivative 1.17, which displays CB2R 
selectivity.  
Firstly, conformational analysis of 1.4, 1.6b, 1.17 and 1.41 was performed to determine the minimum 
energy conformers. In what concerns the N-H-chromenopyrazole 1.4, two tautomers can exist,
however, we only considered the tautomer displayed in figure 18. This consideration was based on 
our previous studies concerning annular tautomerism (OH···N and/or NH···O) of 
hydroxychromenopyrazoles, in which the tautomer OH···N was shown to be the predominant 
specie in solution.151 Figure 18, illustrates the global minimum energy conformers of 1.4, 1.6b, 1.17
and 1.41.
Figure 18. Minimum energy conformers of compounds 1.4, 1.6b, 1.17 and 1.41.
Furthermore, we have calculated the electrostatic potential maps of minimum energy conformers of 
compounds 1.4, 1.6b, 1.17 and 1.41 (figure 19). The range of the electrostatic potential has been 
normalized to be the same for all of the analogues and is given in kJ/mol. The phenolic hydroxyl 
group revealed to be the most negative electrostatic potential region (in red) of compounds 1.4 and 
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1.6b. Chromenoisoxazole 1.41 showed two electron rich hot spots (in red) originated by the 
phenolic hydroxyl group and by the isoxazole nitrogen, this last one being the most electronegative 
region of the molecule. As expected, the O-methoxy chromenopyrazole 1.17 displayed a weaker 
electronegative region due to the low exposure of the free lone pair of electrons of the methylated 
phenolic oxygen.  
Figure 19. The molecular electrostatic potential maps of the minimum energy conformations of compounds 
1.4, 1.6b, 1.17 and 1.41 are illustrated here. The electrostatic potential scale (in kJ/mol) is provided as a color 
scale. This scale is from blue (most electropositive) to red (most electronegative).
The global energy minima of 1.4, 1.6b, 1.17 and 1.41 were docked using a model of the active state 
(R*) of the cannabinoid receptors CB1R and CB2R.152,153 These models include the extracellular and 
intracellular loops, the N-terminus (truncated in CB1R) and the C-terminus, including the 
intracellular helix portion of each receptor, termed Helix 8. Cannabinoid receptor docking studies 
were performed in the same binding site described for HU210154 in the CB1R* model and for 
AM841155,156 in the CB2R* model.
Chromenopyrazole 1.4/CB1R* docking studies.
Lysine K3.28(192) was used as the primary interaction site for the phenolic hydroxyl group 
compound of 1.4. The choice of this primary interaction is supported by the fact that mutation of 
this residue in CB1R resulted in the loss of binding of classical, non-classical and endocannabinoids. 
CB1R selectivity
CB1R/CB2R
CB2R selectivity
1.4 1.41
1.6b 1.17
Results
39 
Thus, the lysine K3.28(192) is considered crucial for CB1R binding of this class of ligand.157 Figure 
20 (left) presents docking results for 1.4 binding at CB1R* from a cellular transmembrane view. As 
illustrated in this figure, the energy-minimized 1.4/CB1R* complex shows two main binding site 
anchoring interactions. The phenolic oxygen of 1.4 is engaged in hydrogen bond with K3.28(192) 
[hydrogen bond (N-O) distance = 2.75 Å and (N-H--O) angle = 151]. The N1-pyrazole nitrogen 
establishes a hydrogen bond with serine S7.39(383) ) [ hydrogen bond (N-O) distance = 3.02 Å and 
(O-H--N) angle = 140]. The ligand 1.4 exhibits the greatest pairwise interaction energy with 
K3.28(192) (-11.88 kcal/mol) and S7.39(383) (-10.88 kcal/mol) followed by significant interactions 
with C7.42(386) (-6.22 kcal/mol), D2.50(163) (-6.03 kcal/mol), L7.43(387) (-5.20 kcal/mol), 
N7.45(389) (-5.13 kcal/mol) and V3.32(196) (-4.40 kcal/mol). The energy difference between the 
initial 1.4 conformation and the final docked conformation in the energy-minimized complex was 
found to be 6.51 kcal/mol at the HF 6-31G* level.  The overall interaction energy for 1.4 at CB1R* 
was found to be -63.92 kcal/mol (see table A in the experimental section). 
Chromenoisoxazole 1.41/CB1R* docking studies. 
The docking of 1.41 in the CB1R* receptor model revealed a similar occupation of the binding site 
with hydrogen bonds involving the lysine K3.28(192) [hydrogen bond (N-O) distance = 2.82 Å and 
(N-H--O) angle = 153] and the serine S7.39(383) [ hydrogen bond (N-O) distance = 2.77 Å and 
(O-H--N) angle = 130] as key residues (figure 20, right). It is interesting to note that an additional 
hydrogen bond between the pyran oxygen and cysteine C7.42(386) was revealed in the 1.41/CB1R* 
complex [hydrogen bond (S-O) distance = 3.19 Å and (S-H-O) angle = 167]. Comparing the 
energies involved in this complex, 1.41 displays the greatest pairwise interaction energy with 
K3.28(192) (-9.59 kcal/mol) and C7.42(386) (-7.39 kcal/mol). The interaction with S7.39(383) was 
found to be only -4.36 kcal/mol, indicating a weak hydrogen bond with the isoxazole nitrogen. 
Other favourable electrostatic and van der Waals interactions were found with D2.50(163) (-4.85 
kcal/mol), L7.43(387) (-5.12 kcal/mol), N7.45(389) (-5.20 kcal/mol) and V3.32(196) (-4.30 
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kcal/mol). The energy difference between the initial 1.41 conformation and the final docked 
conformation in the energy-minimized complex was found to be 2.07 kcal/mol at the HF 6-31G* 
level.  The overall interaction energy for 1.41 at CB1R* was found to be -60.87 kcal/mol (see table B 
in the experimental section).
Figure 20. Binding site of 1.4 (left, in green) and 1.41 (right, in green) in the CB1R* model. Hydrogen bonds 
are represented with magenta dashed lines.  
Chromenopyrazole 1.6b/CB1R* docking studies.
As illustrated in figure 21 (left), the energy minimized 1.6b/CB1R* complex presents two hydrogen 
bonds with K3.28(192). The first involved K3.28(192) as hydrogen donor to the phenolic oxygen of 
1.6b [hydrogen bond (N-O) distance = 2.75 Å and (N-H--O) angle = 152]. The second interaction 
involved K3.28(192) hydrogen bonding with the pyrazole N1 nitrogen [hydrogen bond (N-N) 
distance = 3.10 Å and (N-H--N) angle = 132]. This pyrazole nitrogen also forms a hydrogen bond 
with S7.39(383) [hydrogen bond (N-O) distance = 3.15 Å and (O-H--N) angle =134]. However, 
this interaction is weaker than the corresponding one in the 1.4/CB1R* complex. 
Chromenopyrazole 1.6b displays its greatest pairwise interaction energy with K3.28(192) (-14.34 
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kcal/mol, mainly electrostatic energy), followed by N7.45(389) (-5.19 kcal/mol), L7.43(387) (-5.13 
kcal/mol) and C7.42(386) (-4.76 kcal/mol) which are predominantly van der Waals energy. 
Moreover, the complex exhibits significant interactions with V3.32(196) (-4.72 kcal/mol) and 
D2.50(163) (-4.70 kcal/mol). The energy difference between the initially docked 1.6b conformation 
and the final conformation in the energy-minimized complex was found to be 5.13 kcal/mol at the 
HF 6-31G* level.  The overall interaction energy for 1.6b/CB1R* complex was found to be -59.92 
kcal/mol (see table C in the experimental section). 
Chromenopyrazole 1.17/CB1R* docking studies.
Compound 1.17 was also docked in the CB1R* model at the same binding site. However, consistent 
with its poor affinity for CB1R, it was unable to form any hydrogen bond with any residue of the 
receptor. Furthermore, the methoxy group shows a steric overlap with phenylalanine F2.57(170) and 
leucine L7.43(387) as illustrated in figure 21 (right). In this model, the hydrogen bond between the 
phenolic oxygen of 1.17 and K3.28(192) does not take place due to the low accessibility of the lone 
pairs of electrons. As demonstrated for other tricyclic cannabinoids, this electronic density is crucial 
for ligand-CB1R157,158 and explains the low affinity for this receptor displayed by 1.17. 
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Figure 21. Binding site of 1.6b (left, in green) in the CB1R* model. Hydrogen bonds are represented with 
magenta dashed lines. Structure of 1.17 (right, in green) superimposed on the 1.6b-CB1R* complex. The 
magenta circle indicates van der Waals steric overlap with F2.57 and L7.43 in the CB1R* binding site.  
Chromenopyrazole 1.4/CB2R* docking studies.
After exploring the docking of compound 1.4 in the CB1R* model, we studied the potential 
interactions of this chromenopyrazole in the previously reported advanced CB2R* model153,156,159 at 
the AM841 binding site.156 The CB2R* model contains a salt bridge between the aspartic acid D275 
in the EC-3 loop and lysine K3.28(109). Docking studies of 1.4 revealed a steric clash between the 
pyrazole moiety of the structure and the lysine involved in the ionic lock as illustrated in figure 22
(left). These results are in agreement with the experimental pharmacological data (Ki (CB2R) > 40 
µM).
Chromenoisoxazole 1.41/CB2R* docking studies. 
Compound 1.41 was also docked in the previous CB2R* model at the same binding site. As 
illustrated in figure 22 (right), the energy minimized 1.41/CB2R* complex presents two main 
interactions, a hydrogen bond between the isoxazole nitrogen and K3.28(109) [hydrogen bond (N-
O) distance = 2.86 Å and (N-H--O) angle = 157] and a hydrogen bond involving the phenolic 
oxygen of 1.41 and S6.58(268) [hydrogen bond (O-O) distance = 2.63 Å and (O-H--O) angle = 
170]. Chromenoisoxazole 1.41 displays its greatest pairwise interaction energy with K3.28(109) (-
10.33 kcal/mol) and S6.58(268) (-7.84 kcal/mol). The complex also establishes significant 
interactions (mainly van der Waals energy) with V3.32(113) (-6.26 kcal/mol) followed by S7.39(285) 
(-4.78 kcal/mol), L7.43(289) (-3.52 kcal/mol) C7.42(288) (-3.13 kcal/mol) and M6.55(265) (-3.11 
kcal/mol). Phenylalanines F3.25(106) and F7.35(281) as well as the residues involved in the ionic 
lock (K3.28 and D275) define the top of the binding site for this ligand. The energy difference 
between the initial 1.41 conformation and the final docked conformation in the energy-minimized 
complex was found to be 2.56 kcal/mol at the HF 6-31G* level. The overall interaction energy for 
1.41/CB2R* complex was found to be -60.25 kcal/mol (see table D in the experimental section). 
Comparing the docking studies of chromenoisoxazole 1.41 with the corresponding 
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chromenopyrazole 1.4 in the CB2R* model, there is a clear difference. The hydrogen of the pyrazole 
moiety unables the lysine involved in the ionic lock to interact with the heterocycle, whereas the 
isoxazole nitrogen does not exhibit steric overlapping. Thus, these modeling features corroborate 
the experimental binding affinities obtained for both compounds.
Figure 22. Binding site of 1.41 (right, in green) in the CB2R* model.  Hydrogen bonds are represented with 
magenta dashed lines. Structure of 1.4 (left, in green) was superimposed on the 1.41-CB2R* complex. The 
magenta circle indicates van der Waals steric overlap with K3.28 which forms a salt bridge with D275 in the 
CB2R* binding site.
Chromenopyrazole 1.6b/CB2R* docking studies.
As previously shown in the 1.4/CB2R* complex (figure 22, left), chromenopyrazole 1.6b exhibits a 
steric clash between the pyrazole moiety of the structure and the ionic lock formed by aspartic acid 
D275 and lysine K3.28(109). Moreover, as shown in figure 23, a major steric overlap with 
phenylalanine F7.35(281) is displayed. These findings likely explain the lack of affinity of 
chromenopyrazole 1.6b for CB2R.
Chromenopyrazole 1.17/CB2R* docking studies.
Docking studies of the methoxy derivative 1.17 performed in the CB1R* model clearly showed a lack 
of affinity towards this receptor type. Here, we docked 1.17 in the CB2R* model. Figure 23 (right) 
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illustrates the energy-minimized 1.17/CB2R* complex. Compound 1.17 displays similar occupation 
of the binding site but it adopts a different orientation than the free phenolic hydroxyl ligands 1.4, 
1.41, and 1.6b. This orientation enables serine S6.58(268) to form a hydrogen bond with the pyran 
oxygen [hydrogen bond (O-O) distance = 3.21 Å and (O-H--O) angle = 110]. Compound 1.17
exhibits the greatest pairwise interaction energy with S6.58(268) (-5.55 kcal/mol) and D275 (-6.79 
kcal/mol) which are mainly constituted by electrostatic energy. Significant van der Waals 
interactions are established between the ligand and the following residues: S7.39(285) (-6.17 
kcal/mol), F3.36(117) (-4.85 kcal/mol), V3.32(113) (-4.41 kcal/mol), C7.42(288) (-3.88 kcal/mol) 
and M6.55(265) (-3.07 kcal/mol). The energy difference between the initial 1.17 conformation and 
the final docked conformer in the energy-minimized complex was found to be 2.79 kcal/mol at the 
HF 6-31G* level. The overall interaction energy for 1.17/CB2R* complex was found to be -53.82 
kcal/mol (table E, experimental section). The overall energy of this complex is higher than in the 
1.41/CB2R* complex what explains the affinity differences obtained by radioligand binding 
experiments.  
Docking studies of other methoxy chromenopyrazoles were performed within the same binding site 
in the CB2R* model achieving similar results. 
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Figure 23. Binding site of 1.17 (right, in green) in the CB2R* model.  Hydrogen bonds are represented with 
magenta dashed lines. Structure of 1.6b (left, in green) was superimposed on the 1.41-CB2R* complex. The 
magenta circle indicates van der Waals steric overlap with K3.28 and F7.35. K3.28 and D275 form a salt 
bridge with in the CB2R* binding site. K3.28 is facing the molecule as in the 1.41-CB2R* complex but is 
hidden by the molecule from this perspective, while F7.35 is not displayed as van der Waals volume to 
facilitate the view. 
From these CB2R complexes we can see the importance of serine S6.58(268) in the binding site as 
already revealed by the AM851/CB2R* complex.156 Pei and coworkers suggested that for the binding 
of AM841, the conserved residue K3.28(109) appears to play little role in ligand-CB2R interaction.156
However, in our docking studies, in the 1.41/CB2R* complex, K3.28(109) establishes a hydrogen 
bond with the isoxazole nitrogen. The importance of this residue was previously observed in the 
recently reported study of 1,8-naphthyridin-2(1H)-one-3-carboxamides,91 which exhibits a hydrogen 
bond with K3.28(109) in the CB2R active model.
Taking all these data together we can highlight key molecular features involved in the determination 
of CB1R and/or CB2R binding of our compounds. Docking studies suggests that the presence of the 
pyrazole or isoxazole moiety as well as the phenolic oxygen play a crucial role in affinity and 
selectivity. 
For CB1R affinity, the phenolic lone pair have to be available to bind with K3.28(192), as in phenols 
1.4, 1.6b and 1.41, otherwise the affinity for the type 1 cannabinoid receptor is very low. O-alkylation 
of the initial phenolic hydroxyl of our scaffold led to less potent but selective CB2R ligands (as in 
1.17). This fact might be due to the different orientation and low accessibility of the lone pair of 
electrons of the phenolic oxygen, essential for CB1R interaction. The steric hindrance generated by 
the O-substituent in the CB1R binding site impacts their affinity towards this receptor; however, it 
clearly enables CB2R activity. Substituted phenols align in the proper orientation in the CB2R
binding site leading to an interaction of S6.58(268) with the ligand pyran oxygen. The different 
orientation of cannabinoids attending to these structural modifications in the phenol was studied 
with ∆8-THC and Me-∆8-THC by Makriyannis and collaborators.71,160,161 Our results are consistent 
with the SAR of classical cannabinoids. Several studies have demonstrated that the conversion of the 
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C-1 phenolic hydroxyl of a classical cannabinoid, such as THC, to a methoxy group resulted in a 
CB2R-selective ligand.162–165
These observations may help to further explain affinities and selectivities of other compounds from 
our series. For instance, in the case of the N1-cyclohexyl chromenopyrazole 1.13, the decrease in 
CB1R affinity might be due to the low exposure of the phenolic oxygen electrons as a consequence 
of the steric volume created by the pyrazole substituent.  
Furthermore, these structural studies encouraged us to synthesize novel derivatives. At this point, 
we had only synthesized 1.41 of the isoxazole series. It is why, based on the above considerations, 
we underwent the synthesis of the O-methylated isoxazole 1.42 leading to a CB2R selective and 
potent ligand.  
3.1.5 ADME properties  
In silico physicochemical parameters 
Due to the high percentage of drug development failures associated to deficient ADME (absorption, 
distribution, metabolism, and excretion) properties, characterization of drug candidate compounds 
in this field gets increasingly important. Thus, it is necessary to obtain data at early stages of the 
discovery process. After administration, a drug is first carried through the blood stream by 
absorption, permeation and transport processes. Then, the distribution is crucial for the drug to 
reach a specific target in organ or tissue. Finally, the active drug is eliminated by metabolic processes 
and excreted.  
Pharmacokinetic properties of the newly synthesized CB2R ligands and of well-known cannabinoids 
such as 9-THC or CP55,940  have been calculated in silico using QikProp from Maestro Software. 
This program calculates a set of 34 physicochemical descriptors based on the global minimum 
energy conformer of each molecule. The rationale behind in silico approaches are the relatively lower 
cost and the time factor involved, when compared to experimental procedures.166,167
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The predicted data for these new compounds indicated that Lipinski and Jorgensen 
pharmacokinetics rules are followed (table 5).168,169 As displayed in table 5, the prediction of blood-
brain barrier permeability, human oral absorption and potassium channel characteristic of long QT 
syndrome suggests favorable druggability profile for all the chromenopyrazole derivatives. However, 
not all of them present aqueous solubility values within the ranges predicted by QikProp for 95% of 
known oral drugs. For instance, chromenopyrazoles bearing a bromoalkyl or a pyrano group 
(1.36−1.40) displayed high lipophilicity in silico values. Solubility issues are widely known for 
cannabinoids pharmacology because of their lipophilic nature.170,171 It is worth mentioning that 
chromenoisoxazoles and certain chromenopyrazoles displayed an improved solubility profile 
compared to classical cannabinoids such as 9-THC or CBN.
Thus, taking all pharmacological and ADME prediction data into consideration, the highly selective 
and potent CB2R agonist 1.42 may serve as lead structure for further optimizing this novel class of 
CB2R ligands not only with regard to potency but also regarding physicochemical properties. 
Table 5. Physicochemical descriptors calculated by QikProp 3.5 integrated in Maestro (Schrödinger, LLC, 
New York, USA)
Compd QPlogSa QlogBBb QPlogHERGc QPPCacod %Human  oral absorption GIe
1.13 -7.51 -0.20 -5.22 4875 100
1.14 -5.90 -0.43 -5.03 2902 100
1.15 -6.24 -0.02 -5.21 7394 100
1.16 -6.82 -0.10 -5.09 6647 100
1.17 -6.53 -0.01 -5.36 8211 100
1.27 -6.13 -1.13 -5.01 1117 100
1.28 -6.45 -0.71 -5.20 2864 100
1.29 -6.91 -0.52 -4.70 4414 100
1.30 -6.70 -0.69 -5.25 3348 100
1.33 -5.88 -0.84 -5.01 1838 100
1.34 -6.13 -0.19 -5.08 7112 100
1.35 -6.44 -0.18 -5.19 8327 100
1.36 -8.50 -0.03 -5.20 7495 100
1.37 -8.87 -0.01 -5.31 8810 100
1.38 -8.61 -0.02 -4.81 6647 100
1.39 -7.45 -0.06 -4.73 6357 100
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Binding to plasma proteins: SPR-biosensor analysis  
An important factor in this ADME process is the interaction with soluble proteins in plasma. In 
fact, the affinity of a drug toward plasma proteins directly affects bioavailability, tissue distribution, 
metabolism, clearance and toxicity. Accumulation of lipophilic drugs such as cannabinoids occurs in 
body fat resulting in higher concentration in fat than in plasma.171 However, the binding of these 
drugs to the plasma proteins is important for their distribution and transport to their biological 
targets. High concentrations of drugs in plasma will allow penetration in highly vascularized tissues. 
In this context, it was interesting to get information on the interactions between our 
chromenopyrazoles and the main plasma proteins. Human Serum Albumin (HSA) and α1-acid 
glycoprotein (AGP) are the most relevant plasma proteins playing critical roles in transporting drugs, 
metabolites and endogenous ligands.172–174 Therefore, binding towards HSA and AGP of 
representative CB2R ligands has been tested using surface plasmon resonance (SPR). Even though a 
wide variety of experimental assays have been used for this purpose,175,176 SPR has recently emerged 
as a very efficient method for measuring drug-plasma proteins binding.177 SPR is an optical 
technique utilized for detecting binding of a mobile molecule (cannabinoids) to a molecule 
immobilized on a thin metal film (HSA or AGP). SPR technology is based on a biosensor system 
characterized by label-free detection and real-time data acquisition.178–180  Detection of refractive 
1.40 -7.18 0.06 -5.24 8465 100
1.41 -5.64 -0.82 -4.92 1230 100
1.42 -5.31 -0.15 -4.77 4505 100
1.43 -5.90 -0.76 -5.11 2435 100
CBD -6.01 -0.44 -4.8 2693 100
CBN -6.50 -0.12 -5.21 4261 100
CP55,940 -6.10 -1.51 -5.20 642 100
THC -6.65 -0.09 -4.84 4564 100
aPredicted aqueous solubility [-6.5/0.5]; bPredicted log of the brain/blood partition coefficient [-3.0/1.2]; cHERG K+
Channel Blockage (log IC50) [concern below -5]; dApparent Caco-2 cell permeability in nm/s [<25 poor, >500 excellent]; 
eHuman Oral Absorption in GI [<25% is poor]; [range of 95% of drugs].
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index allows the detection of mass differences due to biomolecular interactions around the chip 
surface. The response signal is reported as resonance unit (RU).  
Figure 17. Plot of HSA binding levels determined by SPR for chromenopyrazoles (1.13, 1.15−1.17, 1.27, 1.30,
1.34−1.36, 1.38 and 1.40−1.42), cannabinoids SR141617, SR144528, WIN55212, HU308, CBD, 2AG, AEA 
and CP55,940 and the reference compounds (warfarin, dipiramidol, phenytoin, prednisone, sulfanilamide, and 
phenytoin) at 40 μM.  
In the present study, binding to HSA and AGP was determined by SPR–biosensor binding 
experiments using previously reported protocols.181 Drugs with different binding levels to HSA and 
AGP [Warfarin (HSA>AGP), phenytoin (HSA specific), dipiramidol (HSA=AGP), prednisone 
(HSA specific), and sulfanilamide (negative control for HSA/AGP] were used as controls. As this
experiments had not been previously reported in the literature for cannabinoids, different reference 
cannabinoid ligands (SR141617, SR144528, WIN55212, HU308, CBD, 2AG, AEA and CP55940) 
were also assessed for comparison. A representative set of chromenopyrazoles (1.13, 1.15−1.17, 1.27,
1.30, 1.34−1.36, 1.38 and 1.40−1.42) and reference compounds were evaluated for binding to HSA and 
AGP. The results are summarized in figure 17. Binding levels over 50 RU/Da indicate nonspecific 
interactions with HSA or AGP. 
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First of all, the binding responses collected for the reference HSA and AGP ligands (warfarin, 
phenytoin, dipiramidol, prednisone, and sulphanilamide) agreed with the well documented binding 
properties of these reference compounds. 
The tested reference cannabinoid ligands CBD, 2AG, and AEA showed very high binding levels to 
the plasma protein AGP, whereas CBD, 2AG, and CP55940 bound particularly to HSA. These high 
affinities are probably due to unspecific interactions. It has to be kept in mind that in general 
cannabinoids are very lipophilic compounds. SR141617 and WN55212-2 have a similar profile in 
this test with higher binding to HAS than AGP. Curiously, SR144528 and HU308 did not show 
significant affinity for both plasma proteins. Albeit no clear conclusion is attained from these 
results, intermediate to high plasma protein binding levels are coherent with the results observed 
regarding tissue and plasma in vivo distribution of cannabinoids171 Tested chromenopyrazoles 1.13,
1.15, 1.16, 1.38, 1.40 and 1.42 exhibited medium HSA and AGP binding levels suggesting a 
satisfactory free drug concentration in plasma. Compounds 1.17, 1.27, 1.35, 1.36 and 1.41 showed
very high plasma protein binding that could be interesting for potential in vivo retard effect.
For certain compounds, further SPR studies were attempted but the complexity of their binding 
kinetic sensograms did not lead to clear data. A possible multi binding sites occupancy of HSA or 
AGP has been suggested but the experimental and theoretical kinetic curves did not corroborate this 
fact. Direct analysis of interactions between cannabinoids and plasma proteins are difficult to 
interpret since most of cannabinoids are very lipophilic compounds producing unspecific binding.  
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3.2 Bivalent ligands for CB2Rs  
As commented in the introduction of this chapter, many GPCRs, cannabinoid receptors among 
them, can form physiologically interacting homo- or heterodimers.36,47,49,52 This oligomerization may 
affect receptor’s function, signal transduction or their interaction with drugs. The physiological 
relevance of such dimerization has not yet been fully established for CBRs whereas implication of 
some GPCRs homo- and heterodimers in different pathologies has already been reported in the 
literature.35,182
Within this field, bivalent ligands have emerged as promising new pharmacological entities and 
potential tools for the biological study of their respective dimeric receptors.34,35,183–185 Despite the 
challenges arising from their synthesis,184 bivalent ligands can exhibit enhanced activity and 
selectivity over their respective corresponding parent ligands185 offering unique strategies in drug 
development.  
Bivalent ligands have been synthesized and evaluated for several GPCRs. Opioid,186,187
dopamine188,189 or histamine190 are some of the receptors for which a bivalent compound provided 
higher activity than their monomer counterparts. CB1R homobivalent56–58 and heterobivalent191–193
ligands have been extensively reported and explored. However, in what concerns CB2Rs, there is 
only a very recent study in which the first bivalent compounds for have been designed and 
synthesized.194 Unfortunately, these molecules have largely lost activity and selectivity compared to 
the benzimidazole monomer.195 Thus, the functionality of the parent compound was CB2R agonist 
whereas the corresponding bivalent molecules showed to be weak antagonists/inverse agonists of 
CB1R and CB2R. Subsequently, the purpose of the following research is the identification of 
potential homobivalent ligands able to selectively activate CB2 receptors. 
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3.2.1 Design 
The bivalent ligand approach consists of bridging two pharmacophores in a single entity. In our 
case, the search of homobivalent ligands for CB2 receptors requires two identical recognition units 
covalently linked by the appropriate spacer.  
The first step for this design is the election of a CB2 selective pharmacophore as well as a suitable 
connecting position to place the linker without significantly disturbing CBR affinity and selectivity. 
The results observed on SAR in section 3.1 led us to choose the chromenopyrazole scaffold as 
monomer for this study. Position 9 of our heterocycle was chosen as attachment point for the linker 
regarding the previous data attained after phenolic alkylation. As methyl and ethyl pyrazole 
substituents furnished the best CB2 selectivity ratios in the monomeric chromenopyrazole series, 
they were selected for this bivalent approach (figure 24).  
Figure 24. Design of potential homobivalent ligands for CB2 cannabinoid receptors. 
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The lack of a theoretical or crystallographic structure for the dimeric CB2R complicates the selection 
of an appropriate spacer.196 The nature and the length of the linker is relevant and in most of cases 
crucial for biological activity.184,185 As reported for GPCRs bivalent ligands, optimal chain length 
varies from 5 to 8 atoms, which was the case for dopamine receptors,188,189 to 20 atoms, as described 
for H2 histamine receptor.190
Since there were no previous data on bivalent ligands for CB2R, the closest information is related to 
CB1R. Studies for CB1-μ opioid heteromers showed interesting data in vivo for a chain length of 20 
atoms.193 In what concerns CB1-CB1 receptors, suitable spacers seem to be shorter. The work 
performed by Thomas and coworkers56 indicated that the optimal chain length for CB1R 
homobivalent ligands is 15 atoms, while a study performed in our group revealed peak results for a 7 
atoms linker.58
Hydrophobic alkyl spacers were selected for our new CB2-CB2 compounds regarding the lack of 
affinity obtained with hydrophilic chains (polyethylene glycol or small peptide chains) for CB1R 
bivalent ligands.56,57,197
In a first approximation, alkyl chains containing from 10 to 16 methylenes have been considered as 
linkers. Additionally, the corresponding univalent compounds, 9-alkoxychromenopyrazoles, will be 
synthesized and evaluated in order to compare with their bivalent counterparts.  
3.2.2 Synthesis 
Bivalent chromenopyrazoles and their univalent analogs were synthesized as depicted in scheme 4 
starting from chromenopyrazoles 1.5b, 1.6a and 1.6b (synthetic route described in section 3.1.1). 
Preparation of 9-alkoxychromenopyrazoles (1.44−1.55) was achieved in high yields by 
deprotonation of the hydroxyl group with sodium hydride, followed by rapid addition of an excess 
of the appropriate 1-bromoalkane. For the formation of the bivalent compounds 1.56−1.67, the 
alkylation of the corresponding chromenopyrazoles with 0.5 equivalents of the desired 
dibromoalkane was not as easy as that of their univalent counterparts. Different bases were tested, 
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and finally cesium carbonate was selected and used under inert atmosphere. Thus, the desired 
bivalent compounds (1.56−1.67) were achieved with moderate yields. 
Scheme 4. Synthesis of 9-alkoxychromenopyrazoles 1.44−1.55 and bivalent chromenopyrazoles 1.56−1.67.
Reagents and conditions: (i) a) NaH, anhydrous THF, 10 min, b) 1-bromoalkane, reflux, 2-12 h, 32-90%; (ii)
a) Cs2CO3, anhydrous THF, 10 min, b) 1,(n+2)-dibromoalkane, reflux, 8-72 h, 17-59%. 
 
3.2.3 Cannabinoid binding studies 
Previous radioligand binding experiments revealed the ability of starting compounds 1.5b, 1.6a and 
1.6b to selectively bind to CB1R with high affinity in the nanomolar range.144 The newly synthesized 
uni- and bivalent chromenopyrazole derivatives were evaluated by using the same procedure (section 
3.1.2).  
As displayed in table 6, monovalent compounds 1.44−1.55, did not exhibit affinity towards CB1R 
nor CB2R. These results contrast with the CB2R affinity values obtained for chromenopyrazoles 
bearing a methoxy, bencyloxy or hydroxypropoxy groups (1.14−1.38). These observations allow us 
to conclude that elongation of the alkyl phenolic substituent at position 9 prevents CB2R binding. 
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In what concerns the bivalent compounds (1.56−1.67), most of them are CB2R selective ligands
displaying moderate affinity for this receptor but lacking of activity for CB1R type. The bivalent 
derivatives 1.57, 1.60, 1.61, 1.63 and 1.64 showed affinity in the submicromolar range for CB2R
whereas 1.56, 1.58, 1.59, 1.62 and 1.65−1.67 bind weakly to this receptor. These binding data suggest 
that the optimal linker length for this series is from 12 to 14 methylenes. The ethyl pyrazole 
substituent seems to be preferred among this series regardless the N1 or N2 position.
It is worthy to note that bivalent ligands display an improved CB2R binding profile compared to 
their univalent counterparts. These results are in agreement with the currently observed data for 
other GPCR bivalent ligands. However, to confirm how the presence of two pharmacophoric units 
affects CB2 affinity needs to be further explored. 
Table 6. Binding affinity of alkoxychromenopyrazoles (1.44−1.55) and bivalent chromenopyrazoles 
(1.56−1.67) for hCB1 and hCB2 cannabinoid receptors. 
Compd R1 nb CB1 Ki [µM]a CB2 Ki [µM]a
1.44 N2-Me 8 >40 >40
1.45 N1-Et 8 >40 >40
1.46 N2-Et 8 >40 >40
1.47 N2-Me 10 >40 32.3 ± 8.4
1.48 N1-Et 10 >40 >40
1.49 N2-Et 10 >40 >40
1.50 N2-Me 12 >40 >40
1.51 N1-Et 12 >40 >40
1.52 N2-Et 12 >40 >40
1.53 N2-Me 14 >40 >40
1.54 N1-Et 14 >40 >40
1.55 N2-Et 14 >40 >40
1.56 N2-Me 8 >40 3.47 ± 1.06
1.57 N1-Et 8 >40 0.91 ± 0.19 
1.58 N2-Et 8 >40 5.82 ± 1.46
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1.59 N2-Me 10 >40 10.21 ± 4.70 
1.60 N1-Et 10 >40 0.42 ± 0.14
1.61 N2-Et 10 >40 0.35 ± 0.02
1.62 N2-Me 12 >40 2.58 ± 0.18 
1.63 N1-Et 12 >40 0.84 ± 0.15
1.64 N2-Et 12 >40 0.28 ± 0.06
1.65 N2-Me 14 >40 17.4 ± 5.2
1.66 N1-Et 14 >40 >40
1.67 N2-Et 14 >40 2.12 ± 0.21
aValues obtained from competition curves using [3H]CP55940 as radioligand for hCB1 and hCB2 cannabinoid receptors and are 
expressed as the mean ± SEM of at least three experiments. bn represents the total length of the 9-alkoxy chain.
3.2.4 Functional assays  
Functional properties of our new molecules were investigated by cAMP assays using HEK293 cells 
stably expressing the human CB2R. Bivalent chromenopyrazoles showing submicromolar CB2R 
affinity (1.57, 1.60, 1.61, 1.63 and 1.64) were selected for appraisal. Likewise, their corresponding 
univalent derivatives (1.45, 1.48, 1.49, 1.51 and 1.52) were evaluated for comparison. 
Effects of compounds on forskolin-stimulated cAMP levels were determined in a preliminary 
screening at 200 nM. As shown in figure 25, compounds 1.57, 1.60 and 1.64 inhibit cAMP 
accumulation at tested concentration, what indicates their ability to activate this Gi/o-protein coupled 
receptor. Interestingly and according to binding data, the monovalent analogs did not significantly 
trigger changes in forskolin-stimulated cAMP levels. Unexpectedly, the univalent compound 1.49 
facilitated cAMP production suggesting an inverse agonist profile. 
In addition, cAMP assays were performed in non-transfected HEK293 cells at the same 
concentration (200 nM). As displayed in figure 25, both series, monovalent and bivalent, as well as 
the reference agonist CP55,940, did not exert effect in this cell line. Therefore, these experiments 
allowed us to confirm that the results obtained in HEK293-CB2 cells were fully mediated by CB2R. 
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Figure 25. cAMP screening of novel compounds in HEK293 cells stably expressing the human CB2 receptor 
subtype (A) and normal HEK293 cells (B). Results are expressed as percent of forskolin-stimulated cAMP 
accumulation at a concentration of 200 nM of our compounds and the reference cannabinoid CP55,940. All 
data result from at least three independent experiments, performed in triplicates. 
Dose-response curves of bivalent chromenopyrazoles 1.57, 1.60 and 1.64 were performed to 
determine their activity at CB2R. As display in table 7, these compounds are CB2R selective agonists
exhibiting potency and efficacy in the nanomolar range.
Table 7. Functional potencies of compounds 1.57, 1.60 and 1.64 and the reference cannabinoids CP55,940 
and JWH133 at CB2 receptor determined by measuring the decrease in forskolin-stimulated cAMP levels in 
HEK293-CB2R cells.
Compd R1 n CB2 cAMP assays
aEC50 (nM) bEmax (%)
1.57 N1-Et 8 85.8 ± 22.1 124 ± 15
1.60 N1-Et 10 43.2 ± 21.6 133 ± 14
1.64 N2-Et 12 501.2 ± 22.8 98 ± 8
CP55,940 - - 8.3 ± 1.5 106 ± 9
JWH133 - - 81.8 ± 1.7 98 ± 11
aEC50 values were calculated using nonlinear regression analysis. Data are expressed as the mean ± SEM of at least three 
independent experiments performed in triplicates. bForskolin stimulated cAMP levels were normalized to 100%. Emax is the 
maximum inhibition of forskolin stimulated cAMP levels.
Results attained from this study indicate that for the chromenopyrazole scaffold, bivalency has a 
positive effect on CB2 receptor activity. Moreover, in this cell line, CB2-CB2 dimers have been 
recently identified by our collaborators (Rafael Franco and Gemma Navarro, University of 
Barcelona). By employing FRET and BRET techniques they have demonstrated the presence of 
(B)(A)
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these homodimers in HEK293 cells stably expressing the human CB2R (data not published yet).
Nonetheless, it remains to be determined if the activity of our bivalent ligands is due to the 
interaction with homodimers or if both pharmacophores bind to monomeric CB2 receptors. 
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4. Discussion and conclusions
From CB1R towards CB2R selectivity 
The implication of CBRs in a variety of physiopathological processes highlights their potential in the 
management of a broad range of diseases. Since CB1R is associated with psychotropic effects when 
acting on the CNS, the therapeutic applications of CB1R ligands or non-selective cannabinoids are 
limited. Therefore, different strategies, such as the use of peripherally restricted CB1R or selective 
CB2R ligands, need to be developed. Previous work in our research group allowed the discovery of 
new non-psychoactive CB1R ligands with peripheral analgesic properties.144 Using this scaffold, we 
proposed different structural modifications attempting to develop novel CB2R selective ligands. Our 
optimization efforts kept the 1,1-dimethylheptyl group as the lipophilic chain necessary for activity 
and focused on surveying the pyrazole and phenol substitutions, on a conformational restricted 
analogue, and on replacing the pyrazole core of the scaffold by an isoxazole. The compounds were 
prepared following a 4- to 6- steps synthesis in moderate to high yields. 
The pharmacological profile of the synthesized compounds was evaluated by radioligand binding 
assays for CBRs affinity, and by forskolin-stimulated cAMP and GTPγS binding experiments for 
functionality at CBRs.
Interestingly, fine-tuning of affinity and selectivity was achieved. In terms of receptor selectivity, 
phenol substitution played a key role. CB2R selectivity was achieved when the phenol of the 
chromenopyrazoles was alkylated (1.151.17, 1.221.24, 1.281.30, and 1.341.38), whereas 
unsubstituted phenols (1.41.8) led to CB1R selective compounds. An interesting finding is the 
bioisosteric replacement of the pyrazole by an isoxazole that resulted in the most potent and 
selective CB2R ligand (1.42). The affinity of the chromenopyrazoles derivatives for CBRs depended 
on the nature of the pyrazole substitution but not on its N1 or N2 position. In general, the alkyl 
groups showed better affinity for CB1R or/and CB2R compared to aryl substituents (except 1.8). 
The conformational restricted strategy (1.38, 1.40) did not improve CBR affinity. 
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At functional level, most of the tested CB2R ligands revealed to be agonists being the 
chromenopyrazoles 1.33 and the chromenoisoxazoles 1.40−1.43 the most potent compounds. Three 
of the CB2R ligands (1.15, 1.30 and 1.34) showed antagonistic properties. 
Structural modifications on the phenolic hydroxyl group of classical cannabinoids leading to partial 
CB2R selectivity have been reported.162–165 However, to our knowledge, there is no molecular model 
that rationally explains the structural features and the interactions triggering this selectivity in the 
cannabinoid receptor models. Given the interesting results obtained for the novel 
chromenopyrazoles and chromenoisoxazoles, exploration of the binding site interactions was 
conducted through docking studies of selected derivatives (1.4, 1.41, 1.17, and 1.6b) in CB1R and 
CB2R active state molecular models. These studies confirmed that the phenolic lone pair (1.4, 1.6b
and 1.41) is crucial for binding affinity to CB1R* through lysine K3.28(192) main interaction, 
whereas, O-methylation (1.17) generates steric hindrance in this receptor type. Regarding the 
CB2R*/ligand complexes, serine S6.58(268) seems to play an important role in the binding site of 
our compounds. Previous studies suggested the interaction of this serine in the AM851/CB2R* 
binding pocket.156 Furthermore, in the 1.41/CB2R* complex we propose that the isoxazole nitrogen
establishes a hydrogen bond with lysine K3.28(109). The importance of this residue has also been 
recently confirmed in parallel studies performed in Patricia Reggio’s group on 1,8-naphthyridin-
2(1H)-one-3-carboxamides.91 Therefore, the different ligand-receptor interactions that have been 
studied provide detailed structural information identifying the key molecular features required for 
CB1R and/or CB2R affinity and selectivity.
In silico predicted pharmacokinetic (ADME) properties suggest favorable druggability profile for the 
new CB2R ligands. Moreover, chromenoisoxazoles and certain chromenopyrazoles displayed 
improved solubility profile compared to classical cannabinoids such as 9-THC or CBN. 
Other pharmacokinetic parameters that have been evaluated by SPR–biosensor binding experiments 
concerned interactions between cannabinoids and plasma proteins HSA and AGP. However, direct 
interactions analysis of the tested compounds along with reference cannabinoids were difficult to 
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interpret since most of cannabinoids are very lipophilic compounds and produced unspecific 
binding.  
Despite the research efforts currently directed to the development of CB2R selective ligands, most 
of these compounds exhibit CB1R mediated side effects at high doses. Consequently, the fully 
selective and potent CB2R agonist 1.42 discovered herein is a very interesting lead compound for 
further research. In fact, this chromenoisoxazole has shown a neuroprotective profile in an in in vitro
neuroinflammatory model realized in M213 neurons.198 The isoxazole 1.42 is currently being studied 
in an in vivo model of Huntington´s disease generated by stereotaxic lesions with malonate. 
Preliminary magnetic resonance imaging (MRI) analysis shows that 1.42 administration decreased 
the striatal lesion volume caused by malonate. Overall, the chromenoisoxazole 1.42 that does not 
cause CB1R-mediated psychotropic effects has a promising neuroprotective profile. Therefore, 1.42
could be useful for those neurodegenerative pathologies in which the activation of CB2R may have 
therapeutic value. 
Bivelent ligands for CB2Rs 
Continuing with our research project and regarding the increasing experimental data suggesting the 
importance of CBRs dimers, we decided to design a series of CB2R homobivalent ligands as the 
second aim of this chapter.  CB2R homodimers have been identified in different tissues; however, 
they have not been properly described, characterized and their pharmacological potential has not 
been explored. In this scenario, bivalent compounds may serve as pharmacological tools to study 
CB2R dimerization as well as its functional significance. Thus, following with the chromenopyrazole 
scaffold, molecules in which two pharmacophoric entities are linked by alkyl chains (10 to 16 
methylenes) through the phenolic positions were synthesized. Their respective univalent 9-
alkoxychromenopyrazole analogs were prepared to study the influence of bivalency on binding 
studies. Homobivalent compounds displayed CB2R affinity with total selectivity over CB1R being the 
12 and 14-atoms linkers optimal for binding. It is worthy to note that their corresponding univalent 
analogues did not display affinity for CB1R or CB2R suggesting a possible interaction of both 
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pharmacophores with CB2R. Thus, the second pharmacophore unit seems to play a role in the 
binding that needs to be determined. At that point, two binding modes could be considered. The 
bivalent ligand can interact with the two orthosteric binding sites of two adjacent protomers 
simultaneously or it can target the orthosteric and an allosteric binding sites of the same receptor.184
Both modes of binding evoke positive cooperativity. 
Functional cAMP experiments confirmed that the CB2R bivalent ligands (1.57, 1.60 and 1.64) are 
able to activate CB2R. Additionally, the presence of CB2R homodimers in the hCB2R-HEK293 cells 
used for functional assays has been confirmed by FRET and BRET techniques. This data might 
support the hypothesis of an interaction of a bivalent ligand with two orthosteric binding sites of 
two adjacent protomers. Of course, this needs to be confirmed by additional and complementary 
experiments. To our knowledge, these are the first homobivalent ligands able to selectively activate 
CB2R. Albeit more research is clearly needed to study their mechanism, these novel compounds 
might be helpful tools for designing bivalent probes to investigate CB2R homodimers as well as to 
explore new options in drug development.
Taking all these data together, in this chapter we showed that the chromenopyrazole heterocycle 
represents a versatile cannabinoid scaffold with a high potential for the development of CB2R 
ligands. 
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5. Experimental section 
Chemistry 
General methods and materials. Reagents and solvents were purchased from Sigma-Aldrich Co., 
Fluorochem, Acros Organics, Manchester Organics and Lab-Scan and were used without further 
purification or drying. Silica gel 60 F254 (0.2 mm) thin layer plates were purchased from Merck 
GmbH. Microwave assisted organic synthesis was performed using the microwave reactor Biotage 
Initiator. Products were purified using flash column chromatography (Merck Silica gel 60, 230-400 
mesh) or medium pressure chromatography using Biotage Isolera One with pre-packed silica gel 
columns (Biotage SNAP cartridges). The compounds were characterized by a combination of NMR 
experiments, HPLC-MS, high-resolution mass spectrometry (HRMS) and elemental analysis. HPLC-
MS analysis was performed on a Waters 2695 HPLC system equipped with a photodiode array 2996 
coupled to Micromass ZQ 2000 mass spectrometer (ESI-MS), using a reverse-phase column 
SunFireTM (C-18, 4.6 x 50 mm, 3.5 μm) in a 10 min gradient A: CH3CN/0.1% formic acid, B: 
H2O/0.1% formic acid visualizing at λ = 254 nm. Flow rate was 1 mL/min.  Elemental analyses of 
the compounds were performed using a LECO CHNS-932 apparatus. Deviations of the elemental 
analysis results from the calculated are within ± 0.4%. The purity of compounds 1.44−1.67 was 
determined by LC coupled to HRMS. The experiments were performed in a LC-MS hybrid 
quadrupole/time of flight (QTOF) analyzer equipped with an Agilent 1200 LC coupled to an 
Agilent 6500 Accurate Mass (1-2 ppm mass accuracy) using electrospray ionization in the positive 
mode (ESI+). 1H, 13C, HSQC and HMBC-NMR spectra were recorded on a Bruker 300 (300 and 75 
MHz), or a Varian 500 (500 and 126 MHz) at 25 °C. Samples were prepared as solutions in 
deuterated solvent and referenced to internal non-deuterated solvent peak. Chemical shifts were 
expressed in ppm (δ) downfield of tetramethylsilane. Coupling constants are given in hertzs (Hz). 
Melting points were measured on a MP 70 Mettler Toledo apparatus.  
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5-(1,1-Dimethylheptyl)-1,3-dihydroxybenzene (1.1).199
To a solution of 5-(1,1-dimethylheptyl)-1,3-dimethoxybenzene (0.45 g, 1.90 mmol) in dry CH2Cl2 (9 
mL) was added boron tribromide (1M in CH2Cl2) (19 mL, 19 mmol)  at 0 °C under nitrogen 
atmosphere. The reaction mixture was allowed to warm to room temperature and was stirred 
overnight. After reaction completion, MeOH was carefully added (until pH = 7). The solvent was 
removed under vacuum and the crude was purified by chromatography on silica gel (EtOAc) to 
afford the title compound as a white solid (0.37 g, 92%); mp: 88–91 ºC (98 ºC);199 1H-NMR (300 
MHz, CDCl3) δ: 6.35–6.45 (m, 2H, 4-H), 6.16–6.11 (m, 1H, 2-
H), 4.65–4.62 (br s, 2H, OH), 1.45–1.50 (m, 2H, 2´-H), 1.22 
(s, 6H, C(CH3)2), 1.21–1.10 (m, 6H, 3´-H, 4´-H, 5´-H,), 1.03–
0.99 (br s, 2H, 6´-H), 0.84 ppm (t, J = 6.5 Hz, 3H, CH3); 13C-NMR (75 MHz, CDCl3) δ: 163.2 (3-C), 
154.0 (5-C), 111.2 (4-C), 101.3 (2-C)), 45.0 (2´-C), 35.3, 31.1, 23.9 (3´-C, 4´-C, 5´-C) , 29.8 (8´-C), 
25.1 (6´-C), 14.8 ppm (7´-C); HPLC-MS: [A, 80→95%], tR: 1.19 min, (96%); MS (ES+, m/z) 237 
[M+H]+; Anal. calcd. for C15H24O2: C 76.23, H 10.24, found: C 76.11, H 10.18.
7-(1,1-Dimethylheptyl)-5-hydroxy-2,2-dimethylchroman-4-one (1.2). 
5-(1,1-Dimethylheptyl)resorcinol (2.50 g, 10.59 mmol) and 3,3-dimethylacrylic acid (1.59 g, 15.88 
mmol) both dissolved in methanesulfonic acid (16 mL, 0.24 mmol) were added to P2O5 (1.20 g, 8.81 
mmol) under nitrogen atmosphere. Then, the reaction 
mixture was stirred 8 h at 70 ºC. Afterwards, water was 
added (50 mL) and the product was extracted with EtOAc (3 
x 50 mL). The combined organic layers were dried over MgSO4. The organic solvent was evaporated 
under reduced pressure and the crude was purified by column chromatography on silica gel 
(hexane/EtOAc, 5:1), obtaining the desired compound as a pale yellow solid (2.77 g, 81%), mp: 50–
52 ºC (lit: oil); 1H-NMR (300 MHz, CDCl3) δ: 11.53 (s, 1H, OH), 6.45 (d, J = 1.6 Hz, 1H, 6-H), 6.37 
(d, J = 1.6 Hz, 1H, 8-H), 2.71 (s, 2H, 3-H), 1.60–1.49 (m, 2H, 2’-H), 1.47 (s, 6H, OC(CH3)2), 1.22 (s, 
6H, C(CH3)2), 1.23–1.17 (m, 6H, 3’-H, 4’-H, 5’-H), 1.11–0.94 (m, 2H, 6’-H) 0.84 ppm (t, J = 6.6 Hz, 
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3H, 7’-H); 13C-NMR (75 MHz, CDCl3) δ: 197.4 (4-C), 162.6 (7-C), 161.3 (5-C), 159.5 (8a-C), 106.6 
(6-C), 105.7 (8-C), 105.3 (4a-C), 78.9 (2-C), 48.1 (3-C), 44.0 (2’-C), 38.7 (1’-C), 31.7, 29.9, 22.6 (3’-C, 
4’-C, 5’-C), 28.4 (C(CH3)2), 26.7 (OC(CH3)2), 24.6 (6’-C), 14.0 ppm (7’-C); HPLC-MS: [A, 80→95%], 
tR: 4.94 min, (95%); MS (ES+, m/z) 319 [M + H]+; Anal. calcd. for C20H30O3: C 75.43, H 9.50, found: 
C 75.52, H 9.64.
7-(1,1-Dimethylheptyl)-5-hydroxy-3-hydrodymethylene-2,2-dimethylchroman-4-one (1.3).  
A solution of 1.2 (0.40 g, 1.25 mmol) in anhydrous THF (8 mL) was added to a vial containing dry 
sodium hydride (0.30 g, 12.57 mmol) under nitrogen atmosphere. The mixture was irradiated under 
microwave at 45 ºC for 25 minutes. Subsequently, ethyl 
formate (2.88 mL, 37.70 mmol) was added to the sealed vial 
and it was irradiated under microwave at 45 ºC for 25 
minutes. Water was added and the product was extracted with 
EtOAc (3 x 5 mL). The combined organic layers were dried over MgSO4 and the solvent was 
evaporated under reduced pressure. The crude was purified by column chromatography on silica gel 
(hexane/EtOAc, 4:1), to afford compound 1.3 as a yellow oil (0.33 g, 76%); 1H-NMR (300 MHz, 
CDCl3) δ: 13.49 (d, J = 11.7 Hz, 1H, CHOH), 11.28 (s, 1H, 5-OH), 7.34 (d, J = 11.7 Hz, 1H, 
CHOH), 6.47 (d, J = 1.6 Hz, 1H, 6-H), 6.36 (d, J = 1.6 Hz, 1H, 8-H), 1.58 (s, 6H, OC(CH3)2), 1.56–
1.46 (m, 2H, 2’-H), 1.22 (s, 6H, C(CH3)2), 1.14–1.28 (m, 6H, 3’-H, 4’-H, 5’-H), 1.10–1.04 (m, 2H, 6’-
H), 0.84 ppm (t, J = 6.5 Hz, 3H, 7’-H); 13C-NMR (75 MHz, CDCl3) δ: 189.4 (4-C), 162.7 (7-C), 161.6 
(5-C), 161.5 (CHOH), 158.7 (8a-C), 114.4 (3-C), 107.4 (6-C), 106.2 (8-C), 104.9 (4a-C), 78.3 (2-C), 
44.4 (2’-C), 38.8 (1’-C), 31.7, 29.9, 22.6 (3’-C, 4’-C, 5’-C), 28.4 (C(CH3)2), 28.2 (OC(CH3)2), 24.6 (6’-
C), 14.1 ppm (7’-C); HPLC-MS: [A, 80→95%], tR: 2.88 min, (97%); MS (ES+, m/z) 347 [M + H]+; 
Anal. calcd. for C21H30O4: C 72.80, H 8.73, found: C 73.07, H 8.64.
7-(1,1-Dimethylheptyl)-2,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-ol (1.4).
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A solution of 1.3 (0.50 g, 1.44 mmol) and anhydrous hydrazine (0.11 mL, 3.61 mmol) in EtOH (9
mL) was stirred during 4 h at 40 ºC. The solvent was evaporated under reduced pressure and the 
crude was purified by column chromatography on silica gel (hexane/EtOAc, 2:1) to furnish  1.4 as a
yellow oil (0.40 g, 81%); 1H-NMR (300 MHz, CDCl3) δ: 7.32–7.29 (br s, 1H, NH), 6.58 (d, J = 1.5 
Hz, 1H, 6-H), 6.51 (d, J = 1.5 Hz, 8-H), 6.48 (s, 1H, 3-H), 1.63 (s, 6H, OC(CH3)2), 1.58-1.52 (m, 2H, 
2´-H), 1.25 (s, 6H, C(CH3)2), 1.18 (s, 6H, 3´-H, 4´-H, 5´-H), 
1.12–1.05 (m, 2H, 6´-H), 0.83 ppm (t, J = 6.7 Hz, 3H, 7´-H); 
13C-NMR (75 MHz, CDCl3) δ: 153.7 (9-C), 153.5 (5a-C), 153.4 
(7-C), 144.1 (9b-C), 129.1 (3-C), 123.4 (3a-C), 106.8 (8-C), 106.5 (6-C), 101.7 (9a-C), 77.0 
(OC(CH3)2), 44.9 (2´-C), 38.4 (C(CH3)2), 32.2, 30.4, 30.0 (3´-C, 4´-C, 5´-C), 29.3 (C(CH3)2), 25.0 
(OC(CH3)2), 23.1 (6´-C), 14.5 ppm (7´-C); HPLC-MS: [A, 80→95%], tR: 3.80 min, (98%); MS (ES+, 
m/z) 343 [M+H]+; Anal. calcd. for C21H30N2O2: C 73.65, H 8.83, found: C 74.01, H, 8.59.
7-(1,1-Dimethylheptyl)-1,4-dihydro-1,4,4-trimethylchromeno[4,3-c]pyrazol-9-ol (1.5a) and 7-
(1,1-dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-c]pyrazol-9-ol (1.5b).  
Compounds 1.5a and 1.5b were obtained from 1.3 (1.19 g, 3.40 mmol) using methylhydrazine (0.63 
g, 13.60 mmol) and following the procedure described for 
1.4. Column chromatography on silica gel (hexane/EtOAc, 
3:1) afforded both regioisomers. Compound 1.5a was 
obtained as a yellow solid (24 mg, 2%), mp: 93–95 ºC; 1H-
NMR (300 MHz, CDCl3) δ: 7.68–7.64 (br s, 1H, OH), 7.32 (s, 1H, 3-H), 6.61 (d, J = 1.8 Hz, 1H, 8-
H), 6.50 (d, J= 1.8 Hz, 1H, 6-H), 4.18 (s, 3H, NCH3), 1.57 (s, 6H, OC(CH3)2), 1.49–1.45 (m, 2H, 2’-
H), 1.24 (s, 6H, C(CH3)2), 1.18-1.12 (m, 6H, 4’-H, 5’-H, 6’-H), 1.05–1.01 (m, 2H, 3’-H), 0.83 ppm (t, 
J = 6.4 Hz, 3H, 7’-H); 13C-NMR (75 MHz, CDCl3) δ: 154.2 (9-C), 152.8 (7-C), 150.7 (5a-C), 133.3 
(9b-C), 131.6 (3-C), 123.1 (3a-C), 108.6 (8-C), 107.5 (6-C), 102.7 (9a-C), 76.5 (OC(CH3)2), 44.4 
(NCH3), 41.0 (2’-C), 37.8 (C(CH3)2), 31.8, 30.0, 22.6 (3’-C, 4’-C, 5’-C), 28.7 (C(CH3)2), 27.3 
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(OC(CH3)2), 24.6 (6’-C), 14.1 ppm (7’-C); HPLC-MS: [A, 80→95%], tR: 2.63 min, (98%); MS (ES+, 
m/z) 357 [M + H]+. 
Compound 1.5b was obtained as a yellow oil (0.90 g, 74%); 1H-NMR (300 MHz, CDCl3) δ: 8.24 (s, 
1H, OH), 7.09 (s, 1H, 3-H), 6.58 (d, J = 1.7 Hz, 1H, 8-H), 6.48 (d, J = 1.7 Hz, 1H, 6-H), 3.89 (s, 3H, 
NCH3), 1.60 (s, 6H, OC(CH3)2), 1.59–1.46 (m, 2H, 2’-H), 
1.25 (s, 6H, C(CH3)2), 1.21–1.15 (m, 6H, 3’-H, 4’-H, ’-H), 
1.11–1.03 (m, 2H, 6’-H), 0.83  ppm (t, J = 6.7 Hz, 3H, 7’-H); 
13C-NMR (75 MHz, CDCl3) δ: 153.2 (9-C), 152.8 (7-C), 
152.6 (5a-C), 142.5 (9b-C), 124.0 (3-C), 120.3 (3a-C), 106.5 (6-C), 106.3 (8-C), 101.2 (9a-C), 76.6 
(OC(CH3)2), 45.5 (NCH3), 38.8 (2’-C), 38.0 (C(CH3)2), 31.8, 30.0, 22.6 (3’-C, 4’-C, 5’-C), 29.7 
(OC(CH3)2), 28.9 (C(CH3)2), 24.6 (6’-C), 14.0 ppm (7’-C); HPLC-MS: [A, 80→95%], tR: 5.19 min, 
(99%); MS (ES+, m/z) 357 [M + H]+; Anal. calcd. for C22H32N2O2: C 74.12, H 9.05, found: C 74.30, 
H, 9.38.
7-(1,1-Dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-ol (1.6a) 
and 7-(1,1-dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-ol 
(1.6b).  
Prepared from 1.3 (0.80 g, 2.31 mmol) and ethylhydrazine oxalate (1.21 g, 8.09 mmol) by following 
the procedure described for 1.4. Column chromatography on silica gel (hexane/EtOAc, 2:1) allowed 
isolation of the two isomers. Compound 1.6a was obtained as 
a pale-yellow solid (0.42 g, 52%), mp: 129–131 ºC; 1H-NMR 
(300 MHz, CDCl3) δ: 8.37–8.31 (br s, 1H, OH), 7.39 (s, 1H, 
3-H), 6.61 (d, J = 1.7 Hz, 1H, 8-H), 6.55 (d, J= 1.7 Hz, 1H, 6-
H), 4.68 (q, J = 7.0 Hz, 2H, NCH2CH3), 1.58 (s, 6H, OC(CH3)2), 1.52 (m, 2H, 2’-H), 1.45 (t, J = 7.0 
Hz, 3H, NCH2CH3), 1.24 (s, 6H, C(CH3)2), 1.21–1.12 (m, 6H, 3’-H, 4’-H, 5’-H), 1.08–1.03 (m, 2H, 
6’-H), 0.83 ppm (t, J = 6.6 Hz, 3H, 7’-H); 13C-NMR (75 MHz, CDCl3) δ: 154.3 (9-C), 152.7 (7-C), 
151.7 (5a-C), 132.7 (9b-C), 131.8 (3-C), 123.0 (3a-C), 108.5 (8-C), 107.5 (6-C), 102.8 (9a-C), 76.3 
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(OC(CH3)2), 48.0 (NCH2CH3), 44.4 (2’-C), 37.8 (C(CH3)2), 31.7, 30.0, 22.6 (3’-C, 4’-C, 5’-C), 28.6 
(C(CH3)2), 27.3 (OC(CH3)2), 24.6 (6’-C), 16.0 (NCH2CH3), 14.0 ppm (7’-C); HPLC-MS: [A, 
80→95%], tR: 2.88 min, (98%); MS (ES+, m/z) 371 [M + H]+; Anal. calcd for C23H34N2O2: C 74.55, 
H 9.25, found: C 74.63, H 9.19.
Compound 1.6b was obtained as a yellow oil (0.23 g, 28%); 1H-NMR (300 MHz, CDCl3) δ: 8.32 (s, 
1H, OH), 7.16 (s, 1H, 3-H), 6.57 (d, J = 1.7 Hz, 1H, 8-H), 6.48 (d, J = 1.6 Hz, 1H, 6-H), 4.16 (q, J = 
7.2 Hz, 2H, NCH2CH3), 1.61 (s, 6H, OC(CH3)2), 1.59–1.54 (m, 
2H, 2’-H), 1.51 (t, J = 7.2 Hz, 3H, NCH2CH3), 1.25 (s, 6H, 
C(CH3)2), 1.20–1.16 (m, 6H, 3’-H, 4’-H, 5’-H), 1.12–0.99 (m, 
2H, 6’-H), 0.83 ppm (t, J = 6.8 Hz, 3H, 7’-H); 13C-NMR (75 
MHz, CDCl3) δ: 153.2 (9-C), 152.8 (7-C), 152.5 (5a-C), 142.3 (9b-C), 122.4 (3-C), 119.9 (3a-C), 106.5 
(6-C), 106.3 (8-C), 101.3 (9a-C), 76.8 (OC(CH3)2), 47.0 (NCH2CH3), 44.5 (2’-C), 38.0 (C(CH3)2), 31.8, 
30.0, 22.7 (3’-C, 4’-C, 5’-C), 29.7 (OC(CH3)2), 28.9 (C(CH3)2), 24.6 (6’-C), 15.5 (NCH2CH3), 14.1 
ppm (7’-C); HPLC-MS: [A, 80→95%], tR: 5.84 min, (97%); MS (ES+, m/z) 371 [M + H]+; Anal. calcd 
for C23H34N2O2 : C 74.55, H 9.25, found: C 74.23, H 9.41.
1-(3,4-Dichlorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazol-9-ol (1.7). 
Prepared from 1.3 (17 mg, 0.05 mmol) and 3,4-
dichlorophenylhydrazine hydrochloride (10 mg, 0.05 mmol) 
following the procedure described for 1.4. Column 
chromatography on silica gel (hexane/EtOAc, 2:1) afforded 1.7 
as an orange solid (9 mg, 40%); mp: 124–126 ºC; 1H-NMR (300 
MHz, CDCl3) δ: 7.65 (d, J = 2.3 Hz, 1H, 2-HPh), 7.50 (s, 1H, 3-H), 7.43 (d, J = 8.5 Hz, 1H, 5-HPh), 
7.25 (dd, J = 2.3 Hz, J = 8.5 Hz, 1H, 6-HPh), 6.66 (d, J = 1.6 Hz, 1H, 6-H), 6.24 (d, J = 1.6 Hz, 1H, 
8-H), 1.68 (s, 6H, OC(CH3)2), 1.60–1.54 (m, 2H, 2´-H), 1.22 (s, 6H, C(CH3)2), 1.20–1.09 (m, 6H, 3´-
H, 4´-H and 5´-H), 1.08–1.02 (m, 2H, 6´-H), 0.84 ppm (t, J = 6.5 Hz, 3H, 7´-H); 13C-NMR (75 
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MHz, CDCl3) δ: 154.6 (9-C), 154.0 (5a-C), 150.0 (7-C), 142.3 (1-CPh), 135.3 (3-C), 133.2 (3-CPh), 
132.2 (9b-C), 130.4 (4-CPh), 126.5 (5-CPh), 125.4 (2-CPh), 123.9 (6-CPh), 122.7 (3a-C), 109.6 (6-C), 
108.0 (8-C), 102.4 (9a-C), 76.2 (OC(CH3)2), 44.7 (2´-C), 38.3 (C(CH3)2), 32.1, 30.3, 25.0 (3´-C, 4´-C, 
5´-C), 28.9 (C(CH3)2), 27.7 (OC(CH3)2, 23.0 (6´-C), 14.5 ppm (7´-C); HPLC-MS: [A, 80%→95%], tR:
5.35 min, (98%); MS (ES+, m/z) 487 [M+H]+; Anal. calcd for C27H32Cl2N2O2: C 66.53, H 6.62, 
found: C 66.30, H 6.58.
1-(2,4-Dichlorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazol-9-ol (1.8).
Prepared from 1.3 (50 mg, 0.16 mmol) and 2,4-dichlorophenylhydrazine hydrochloride (0.13 g, 0.63 
mmol) following the procedure described for 1.4. Column chromatography on silica gel 
(hexane/EtOAc, 2:1) afforded 1.8 as an orange oil (52 mg, 
75%); 1H-NMR (300 MHz, CDCl3) δ: 7.43 (s, 1H, 3-H), 7.39 (d, 
J = 2.2 Hz, 1H, 3-HPh), 7.27 (dd, J = 2.2 Hz, J = 8.7 Hz, 1H, 5-
HPh), 7.21 (d, J = 8.7 Hz, 1H, 6-HPh), 6.56 (d, J = 1.6 Hz, 1H, 6-
H), 6.12 (d, J = 1.6 Hz, 1H, 8-H), 1.64 (s, 6H, OC(CH3)2), 1.46–1.41 (m, 2H, 2´-H), 1.16–1.08 (m, 
12H, 3´-H, 4´-H, 5´-H, C(CH3)2), 1.12–0.98 (m, 2H, 6´-H), 0.82 ppm (t, J = 6.9 Hz, 3H, 7´-H); 13C-
NMR (75 MHz, CDCl3) δ: 154.3 (9-C), 153.6 (5a-C), 151.3 (7-C), 140.3 (1-CPh), 135.3 (2-CPh), 135.0 
(4-CPh) , 134.4 (3-C), 133.0 (9b-C), 129.8 (3-CPh), 129.6 (5-CPh), 127.3 (6-CPh), 123.4 (3a-C), 108.8 (6-
C), 107.6 (8-C), 102.6 (9a-C), 77.6 (OC(CH3)2), 44.7 (2´-C), 39.1 (C(CH3)2), 32.1 , 30.3, 24.9 (3´-C, 4´-
C, 5´-C), 28.9 (C(CH3)2), 28.0 (OC(CH3)2), 23.0 (6´-C), 14.5 ppm (7´-C); HPLC-MS: [A, 80→95%], 
tR: 4.70 min, (99%); MS (ES+, m/z) 487 [M+H]+. Anal. calcd for C27H32Cl2N2O2: C 66.53, H 6.62, 
found: C 66.91, H 6.41.
7-(1,1-Dimethylheptyl)-1,4-dihydro-1-(2-hydroxyethyl)-4,4-dimethylchromeno[4,3-c]pyrazol-
9-ol (1.9a) and 7-(1,1-dimethylheptyl)-2,4-dihydro-2-(2-hydroxyethyl)-4,4-
dimethylchromeno[4,3-c]pyrazol-9-ol (1.9b).
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Prepared from 1.3 (40 mg, 0.11 mmol) and 2-hydroxyethylhydrazine (15.64 μL, 0.23 mmol) by 
following the procedure described for 1.4. Column chromatography on silica gel (hexane/EtOAc, 
2:3) allowed isolation of the two isomers. Compound 1.9a was obtained as a white oil (10 mg, 23%); 
1H-NMR (300 MHz, CDCl3) δ: 8.15 (s, 1H, 9-OH), 7.30 (s, 1H, 3-H), 6.62 (d, J = 1.6 Hz, 1H, 8-H), 
6.53 (d, J = 1.6 Hz, 1H, 6-H), 4.29 (t, J = 5.7 Hz, 2H, NCH2CH2OH), 4.10–4.03 (m, 2H, 
NCH2CH2OH), 1.65 (s, 6H, OC(CH3)2), 1.62–1.52 (m, 2H, 2’-H), 1.28 (s, 6H, C(CH3)2), 1.25–1.17 
(m, 6H, 3’-H, 4’-H, 5’-H), 1.16–1.00 (m, 2H, 6’-H), 0.87 ppm (t, J = 6.6 Hz, 3H, 7’-H); 13C-NMR (75 
MHz, CDCl3) δ: 152.9 (9-C), 152.6 (7-C), 152.4 (5a-C), 143.0 
(9b-C), 124.2 (3-C), 120.0 (3a-C), 106.4 (8-C), 106.1 (6-C),
100.8 (9a-C), 76.1 (OC(CH3)2), 61.4 (NCH2CH2OH), 54.0
(NCH2CH2OH), 44.2 (2’-C), 37.8 (C(CH3)2), 31.5, 29.7, 24.4
(3’-C, 4’-C, 5´-H), 29.3 (C(CH3)2), 28.6 (OC(CH3)2), 22.4 (6’-C), 13.8 ppm (7’-C); HPLC-MS: [A, 
70→95%], tR: 5.11 min, (95%); MS (ES+, m/z) 387 [M + H]+; Anal. calcd for C23H34N2O3: C 71.47, 
H 8.87, found: C 71.19, H 9.04.
Compound 1.9b was obtained as a yellow solid (22 mg, 
50%), mp: 93–95 ºC; 1H-NMR (300 MHz, CDCl3) δ: 7.38 
(s, 1H, 3-H), 6.63 (d, J = 1.8 Hz, 1H, 8-H), 6.50 (d, J = 1.9 
Hz, 1H, 6-H), 4.63 (t, J = 5.0 Hz, 2H, NCH2CH2OH), 4.12 
(t, J = 5.0 Hz, 2H, NCH2CH2OH), 1.57 (s, 6H, OC(CH3)2), 1.25 (s, 6H, C(CH3)2), 1.21–1.16 (m, 8H, 
2´-H, 3’-H, 4’-H, 5’-H), 1.13–1.00 (m, 2H, 6’-H), 0.83 ppm (t, J = 6.5 Hz, 3H, 7’-H); 13C-NMR (75 
MHz, CDCl3) δ: 154.4 (9-C), 153.4 (7-C), 150.4 (5a-C), 149.9 (9b-C), 133.7 (3-C), 123.3 (3a-C), 109.3 
(6-C), 108.8 (8-C), 102.9 (9a-C), 76.8 (OC(CH3)2), 62.1 (NCH2CH2OH), 53.5 (NCH2CH2OH), 44.6 
(2’-C), 38.0 (C(CH3)2), 32.0, 30.2, 25.9 (3’-C, 4’-C, 5´-H), 28.9 (OC(CH3)2), 27.5 (C(CH3)2), 22.9 (6’-
C), 14.3 ppm (7’-C); HPLC-MS: [A, 70→95%], tR: 3.93 min, (99%); MS (ES+, m/z) 387 [M + H]+; 
Anal. calcd for C23H34N2O3 : C 71.47, H 8.87, found: C 71.62, H 8.96.
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7-(1,1-Dimethylheptyl)-2,4-dihydro-2-hydroxymethyl-4,4-dimethylchromeno[4,3-c]pyrazol-9-
ol (1.10). 
Formaldehyde (37% in water, 13 µL, 0.17 mmol) was added to chromenopyrazole 1.4 (20 mg, 0.05 
mmol) dissolved in ethanol (2 mL). The mixture was heated under reflux for 5 h and then cooled 
down to room temperature. After evaporation of the solvent under reduced pressure, the crude was 
purified by chromatography on silica gel (hexane/EtOAc, 1:1). Although HPLC-MS of the crude 
displayed both regioisomers, only the major one (N2-
pyrazole) was properly isolated and characterized. 
Compound 1.10 was obtained as a white solid (14 mg, 
69%) mp: 90-92 ºC; 1H-NMR (300 MHz, CDCl3) δ: 7.35 (s, 1H, 3-H), 6.59 (d, J = 1.6 Hz, 1H, 8-H), 
6.51 (d, J = 1.6 Hz, 1H, 6-H), 5.30 (s, 2H, NCH2OH), 1.64 (s, 6H, OC(CH3)2), 1.61–1.49 (m, 2H, 2´-
H), 1.25 (s, 6H, C(CH3)2), 1.23–0.94 (m, 6H, 3’-H, 4’-H, 5’-H), 0.81 ppm (t, J = 4.8 Hz, 3H, 7’-H); 
13C-NMR (75 MHz, CDCl3) δ: 151.7 (9-C), 150.6 (7-C), 149.1 (5a-C), 148.2 (9b-C), 127.0 (3-C), 
124.7 (3a-C), 110.1 (6-C), 109.3 (8-C), 104.9 (9a-C), 75.4 (OC(CH3)2), 65.8 (NCH2OH), 43.2 (2’-C), 
39.5 (C(CH3)2), 32.5, 31.6, 25.5 (3’-C, 4´-C, 5’-C), 28.9 (OC(CH3)2), 27.4 (C(CH3)2), 23.7 (6’-C), 14.7
ppm (7’-C); HPLC-MS: [A, 80→95%], tR: 3.42 min, (96%); MS (ES+, m/z) 373 [M + H]+; Anal. calcd 
for C22H32N2O3: C 70.94, H 8.66, found: C 71.12, H 8.93.
1-(3,5-Difluorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazol-9-ol (1.11). 
Prepared from 1.3 (30 mg, 0.08 mmol) and 3,5-difluorophenylhydrazine hydrochloride (62 mg, 0.34
mmol) following the procedure described for 1.4. Column 
chromatography on silica gel (hexane/EtOAc, 3:1) afforded 1.11
as a yellow oil (32 mg, 82%); 1H-NMR (300 MHz, CDCl3) δ: 7.55 
(s, 1H, 3-H), 7.10–6.98 (m, 3H, 2-HPh, 4-HPh, 6-HPh), 6.65 (d, J = 
1.9 Hz, 1H, 6-H), 6.70 (d, J = 1.9 Hz, 1H, 8-H), 1.62 (s, 6H,
OC(CH3)2), 1.49–1.43 (m, 2H, 2´-H), 1.26 (s, 6H, C(CH3)2), 1.19–1.08 (s, 8H, 3´-H, 4´-H, 5´-H, 6´-
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H), 0.93–0.85 ppm (m, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 155.2 (9-C), 154.0 (5a-C), 152.6 (7-
C), 141.7 (1-CPh), 136.3 (3-C), 135.7 (3-CPh) , 135.4 (3-CPh), 134.2 (9b-C), 130.1, 128.7, 126.0 (2-CPh, 
4-CPh, 6-CPh), 122.9 (3a-C), 109.3 (6-C), 108.1 (8-C), 103.9 (9a-C), 75.6 (OC(CH3)2), 44.0 (2´-C), 38.8 
(C(CH3)2), 32.6, 31.0, 25.7, 23.2 (3´-C, 4´-C, 5´-C, 6´-C), 28.7 (C(CH3)2), 27.4 (OC(CH3)2), 15.1 ppm 
(7´-C); HPLC-MS: [A, 80%→95%], tR: 4.22 min, (99%); MS (ES+, m/z) 455 [M+H]+; Anal. calcd for 
C27H32F2N2O2: C 71.34, H 7.10, found: C 71.02, H 6.95.
7-(1,1-dimethylheptyl)-1,4-dihydro-1-(3-methoxyphenyl)-4,4-dimethylchromeno[4,3-
c]pyrazol-9-ol (1.12).
Prepared from 1.3 (80 mg, 0.23 mmol) and 3-methoxyphenylhydrazine hydrochloride (0.16 g, 0.92 
mmol) following the procedure described for 1.4. Column chromatography on silica gel 
(hexane/EtOAc, 3:1) afforded 1.12 as a yellow oil (48 mg, 47%); 
1H-NMR (300 MHz, CDCl3) δ: 7.47 (s, 1H, 3-H), 7.32 (t, J = 7.5 
Hz, 1H, 5-HPh), 7.27 (t, J = 1.7 Hz, 1H, 2-HPh), 7.18–7.13 (m, 1H, 
6-HPh), 7.01– 6.96 (m, 1H, 4-HPh), 6.60 (d, J = 1.8 Hz, 1H, 6-H), 
6.53 (d, J = 1.8 Hz, 1H, 8-H), 3.75 (s, 3H, OCH3), 1.63 (s, 6H, 
OC(CH3)2), 1.60–1.52 (m, 2H, 2´-H), 1.31–1.20 (m, 12H, 3´-H, 4´-H, 5´-H, C(CH3)2), 1.16–1.09  (m, 
2H, 6´-H), 0.89–0.79 ppm (m, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 156.1 (9-C), 154.1 (3-CPh), 
150.9 (5a-C), 141.2 (7-C), 138.2 (1-CPh), 136.2 (3-C), 133.4 (9b-C), 130.2 (5-CPh), 113.4 (6-CPh), 122.3 
(4-CPh), 120.3 (3a-C), 109.0 (2-CPh), 108.6 (6-C), 105.0 (8-C), 103.4 (9a-C), 75.0 (OC(CH3)2), 56.3 
(OCH3), 44.8 (2´-C), 38.7 (C(CH3)2), 31.7, 30.2, 26.1 (3´-C, 4´-C, 5´-C), 28.9 (C(CH3)2), 27.6 
(OC(CH3)2), 23.0 (6´-C), 14.3 ppm (7´-C); HPLC-MS: [A, 80→95%], tR: 3.81 min, (94%); MS (ES+, 
m/z) 449 [M+H]+. Anal. calcd for C28H36N2O3: C 74.97, H 8.09, found: C 75.06, H 7.78.
1-Cyclohexyl-7-(1,1-dimethylheptyl)-1,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-ol 
(1.13). 
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Prepared from 1.3 (93 mg, 0.27 mmol) and cyclohexylhydrazine hydrochloride (0.12 g, 0.80 mmol) 
by following the procedure described for 1.4. Column chromatography on silica gel 
(hexane/EtOAc, 2:1) afforded compound 1.13 as a pale-yellow 
solid (39 mg, 35%), mp: 98–100 ºC; 1H-NMR (300 MHz, 
CDCl3) δ: 7.38 (s, 1H, 3-H), 6.62 (d, J = 1.7 Hz, 1H, 6-H), 6.57 
(d, J = 1.7 Hz, 1H, 8-H), 4.61–4.52 (m, 1H, Ha), 1.86–1.80 (m, 
4H, Hb and Hf), 1.76–1.69 (m, 6H, Hc, Hd, He), 1.64 (s, 6H, 
OC(CH3)2), 1.49–1.44 (m, 2H, 2´-H), 1.24 (s, 6H, C(CH3)2), 1.19–1.08 (m, 8H, 3’-H, 4’-H, 5’-H, 6´-
H), 0.92–0.86 ppm (m, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 152.8 (9-C), 151.6 (7-C), 149.9 (5a-
C), 134.8 (9b-C), 130.6 (3-C), 125.3 (3a-C), 109.3 (8-C), 106.1 (6-C), 103.2 (9a-C), 75.7 (OC(CH3)2), 
50.3 (Ca), 43.1 (2’-C), 38.2 (C(CH3)2), 32.6 (Cb, Cf), 31.6, 31.0, 24.0, 22.8 (3’-C, 4’-C, 5’-C, 6´-C), 28.9 
(C(CH3)2), 27.7 (OC(CH3)2), 26.9, 26.3 (Cc, Cd,Ce), 14.7 ppm (7’-C); HPLC-MS: [A, 80→95%], tR:
5.02 min, (97%); MS (ES+, m/z) 426 [M + H]+; Anal. calcd for C27H40N2O2: C 76.37, H 9.50, found: 
C 76.11, H 9.74.
7-(1,1-Dimethylheptyl)-2,4-dihydro-9-methoxy-4,4-dimethylchromeno[4,3-c]pyrazole (1.14).
A solution of 1.4 (50 mg, 0.14 mmol) in anhydrous THF (3 mL) was added dropwise to a precooled 
suspension of sodium hydride (5.2 mg, 0.22 mmol) in anhydrous THF (1 mL) under nitrogen 
atmosphere. The resulting yellow solution was stirred for 10 
minutes at room temperature. Then, iodomethane (27 µL, 
0.43 mmol) was rapidly added. The reaction mixture was 
refluxed for 1 hour. The crude was diluted with diethyl 
ether, filtered and concentrated in vacuo. Column chromatography on silica gel (hexane/EtOAc, 
3:1) afforded 1.14 as a yellow oil (21 mg, 40%); 1H-NMR (300 MHz, CDCl3) δ: 8.13–8.09 (br s, 1H, 
NH), 7.31 (d, J = 1.5 Hz, 1H, 6-H), 7.19 (d, J = 1.5 Hz, 8-H), 6.74 (s, 1H, 3-H), 3.95 (s, 3H, OCH3), 
1.69–1.60 (br s, 6H, OC(CH3)2), 1.60–1.56 (m, 2H, 2´-H), 1.39 (s, 6H, C(CH3)2), 1.25–1.22 (m, 6H, 
3´-H, 4´-H, 5´-H), 1.17–1.08 (m, 2H, 6´-H), 0.81 ppm (t, J = 6.7 Hz, 3H, 7´-H); 13C-NMR (75 MHz,
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CDCl3) δ: 157.0 (9-C), 155.4 (5a-C), 154.1 (7-C), 143.2 (9b-C), 125.6 (3-C), 120.1 (3a-C), 108.0 (8-C), 
107.5 (6-C), 102.3 (9a-C), 76.8 (OC(CH3)2), 49.6 (OCH3), 43.7 (2´-C), 40.2 (C(CH3)2), 37.2, 34.7, 24.6 
(3´-C, 4´-C, 5´-C), 29.1 (C(CH3)2), 28.3 (OC(CH3)2), 22.7 (6´-C), 15.1 ppm (7´-C); HPLC-MS: [A, 
80%→95%], tR: 5.41 min, (97%); MS (ES+, m/z) 357 [M+H]+; Anal. calcd. for C22H32N2O2: C 74.12, 
H 9.05, found: C 74.35, H, 8.87.
7-(1,1-Dimethylheptyl)-2,4-dihydro-9-methoxy-2,4,4-trimethylchromeno[4,3-c]pyrazole 
(1.15).
Prepared from 1.5b (25 mg, 0.07 mmol), sodium hydride (2.5 mg, 0.10 mmol) and iodomethane (13
µL, 0.21 mmol) following the procedure described for 1.14. Column chromatography on silica gel 
(hexane/EtOAc, 2:1) afforded 1.15 as a white solid (17 mg, 68%); mp: 85–87 ºC; 1H-NMR (300 
MHz, CDCl3) δ: 7.63 (s, 1H, 3-H), 6.91 (d, J = 1.8 Hz, 1H, 6-
H), 6.76 (d, J = 1.8 Hz, 1H, 8-H), 4.02 (s, 3H, NCH3), 3.90 
(s, 3H, OCH3), 1.59 (s, 6H, OC(CH3)2), 1.45–1.36 (m, 2H, 
2´-H), 1.30 (s, 6H, C(CH3)2), 1.2–1.13 (m, 6H, 3´-H, 4´-H, 
5´-H), 1.10–1.03 (m, 2H, 6´-H), 0.87 ppm (t, J = 7.0 Hz, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 
153.2 (9-C), 152.6 (5a-C), 151.8 (7-C), 142.1 (9b-C), 124.3 (3-C), 122.0 (3a-C), 109.5 (6-C), 105.7 (8-
C), 103.1 (9a-C), 76.2 (OC(CH3)2), 57.0 (OCH3), 45.3 (NCH3), 39.2 (2´-C), 37.8 (C(CH3)2), 32.0, 31.3, 
25.3 (3´-C, 4´-C, 5´-C), 29.5 (C(CH3)2), 27.8 (OC(CH3)2), 23.5 (6´-C), 13.8 ppm (7´-C); HPLC-MS: 
[A, 80%→95%], tR: 3.58 min, (99%); MS (ES+, m/z) 371 [M+H]+; Anal. calcd. for C23H34N2O2: C 
74.55, H 9.25, found: C 74.89, H, 8.96.
7-(1,1-Dimethylheptyl)-1-ethyl-1,4-dihydro-9-methoxy-4,4-dimethylchromeno[4,3-c]pyrazole 
(1.16).
Prepared from 1.6a (25 mg, 0.067 mmol), sodium hydride (2.5 mg, 0.1 mmol) and iodomethane (12
µL, 0.20 mmol) following the procedure previously described for 1.14. Column chromatography on 
silica gel (hexane/EtOAc, 3:1) afforded 1.16 as a white solid (13 mg, 52%); mp: 90–91 ºC; 1H-NMR 
(300 MHz, CDCl3) δ: 7.34 (s, 1H, 3-H), 6.70 (d, J = 1.5 Hz, 2H, 6-H), 6.52 (d, J = 1.5 Hz, 1H, 8-H),
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4.42 (q, J = 7.9 Hz, 2H, NCH2CH3), 3.81 (s, 3H, OCH3), 1.60 (s, 6H, OC(CH3)2), 1.54-1.50 (m, 2H, 
2´-H), 1.45 (t, J = 7.9 Hz, 3H, NCH2CH3), 1.31 (s, 6H, 
C(CH3)2), 1.24–1.19 (br s, 8H, 3´-H, 4´-H, 5´-H, 6´-H), 0.86 
ppm (t, J = 8.0 Hz, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 
153.0 (9-C), 152.6 (5a-C), 150.4 (7-C), 132.3 (3-C), 131.7 (9b-
C), 121.9 (3a-C), 109.0 (8-C), 105.3 (6-C), 101.1 (9a-C), 76.8 (OC(CH3)2), 54.5 (OCH3), 49.6 
(NCH2CH3), 43.9 (2´-C), 38.4 (C(CH3)2), 31.8, 30.5, 26.0 (3´-C, 4´-C, 5´-C), 28.7 (C(CH3)2), 26.9 
(OC(CH3)2), 22.9 (6´-C), 15.8 (NCH2CH3), 14.6 ppm (7´-C); HPLC-MS: [A, 15% - 95%], tR: 5.81 
min, (98%); MS (ES+, m/z) 385 [M+H]+; Anal. calcd. for C24H36N2O2: C 74.96, H 9.44, found: C 
74.57, H 9.25.
7-(1,1-Dimethylheptyl)-2-ethyl-2,4-dihydro-9-methoxy-4,4-dimethylchromeno[4,3-c]pyrazole 
(1.17).
Prepared from 1.6b (25 mg, 0.07 mmol), sodium hydride (2.5 mg, 0.1 mmol) and iodomethane (12 
µL, 0.20 mmol) following the procedure described for 1.14. Column chromatography on silica gel 
(hexane/EtOAc, 1:1) afforded 1.17 as a white solid (20 mg, 77%); mp: 87–88 ºC; 1H-NMR (300 
MHz, CDCl3) δ: 7.09 (s, 1H, 3-H), 6.50 (d, J = 1.3 Hz, 8-H), 6.37 (s, 1H, J = 1.3 Hz, 6-H), 4.19 (q, 
2H, J = 7.2 Hz, NCH2CH3), 3.90 (s, 3H, OCH3), 1.64 (s, 6H, OC(CH3)2), 1.57–1.54 (br s, 2H, 2´-H), 
1.53 (t, 3H, J = 7.6 Hz, NCH2CH3), 1.27 (s, 6H, C(CH3)2), 
1.20–1.11 (m, 6H, 3´-H, 4´-H, 5´-H), 1.09–1.04 (br s, 2H, 6´-
H), 0.83 ppm (t, J = 7.8 Hz, 3H, 7´-H); 13C-NMR (75 MHz,
CDCl3) δ: 155.3 (9-C), 154.0 (5a-C), 153.8 (7-C), 143.7 (9b-C),
128.2 (3-C), 126.1 (3a-C), 107.4 (6-C), 106.8 (8-C), 103.7 (9a-C), 78.0 (OC(CH3)2), 56.8 (OCH3), 47.3 
(NCH2CH3), 45.7 (2´-C), 39.0 (C(CH3)2), 32.3, 31.1, 25.7 (3´-C, 4´-C, 5´-C), 29.1 (C(CH3)2), 27.4 
(OC(CH3)2), 23.3 (6´-C), 16.2 (NCH2CH3), 14.0 ppm (7´-C); HPLC-MS: [A, 80% - 95%], tR: 3.95 
min, (99%); MS (ES+, m/z) 385 [M+H]+; Anal. calcd. for C24H36N2O2: C 74.96, H 9.44, found: C 
75.02, H 9.18.
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1-(3,4-Dichlorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-9-methoxy-4,4-
dimethylchromeno[4,3-c]pyrazole (1.18).
Prepared from 1.7 (27 mg, 0.05 mmol), sodium hydride (2 mg, 0.08 mmol) and iodomethane (10 µL, 
0.16 mmol) following the procedure previously described for 1.14. Column chromatography on silica 
gel (hexane/EtOAc, 1:1) afforded 1.18 as a yellow oil (11 mg, 
47%); 1H-NMR (300 MHz, CDCl3) δ: 7.81 (d, J = 1.9 Hz, 1H, 2-
HPh), 7.72 (s, 1H, 3-H), 7.49 (d, J = 7.8 Hz, 1H, 5-HPh), 7.37 (dd, J
= 7.8 Hz, J = 1.9 Hz, 1H, 6-HPh), 6.74 (d, J = 1.4 Hz, 1H, 6-H), 
6.30 (d, J = 1.4 Hz, 1H, 8-H), 3.28 (s, 3H, OCH3), 1.72 (s, 6H, 
OC(CH3)2), 1.68–1.60 (m, 2H, 2´-H), 1.39 (s, 6H, C(CH3)2), 1.27–1.18 (m, 6H, 3´-H, 4´-H, 5´-H), 
1.12–1.08 (br s, 2H, 6´-H), 0.91 ppm (t, J = 7.1 Hz, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 154.2 
(9-C), 153.8 (5a-C), 152.1 (7-C), 143.1 (1-CPh), 135.7 (3-C), 134.2 (3-CPh), 132.6 (9b-C), 130.8 (4-CPh), 
126.3 (5-CPh), 125.9 (2-CPh), 124.0 (6-CPh), 120.1 (3a-C), 109.3 (6-C), 108.4 (8-C), 103.5 (9a-C), 76.1 
(OC(CH3)2), 54.9 (OCH3), 43.5 (2´-C), 39.0 (C(CH3)2), 33.9, 32.3, 26.8 (3´-C, 4´-C, 5´-C), 28.3 
(C(CH3)2), 27.1 (OC(CH3)2, 22.7 (6´-C), 14.0 ppm (7´-C); HPLC-MS: [A, 80%→95%], tR: 11.13 min, 
(95%); MS (ES+, m/z) 501 [M+H]+; Anal. calcd. for C28H34Cl2N2O2: C 67.06, H 6.83, found: C 66.79, 
H 6.55.
1-(2,4-Dichlorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-9-methoxy-4,4-
dimethylchromeno[4,3-c]pyrazole (1.19).
Prepared from 1.8 (26 mg, 0.05 mmol), sodium hydride (2 mg, 0.08 mmol) and iodomethane (10 µL, 
0.16 mmol) following the procedure previously described. 
Column chromatography on silica gel (hexane/EtOAc, 1:1) 
afforded 1.19 as a orange oil (12 mg, 50%); 1H-NMR (300 MHz, 
CDCl3) δ: 7.51 (s, 1H, 3-H), 7.47 (d, J = 2.0 Hz, 1H, 3-HPh), 7.35 
(dd, J = 2.0 Hz, J = 8.1 Hz, 1H, 5- HPh), 7.38 (d, J = 8.1 Hz, 1H, 
6-HPh), 6.60 (d, J = 1.7 Hz, 1H, 6-H), 6.28 (d, J = 1.7 Hz, 1H, 8-H), 3.21 (s, 3H, OCH3), 1.59 (s, 6H, 
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OC(CH3)2), 1.52-1.46 (m, 2H, 2´-H), 1.30 (s, 6H, C(CH3)2), 1.19–1.07 (m, 6H, 3´-H, 4´-H, 5´-H), 
1.07–1.02 (br s, 2H, 6´-H), 0.79 ppm (t, J = 7.0 Hz, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 157.0 
(9-C), 156.3 (5a-C), 155.8 (7-C), 141.7 (1-CPh), 136.1 (2-CPh), 135.5 (4-CPh), 133.9 (3-C), 131.2 (9b-C), 
130.8 (3-CPh), 129.7 (5-CPh), 128.3 (6-CPh), 122.9 (3a-C), 109.7 (6-C), 105.2 (8-C), 103.1 (9a-C), 77.4 
(OC(CH3)2), 56.0 (OCH3), 43.6 (2´-C), 38.5 (C(CH3)2), 33.1 , 31.7,  26.4 (3´-C, 4´-C, 5´-C), 29.2
(C(CH3)2), 27.9 (OC(CH3)2), 24.3 (6´-C), 13.9 ppm (7´-C); HPLC-MS: [A, 80%→95%], tR: 9.17 min, 
(98%); MS (ES+, m/z) 501 [M+H]+; Anal. calcd. for C28H34Cl2N2O2: C 67.06, H 6.83, found: C 66.85, 
H 7.02.
1-(3,4-Dichlorophenyl)-7-(1,1-dimethylheptyl)-9-ethoxy-1,4-dihydro-4,4-
dimethylchromeno[4,3-c]pyrazole (1.20).
Prepared from 1.7 (20 mg, 0.04 mmol), sodium hydride (1.5 mg, 0.06 mmol) and iodoethane (10 µL, 
0.12 mmol) following the procedure previously described for 
1.14. Column chromatography on silica gel (hexane/EtOAc, 3:1) 
afforded 1.20 as a yellow oil (8 mg, 39%); 1H-NMR (300 MHz, 
CDCl3) δ: 7.75 (d, J = 1.5 Hz, 1H, 2-HPh), 7.63 (s, 1H, 3-H), 7.41 
(d, J = 7.2 Hz, 1H, 5-HPh), 7.29 (dd, J = 7.2 Hz, J = 1.5 Hz, 1H, 
6-HPh), 6.60 (d, J = 1.6 Hz, 1H, 6-H), 6.41 (d, J = 1.6 Hz, 1H, 8-H), 3.72 (q, J = 7.3 Hz, 2H, 
OCH2CH3), 1.67 (s, 6H, OC(CH3)2), 1.55–1.49 (m, 2H, 2´-H), 1.34 (s, 6H, C(CH3)2), 1.29–1.20 (m, 
6H, 3´-H, 4´-H, 5´-H), 1.16–1.13 (br s, 2H, 6´-H), 1.01 (t, J = 7.3 Hz, 3H, OCH2CH3), 0.85 ppm (t, 
J = 6.9 Hz, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 155.4 (9-C), 154.7 (5a-C), 153.5 (7-C), 142.9 
(1-CPh), 134.6 (3-C), 133.1 (3-CPh), 131.8 (9b-C), 130.6 (4-CPh), 127.1 (5-CPh), 126.6 (2- CPh), 123.1 (6-
CPh), 110.2 (6-C), 106.4 (8-C), 105.8 (9a-C), 76.0 (OC(CH3)2),63.2 (OCH3), 44.7 (2´-C), 39.8 
(C(CH3)2), 33.7, 32.0, 27.5 (3´-C, 4´-C, 5´-C), 30.6 (C(CH3)2), 28.2 (OC(CH3)2, 23.0 (6´-C), 14.2 
(OCH2CH3), 13.9 ppm (7´-C); HPLC-MS: [iso 95% - 5%], tR: 5.57 min, (95%); MS (ES+, m/z) 515 
[M+H]+; Anal. calcd. for C29H36Cl2N2O2: C 67.57, H 7.04, found: C 67.23, H 6.89.
General procedure for the synthesis of alkoxychromenopyrazoles 1.21−1.38 
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A solution of the corresponding chromenopyrazole (1 eq) in anhydrous THF (1-5 mL) was added 
dropwise to a precooled suspension of sodium hydride (1.1−2.5 eq) in anhydrous THF (0.5-2 mL) 
under nitrogen atmosphere. The resulting solution was stirred for 10 minutes at room temperature. 
The corresponding alkyl halide (3-5 eq) was rapidly added, the reaction mixture was refluxed for 1-
12 hours. The crude was dissolved in EtOAc, washed with water and extracted three times with 
EtOAc. The organic layers were combined and dried over MgSO4. After removal of the solvent 
under vacuum, the crude was purified by chromatography on silica gel. The chromatography eluents 
and yields are indicated below for each reaction.
9-Benzyloxy-2,4-dihydro-7-(1,1-dimethylheptyl)-4,4-dimethylchromeno[4,3-c]pyrazole (1.21). 
Prepared from 1.4 (10 mg, 0.03 mmol), sodium hydride (1.20 mg, 0.04 mmol) and benzyl bromide 
(10 µL, 0.09 mmol). Column chromatography on silica gel 
(hexane/EtOAc, 3:1) afforded the title compound. Compound 
1.21 was obtained as a yellow solid (5 mg, 41%); mp: 110–112
ºC; 1H-NMR (300 MHz, CDCl3) δ: 7.55–7.29 (m, 5H, 2-HBn, 3-
HBn, 4-HBn, 5-HBn, 6-HBn), 7.16 (s, 1H, 3-H), 6.62 (d, J = 1.5 Hz, 1H, 6-H), 6.57 (d, J = 1.5 Hz, 1H, 
8-H), 5.18 (s, 2H, OCH2), 1.64 (s, 6H, OC(CH3)2), 1.58–1.48 (m, 2H, 2´-H), 1.25 (s, 6H, C(CH3)2), 
1.22–1.12 (m, 6H, 3´-H, 4´-H, 5´-H), 1.12–0.96 (m, 2H, 6´-H), 0.90–0.79 ppm (m, 3H, 7´-H); 13C-
NMR (75 MHz, CDCl3) δ: 157.0 (9-C), 155.2 (5a-C), 153.7 (7-C), 142.5 (9b-C), 139.6 (1-CBn), 134.8 
(3-C), 129.3, 128.1, 127.5 (2-CBn, 3-CBn, 4-CBn, 5-CBn, 6-CBn), 124.3 (3a-C), 111.4 (6-C), 108.6 (8-C), 
106.3 (9a-C), 75.7 (OC(CH3)2), 71.3 (OCH2), 43.1 (2´-C), 39.4 (C(CH3)2), 32.8, 30.6, 25.8 (3´-C, 4´-C, 
5´-C), 28.2 (C(CH3)2), 27.3 (OC(CH3)2), 23.9 (6´-C), 15.1 ppm (7´-C); ppm (7´-C); HPLC-MS: [iso 
95% - 5%], tR: 2.25 min, (95%); MS (ES+, m/z) 433 [M+H]+; Anal. calcd. for C28H36N2O2: C 77.74, 
H 8.39, found: C 77.92, H, 8.16.
9-Benzyloxy-7-(1,1-dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-c]pyrazole 
(1.22).
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Prepared from 1.5b (10 mg, 0.03 mmol), sodium hydride (1.10 mg, 0.04 mmol) and benzyl bromide 
(10 µL, 0.09 mmol) following the procedure previously described. Column chromatography on silica 
gel (hexane/EtOAc, 2:1) afforded the title compound as a pale yellow oil (12 mg, 96%); 1H-NMR 
(300 MHz, CDCl3) δ: 7.71 (d, J = 7.0 Hz, 2H, 2-HBn, 6-HBn), 
7.41–7.36 (m, 2H, 3-HBn, 5-HBn), 7.31–7.26 (m, 1H, 4-HBn), 
7.11 (s, 1H, 3-H), 6.58 (d, J = 1.3 Hz, 1H, 6-H), 6.50 (d, J = 
1.3 Hz, 1H, 8-H), 5.92 (s, 2H, OCH2), 3.98 (s, 3H, NCH3), 
1.56 (s, 6H, OC(CH3)2), 1.50–1.44 (m, 2H, 2´-H), 1.22 (s, 6H, C(CH3)2), 1.16–1.11 (m, 6H, 3´-H, 4´-
H, 5´-H), 1.05–0.99 (br s, 2H, 6´-H), 0.81 ppm (t, J = 8.0 Hz, 3H, 7´-H); 13C-NMR (75 MHz,
CDCl3) δ: 154.3 (9-C), 153.8 (5a-C), 151.2 (7-C), 141.0 (9b-C), 137.8 (1-CBn), 128.1 (3-CBn, 5-CBn), 
127.1 (4-CBn), 126.9 (2-CBn, 6-CBn), 123.2 (3-C), 122.1 (3a-C), 108.9 (6-C), 105.7 (8-C), 104.9 (9a-C), 
75.5 (OC(CH3)2), 70.6 (OCH2), 44.5 (NCH3), 39.0 (2´-C), 37.9 (C(CH3)2), 31.7, 29.8, 24.5 (3´-C, 4´-C, 
5´-C), 28.9 (C(CH3)2), 28.7 (OC(CH3)2), 22.5 (6´-C), 14.0 ppm (7´-C); HPLC-MS: [iso 95% - 5%], tR: 
2.47 min, (100%); MS (ES+, m/z) 447 [M+H]+; Anal. calcd. for C29H38N2O2: C 77.99, H 8.58, found: 
C 77.65, H, 8.81.
9-Benzyloxy-7-(1,1-dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazole (1.23).
Prepared from 1.6a (20 mg, 0.05 mmol), sodium hydride (1.9 mg, 0.08 mmol) and benzyl bromide 
(19 µL, 0.16 mmol) following the general procedure. Column 
chromatography on silica gel (hexane/EtOAc, 2:1) afforded 1.23
as a yellow oil (14 mg, 70%); 1H-NMR (300 MHz, CDCl3) δ: 7.78
(d, J = 7.1 Hz, 2H, 2-HBn, 6-HBn), 7.49–7.45 (m, 2H, 3-HBn, 5-
HBn), 7.38–7.33 (m, 1H, 4-HBn), 7.30 (s, 1H, 3-H), 6.58 (d, J = 1.9 Hz, 1H, 6-H), 6.50 (d, J = 1.9 Hz, 
1H, 8-H), 5.45 (s, 2H, OCH2), 4.38 (q, J = 7.5 Hz, 2H, NCH2CH3), 1.63 (s, 6H, OC(CH3)2), 1.59-
1.55 (br s, 2H, 2´-H), 1.49 (t, 3H, J = 7.5 Hz, NCH2CH3), 1.29 (s, 6H, C(CH3)2), 1.22–1.13 (m, 6H, 
3´-H, 4´-H, 5´-H), 1.10–1.02 (m, 2H, 6´-H), 0.90 ppm (t, J = 6.7 Hz, 3H, 7´-H); 13C-NMR (75 MHz,
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CDCl3) δ: 152.5 (9-C), 151.9 (5a-C), 150.6 (7-C), 141.0 (9b-C), 138.5 (1-CBn), 129.2 (3-CBn, 5-CBn), 
127.0 (4-CBn), 125.3 (2-CBn, 6-CBn), 123.1 (3-C), 121.9 (3a-C), 108.1 (6-C), 106.5 (8-C), 103.9 (9a-C), 
74.9 (OC(CH3)2), 71.5 (OCH2), 48.3 (NCH2CH3), 45.8 (2´-C), 39.4 (C(CH3)2), 32.1, 30.8, 25.6 (3´-C, 
4´-C, 5´-C), 29.3 (C(CH3)2), 28.1 (OC(CH3)2), 23.0 (6´-C), 14.9 (NCH2CH3), 13.7 ppm (7´-C); HPLC-
MS: [iso 95% - 5%], tR: 3.28 min, (96%); MS (ES+, m/z) 461 [M+H]+; Anal. calcd. for for 
C30H40N2O2: C 78.22, H 8.75, found: C 77.98, H 9.06.
9-Benzyloxy-7-(1,1-dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazole (1.24).
Prepared from 1.6b (14 mg, 0.04 mmol), sodium hydride (1.50 mg, 0.05 mmol) and benzyl bromide
(13 µL, 0.11 mmol) following the procedure previously described. Column chromatography on silica 
gel (hexane/EtOAc, 3:1) afforded the title compound as a 
white oil (14 mg, 81%); 1H-NMR (300 MHz, CDCl3) δ: 7.76 
(d, J = 7.1 Hz, 2H, 2-HBn, 6-HBn), 7.40–7.37 (m, 2H, 3-HBn, 5-
HBn), 7.32–7.27 (m, 1H, 4-HBn), 7.15 (s, 1H, 3-H), 6.60 (d, J = 
1.7 Hz, 1H, 6-H), 6.59 (d, J = 1.7 Hz, 1H, 8-H), 5.28 (s, 2H, OCH2), 4.24 (q, J = 7.3 Hz, 2H, 
NCH2CH3), 1.63–1.58 (m, 11H, OC(CH3)2, 2´-H, NCH2CH3), 1.25 (s, 6H, C(CH3)2), 1.20–1.07 (m, 
6H, 3´-H, 4´-H, 5´-H), 1.08–0.91 (m, 2H, 6´-H), 0.83 ppm (t, J = 6.9 Hz, 3H, 7´-H); 13C-NMR (75 
MHz, CDCl3) δ: 154.4 (9-C), 153.8 (5a-C), 151.1 (7-C), 140.8 (9b-C), 137.9 (1-CBn), 128.1 (3-CBn, 5-
CBn), 127.1 (4-CBn), 126.9 (2-CBn, 6-CBn), 121.7 (3-C), 121.0 (3a-C), 109.0 (6-C), 105.9 (8-C), 104.7
(9a-C), 75.6 (OC(CH3)2), 70.5 (OCH2), 47.1 (NCH2CH3), 44.6 (2´-C), 38.0 (C(CH3)2), 31.7, 29.9, 24.6 
(3´-C, 4´-C, 5´-C), 28.9 (C(CH3)2), 27.8 (OC(CH3)2), 22.6 (6´-C), 15.4 (NCH2CH3), 14.1 ppm (7´-C);
HPLC-MS: [iso 95% - 5%], tR: 2.67 min, (99%); MS (ES+, m/z) 461 [M+H]+; Anal. calcd. for 
C30H40N2O2: C 78.22, H 8.75, found: C 78.50, H 8.97.
9-Benzyoxy-1-(3,4-dichlorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-4,4-
dimethylchromeno[4,3-c]pyrazole (1.25).
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Prepared from 1.7 (15 mg, 0.03 mmol), sodium hydride (1.20 mg, 0.04 mmol) and benzyl bromide 
(11 µL, 0.09 mmol) following the procedure previously described. Column chromatography on silica 
gel (hexane/EtOAc, 3:1) afforded the title compound as a pale 
yellow oil (13 mg, 75%); 1H-NMR (300 MHz, CDCl3) δ: 7.44 (s, 
1H, 3-H), 7.32–7.19 and 7.12–6.95 (m and m, 4H and 4H, 2-HBn, 
3-HBn, 4-HBn, 5-HBn, 6-HBn, 2-HPh, 5-HPh, 6-HPh), 6.66 (d, J = 1.6 
Hz, 1H, 6-H), 6.44 (d, J = 1.6 Hz, 1H, 8-H), 4.53 (s, 2H, OCH2), 
1.55 (s, 8H, OC(CH3)2, 2´-H), 1.20 (s, 6H, C(CH3)2), 1.14–1.10 (m, 6H, 3´-H, 4´-H, 5´-H), 1.07–0.88 
(m, 2H, 6´-H), 0.83–0.72 ppm (m, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 154.0 (9-C), 153.3 (5a-
C), 152.9 (7-C), 142.0 (9b-C), 135.5 (3-C), 134.9, 132.5, 131.7, 130.2, 129.4, 128.4, 128.2, 128.0, 
127.8, 127.6, 127.4, 125.2 (1-CBn, 2-CBn, 3-CBn, 4-CBn, 5-CBn, 6-CBn, 1-CPh, 2-CPh, 3-CPh, 4-CPh, 5-CPh, 6-
CPh), 124.7 (3a-C), 122.2 (9a-C), 109.6 (6-C), 103.6 (8-C), 76.2 (OC(CH3)2), 70.0 (OCH2), 44.4 (2´-C), 
38.2 (C(CH3)2), 31.7, 29.9, 24.6 (3´-C, 4´-C, 5´-C), 28.7(C(CH3)2), 27.2 (OC(CH3)2), 22.6 (6´-C), 14.1 
ppm (7´-C); HPLC-MS: [iso 95% - 5%], tR: 6.44 min, (94%); MS (ES+, m/z) 577 [M+H]+; Anal. 
calcd. for C34H38Cl2N2O2: C 70.70, H 6.63, found: C 70.82, H 6.57.
9-Benzyloxy-1-(2,4-dichlorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-4,4-dimethyl-9-
methoxychromeno[4,3-c]pyrazole (1.26).
Prepared from 1.8 (18 mg, 0.04 mmol), sodium hydride (1.40 mg, 0.05 mmol) and benzyl bromide 
(13 µL, 0.11 mmol) following the procedure previously described. Column chromatography on silica 
gel (hexane/EtOAc, 3:1) afforded the title compound as an 
orange oil (13 mg, 61%); 1H-NMR (300 MHz, CDCl3) δ: 7.55 (s, 
1H, 3-H), 7.36–7.27 (m, 4H, 2-HBn, 3-HBn, 5-HBn, 6-HBn), 7.15 (d, 
J = 2.3 Hz, 1H, 3-HPh), 7.13–7.02 (m, 2H, 6-HPh, 4-HBn), 6.97 
(dd, J = 8.5, 2.3 Hz, 1H, 5-HPh), 6.65 (d, J = 1.6 Hz, 1H, 6-H), 
6.35 (d, J = 1.6 Hz, 1H, 8-H), 4.53 (s, 2H, OCH2), 1.64 (s, 6H, OC(CH3)2), 1.52–1.36 (m, 2H, 2´-H), 
1.22 (s, 6H, C(CH3)2), 1.20–1.09 (m, 6H, 3´-H, 4´-H, 5´-H), 1.03–0.89 (m, 2H, 6´-H), 0.88–0.79 ppm 
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(m, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 154.1 (9-C), 153.7 (5a-C), 153.3 (7-C), 140.3 (9b-C), 
136.8 (3-C), 135.2, 134.8, 133.9, 131.7, 131.7, 129.8, 128.9, 128.8, 128.5, 128.3, 127.7, 127.1 (1-CBn, 2-
CBn, 3-CBn, 4-CBn, 5-CBn, 6-CBn, 1-CPh, 2-CPh, 3-CPh, 4-CPh, 5-CPh, 6-CPh), 123.7 (9a-C), 109.7 (6-C), 
104.2 (8-C), 77.6 (OC(CH3)2), 70.6 (OCH2), 44.8 (2´-C), 38.5 (C(CH3)2), 32.1, 30.2, 24.9 (3´-C, 4´-C, 
5´-C), 29.1 (C(CH3)2), 27.9 (OC(CH3)2), 23.0 (6´-C), 14.5 ppm (7´-C); HPLC-MS: [iso 95% - 5%], tR: 
4.12 min, (94%); MS (ES+, m/z) 577 [M+H]+; Anal. calcd. for C34H38Cl2N2O2: C 70.70, H 6.63, 
found: C 70.95, H 6.49.
7-(1,1-Dimethylheptyl)-2,4-dihydro-9-(3-hydroxypropoxy)-4,4-dimethylchromeno[4,3-
c]pyrazole (1.27). 
Prepared from 1.4 (0.10 g, 0.29 mmol), sodium hydride (14 mg, 0.58 mmol) and 3-bromo-1-
propanol (0.19 mL, 1.46 mmol). Column chromatography on silica gel (hexane/EtOAc, 1:1) 
afforded the title compound as a white solid (55 mg, 47%); mp: 82–84 ºC; 1H-NMR (300 MHz, 
CDCl3) δ: 8.28–8.21 (br s, 1H, NH), 7.18 (s, 1H, 3-H), 6.58 (d, J = 1.6 Hz, 1H, 6-H), 6.49 (d, J = 1.6 
Hz, 1H, 8-H), 4.29 (t, J = 6.5 Hz, 2H, OCH2CH2CH2OH), 3.67 (t, J = 6.3 Hz, 2H, 
OCH2CH2CH2OH), 2.13 (p, J = 6.3 Hz, 2H, OCH2CH2CH2OH), 1.61 (s, 6H, OC(CH3)2), 1.59–1.45 
(m, 2H, 2´-H), 1.25 (s, 6H, C(CH3)2), 1.22–1.12 (m, 8H, 3´-H, 
4´-H, 5´-H, 6´-H), 0.83 ppm (t, J = 6.7 Hz, 3H, 7´-H); 13C-NMR 
(75 MHz, CDCl3) δ: 153.8 (9-C), 153.2 (5a-C), 152.9 (7-C), 
142.5 (9b-C), 123.8 (3-C), 120.0 (3a-C), 106.6 (6-C), 106.4 (8-C), 101.1 (9a-C), 76.6 (OC(CH3)2), 59.3
(OCH2CH2CH2OH), 48.8 (OCH2CH2CH2OH), 44.5 (2´-C), 38.0 (C(CH3)2), 32.7
(OCH2CH2CH2OH), 31.8, 30.0, 24.6, 22.6 (3´-C, 4´-C, 5´-C, 6´-C), 29.7 (C(CH3)2), 28.9 (OC(CH3)2), 
14.1 ppm (7´-C); HPLC-MS: [A, 80%→95%], tR: 3.85 min, (97%); MS (ES+, m/z) 401 [M+H]+; 
Anal. calcd. for C24H36N2O3: C 71.96, H 9.06, found: C 72.23, H, 9.10.
7-(1,1-Dimethylheptyl)-2,4-dihydro-9-(3-hydroxypropoxy)-2,4,4-trimethylchromeno[4,3-
c]pyrazole (1.28).
Experimental section
83 
Prepared from 1.5b (30 mg, 0.08 mmol), sodium hydride (3 mg, 0.12 mmol) and 3-bromo-1-
propanol (51 µL, 0.37 mmol) following the procedure previously described. Column 
chromatography on silica gel (hexane/EtOAc, 1:1) afforded the title compound as a pale orange oil 
(20 mg, 59%); 1H-NMR (300 MHz, CDCl3) δ: 7.01 (s, 1H, 3-H), 6.52 (d, J = 1.6 Hz, 1H, 6-H), 6.45 
(d, J = 1.6 Hz, 1H, 8-H), 4.18 (t, J = 6.5 Hz, 2H, OCH2CH2CH2OH), 4.01 (s, 3H, NCH3), 3.86–3.80 
(m, 2H, OCH2CH2CH2OH), 2.13–1.96 (m, 2H, 
OCH2CH2CH2OH), 1.52 (s, 6H, OC(CH3)2), 1.42–1.38 (m, 2H, 
2´-H), 1.19 (s, 6H, C(CH3)2), 1.16–0.92 (m, 8H, 3´-H, 4´-H, 5´-
H, 6´-H), 0.77 ppm (t, J = 6.6 Hz, 3H, 7´-H); 13C-NMR (75 
MHz, CDCl3) δ: 153.6 (9-C), 152.7 (5a-C), 150.8 (7-C), 139.5 (9b-C), 122.6 (3-C), 120.5 (3a-C), 109.2 
(6-C), 107.6 (8-C), 101.3 (9a-C), 74.8 (OC(CH3)2), 59.5 (OCH2CH2CH2OH), 50.1 
(OCH2CH2CH2OH), 45.3 (NCH3), 39.5 (2´-C), 37.6 (C(CH3)2), 32.8 (OCH2CH2CH2OH), 31.5, 30.9, 
24.6, 22.6 (3´-C, 4´-C, 5´-C, 6´-C), 29.4 (C(CH3)2), 28.9 (OC(CH3)2), 13.0 ppm (7´-C); HPLC-MS: [A, 
80%→95%], tR: 4.07 min, (93%); MS (ES+, m/z) 415 [M+H]+; Anal. calcd. for C25H38N2O2: C 72.43, 
H 9.24, found: C 72.12, H 8.98.
7-(1,1-Dimethylheptyl)-1-ethyl-1,4-dihydro-9-(3-hydroxypropoxy)-4,4-dimethylchromeno[4,3-
c]pyrazole (1.29).
Prepared from 1.6a (56 mg, 0.15 mmol), sodium hydride (9 mg, 0.38 mmol) and 3-bromo-1-
propanol (0.10 mL, 0.75 mmol) following the general procedure. Column chromatography on silica 
gel (hexane/EtOAc, 1:1) afforded 1.29 as a yellow solid (31 mg, 48%); mp: 91–93 ºC; 1H-NMR (300 
MHz, CDCl3) δ: 7.37 (s, 1H, 3-H), 6.60 (d, J = 1.8 Hz, 1H, 6-
H), 6.57 (d, J = 1.8 Hz, 1H, 8-H), 4.40–4.33 (m, 2H, 
OCH2CH2CH2OH), 4.07–3.89 (m, 2H, NCH2CH3), 3.62–3.51
(m, 2H, OCH2CH2CH2OH), 2.11 (p, J = 6.4 Hz, 2H, 
OCH2CH2CH2OH), 1.55 (s, 6H, OC(CH3)2), 1.50 (t, J = 7.0
Hz, 3H, NCH2CH3), 1.41–1.36 (m, 2H, 2´-H), 1.24 (s, 6H, C(CH3)2), 1.12–0.98 (m, 8H, 3´-H, 4´-H, 
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5´-H, 6´-H), 0.85 ppm (t, J = 6.6 Hz, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 154.8 (9-C), 153.5 
(5a-C), 151.6 (7-C), 141.4 (9b-C), 131.6 (3-C), 124.5 (3a-C), 110.3 (6-C), 107.9 (8-C), 102.6 (9a-C), 
75.0 (OC(CH3)2), 63.2 (OCH2CH2CH2OH), 57.6 (OCH2CH2CH2OH), 46.5 (NCH2CH3), 44.7 (2´-C), 
38.0 (C(CH3)2), 32.6 (OCH2CH2CH2OH), 30.9, 29.6, 24.5, 21.7 (3´-C, 4´-C, 5´-C, 6´-C), 29.2 
(C(CH3)2), 28.1 (OC(CH3)2), 15.0 (NCH2CH3), 14.1 ppm (7´-C); HPLC-MS: [A, 80%→95%], tR: 3.42 
min, (99%); MS (ES+, m/z) 429 [M+H]+; Anal. calcd. for for C26H40N2O3: C 72.86, H 9.41, found: C 
72.75, H 9.63. 
7-(1,1-Dimethylheptyl)-2-ethyl-2,4-dihydro-9-(3-hydroxypropoxy)-4,4-
dimethylchromeno[4,3-c]pyrazole (1.30). 
Prepared from 1.6b (25 mg, 0.07 mmol), sodium hydride (2.40 mg, 0.10 mmol) and 3-bromo-1-
propanol (28 µL, 0.20 mmol) following the procedure previously described. Column 
chromatography on silica gel (hexane/EtOAc, 1:1) afforded 
the title compound as a yellow gummy solid (22 mg, 76%); 1H-
NMR (300 MHz, CDCl3) δ: 7.13 (s, 1H, 3-H), 6.58 (d, J = 1.6 
Hz, 1H, 6-H), 6.52 (d, J = 1.6 Hz, 1H, 8-H), 4.31–4.25 (m, 2H, 
OCH2CH2CH2OH), 4.09–3.98 (m, 2H, NCH2CH3), 3.66–3.45 (m, 2H, OCH2CH2CH2OH), 2.14–
2.10 (m, 2H, OCH2CH2CH2OH), 1.59 (s, 6H, OC(CH3)2), 1.51 (t, J = 7.2 Hz, 3H, NCH2CH3), 1.46–
1.42 (m, 2H, 2´-H), 1.26 (s, 6H, C(CH3)2), 1.22–0.96 (m, 8H, 3´-H, 4´-H, 5´-H, 6´-H), 0.87–0.79 
ppm (m, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 153.5 (9-C), 152.8 (5a-C), 150.9 (7-C), 139.2 (9b-
C), 120.8 (3-C), 120.3 (3a-C), 109.0 (6-C), 107.6 (8-C), 101.3 (9a-C), 74.8 (OC(CH3)2), 65.3 
(OCH2CH2CH2OH), 60.8 (OCH2CH2CH2OH), 46.0 (NCH2CH3), 43.5 (2´-C), 37.1 (C(CH3)2), 31.5 
(OCH2CH2CH2OH), 30.7, 28.9, 23.6, 21.6 (3´-C, 4´-C, 5´-C, 6´-C), 28.1 (C(CH3)2), 27.8 (OC(CH3)2), 
14.7 (NCH2CH3), 13.0 ppm (7´-C); HPLC-MS: [A, 80%→95%], tR: 4.63 min, (96%); MS (ES+, m/z) 
429 [M+H]+; Anal. calcd. for for C26H40N2O3: C 72.86, H 9.41, found: C 72.88, H 9.19. 
1-(3,4-Dichlorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-9-(3-hydroxypropoxy)- 
4,4-dimethylchromeno[4,3-c]pyrazole (1.31).  
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Prepared from 1.7 (20 mg, 0.04 mmol), sodium hydride (2.50 mg, 0.10 mmol) and 3-bromo-1-
propanol (28 µL, 0.20 mmol) following the procedure previously described. Column 
chromatography on silica gel (hexane/EtOAc, 1:1) afforded the 
title compound as a yellow oil (9 mg, 40%); 1H-NMR (300 MHz, 
CDCl3) δ: 7.97 (d, J = 2.5 Hz, 1H, 2- HPh), 7.71 (dd, J = 7.8, 2.5 
Hz, 1H, 6-HPh), 7.49 (d, J = 7.8 Hz, 1H, 5- HPh), 7.47 (s, 1H, 3-
H), 6.62 (d, J = 1.7 Hz, 1H, 6-H), 6.60 (d, J = 1.7 Hz, 1H, 8-H), 
4.12 (t, J = 6.2 Hz, 2H, OCH2CH2CH2OH), 3.88 (t, J = 6.2 Hz, 2H, OCH2CH2CH2OH), 2.09 (p, J = 
6.2 Hz, 2H, OCH2CH2CH2OH), 1.65 (s, 6H, OC(CH3)2), 1.60–1.40 (m, 2H, 2´-H), 1.22 (s, 6H, 
C(CH3)2), 1.20–0.94 (m, 8H, 3´-H, 4´-H, 5´-H, 6´-H), 0.83–0.72 ppm (m, 3H, 7´-H); 13C-NMR (75 
MHz, CDCl3) δ: 155.2 (9-C), 153.9 (5a-C), 152.5 (7-C), 140.7 (1-CPh), 139.7 (9b-C), 136.0 (3-CPh), 
130.3 (3-C), 129.6 (4-CPh), 127.4 (5-CPh), 125.3 (2-CPh), 124.1 (6-CPh), 121.6 (3a-C), 110.7 (6-C), 108.5 
(8-C), 102.3 (9a-C), 75.1 (OC(CH3)2), 67.9 (OCH2CH2CH2OH), 62.1 (OCH2CH2CH2OH), 44.6 (2´-
C), 38.2 (C(CH3)2), 31.7 (OCH2CH2CH2OH), 30.9, 29.1, 24.0, 21.3 (3´-C, 4´-C, 5´-C, 6´-C), 28.6
(C(CH3)2), 27.9 (OC(CH3)2), 14.3 ppm (7´-C); HPLC-MS: [A, 80%→95%], tR: 4.58 min, (93%); MS 
(ES+, m/z) 545 [M+H]+; Anal. calcd. for C30H38Cl2N2O3: C 66.05, H 7.02, found: C 65.81, H 7.13. 
1-(2,4-Dichlorophenyl)-7-(1,1-dimethylheptyl)-1,4-dihydro-9-(3-hydroxypropoxy)-4,4-
dimethyl-9-methoxychromeno[4,3-c]pyrazole (1.32). 
Prepared from 1.8 (51 mg, 0.10 mmol), sodium hydride (5 mg, 0.21 mmol) and 3-bromo-1-propanol 
(71 µL, 0.52 mmol) following the procedure previously described. Column chromatography on silica 
gel (hexane/EtOAc, 1:1) afforded the title compound as a yellow 
gummy solid (18 mg, 31%); 1H-NMR (300 MHz, CDCl3) δ: 7.57 
(s, 1H, 3-H), 7.51 (d, J = 1.8 Hz, 1H, 3-HPh), 7.25–7 .18 (m, 2H, 
5- HPh, 6-HPh), 6.66 (d, J = 1.6 Hz, 1H, 6-H), 6.40 (d, J = 1.6 Hz, 
1H, 8-H), 3.82–3.60 (m, 2H, OCH2CH2CH2OH), 3.56 (t, J = 6.0 
Hz, 2H, OCH2CH2CH2OH), 1.90–1.85 (m, 2H, OCH2CH2CH2OH), 1.63 (s, 6H, OC(CH3)2), 1.57–
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1.46 (m, 2H, 2´-H), 1.24 (s, 6H, C(CH3)2), 1.22–0.96 (m, 8H, 3´-H, 4´-H, 5´-H, 6´-H), 0.84 ppm (t, J
= 6.6 Hz, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 153.6 (9-C), 153.3 (5a-C), 153.2 (7-C), 140.0 (1-
CPh), 134.8 (9b-C), 134.4 (2-CPh), 133.5 (4-CPh), 131.1 (3-C), 129.6 (3-CPh), 128.6 (5-CPh), 127.0 (6-
CPh), 123.5 (3a-C), 109.1 (6-C), 103.7 (8-C), 103.0 (9a-C), 76.5 (OC(CH3)2), 64.9 (OCH2CH2CH2OH), 
59.4 (OCH2CH2CH2OH), 44.3 (2´-C), 38.1 (C(CH3)2), 31.6 (OCH2CH2CH2OH), 31.0, 29.8, 24.5, 
22.5 (3´-C, 4´-C, 5´-C, 6´-C), 28.5 (C(CH3)2), 27.3 (C(CH3)2), 14.0 ppm (7´-C); HPLC-MS: [A, 
80%→95%], tR: 4.72 min, (96%); MS (ES+, m/z) 545 [M+H]+; Anal. calcd. for C30H38Cl2N2O3: C 
66.05, H 7.02, found: C 66.26, H 6.97. 
7-(1,1-Dimethylheptyl)-2,4-dihydro-9-(2-hydroxyethoxy)-4,4-dimethylchromeno[4,3-
c]pyrazole (1.33).  
Prepared from 1.4 (20 mg, 0.06 mmol), sodium hydride (2 mg, 0.08 mmol) and 2-bromoetanol (20 
µL, 0.29 mmol). Column chromatography on silica gel (hexane/EtOAc, 1:1) afforded the title 
compound as a white solid (12 mg, 54%); mp: 85–87 ºC; 1H-NMR (300 MHz, CDCl3) δ: 7.34 (s, 1H, 
3-H), 6.60 (d, J = 1.7 Hz, 1H, 6-H), 6.52 (d, J = 1.7 Hz, 1H, 8-H), 4.19–4.07 (m, 2H, 
OCH2CH2OH), 3.56–3.45 (m, 2H, OCH2CH2OH), 1.64 (s, 6H, OC(CH3)2), 1.60–1.48 (m, 2H, 2´-
H), 1.25 (s, 6H, C(CH3)2), 1.23–0.97 (m, 8H, 3´-H, 4´-H, 5´-H, 
6´-H), 0.88–0.79 ppm (m, 3H, 7´-H); 13C-NMR (75 MHz,
CDCl3) δ: 155.2 (9-C), 154.1 (5a-C), 152.6 (7-C), 141.3 (9b-C), 
124.9 (3-C), 121.9 (3a-C), 109.3 (6-C), 106.6 (8-C), 102.7 (9a-C), 
74.8 (OC(CH3)2), 60.1 (OCH2CH2OH), 51.4 (OCH2CH2OH), 43.2 (2´-C), 37.7 (C(CH3)2), 32.0, 31.4, 
25.7, 22.3 (3´-C, 4´-C, 5´-C, 6´-C), 29.8 (C(CH3)2), 27.9 (OC(CH3)2), 15.0 ppm (7´-C); HPLC-MS: 
[A, 80%→95%], tR: 3.45 min, (93%); MS (ES+, m/z) 387 [M+H]+; Anal. calcd. for C23H34N2O3: C 
71.47, H 8.87, found: C 71.80, H, 8.64.
7-(1,1-Dimethylheptyl)-2,4-dihydro-9-(2-hydroxyethoxy)-2,4,4-trimethylchromeno[4,3-
c]pyrazole (1.34).
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Prepared from 1.5b (20 mg, 0.05 mmol), sodium hydride (2 mg, 0.08 mmol) and 2-bromoetanol (16 
µL, 0.22 mmol) following the procedure previously described. Column chromatography on silica gel 
(hexane/EtOAc, 1:2) afforded the title compound as a pale yellow oil (16 mg, 73%); 1H-NMR (300 
MHz, CDCl3) δ: 7.19 (s, 1H, 3-H), 6.59 (d, J = 1.8 Hz, 1H, 6-
H), 6.51 (d, J = 1.8 Hz, 1H, 8-H), 4.30–4.25 (m, 2H, 
OCH2CH2OH), 4.05 (s, 3H, NCH3), 3.81–3.74 (m, 2H, 
OCH2CH2OH), 1.60 (s, 6H, OC(CH3)2), 1.40–1.35 (m, 2H, 2´-
H), 1.21 (s, 6H, C(CH3)2), 1.12–0.89 (m, 8H, 3´-H, 4´-H, 5´-H, 6´-H), 0.81 ppm (t, J = 6.9 Hz, 3H, 
7´-H); 13C-NMR (75 MHz, CDCl3) δ: 154.1 (9-C), 153.5 (5a-C), 152.3 (7-C), 140.5 (9b-C), 123.8 (3-
C), 121.4 (3a-C), 111.2 (6-C), 108.5 (8-C), 103.6 (9a-C), 76.0 (OC(CH3)2), 64.3 (OCH2CH2OH), 59.2 
(OCH2CH2OH), 40.6 (NCH3), 39.0 (2´-C), 38.1 (C(CH3)2), 32.1, 30.8, 25.7, 21.3 (3´-C, 4´-C, 5´-C, 
6´-C), 29.7 (C(CH3)2), 28.0 (OC(CH3)2), 14.7 ppm (7´-C); HPLC-MS: [A, 80%→95%], tR: 3.41 min, 
(99%); MS (ES+, m/z) 401 [M+H]+; Anal. calcd. for C24H36N2O3: C 71.96, H 9.06, found: C 71.67, 
H, 8.84.
7-(1,1-Dimethylheptyl)-2-ethyl-2,4-dihydro-9-(2-hydroxyethoxy)-4,4-dimethylchromeno[4,3-
c]pyrazole (1.35).
Prepared from 1.6b (25 mg, 0.07 mmol), sodium hydride (4 mg, 0.16 mmol) and 2-bromoetanol (23 
µL, 0.33 mmol) following the procedure previously described. 
Column chromatography on silica gel (hexane/EtOAc, 1:1) 
afforded the title compound as a white oil (13 mg, 48%); 1H-
NMR (300 MHz, CDCl3) δ: 7.22 (s, 1H, 3-H), 6.61 (d, J = 1.8
Hz, 1H, 6-H), 6.57 (d, J = 1.8 Hz, 1H, 8-H), 4.30–4.23 (m, 2H, OCH2CH2OH), 3.95 (q, J = 7.1 Hz,
2H, NCH2CH3), 3.63–3.59 (m, 2H, OCH2CH2OH), 1.62 (s, 6H, OC(CH3)2), 1.54 (t, J = 7.1 Hz, 3H, 
NCH2CH3), 1.40–1.33 (br s, 2H, 2´-H), 1.28 (s, 6H, C(CH3)2), 1.23–0.91 (m, 8H, 3´-H, 4´-H, 5´-H, 
6´-H), 0.88–0.81 ppm (m, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 155.2 (9-C), 153.7 (5a-C), 151.8 
(7-C), 140.3 (9b-C), 124.6 (3-C), 121.5 (3a-C), 110.2 (6-C), 108.6 (8-C), 102.4 (9a-C), 75.1 
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(OC(CH3)2), 68.5 (OCH2CH2OH), 61.3 (OCH2CH2OH), 47.3 (NCH2CH3), 42.9 (2´-C), 37.7
(C(CH3)2), 31.7, 30.2, 25.3, 22.5 (3´-C, 4´-C, 5´-C, 6´-C), 29.2 (C(CH3)2), 28.3 (OC(CH3)2), 15.2 
(NCH2CH3), 14.3 ppm (7´-C); HPLC-MS: [A, 80%→95%], tR: 5.22 min, (92%); MS (ES+, m/z) 415 
[M+H]+; Anal. calcd. for C25H38N2O3: C 72.43, H 9.24, found: C 72.60, H 9.08.
9-(3-Bromopropoxy)-7-(1,1-dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-
c]pyrazole (1.36).
Prepared from 1.5b (43 mg, 0.12 mmol), sodium hydride (4 mg, 0.18 mmol) and 1,3-
dibromopropane (61 µL, 0.60 mmol) following the procedure previously described. Column 
chromatography on silica gel (hexane/EtOAc, 3:1) afforded the title compound as a white solid (27 
mg, 47%); mp: 96–98 ºC; 1H-NMR (300 MHz, CDCl3) δ: 7.49 (s, 1H, 3-H), 6.73 (d, J = 1.8 Hz, 1H, 
6-H), 6.68 (d, J = 1.8 Hz, 1H, 8-H), 4.34 (t, J = 6.3 Hz, 2H, OCH2CH2CH2Br), 4.07 (s, 3H, NCH3), 
3.87 (t, J = 6.3 Hz, 2H, OCH2CH2CH2Br), 2.49 (p, J = 6.3 
Hz, 2H, OCH2CH2CH2Br), 1.60 (s, 6H, OC(CH3)2), 1.58–
1.46 (m, 2H, 2´-H), 1.27 (s, 6H, C(CH3)2), 1.24–0.94 (m, 8H, 
3´-H, 4´-H, 5´-H, 6´-H), 0.90–0.77 ppm (m, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 153.0 (9-C), 
152.5 (5a-C), 151.3 (7-C), 141.0 (9b-C), 124.7 (3-C), 121.8 (3a-C), 109.9 (6-C), 108.5 (8-C), 103.2 (9a-
C), 75.1 (OC(CH3)2), 62.3 (OCH2CH2CH2Br), 46.7 (NCH3), 38.6 (2´-C), 37.3 (C(CH3)2), 33.1 
(OCH2CH2CH2Br), 31.7 (OCH2CH2CH2Br), 30.8, 30.1, 25.6, 21.3 (3´-C, 4´-C, 5´-C, 6´-C), 29.7
(C(CH3)2), 28.1 (OC(CH3)2), 14.0 ppm (7´-C); HPLC-MS: [A, 80%→95%], tR: 5.55 min, (96%); MS 
(ES+, m/z) 477 [M+H]+; Anal. calcd. for C25H37BrN2O2: C 62.89, H 7.81, found: C 63.05, H 7.72.
9-(3-Bromopropoxy)-7-(1,1-dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazole (1.37).
Prepared from 1.6b (20 mg, 0.05 mmol), sodium hydride (2 mg, 0.08 mmol) and 1,3-
dibromopropane (27 µL, 0.27 mmol) following the procedure previously described. Column 
chromatography on silica gel (hexane/EtOAc, 3:1) afforded the title compound as a yellow oil (15 
mg, 55%); 1H-NMR (300 MHz, CDCl3) δ: 7.21 (s, 1H, 3-H), 6.62 (d, J = 1.7 Hz, 1H, 6-H), 6.56 (d, J
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= 1.7 Hz, 1H, 8-H), 4.29–4.16 (m, 2H, OCH2CH2CH2Br), 4.11 (q, 2H, J = 7.0 Hz, NCH2CH3), 
3.52–3.47 (m, 2H, OCH2CH2CH2Br), 2.12–2.04 (m, 2H, OCH2CH2CH2Br), 1.65 (s, 6H, OC(CH3)2), 
1.60 (t, J = 7.0 Hz, 3H, NCH2CH3), 1.40–1.34 (m, 2H, 2´-H), 
1.29 (s, 6H, C(CH3)2), 1.23–0.98 (m, 8H, 3´-H, 4´-H, 5´-H, 6´-
H), 0.86 ppm (t, J = 7.1 Hz, 3H, 7´-H); 13C-NMR (75 MHz,
CDCl3) δ: 152.9 (9-C), 152.1 (5a-C), 150.3 (7-C), 138.4 (9b-C), 
121.7 (3-C), 120.1 (3a-C), 108.3 (6-C), 106.5 (8-C), 101.8 (9a-C), 75.3 (OC(CH3)2), 65.2 
(OCH2CH2CH2Br), 45.9 (NCH2CH3), 44.1 (2´-C), 38.0 (C(CH3)2), 32.7 (OCH2CH2CH2Br), 31.9
(OCH2CH2CH2Br), 31.0, 29.8, 24.2, 21.6 (3´-C, 4´-C, 5´-C, 6´-C), 28.7 (C(CH3)2), 27.5 (OC(CH3)2), 
14.8 (NCH2CH3), 13.5 ppm (7´-C); HPLC-MS: [A, 80%→95%], tR: 5.14 min, (95%); MS (ES+, m/z) 
491 [M+H]+; Anal. calcd. for C26H39BrN2O2: C 63.54, H 8.00, found: C 63.87, H 8.12. 
9-(2-Bromoethoxy)-7-(1,1-dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazole (1.38).
Prepared from 1.6a (20 mg, 0.05 mmol), sodium hydride (2 mg, 0.08 mmol) and 1,2-dibromoethane 
(23 µL, 0.27 mmol) following the general procedure. Column chromatography on silica gel 
(hexane/EtOAc, 2:1) afforded 1.38 as a yellow oil (16 mg, 
64%); 1H-NMR (300 MHz, CDCl3) δ: 7.29 (s, 1H, 3-H), 6.69
(d, J = 1.5 Hz, 1H, 6-H), 6.61 (d, J = 1.5 Hz, 1H, 8-H), 4.38–
4.31 (m, 2H, OCH2CH2Br), 4.03 (q, J = 7.5 Hz, 2H, 
NCH2CH3), 3.71–3.62 (m, 2H, OCH2CH2Br), 1.56 (s, 6H, OC(CH3)2), 1.53 (t, J = 7.5 Hz, 3H, 
NCH2CH3), 1.50–1.42 (m, 2H, 2´-H), 1.27 (s, 6H, C(CH3)2), 1.17–1.04 (m, 8H, 3´-H, 4´-H, 5´-H, 6´-
H), 0.88 ppm (t, J = 6.6 Hz, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 155.3 (9-C), 154.0 (5a-C), 
152.5 (7-C), 142.6 (9b-C), 133.7 (3-C), 124.8 (3a-C), 109.9 (6-C), 108.1 (8-C), 103.5 (9a-C), 76.2 
(OC(CH3)2), 64.7 (OCH2CH2Br), 45.9 (NCH2CH3), 43.8 (2´-C), 37.5 (C(CH3)2), 31.2 (OCH2CH2Br), 
30.3, 29.7, 25.7, 22.3 (3´-C, 4´-C, 5´-C, 6´-C), 29.0 (C(CH3)2), 27.7 (OC(CH3)2), 15.2 (NCH2CH3), 
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14.0 ppm (7´-C); HPLC-MS: [A, 80%→95%], tR: 5.64 min, (95%); MS (ES+, m/z) 477 [M+H]+; 
Anal. calcd. for C25H37BrN2O2: C 62.89, H 7.81, found: C 62.61, H 8.03.
7-(1,1-Dimethylheptyl)-1-ethyl-1,4,9,10-tetrahydro-4,4-dimethyl-8H-
pyrano[2',3':5,6]chromeno[4,3-c]pyrazole (1.39). 
Compound 1.29 (25 mg, 0.06 mmol) in 1.5 mL of dry toluene was added to a stirred suspension of 
P205 (16 mg, 0.12 mmol) in 2 mL of dry toluene under nitrogen atmosphere and the mixture was 
refluxed for 1 hour. After completion, the reaction mixture was cooled to room temperature and 
filtered. The filtrate was diluted with EtOAc and washed with NaOH (0.1 N), water, brine and 
extracted three times with EtOAc. The combined organic layers were dried over MgSO4 and the 
solvent was removed under vacuum. Column chromatography on silica gel (hexane/EtOAc, 4:1) 
afforded 1.39 as a yellow oil (20 mg, 87%); 1H-NMR (300 MHz, CDCl3) δ: 7.39 (s, 1H, 3-H), 6.59 (s, 
1H, 6-H), 4.41–4.32 (m, 2H, OCH2CH2CH2), 4.21–4.16 (m, 
2H, NCH2CH3), 2.84–2.78 (m, 2H, OCH2CH2CH2), 2.09–
2.01 (m, 2H, OCH2CH2CH2), 1.61 (s, 6H, OC(CH3)2), 1.56 (t, 
J = 6.7 Hz, 3H, NCH2CH3), 1.45–1.40 (m, 2H, 2´-H), 1.27 (s, 
6H, C(CH3)2), 1.10–0.96 (m, 8H, 3´-H, 4´-H, 5´-H, 6´-H), 0.85–0.79 ppm (m, 3H, 7´-H); 13C-NMR 
(75 MHz, CDCl3) δ: 153.9 (11a-C), 152.8 (5a-C), 152.0 (7-C), 142.5 (11c-C), 132.3 (3-C), 128.0 (3a-
C), 109.6 (7a-C), 108.3 (6-C), 103.5 (11b-C), 74.9 (OC(CH3)2), 63.7 (OCH2CH2CH2), 46.1
(NCH2CH3), 43.4 (2´-C), 37.7 (C(CH3)2), 32.0, 31.3, 29.4, 24.6, 23.9, 21.2 (3´-C, 4´-C, 5´-C, 6´-C, 
OCH2CH2CH2), 29.0 (C(CH3)2), 28.5 (OC(CH3)2), 15.4 (NCH2CH3), 14.1 ppm (7´-C); HPLC-MS: [A, 
80%→95%], tR: 5.82 min, (95%); MS (ES+, m/z) 411 [M+H]+; Anal. calcd. for C26H38N2O2: C 76.06, 
H 9.33, found: C 75.82, H 9.08.
7-(1,1-Dimethylheptyl)-2-ethyl-2,4,9,10-tetrahydro-4,4-dimethyl-8H-
pyrano[2',3':5,6]chromeno[4,3-c]pyrazole (1.40).
Prepared from 1.30 (71 mg, 0.16 mmol), and P205 (46 mg, 0.33 mmol) following the procedure 
previously described for 1.39. Column chromatography on silica gel (hexane/EtOAc, 4:1) afforded 
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the title compound as a pale yellow oil (23 mg, 52%); 1H-NMR (300 MHz, CDCl3) δ: 7.20 (s, 1H, 3-
H), 6.61 (s, 1H, 6-H), 4.31–4.27 (m, 2H, OCH2CH2CH2), 4.20–
4.16 (m, 2H, NCH2CH3), 2.72–2.69 (m, 2H, OCH2CH2CH2), 
2.11–2.04 (m, 2H, OCH2CH2CH2), 1.67 (s, 6H, OC(CH3)2), 1.52
(t, J = 7.0 Hz, 3H, NCH2CH3), 1.50–1.46 (m, 2H, 2´-H), 1.26 (s, 
6H, C(CH3)2), 1.15–0.99 (m, 8H, 3´-H, 4´-H, 5´-H, 6´-H), 0.84 ppm (t, J = 6.9 Hz, 3H, 7´-H); 13C-
NMR (75 MHz, CDCl3) δ: 154.0 (11a-C), 153.7 (5a-C), 152.5 (7-C), 140.9 (11c-C), 122.3 (3-C), 119.6 
(3a-C), 108.8 (7a-C), 108.1 (6-C), 104.2 (11b-C), 75.3 (OC(CH3)2), 65.0 (OCH2CH2CH2), 45.9 
(NCH2CH3), 44.1 (2´-C), 38.2 (C(CH3)2), 31.4, 30.8, 29.5, 24.9, 24.0, 22.6 (3´-C, 4´-C, 5´-C, 6´-C, 
OCH2CH2CH2), 29.1 (C(CH3)2), 28.7 (OC(CH3)2), 14.9 (NCH2CH3), 13.8 ppm (7´-C); HPLC-MS: [A, 
80%→95%], tR: 5.07 min, (98%); MS (ES+, m/z) 411 [M+H]+; Anal. calcd. for C26H38N2O2: C 76.06, 
H 9.33, found: C 76.35, H 8.99.
7-(1,1-Dimethylheptyl)-4,4-dimethyl-4H-chromeno[3,4-d]isoxazol-9-ol (1.41).  
A solution of 7-(1,1-dimethylheptyl)-5-hydroxy-3-hydroxymethylene-2,2-dimethylchroman-4-one 
(1.3) (0.12 g, 0.35 mmol) and hydroxylamine hydrochloride (49 mg, 0.71 mmol) in ethanol (4 mL) 
was refluxed for 45 minutes. After cooling the mixture, the crude was filtered and washed with cold 
ethanol. After removal of the solvent, the crude was purified by chromatography on silica gel 
(hexane/EtOAc, 2:1) to obtain 1.41 as a pale yellow solid (0.11 g; 91%); mp: 109-111 ºC; 1H-NMR 
(300 MHz, CDCl3) δ: 8.12 (s, 1H, 3-H), 6.57 (d, J = 1.6 Hz, 1H, 8-H), 6.55 (d, J = 1.4 Hz, 6-H), 1.64 
(s, 6H, OC(CH3)2), 1.59–1.47 (m, 2H, 2´-H), 1.24 (s, 6H, 
C(CH3)2), 1.17–1.09  (br s, 8H, 3´-H, 4´-H, 5´-H, 6´-H), 0.82 
ppm (t, J = 7.0 Hz, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 
160.2 (9-C), 156.6 (9b-C), 153.6 (5a-C), 151.7 (7-C), 145.4 (3-C), 
119.4 (9a-C), 109.5 (8-C), 108.1 (6-C), 105.9 (3a-C), 78.0 (OC(CH3)2), 44.5 (2´-C), 38.5 (C(CH3)2), 
31.9, 30.1, 24.8 (3´-C, 4´-C, 5´-C), 29.2 (C(CH3)2), 28.9 (OC(CH3)2), 22.9 (6´-C), 14.3 ppm (7´-C); 
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HPLC-MS: [A, 80%→95%], tR: 2.77 min, (99%); MS (ES+, m/z) 344 [M+H]+; Anal. calcd. for 
C21H29NO3: C 73.44, H 8.51, found: C 73.81, H, 8.59.
7-(1,1-Dimethylheptyl)-9-methoxy-4,4-dimethyl-4H-chromeno[3,4-d]isoxazole (1.42).
Prepared from 1.41 (30 mg, 0.09 mmol), sodium hydride (3 mg, 0.13 mmol), and iodomethane (16 
µL, 0.26 mmol) following the procedure described for 1.14. Column chromatography on silica gel 
(hexane/EtOAc, 2:1) afforded 1.42 as a yellow oil (19 mg, 
61%); 1H-NMR (300 MHz, CDCl3) δ: 8.10 (s, 1H, 3-H), 
6.47 (d, J = 1.6 Hz, 1H, 8-H), 6.35 (d, J = 1.6 Hz, 1H, 6-H), 
3.59 (s, 3H, OCH3), 1.77 (s, 6H, OC(CH3)2), 1.54– 1.31 (m, 
2H, 2´-H), 1.26 (s, 6H, C(CH3)2), 1.17–0.98 (m, 8H, 3´-H, 4´-H, 5´-H, 6´-H), 0.83–0.78 ppm (m, 3H, 
7´-H); 13C-NMR (75 MHz, CDCl3) δ: 165.6 (9-C), 162.2 (9b-C), 157.8 (5a-C), 153.5 (7-C), 150.1 (3-
C), 118.0 (9a-C), 108.3 (8-C), 106.5 (6-C), 103.0 (3a-C), 76.7 (OC(CH3)2), 52.2 (OCH3), 44.3 (2´-C), 
39.4 (C(CH3)2), 32.1, 30.3, 24.8, 23.6 (3´-C, 4´-C, 5´- C, 6´-C), 28.7 (C(CH3)2), 26.0 (OC(CH3)2), 14.6
ppm (7´-C); HPLC-MS: [A, 80%→95%], tR: 4.97 min, (98%); MS (ES+, m/z) 358 [M+H]+; Anal. 
calcd. for C22H31NO3: C 73.92, H 8.74, found: C 74.11, H, 8.95.
7-(1,1-Dimethylheptyl)-9-(3-hydroxypropoxy)-4,4-dimethyl-4H-chromeno[3,4-d]isoxazole 
(1.43). 
Prepared from 1.41 (50 mg, 0.14 mmol), sodium hydride (7 mg, 0.29 mmol) and 3-bromo-1-
propanol (99 µL, 0.72 mmol) as described for compounds 1.21−1.38. Column chromatography on 
silica gel (hexane/EtOAc, 2:1) afforded the title compound. 
Compound 1.43 was obtained as a yellow oil (13 mg, 22%); 1H-
NMR (300 MHz, CDCl3) δ: 8.11 (s, 1H, 3-H), 6.69 (d, J = 1.6 
Hz, 1H, 8-H), 6.58 (d, J = 1.6 Hz, 1H, 6-H), 4.15 (t, J = 7.1 Hz, 
2H, OCH2CH2CH2OH), 3.78 (t, J = 4.7 Hz, 2H, OCH2CH2CH2OH), 2.11–2.09 (m, 2H, 
OCH2CH2CH2OH), 1.65 (s, 6H, OC(CH3)2), 1.61–1.57 (m 2H, 2´-H), 1.51 (s, 6H, C(CH3)2), 1.23–
1.14 (m, 8H, 3´-H, 4´-H, 5´-H, 6´-H), 0.86–0.80 ppm (m, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 
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160.5 (9-C), 155.7 (9b-C), 154.0 (5a-C), 150.9 (7-C), 143.5 (3-C), 120.6 (9a-C), 108.9 (8-C), 106.3 (6-
C), 105.8 (3a-C), 75.0 (OC(CH3)2), 66.3 (OCH2CH2CH2OH), 62.8 (OCH2CH2CH2OH), 44.3 (2´-C), 
40.1 (OCH2CH2CH2OH), 38.3 (C(CH3)2), 32.7, 31.5, 23.9, 22.6 (3´-C, 4´-C, 5´-C, 6´-C), 28.3 
(C(CH3)2), 27.1 (OC(CH3)2), 14.7 ppm (7´-C); HPLC-MS: [A, 80%→95%], tR: 2.96 min, (95%); MS 
(ES+, m/z) 402 [M+H]+; Anal. calcd. for C24H35NO4: C 71.79, H 8.79, found: C 72.06, H, 8.55.
General procedure for the synthesis of alkoxychromenopyrazoles 1.44−1.55
The corresponding chromenopyrazole (1eq) was dissolved in anhydrous THF (1-5 mL); the solution 
was added over sodium hydride (1.5-3 eq) under nitrogen atmosphere. After 10 minutes stirring at 
room temperature, an excess of the corresponding 1-bromoalkane (5-10 eq) was rapidly added to 
the solution and the mixture was refluxed (2-12 h). After completion of the reaction (determined by 
TLC), the mixture was dissolved in EtOAc, washed with water and extracted three times with 
EtOAc. The combined organic layers were dried over MgSO4 and the solvent was removed under 
vacuum. The crude was purified by gradient flash column chromatography with hexane and EtOAc 
performed on a Biotage Isolera One.  
9-Decyloxy-7-(1,1-dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-c]pyrazole 
(1.44). 
1.44 was prepared from 1.5b (20 mg, 0.056 mmol), sodium hydride (3.3 mg, 0.14 mmol) and 1-
bromodecane (81 μL, 0.39 mmol). A pale-yellow oil was obtained (18 mg, 66%). 1H-NMR (500 
MHz, CDCl3) δ: 7.07 (s, 1H, 3-H), 6.56 (d, J = 1.7 Hz, 1H, 8-H), 6.53 (d, J = 1.7 Hz, 1H, 6-H), 4.10 
(t, J = 7.1 Hz, 2H, 1’’-H), 3.92 (s, 3H, NCH3), 1.92 (p, J =7.1 Hz, 2H, 2’’-H), 1.62–1.50 (br s, 10H, 
OC(CH3)2, alkyl chain), 1.42–1.39 (m, 2H, 2’-H), 1.35–1.22 (m, 18H, C(CH3)2, alkyl chain), 1.21–1.12 
(m, 4H, alkyl chain), 1.10–0.96 (m, 2H, 3’-H), 0.88 (t, J = 6.8 
Hz, 3H, 12’’-H), 0.83 ppm (t, J = 7.2 Hz, 3H, 7’-H); 13C-
NMR (126 MHz, CDCl3) δ: 155.0 (9-C), 153.7 (7-C), 151.1 
(5a-C), 141.3 (9b-C), 123.1 (3-C), 122.1 (3a-C), 108.4 (8-C), 105.4 (6-C), 103.9 (9a-C), 75.4 
(OC(CH3)2), 69.0 (1’’-C), 44.5 (NCH3), 39.0 (2’-C), 38.0 (C(CH3)2), 32.8, 31.9, 31.8, 29.9, 29.7, 29.6, 
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29.5, 29.4, 25.9, 22.7 and 22.6 (alkyl chain), 28.9 (OC(CH3)2), 28.8 (C(CH3)2), 24.5 (3’-C), 14.1 (7’-C), 
14.0 ppm (10’’-C); HRMS calcd for C32H53N2O2 [M+H]+: 497.4102, found: 497.4106. 
9-Decyloxy-7-(1,1-dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazole 
(1.45). 
1.45 was prepared from 1.6a (14 mg, 0.038 mmol), sodium 
hydride (2 mg, 0.95 mmol) and 1-bromodecane (55 μL, 0.27 
mmol). A white oil was obtained (12 mg, 62%). 1H-NMR (500 
MHz, CDCl3) δ: 7.32 (s, 1H, 3-H), 6.66 (d, J = 1.7 Hz, 1H, 8-H), 6.54 (d, J = 1.7 Hz, 1H, 6-H), 4.53 
(q, J = 7.2 Hz, 2H, NCH2CH3), 4.08 (t, J = 7.0 Hz, 2H, 1’’-H), 1.85 (p, J = 7.0 Hz, 2H, 2’’-H), 1.55 
(s, 6H, OC(CH3)2), 1.48–1.40 (m, 2H, 2’-H), 1.38 (t, J = 7.2 Hz, 3H, NCH2CH3), 1.33–1.21 (m, 20H, 
alkyl chain), 1.22–1.15 (m, 6H, C(CH3)2), 1.11–1.04 (m, 2H, 3’-H), 0.88 (t, J = 6.8 Hz, 3H, 10’’-H), 
0.84 ppm (t, J = 7.0 Hz, 3H, 7’-H); 13C-NMR (126 MHz, CDCl3) δ: 153.9 (9-C), 153.4 (7-C), 152.1 
(5a-C), 132.2 (9b-C), 132.0 (3-C), 123.2 (3a-C), 109.5 (6-C), 104.6 (8-C), 103.7 (9a-C), 76.4 
(OC(CH3)2), 69.0 (1’’-C), 47.9 (NCH2CH3), 44.4 (2’-C), 38.0 (C(CH3)2), 31.9, 31.7, 29.9, 29.54, 29.52, 
29.4, 29.3, 29.2, 26.1, 22.7 and 22.6 (alkyl chain), 28.7 (C(CH3)2), 27.2 (OC(CH3)2), 24.6 (3’-C), 15.5 
(NCH2CH3), 14.1 (7’-C), 14.0 ppm (10’’-C); HRMS calcd for C33H55N2O2 [M+H]+: 511.4258, found: 
511.4260.
9-Decyloxy-7-(1,1-dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazole 
(1.46). 
Compound 1.46 was prepared from 1.6b (18 mg, 0.048 mmol), sodium hydride (2.9 mg, 0.12 mmol) 
and 1-bromodecane (70 μL, 0.34 mmol). A pale-yellow oil was obtained (18 mg, 75%). 1H-NMR 
(500 MHz, CDCl3) δ: 7.11 (s, 1H, 3-H), 6.56 (d, J = 1.7 Hz, 1H, 8-H), 6.52 (d, J = 1.7 Hz, 1H, 6-H), 
4.19 (q, J = 7.3 Hz, 2H, NCH2CH3), 4.09 (t, J = 6.6 Hz, 2H, 1’’-H), 1.91 (p, J = 6.6 Hz, 2H, 2’’-H), 
1.58 (s, 6H, OC(CH3)2), 1.52 (t, J = 7.3 Hz, 3H, NCH2CH3), 1.43–1.33 (m, 2H, 2’-H), 1.32 – 1.22 (br 
s, 20H, C(CH3)2, alkyl chain), 1.19–1.13 (m, 6H, alkyl chain), 1.09–0.97 (m, 2H, 3’-H), 0.87 (t, J = 6.8, 
3H, 10’’-H), 0.83 ppm (t, J = 7.0 Hz, 3H, 7’-H); 13C-NMR (126 MHz, CDCl3) δ: 155.0 (9-C), 153.7 
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(7-C), 151.0 (5a-C), 140.9 (9b-C), 121.7 (3-C), 121.3 (3a-C), 108.4 (6-C), 105.6 (8-C), 103.9 (9a-C), 
75.5 (OC(CH3)2), 68.9 (1’’-C), 47.0 (NCH2CH3), 44.6 (2’-C), 
37.9 (C(CH3)2), 31.9, 31.7, 29.9, 29.7, 29.6, 29.5, 29.3, 26.1, 
22.7 and 22.6 (alkyl chain), 28.9 (OC(CH3)2), 28.8 (C(CH3)2), 
24.6 (3’-C), 15.4 (NCH2CH3), 14.1 (7’-C), 14.0 ppm (10’’-C); 
HRMS calcd for C33H55N2O2 [M+H]+: 511.4258, found: 511.4277.
7-(1,1-Dimethylheptyl)-9-dodecyloxy-2,4-dihydro-2,4,4-trimethylchromeno[4,3-c]pyrazole 
(1.47). 
Compound 1.47 was prepared from 1.5b (30 mg, 0.084 mmol), sodium hydride (5 mg, 0.21 mmol) 
and 1-bromododecane (0.14 mL, 0.59 mmol). A yellow 
oil was obtained (14 mg, 32%). 1H-NMR (500 MHz, 
CDCl3) δ: 7.08 (s, 1H, 3-H), 6.56 (d, J = 1.6 Hz, 1H, 8-
H), 6.53 (d, J = 1.6 Hz, 1H, 6-H), 4.10 (t, J = 6.9 Hz, 2H, 1’’-H), 3.92 (s, 3H, NCH3), 1.92 (p, J =7.0 
Hz, 2H, 2’’-H), 1.58–1.56 (br s, 8H, alkyl chain), 1.55 (s, 6H, OC(CH3)2), 1-40–1.36 (m, 2H, 2’-H), 
1.30–1.24 (br s, 18H, C(CH3)2, alkyl chain), 1.24–1.14 (m, 4H, alkyl chain), 1.08–1.01 (m, 2H, 3’-H), 
0.88 (t, J = 6.9 Hz, 3H, 12’’-H), 0.83 ppm (t, J = 7.0 Hz, 3H, 7’-H); 13C-NMR (126 MHz, CDCl3) δ: 
155.1 (9-C), 153.8 (7-C), 151.2 (5a-C), 141.3 (9b-C), 123.1 (3-C), 122.1 (3a-C), 108.4 (8-C), 106.3 (6-
C), 103.9 (9a-C), 75.4 (OC(CH3)2), 69.0 (1’’-C), 44.6 (NCH3), 39.1 (2’-C), 38.0 (C(CH3)2), 31.9, 31.8, 
30.0, 29.72, 29.70, 29.66, 29.65, 29.58, 29.38, 29.37, 26.0, 22.7 and 22.6 (alkyl chain), 28.9 (OC(CH3)2), 
28.8 (C(CH3)2), 24.6 (3’-C), 14.1 (7’-C), 14.0 ppm (12’’-C); HRMS calcd for C34H57N2O2 [M+H]+: 
525.4415, found: 525.4414.
7-(1,1-Dimethylheptyl)-9-dodecyloxy-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazole (1.48). 
1.48 was prepared from 1.6a (30 mg, 0.08 mmol), sodium hydride (6 mg, 0.24 mmol) and 1-
bromododecane (0.19 mL, 0.81 mmol). A yellow oil was obtained (17 mg, 39%). 1H-NMR (500 
MHz, CDCl3) δ: 7.32 (s, 1H, 3-H), 6.66 (d, J = 1.7 Hz, 1H, 8-H), 6.54 (d, J = 1.7 Hz, 1H, 6-H), 4.53 
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(q, J = 7.2 Hz, 2H, NCH2CH3), 4.08 (t, J = 7.0 Hz, 2H, 1’’-H), 1.85 (p, J = 7.2 Hz, 2H, 2’’-H), 1.59–
1.51 (m, 10H, OC(CH3)2, alkyl chain), 1.46–1.40 (m, 
2H, 2’-H), 1.38 (t, J = 7.2 Hz, 3H, NCH2CH3), 1.28 -
1.26 (br s, 10H, alkyl chain), 1.26–1.25 (br s, 12H, 
C(CH3)2, alkyl chain), 1.21–1.18 (m, 4H, alkyl chain), 
1.10–1.03 (m, 2H, 3’-H), 0.88 (t, J = 6.9 Hz, 3H, 12’’-H), 0.84 ppm (t, J = 6.8 Hz, 3H, 7’-H); 13C-
NMR (126 MHz, CDCl3) δ: 153.9 (9-C), 153.4 (7-C), 152.2 (5a-C), 132.2 (9b-C), 132.1 (3-C), 123.3 
(3a-C), 109.5 (6-C), 104.6 (8-C), 103.7 (9a-C), 76.4 (OC(CH3)2), 69.0 (1’’-C), 47.9 (NCH2CH3), 44.4 
(2’-C), 38.0 (C(CH3)2), 31.9, 31.7, 29.9, 29.7, 29.6, 29.58, 29.56, 29.46, 29.3, 29.2, 26.1, 22.7 and 22.6 
(alkyl chain), 28.8 (C(CH3)2), 27.2 (OC(CH3)2), 24.6 (3’-C), 15.5 (NCH2CH3), 14.1 (7’-C), 14.0 ppm 
(12’’-C); HRMS calcd for C35H59N2O2 [M+H]+: 539.4571, found: 539.4556.
7-(1,1-Dimethylheptyl)-9-dodecyloxy-2-ethyl-2,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazole (1.49). 
Compound 1.49 was prepared from 1.6b (42 mg, 0.11 mmol), sodium hydride (7 mg, 0.28 mmol) 
and 1-bromododecane (0.19 mL, 0.79 mmol). A yellow oil was obtained (45 mg, 74%). 1H-NMR 
(500 MHz, CDCl3) δ: 7.11 (s, 1H, 3-H), 6.56 (d, J = 
1.6 Hz, 1H, 8-H), 6.52 (d, J = 1.6 Hz, 1H, 6-H), 4.19 
(q, J = 7.3 Hz, 2H, NCH2CH3), 4.09 (t, J = 6.6 Hz, 
2H, 1’’-H), 1.91 (p, J = 6.6 Hz, 2H, 2’’-H), 1.62 (p, J = 
7.1 Hz, 2H, alkyl chain), 1.58 (s, 6H, OC(CH3)2), 1.53 (t, J = 7.3 Hz, 3H, NCH2CH3), 1.43–1.35 (m, 
2H, 2’-H), 1.27–1.25 (br s, 22H, C(CH3)2, alkyl chain), 1.19 – 1.14 (m, 6H, alkyl chain), 1.07 – 1.00 (m, 
2H, 3’-H), 0.88 (t, J = 7.1, 3H, 12’’-H), 0.83 ppm (t, J = 7.0 Hz, 3H, 7’-H); 13C-NMR (126 MHz, 
CDCl3) δ: 155.1 (9-C), 153.7 (7-C), 151.0 (5a-C), 140.9 (9b-C), 121.8 (3-C), 121.4 (3a-C), 108.4 (6-C), 
105.6 (8-C), 104.0 (9a-C), 75.5 (OC(CH3)2), 67.0 (1’’-C), 47.0 (NCH2CH3), 44.6 (2’-C), 38.0 
(C(CH3)2), 31.9, 31.8, 30.0, 29.72, 29.71, 29.68, 29.65, 29.64, 29.5, 29.4, 26.1, 22.7 and 22.6 (alkyl 
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chain), 28.9 (OC(CH3)2), 28.8 (C(CH3)2), 24.6 (3’-C), 15.4 (NCH2CH3), 14.1 (7’-C), 14.0 ppm (12’’-C); 
HRMS calcd for C35H59N2O2 [M+H]+: 539.4571, found: 539.4578. 
7-(1,1-Dimethylheptyl)-2,4-dihydro-9-tetradecyloxy-2,4,4-trimethylchromeno[4,3-c]pyrazole 
(1.50) 
Compound 1.50 was prepared from 1.5b (28 mg, 0.078 mmol), sodium hydride (4.7 mg, 0.19 mmol) 
and 1-bromotetradecane (0.15 mL, 0.52 mmol). A yellow oil was obtained (32 mg, 74%). 1H-NMR 
(500 MHz, CDCl3) δ: 7.07 (s, 1H, 3-H), 6.56 (d, J = 
1.7 Hz, 1H, 8-H), 6.53 (d, J = 1.7 Hz, 1H, 6-H), 
4.10 (t, J = 6.8 Hz, 2H, 1’’-H), 3.91 (s, 3H, NCH3), 
1.92 (p, J =6.8 Hz, 2H, 2’’-H), 1.57–1.54 (br s, 12H, OC(CH3)2, alkyl chain), 1.42–1.36 (m, 2H, 2’-H), 
1.31–1.23 (m, 22H, C(CH3)2, alkyl chain), 1.20–1.15 (m, 6H, alkyl chain), 1.09–1.00 (m, 2H, 3’-H), 0.88 
(t, J = 6.7 Hz, 3H, 14’’-H), 0.83 ppm (t, J = 6.8 Hz, 3H, 7’-H); 13C-NMR (126 MHz, CDCl3) δ: 155.0 
(9-C), 153.7 (7-C), 151.1 (5a-C), 141.2 (9b-C), 123.1 (3-C), 122.1 (3a-C), 108.4 (8-C), 105.4 (6-C), 
103.8 (9a-C), 75.3 (OC(CH3)2), 69.0 (1’’-C), 44.5 (NCH3), 39.0 (2’-C), 37.9 (C(CH3)2), 31.9, 31.7, 29.9, 
29.7, 29.69, 29.63, 29.60, 29.5, 29.4, 29.3, 26.0, 22.7 and 22.6 (alkyl chain), 28.9 (OC(CH3)2), 28.8 
(C(CH3)2), 24.5 (3’-C), 14.1 (7’-C), 14.0 ppm (14’’-C); HRMS calcd for C36H61N2O2 [M+H]+: 
553.4728, found: 553.4736.
7-(1,1-Dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethyl-9-tetradecyloxychromeno[4,3-
c]pyrazole (1.51) 
Compound 1.51 was prepared from 1.6a (16.5 mg, 0.045 mmol), sodium hydride (3 mg, 0.11 mmol) 
and 1-bromotetradecane (94 μL, 0.32 mmol). A yellow oil was obtained (19 mg, 75%). 1H-NMR 
(500 MHz, CDCl3) δ: 7.32 (s, 1H, 3-H), 6.66 (d, J = 
1.7 Hz, 1H, 8-H), 6.54 (d, J = 1.7 Hz, 1H, 6-H), 
4.53 (q, J = 7.2 Hz, 2H, NCH2CH3), 4.08 (t, J = 7.0 
Hz, 2H, 1’’-H), 1.85 (p, J = 7.0 Hz, 2H, 2’’-H), 1.55 (s, 6H, OC(CH3)2), 1.47–1.40 (m, 2H, 2’-H), 
1.38 (t, J = 7.2 Hz, 3H, NCH2CH3), 1.28 (s, 6H, C(CH3)2), 1.27–1.24 (m, 22H, alkyl chain), 1.23–1.16 
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(m, 6H, alkyl chain), 1.11–1.03 (m, 2H, 3’-H), 0.88 (t, J = 6.8 Hz, 3H, 14’’-H), 0.84 ppm (t, J = 7.2 
Hz, 3H, 7’-H); 13C-NMR (126 MHz, CDCl3) δ: 153.9 (9-C), 153.4 (7-C), 152.1 (5a-C), 132.2 (9b-C), 
132.0 (3-C), 123.2 (3a-C), 109.5 (6-C), 104.6 (8-C), 103.7 (9a-C), 76.3 (OC(CH3)2), 69.0 (1’’-C), 47.9 
(NCH2CH3), 44.4 (2’-C), 38.0 (C(CH3)2), 31.9, 31.7, 29.9, 29.7, 29.63, 29.58, 29.55, 29.4, 29.3, 29.2, 
26.1, 22.7 and 22.6 (alkyl chain), 28.7(C(CH3)2), 27.2 (OC(CH3)2), 24.6 (3’-C), 15.5 (NCH2CH3), 14.1 
(7’-C), 14.0 ppm (14’’-C); HRMS calcd for C37H63N2O2 [M+H]+: 567.4884, found: 567.4898.
7-(1,1-Dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethyl-9-tetradecyloxychromeno[4,3-
c]pyrazole (1.52) 
Compound 1.52 was prepared from 1.6b (23 mg, 0.06 mmol), sodium hydride (3.7 mg, 0.15 mmol) 
and 1-bromotetradecane (0.13 mL, 0.43 mmol). A yellow oil was obtained (23 mg, 66%). 1H-NMR 
(500 MHz, CDCl3) δ: 7.11 (s, 1H, 3-H), 6.56 (d, J = 
1.7 Hz, 1H, 8-H), 6.52 (d, J = 1.7 Hz, 1H, 6-H), 
4.19 (q, J = 7.3 Hz, 2H, NCH2CH3), 4.09 (t, J = 6.7 
Hz, 2H, 1’’-H), 1.92 (p, J = 6.7 Hz, 2H, 2’’-H), 1.58 
(s, 6H, OC(CH3)2), 1.53 (t, J = 7.3 Hz, 3H, NCH2CH3), 1.45–1.32 (m, 8H, 2’-H, alkyl chain), 1.26–
1.24 (br s, 22H, C(CH3)2, alkyl chain), 1.20–1.13 (m, 6H, alkyl chain), 1.08–1.00 (m, 2H, 3’-H), 0.88 (t, 
J = 6.7, 3H, 14’’-H), 0.83 ppm (t, J = 7.0 Hz, 3H, 7’-H); 13C-NMR (126 MHz, CDCl3) δ:  155.0 (9-
C), 153.7 (7-C), 151.0 (5a), 140.9 (9b-C), 121.7 (3-C), 121.3 (3a-C), 108.4 (6-C), 105.5 (8-C), 103.9 
(9a-C), 75.4 (OC(CH3)2), 68.9 (1’’-C), 47.0 (NCH2CH3), 44.6 (2’-C), 37.9 (C(CH3)2), 31.9, 31.7, 29.9, 
29.71, 29.70, 29.65, 29.63, 29.5, 29.4, 22.7 and 22.6 (alkyl chain), 28.9 (OC(CH3)2), 28.8 (C(CH3)2), 
24.5 (3’-C), 15.4 (NCH2CH3), 14.1 (7’-C), 14.0 ppm (14’’-C); HRMS calcd for C37H63N2O2 [M+H]+: 
567.4884, found: 567.4899. 
7-(1,1-Dimethylheptyl)-9-hexadecyloxy-2,4-dihydro-2,4,4-trimethylchromeno[4,3-c]pyrazole 
(1.53)
Compound 1.53 was prepared from 1.5b (50 mg, 0.14 mmol), sodium hydride (5 mg, 0.21 mmol) 
and 1-bromohexadecane (0.21 mL, 0.7 mmol). A pale-yellow oil was obtained (73 mg, 90%). 1H-
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NMR (500 MHz, CDCl3) δ: 7.07 (s, 1H, 3-H), 6.56 (d, J = 1.6, 1H, 8-H), 6.53 (d, J = 1.6 Hz, 1H, 6-
H), 4.10 (t, J = 6.8 Hz, 2H, 1’’-H), 3.92 (s, 3H, 
NCH3), 1.92 (p, J = 6.9 Hz, 2H, 2’’-H), 1.57 (s, 
6H, OC(CH3)2), 1.56–1.54 (br s, 12H, alkyl chain), 
1.41–1.36 (m, 2H, 2’-H), 1.27–1.24 (m, 22H, C(CH3)2, alkyl chain), 1.17 (m, 4H, alkyl chain), 1.08 –
1.01 (m, 2H, 3’-H), 0.88 (t, J = 7.0, 3H, 16’’-H), 0.83 ppm (t, J = 7.0, 3H, 7’-H); 13C-NMR (126 
MHz, CDCl3) δ: 155.1 (9-C), 153.8 (7-C), 151.1 (5a-C), 141.3 (9b-C), 123.1 (3-C), 122.1 (3a-C), 108.4 
(6-C), 105.5 (8-C), 103.9 (9a-C), 75.4 (OC(CH3)2), 69.0 (1’’-C), 44.6 (NCH3), 39.0 (2’-C), 38.0 
(C(CH3)2), 31.9, 31.8, 30.0, 29.71, 29.66, 29.59, 29.38, 29.36, 26.0, 22.7 and 22.6 (alkyl chain), 28.9 
(OC(CH3)2), 28.8 (C(CH3)2), 24.6 (3’-C), 14.1 (7’-C), 14.0 ppm (16’’-C); HRMS calcd for C38H65N2O2
[M+H]+: 581.5041, found: 581.5045.
7-(1,1-Dimethylheptyl)-1-ethyl-9-hexadecyloxy-1,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazole (1.54). 
Compound 1.54 was prepared from 1.6a (50 mg, 0.14 mmol), sodium hydride (10 mg, 0.41 mol) and 
1-bromohexadecane (0.21 mL, 1.4 mmol). A 
orange oil was obtained (46 mg, 57%). 1H-NMR 
(500 MHz, CDCl3) δ: 7.32 (s, 1H, 3-H), 6.66 (d, J = 
1.7 Hz, 1H, 8-H), 6.54 (d, J = 1.7 Hz, 1H, 6-H), 
4.53 (q, J = 7.2 Hz, 2H, NCH2CH3), 4.08 (t, J = 7.0 Hz, 2H, 1’’-H), 1.85 (p, J = 7.1 Hz, 2H, 2’’-H), 
1.55 (s, 6H, OC(CH3)2), 1.46–1.41 (m, 2H, 2’-H), 1.38 (t, J = 7.2 Hz, 3H, NCH2CH3), 1.27 (s, 6H, 
C(CH3)2), 1.26–1.25 (br s, 24H, alkyl chain), 1.22–1.18 (m, 8H, alkyl chain), 1.11–1.03 (m, 2H, 3’-H), 
0.87 (t, J = 6.8 Hz, 3H, 16’’-H), 0.83 ppm (t, J = 6.6 Hz, 3H, 7’-H); 13C-NMR (126 MHz, CDCl3) δ: 
153.9 (9-C), 153.4 (7-C), 152.1 (5a-C), 132.2 (9b-C), 132.0 (3-C), 123.3 (3a-C), 109.5 (6-C), 104.6 (8-
C), 103.7 (9a-C), 76.4 (OC(CH3)2), 69.0 (1’’-C), 47.9 (NCH2CH3), 44.4 (2’-C), 38.0 (C(CH3)2), 31.9, 
31.7, 29.9, 29.69, 29.65, 29.59, 29.56, 29.5, 29.4, 29.2, 26.1, 22.7 and 22.6 (alkyl chain), 28.8 (C(CH3)2), 
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27.2 (OC(CH3)2), 24.6 (3’-C), 15.5 (NCH2CH3), 14.1 (7’-C), 14.0 ppm (16’’-C); HRMS calcd for 
C39H67N2O2 [M+H]+: 595.5197, found: 595.5213. 
7-(1,1-Dimethylheptyl)-2-ethyl-9-hexadecyloxy-2,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazole (1.55).
Compound 1.55 was prepared from 1.6b (45 mg, 0.12 mmol), sodium hydride (9 mg, 0.36 mmol) 
and 1-bromohexadecane (0.26 mL, 0.85 mmol). A orange oil was obtained (31 mg, 43%). 1H-NMR 
(500 MHz, CDCl3) δ: 7.11 (s, 1H, 3-H), 6.55 (d, J = 
1.6 Hz, 1H, 8-H), 6.52 (d, J = 1.6 Hz, 1H, 6-H), 
4.19 (q, J = 7.3 Hz, 2H, NCH2CH3), 4.09 (t, J = 6.8 
Hz, 2H, 1’’-H), 1.91 (p, J = 6.8 Hz, 2H, 2’’-H), 
1.65–1.59 (m, 2H, alkyl chain), 1.58 (s, 6H, OC(CH3)2), 1.52 (t, J = 7.3 Hz, 3H, NCH2CH3), 1.42–1.34 
(m, 2H, 2’-H), 1.27–1.25 (br s, 30H, C(CH3)2, alkyl chain), 1.22–1.10 (m, 6H, alkyl chain), 1.04–1.00 
(m, 2H, 3’-H), 0.88 (t, J = 7.0 Hz, 3H, 16’’-H), 0.83 ppm (t, J = 7.0 Hz, 3H, 7’-H); 13C-NMR (126 
MHz, CDCl3) δ: 155.1 (9-C), 153.7 (7-C), 151.0 (5a-C), 140.9 (9b-C), 121.8 (3-C), 121.4 (3a-C), 108.4 
(6-C), 105.6 (8-C), 104.0 (9a-C), 75.5 (OC(CH3)2), 69.0 (1’’-C), 47.0 (NCH2CH3), 44.6 (2’-C), 38.0 
(C(CH3)2), 31.9, 31.8, 30.0, 29.73, 29.71, 29.69, 29.66, 29.65, 29.5, 29.4, 26.1, 22.7 and 22.6 (alkyl 
chain), 28.9 (OC(CH3)2), 28.8 (C(CH3)2), 24.6 (3’-C), 15.4 (NCH2CH3), 14.1 (7’-C), 14.0 ppm (16’’-C); 
HRMS calcd for C39H67N2O2 [M+H]+: 595.5197, found: 595.5203.
General procedure the synthesis of bivalent chromenopyrazoles 1.56−1.67
A solution of the corresponding chromenopyrazole (1 eq) in anhydrous THF (1-5 mL) was added to 
a Kimax® vial containing Cs2CO3 (10 eq) under nitrogen atmosphere. After 10 minutes stirring, the 
correspondent dibromoalkane (0.5 eq) was added. The mixture was heated at reflux temperature for 
8-72 hours. Then, the mixture was dissolved in EtOAc, washed with water and extracted three times 
with EtOAc. The organic layers were combined and dried over MgSO4, filtered and the solvent was 
evaporated under reduced pressure. The crude was purified by gradient flash column 
chromatography with hexane and EtOAc performed on a Biotage Isolera One.  
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1,10-Bis[(7-(1,1-dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-c]pyrazol-9-
yl)oxy]decane (1.56). 
 Compound 1.56 was prepared from 1.5b (28 mg, 0.08 mmol), Cs2CO3 (0.25 g, 0.78 mmol) and 1,10-
dibromodecane (11 mg, 0.039 mmol). A yellow oil was 
obtained (6 mg, 18%). 1H-NMR (500 MHz, CDCl3) δ: 
7.07 (s, 2H, 3-H), 6.56 (d, J = 1.7 Hz, 2H, 8-H), 6.53 
(d, J = 1.7 Hz, 2H, 6-H), 4.10 (t, J = 6.8 Hz, 4H, 1’’-
H), 3.91 (s, 6H, NCH3), 1.92 (p, J = 6.9 Hz, 4H, 2’’-H), 1.63–1.49 (m, 24H, OC(CH3)2, alkyl chain), 
1.42–1.38 (m, 8H, 2’-H, alkyl chain), 1.26 (s, 12H, C(CH3)2), 1.23–1.13 (m, 12H, alkyl chain), 1.08–1.00 
(m, 4H, 3’-H), 0.83 ppm (t, J = 7.0 Hz, 6H, 7’-H); 13C-NMR (126 MHz, CDCl3) δ: 155.1 (9-C), 153.8 
(7-C), 151.2 (5a-C), 141.2 (9b-C), 123.2 (3-C), 122.1 (3a-C), 108.4 (8-C), 105.4 (6-C), 103.9 (9a-C), 
75.4 (OC(CH3)2), 69.0 (1’’-C), 44.6 (NCH3), 39.0 (2’-C), 38.0 (C(CH3)2), 31.7, 29.9, 29.66, 29.61, 29.4, 
26.0 and 22.6 (alkyl chain), 28.9 (OC(CH3)2), 28.8 (C(CH3)2), 24.6 (3’-C), 14.1 ppm (7’-C); HRMS 
calcd for C54H83N4O4 [M+H]+: 851.6409, found: 851.6392.
1,10-Bis[(7-(1,1-dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-
yl)oxy]decane (1.57). 
 Compound 1.57 was prepared from 1.6a (23 mg, 0.062 mmol), Cs2CO3 (0.20 g, 0.62 mmol) and 
1,10-dibromodecane (9.0 mg, 0.03 mmol). A yellow oil was obtained (12 mg, 44%). 1H-NMR (500 
MHz, CDCl3) δ: 7.32 (s, 2H, 3-H), 6.66 (d, J = 1.7 Hz, 2H, 8-H), 6.54 (d, J = 1.7 Hz, 2H, 6-H), 4.53 
(q, J = 7.2 Hz, 4H, NCH2CH3), 4.08 (t, J = 7.1 Hz, 4H, 1’’-H), 1.85 (p, J = 7.1 Hz, 4H, 2’’-H), 1.54–
1.57 (br s, 24H, OC(CH3)2, alkyl chain), 1.48–1.40 (m, 
4H, 2’-H), 1.37 (t, J = 7.2 Hz, 6H, NCH2CH3), 1.33–
1.29 (m, 8H, alkyl chain), 1.27–1.25 (br s, 12H, C(CH3)2), 
1.23–1.15 (m, 4H, alkyl chain), 1.13–1.02 (m, 4H, 3’-H), 
0.82 ppm (t, J = 7.0 Hz, 6H, 7’-H); 13C-NMR (126 MHz, CDCl3) δ: 153.9 (9-C), 153.4 (7-C), 152.1 
(5a-C), 132.2 (9b-C), 132.0 (3-C), 123.3 (3a-C), 109.5 (6-C), 104.6 (8-C), 103.6 (9a-C), 76.4 
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(OC(CH3)2), 69.0 (1’’-C), 47.9 (NCH2CH3), 44.4 (2’-C), 38.0 (C(CH3)2), 31.7, 29.9, 29.50, 29.47, 29.2, 
26.1 and 22.6 (alkyl chain), 28.7 (C(CH3)2), 27.2 (OC(CH3)2), 24.6 (3’-C), 15.5 (NCH2CH3), 14.1 ppm 
(7’-C); HRMS calcd for C56H87N4O4 [M+H]+: 879.6722, found: 879.6704.
1,10-Bis[(7-(1,1-dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-
yl)oxy]decane (1.58). 
 Compound 1.58 was prepared from 1.6b (29 mg, 0.079 mmol), Cs2CO3 (0.26 g, 0.79 mmol) and 
1,10-dibromodecane (11.6 mg, 0.04 mmol). A yellow oil was obtained (10 mg, 29%). 1H-NMR (500 
MHz, CDCl3) δ: 7.26 (s, 2H, 3-H), 6.56 (d, J = 1.7 Hz, 
2H, 8-H), 6.52 (d, J = 1.7 Hz, 2H, 6-H), 4.18 (q, J = 7.3 
Hz, 4H, NCH2CH3), 4.09 (t, J = 6.6 Hz, 4H, 1’’-H), 1.91 
(p, J = 6.6 Hz, 4H, 2’’-H), 1.57 – 1.55  (br s, 26H, 
OC(CH3)2), 1.51 (t, J = 7.3 Hz, 6H, NCH2CH3), 1.42–1.33 (m, 8H, 2’-H, alkyl chain), 1.26 (s, 12H, 
C(CH3)2), 1.21–1.13 (m, 6H, alkyl chain), 1.09–0.98 (m, 4H, 3’-H), 0.83 ppm (t, J = 7.0 Hz, 6H, 7’-H); 
13C-NMR (126 MHz, CDCl3) δ: 155.1 (9-C), 153.7 (7-C), 151.0 (5a-C), 140.9 (9b-C), 121.7 (3-C), 
121.4 (3a-C), 108.5 (6-C), 105.6 (8-C), 103.9 (9a-C), 75.5 (OC(CH3)2), 68.9 (1’’-C), 47.0 (NCH2CH3), 
44.6 (2’-C), 38.0 (C(CH3)2), 31.7, 30.0, 29.73, 29.69, 29.5, 26.1 and 22.6 (alkyl chain), 28.9 (OC(CH3)2), 
28.8 (C(CH3)2), 24.5 (3’-C), 15.4 (NCH2CH3), 14.1 ppm (7’-C); HRMS calcd for C56H87N4O4
[M+H]+: 879.6722, found: 879.6736.
1,12-Bis[(7-(1,1-dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-c]pyrazol-9-
yl)oxy]dodecane (1.59). 
 Compound 1.59 was prepared from 1.5b (25 mg, 0.07 mmol), Cs2CO3 (0.23 g, 0.70 mmol) and 1,12-
dibromododecane (11.1 mg, 0.03 mmol). A pale-yellow oil was isolated (9 mg, 29%). 1H-NMR (500 
MHz, CDCl3) δ: 7.07 (s, 2H, 3-H), 6.56 (d, J = 1.6 Hz, 2H, 8-H), 6.53 (d, J = 1.6 Hz, 2H, 6-H), 4.10 
(t, J = 6.8 Hz, 4H, 1’’-H), 3.91 (s, 6H, NCH3), 1.92 (p, J = 6.8 Hz, 4H, 2’’-H), 1.60–1.51 (m, 28H, 
OC(CH3)2, alkyl chain), 1.41–1.29 (m, 4H, 2’-H), 1.26 (s, 12H, C(CH3)2), 1.23–1.14 (m, 12H, alkyl 
chain), 1.10–0.97 (m, 4H, 3’-H), 0.83 ppm (t, J = 6.9 Hz, 6H, 7’-H); 13C-NMR (126 MHz, CDCl3) δ: 
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155.1 (9-C), 153.8 (7-C), 151.2 (5a-C), 141.3 (9b-C), 123.2 (3-C), 122.1 (3a-C), 108.4 (8-C), 105.4 (6-
C), 103.9 (9a-C), 75.4 (OC(CH3)2), 69.0 (1’’-C), 44.6 
(NCH3), 39.1 (2’-C), 38.0 (C(CH3)2), 31.7, 30.0, 29.72, 
29.70, 29.6, 29.4, 26.0 and 22.6 (alkyl chain), 28.9 
(OC(CH3)2), 28.8 (C(CH3)2), 24.6 (3’-C), 14.1 ppm 
(7’-C); HRMS calcd for C56H87N4O4 [M+H]+: 879.6722, found: 879.6697.
1,12-Bis[(7-(1,1-dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-
yl)oxy]dodecane (1.60). 
 Compound 1.60 was prepared from 1.6a (25 mg, 0.07 mmol), Cs2CO3 (0.22 g, 0.68 mmol) and 1,12-
dibromododecane (10.7 mg, 0.03 mmol). A white oil 
was obtained (10 mg, 32%). 1H-NMR (500 MHz, 
CDCl3) δ: 7.32 (s, 2H, 3-H), 6.66 (d, J = 1.7, 2H, 8-
H), 6.54 (d, J = 1.7 Hz, 2H, 6-H), 4.53 (q, J = 7.2 Hz, 
4H, NCH2CH3), 4.08 (t, J = 7.0 Hz, 4H, 1’’-H), 1.85 (p, J = 6.9 Hz, 4H, 2’’-H), 1.60–1.52 (m, 20H, 
OC(CH3)2, alkyl chain), 1.47–1.40 (m, 4H, 2’-H), 1.38 (t, J = 7.2 Hz, 6H, NCH2CH3), 1.29–1.26 (br s, 
20H, C(CH3)2, alkyl chain), 1.24–1.17 (m, 12H, alkyl chain), 1.11–1.04 (m, 4H, 3’-H), 0.83 ppm (t, J = 
6.9 Hz, 6H, 7’-H); 13C-NMR (126 MHz, CDCl3) δ: 153.9 (9-C), 153.4 (7-C), 152.2 (5a-C), 132.2 (9b-
C), 132.0 (3-C), 123.3 (3a-C), 109.5 (6-C), 104.6 (8-C), 103.6 (9a-C), 76.4 (OC(CH3)2), 69.0 (1’’-C), 
47.9 (NCH2CH3), 44.4 (2’-C), 38.0 (C(CH3)2), 31.7, 30.9, 29.9, 29.6, 29.5, 29.2, 26.1 and 22.6 (alkyl 
chain), 28.8 (C(CH3)2), 27.2 (OC(CH3)2), 24.6 (3’-C), 15.5 (NCH2CH3), 14.1 ppm (7’-C); HRMS calcd 
for C58H91N4O4 [M+H]+: 907.7035, found: 907.7042.
1,12-Bis[(7-(1,1-dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-
yl)oxy]dodecane (1.61). 
Compound 1.61 was prepared from 1.6b (52 mg, 0.14 mmol), Cs2CO3 (0.46 g, 1.40 mmol) and 1,12-
dibromododecane (22.10 mg, 0.07 mmol). A yellow oil was isolated (11 mg, 18%). 1H-NMR (500 
MHz, CDCl3) δ: 7.11 (s, 2H, 3-H), 6.56 (d, J = 1.6 Hz, 2H, 8-H), 6.52 (d, J = 1.6 Hz, 2H, 6-H), 4.18 
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(q, J = 7.3 Hz, 4H, NCH2CH3), 4.09 (t, J = 6.6 Hz, 4H, 1’’-H), 1.96–1.89 (m, 4H, 2’’-H), 1.65–1.59 
(m, 4H, alkyl chain), 1.57 (s, 12H, OC(CH3)2), 1.52 (t, J = 7.3 Hz, 6H, NCH2CH3), 1.41–1.28 (m, 
20H, 2’-H, alkyl chain), 1.26 (s, 12H, C(CH3)2), 1.20–
1.13 (m, 8H, alkyl chain), 1.06–1.01 (m, 4H, 3’-H), 
0.83 ppm (t, J = 7.0 Hz, 6H, 7’-H); 13C-NMR (126 
MHz, CDCl3) δ:155.1 (9-C), 153.7 (7-C), 151.0 (5a-
C), 140.9 (9b-C), 121.8 (3-C), 121.4 (3a-C), 108.5 (6-C), 105.6 (8-C), 103.9 (9a-C), 75.5 (OC(CH3)2), 
69.0 (1’’-C), 47.0 (NCH2CH3), 44.6 (2’-C), 38.0 (C(CH3)2), 31.8, 30.0, 29.8, 29.7, 29.5, 26.1, 24.6 and 
22.6 (alkyl chain), 28.9 (OC(CH3)2), 28.8 (C(CH3)2), 15.4 (NCH2CH3), 14.1 ppm (7’-C); HRMS calcd 
for C58H91N4O4 [M+H]+: 907.7035, found: 907.7031.
1,14-Bis[(7-(1,1-dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-c]pyrazol-9-
yl)oxy]tetradecane (1.62). 
 Compound 1.62 was prepared from 1.5b (20 mg, 0.056 mmol), Cs2CO3 (0.18 g, 0.56 mmol) and 
1,14-dibromotetradecane (9.9 mg, 0.028 mmol). A white oil was obtained (11 mg, 43%). 1H-NMR 
(500 MHz, CDCl3) δ: 7.07 (s, 2H, 3-H), 6.56 (d, J
= 1.7 Hz, 2H, 8-H), 6.53 (d, J = 1.7 Hz, 2H, 6-H), 
4.10 (t, J = 6.8 Hz, 4H, 1’’-H), 3.91 (s, 6H, NCH3), 
1.94 (p, J = 6.8 Hz, 4H, 2’’-H), 1.59–1.55 (m, 24H, 
OC(CH3)2, alkyl chain), 1.38–1.34 (m, 10H, alkyl chain), 1.26 (s, 12H, C(CH3)2), 1.20–1.16 (m, 14H, 
alkyl chain), 1.07–1.03 (m, 4H, 3’-H), 0.83 ppm (t, J = 6.9 Hz, 6H, 7’-H); 13C-NMR (126 MHz, 
CDCl3) δ: 155.1 (9-C), 153.8 (7-C), 151.2 (5a-C), 141.3 (9b-C), 123.1 (3-C), 122.1 (3a-C), 108.4 (8-C), 
105.5 (6-C), 103.9 (9a-C), 75.4 (OC(CH3)2), 69.0 (1’’-C), 44.6 (NCH3), 39.0 (2’-C), 38.0 (C(CH3)2), 
31.7, 30.0, 29.8, 29.72, 29.70, 29.6, 29.4, 26.0 and 22.6 (alkyl chain), 28.9 (OC(CH3)2), 28.8 (C(CH3)2), 
24.6 (3’-C), 14.1 ppm (7’-C); HRMS calcd for C58H91N4O4 [M+H]+: 907.7034, found: 907.7017.
1,14-Bis[(7-(1,1-dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-
yl)oxy]tetradecane (1.63). 
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 Compound 1.63 was prepared from 1.6a (18 mg, 0.048 mmol), Cs2CO3 (0.15 g, 0.48 mmol) and 
1,14-dibromotetradecane (8.6 mg, 0.024 mmol). A pale-yellow oil was obtained (9 mg, 39%). 1H-
NMR (500 MHz, CDCl3) δ: 7.32 (s, 2H, 3-H), 6.66 (d, J = 1.7 Hz, 2H, 8-H), 6.54 (d, J = 1.7 Hz, 2H, 
6-H), 4.53 (q, J = 7.2 Hz, 4H, NCH2CH3), 4.08 (t, 
J = 7.0 Hz, 4H, 1’’-H), 1.85 (p, J = 7.0 Hz, 4H, 2’’-
H), 1.59–1.53 (m, 22H, OC(CH3)2, alkyl chain), 
1.48–1.42 (m, 4H, 2’-H), 1.37 (t, J = 7.2 Hz, 6H, NCH2CH3), 1.27 (s, 24H, C(CH3)2, alkyl chain), 
1.22–1.17 (m, 10H, alkyl chain), 1.12–1.06 (m, 4H, 3’-H), 0.83 ppm (t, J = 6.9 Hz, 6H, 7’-H); 13C-
NMR (126 MHz, CDCl3) δ: 153.9 (9-C), 153.4 (7-C), 152.1 (5a-C), 132.2 (9b-C), 132.0 (3-C), 123.3 
(3a-C), 109.5 (6-C), 104.6 (8-C), 103.7 (9a-C), 76.4 (OC(CH3)2), 69.0 (1’’-C), 47.9 (NCH2CH3), 44.4 
(2’-C), 38.0 (C(CH3)2), 31.7, 29.9, 29.7, 29.6, 29.57, 29.50, 29.2, 26.1 and 22.6 (alkyl chain), 28.8 
(C(CH3)2), 27.2 (OC(CH3)2), 24.6 (3’-C), 15.5 (NCH2CH3), 14.1 ppm (7’-C); HRMS calcd for 
C60H95N4O4 [M+H]+: 935.7347, found: 935.7360.
1,14-Bis[(7-(1,1-dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-
yl)oxy]tetradecane (1.64). 
 Compound 1.64 was prepared from 1.6b (20 mg, 0.054 mmol), Cs2CO3 (0.17 g, 0.54 mmol) and 
1,14-dibromotetradecane (9.6 mg, 0.027 mmol). A yellow oil was obtained (15 mg, 59%). 1H-NMR 
(500 MHz, CDCl3) δ: 7.10 (s, 2H, 3-H), 6.56 (d, J
= 1.6 Hz, 2H, 8-H), 6.51 (d, J = 1.6 Hz, 2H, 6-
H), 4.18 (q, J = 7.3 Hz, 4H, NCH2CH3), 4.09 (t, J
= 6.6 Hz, 4H, 1’’-H), 1.90 (q, J = 7.2, 6.8 Hz, 4H, 
2’’-H), 1.60–1.55 (m, 26H, OC(CH3)2, alkyl chain), 1.52 (t, J = 7.3 Hz, 6H, NCH2CH3), 1.33–1.22 (br 
s, 12H, C(CH3)2), 1.22–1.11 (m, 22H, alkyl chain), 1.06–1.00 (m, 4H, 3’-H), 0.83 ppm (t, J = 6.7 Hz, 
6H, 7’-H); 13C-NMR (126 MHz, CDCl3) δ: 155.1 (9-C), 153.8 (7-C), 151.0 (5a-C), 140.9 (9b-C), 121.8 
(3-C), 121.4 (3a-C), 108.5 (6-C), 105.6 (8-C), 104.0 (9a-C), 75.5 (OC(CH3)2), 69.0 (1’’-C), 47.0 
(NCH2CH3), 44.6 (2’-C), 38.0 (C(CH3)2), 31.8, 30.0, 29.74, 29.72, 29.69, 29.5, 26.1 and 22.6 (alkyl 
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chain), 29.0 (OC(CH3)2), 28.9 (C(CH3)2), 24.6 (3’-C), 15.4 (NCH2CH3), 14.1 ppm (7’-C); HRMS calcd 
for C60H95N4O4 [M+H]+: 935.7347, found: 935.7359. 
1,16-Bis[(7-(1,1-dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-c]pyrazol-9-
yl)oxy]hexadecane (1.65).
Compound 1.65 was prepared from 1.5b (35 mg, 0.098 mmol), Cs2CO3 (0.32 g, 0.98 mmol) and 
1,16-dibromohexadecane (18 mg, 0.049 mmol). A yellow oil was isolated (20 mg, 44%). 1H-NMR 
(500 MHz, CDCl3) δ: 7.07 (s, 2H, 3-H), 6.56 
(d, J = 1.7 Hz, 2H, 8-H), 6.53 (d, J = 1.7 Hz, 
2H, 6-H), 4.10 (t, J = 6.8 Hz, 4H, 1’’-H), 3.91 
(s, 6H, NCH3), 1.92 (p, J = 7.9 Hz, 4H, 2’’-H), 
1.61–1.50 (m, 24H, OC(CH3)2, alkyl chain), 1.41–1.36 (m, 4H, 2’-H), 1.28–1.24 (br s, 24H, C(CH3)2, 
alkyl chain), 1.21–1.14 (m, 12H, alkyl chain), 1.09–0.99 (m, 4H, 3’-H), 0.83 ppm (t, J = 6.9 Hz, 6H, 7’-
H); 13C-NMR (126 MHz, CDCl3) δ: 155.1 (9-C), 153.8 (7-C), 151.1 (5a-C), 141.3 (9b-C), 123.1 (3-C), 
122.1 (3a-C), 108.4 (8-C), 105.5 (6-C), 103.9 (9a-C), 75.4 (OC(CH3)2), 69.0 (1’’-C), 44.6 (NCH3), 39.0 
(2’-C), 38.0 (C(CH3)2), 31.7, 30.0, 29.75, 29.73, 29.70, 29.66, 29.60, 29.4, 26.0 and 22.6 (alkyl chain), 
28.9 (OC(CH3)2), 28.8 (C(CH3)2), 24.6 (3’-C), 14.1 ppm (7’-C); HRMS calcd for C60H95N4O4 [M+H]+: 
935.7348, found: 935.7336.
1,16-Bis[(7-(1,1-dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-
yl)oxy]hexadecane (1.66). 
Compound 1.66 was prepared from 1.6a (35 mg, 0.095 mmol), Cs2CO3 (0.31 g, 0.95 mmol) and 
1,16-dibromohexadecane (17.5 mg, 0.048 mmol). A orange oil was isolated (8 mg, 17%). 1H-NMR 
(500 MHz, CDCl3) δ: 7.33 (s, 2H, 3-H), 6.66 
(d, J = 1.8 Hz, 2H, 8-H), 6.54 (d, J = 1.8 Hz, 
2H, 6-H), 4.54 (q, J = 7.2 Hz, 4H, NCH2CH3), 
4.08 (t, J = 7.0 Hz, 4H, 1’’-H), 1.85 (p, J = 7.2 
Hz, 4H, 2’’-H), 1.53–1.58 (br s, 20H, OC(CH3)2, alkyl chain), 1.46–1.42 (m, 4H, 2’-H), 1.38 (t, J = 7.2 
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Hz, 6H, NCH2CH3), 1.30–1.23 (m, 28H, C(CH3)2, alkyl chain), 1.22–1.17 (m, 12H, alkyl chain), 1.11–
1.03 (m, 4H, 3’-H), 0.84 ppm (t, J = 6.8 Hz, 6H, 7’-H); 13C-NMR (126 MHz, CDCl3) δ: 153.9 (9-C), 
153.4 (7-C), 152.2 (5a-C), 132.1 (9b-C), 132.1 (3-C), 123.3 (3a-C), 109.5 (6-C), 104.6 (8-C), 103.7 (9a-
C), 76.3 (OC(CH3)2), 69.0 (1’’-C), 47.9 (NCH2CH3), 44.4 (2’-C), 38.1 (C(CH3)2), 31.7, 29.9, 29.70, 
29.67, 29.62, 29.58, 29.49, 29.2, 26.1 and 22.6 (alkyl chain), 28.8 (C(CH3)2), 27.2 (OC(CH3)2), 24.6 (3’-
C), 15.5 (NCH2CH3), 14.1 ppm (7’-C); HRMS calcd for C62H99N4O4 [M+H]+: 963.7661, found: 
963.7635.
1,16-Bis[(7-(1,1-dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-
yl)oxy]hexadecane (1.67). 
Compound 1.67 was prepared from 1.6b (19 mg, 0.051 mmol), Cs2CO3 (0.17 g, 0.51 mmol) and 
1,16-dibromohexadecane (9.4 mg, 0.025 mmol). A yellow oil was isolated (7 mg, 29%). 1H-NMR 
(500 MHz, CDCl3) δ: 7.11 (s, 2H, 3-H), 6.56 (d, J = 1.6 Hz, 2H, 8-H), 6.52 (d, J = 1.6 Hz, 2H, 6-H), 
4.19 (q, J = 7.3 Hz, 4H, NCH2CH3), 4.09 (t, J
= 6.6 Hz, 4H, 1’’-H), 1.91 (p, J = 7.3 Hz, 4H, 
2’’-H), 1.64–1.59 (m, 8H, alkyl chain), 1.57 (s, 
12H, OC(CH3)2), 1.52 (t, J = 7.3 Hz, 6H, 
NCH2CH3), 1.42–1.34 (m, 4H, 2’’-H), 1.28–1.25 (br s, 28H, C(CH3)2, alkyl chain), 1.23–1.13 (m, 12H, 
alkyl chain), 1.08–1.00 (m, 4H, 3’’-H), 0.83 ppm (t, J = 7.0 Hz, 6H, 7’-H); 13C-NMR (126 MHz, 
CDCl3) δ: 155.1 (9-C), 153.8 (7-C), 151.0 (5aC), 140.9 (9b-C), 121.7 (3-C), 121.4 (3a-C), 108.4 (6-C), 
105.5 (8-C), 104.0 (9a-C), 75.5 (OC(CH3)2), 69.0 (1’’-C), 47.0 (NCH2CH3), 44.6 (2’-C), 38.0 
(C(CH3)2), 31.8, 30.0, 29.8, 29.74, 29.71, 29.66, 29.5, 26.1 and 22.6 (alkyl chain), 28.9 (OC(CH3)2), 28.8 
(C(CH3)2), 24.6 (3’-C), 15.5 (NCH2CH3), 14.1 ppm (7’-C); HRMS calcd for C62H99N4O4 [M+H]+: 
963.7661, found: 963.7691.
Pharmacological assays 
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Cannabinoid binding experiments. Membranes from transfected cells with human CB1 or CB2
expressed cannabinoid receptors (RBHCB1M400UA and RBXCB2M400UA) were supplied by 
Perkin-Elmer Life and Analytical Sciences (Boston, MA). The protein concentration for the CB1
receptor membranes was 8.0 mg/mL, whereas for the CB2 receptor membranes was 4.0 mg/mL or 
3.6 mg/mL depending on the batch. The commercial membranes were diluted (approximatively 
1:20) with the binding buffer (50 mM TrisCl, 5 mM MgCl2.H2O, 2.5 mM EDTA, 0.5 mg/mL BSA 
and pH = 7.4 for CB1 binding; 50 mM TrisCl, 5 mM MgCl2.H2O, 2.5 mM EGTA, 1 mg/mL BSA 
and pH = 7.5 for CB2 binding). The final membrane protein concentration was 0.4 mg/mL of 
incubation volume and 0.2 mg/mL of incubation volume for the CB1 and the CB2 receptor assays, 
respectively. The radioligand used was [3H]-CP55940 (PerkinElmer) at a concentration of membrane 
KD x 0.8 nm, and the final volume was 200 µL for CB1 binding and was 600 µL for CB2 binding. 96-
Well plates and the tubes necessary for the experiment were previously siliconized with Sigmacote 
(Sigma). 
Membranes were resuspended in the corresponding buffer and were incubated with the radioligand 
and each compound (10-4-10-11 M) for 90 min at 30 ºC. Non-specific binding was determined with 
10 µM WIN55212-2 and 100 % binding of the radioligand to the membrane was determined by its 
incubation with membrane without any compound. Filtration was performed by a Harvester® 
filtermate (Perkin-Elmer) with Filtermat A GF/C filters pretreated with polyethylenimine 0.05%. 
After filtering, the filter was washed nine times with binding buffer, dried and a melt-on scintillation 
sheet (MeltilexTM A, Perkin Elmer) was melted onto it. Then, radioactivity was quantified by a liquid 
scintillation spectrophotometer (Wallac MicroBeta Trilux, Perkin-Elmer). Competition binding data 
were analyzed by using GraphPad Prism program and Ki values are expressed as mean ± SEM of at 
least three experiments performed in triplicate for each point.  
cAMP accumulation assay. cAMP accumulation in HEK293 cells stably expressing CB2 receptor 
was performed using the HTRF-cAMP dynamic kit (CisBio, France) according to manufacturer's 
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instructions. Briefly, cells were treated with the indicated ligands for 10 min, incubated in lysis buffer 
(20 mM Tris, 1% Triton X-100, pH 7.5) for 30 min and dispensed in white 384-well microplates at a 
density of 30,000 cells per well. The cellular lysates were incubated for 60 min at room temperature 
containing HTRF assay reagents, and time-resolved Förster´s resonance energy transfer (FRET) 
signals were measured after excitation at 320 nm using the Envision 2104 Multilabel Reader 
(PerkinElmer). Data analysis was made based on the fluorescence ratio emitted by the labelled 
cAMP probe (665 nm) over the light emitted by the europium cryptate-labelled anti-cAMP antibody 
(620 nm). A standard curve was used to calculate cAMP concentration. Forskolin stimulated cAMP 
levels were normalized to 100%. Data was analyzed by using GraphPad Prism program using 
nonlinear regression analysis. EC50 and Emax values are expressed as mean ± SEM of at least three 
experiments performed in triplicates and were calculated. 
[35S]-GTPγS binding assays.  
Protocol for CB1 receptors: 
Cell culture: HEK293-CB1 cells were grown to confluence under 5% CO2 in Dulbecco's Modified 
Eagle's Medium (Lonza) containing 10% fetal bovine serum (Sigma), 1X Penicillin-Streptomycin-
Amphotericin B antibiotics (Lonza), and ultraglutamine 2 mM (Lonza). 
Membrane preparation: Cells were washed twice with ice-cold phosphate-buffer saline, detached from 
flasks by incubation with lifting buffer (glucose 5.6 mM, KCl 5 mM, HEPES 5 mM, NaCl 137 mM 
and EGTA 1 mM, pH 7.4) and collected by centrifugation (500xg). The cells were resuspended in 
ice-cold lysis buffer (MgSO4 0.2 mM, KH2PO4 0.38 mM , Na2HPO4 0.61 mM , pH 7.4) and 
homogenized using a glass-PTFE homogenizer. Crude membranes were isolated by centrifugation 
for 20 min at 20,000xg. The resulting membrane pellets were resuspended in 50 mM Tris-HCl 
buffer (pH 7.4) and stored at -80 ºC in aliquots of 0.8 mg/ml protein determined for Bio-Rad DCTM
Protein Assay. All procedures were performed at 4°C. 
Agonist-Stimulated [35S]GTPγS Binding: Cannabinoid agonist stimulation of [35S]GTPγS binding was 
determined using several concentrations of compounds from 10-4 to 10-11 M, incubated with 
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HEK293-CB1 membranes (20 μg/well) for 60 min at 30°C in assay buffer (100 mM NaCl, 50 mM 
Tris-HCl, 5 mM MgCl2, 1 mM EGTA, 1 mM DTT, 50 μM GDP, 10 mU/ml adenosine deaminase 
and 1 mg/ml BSA, pH 7.4) containing 0.1 nM [35S]GTPγS (Perkinelmer). Nonspecific binding was 
determined in the presence of 10 μM GTPγS. 96-Well plates and the tubes necessary for the 
experiment were previously siliconized with Sigmacote (Sigma).  
Experiments were terminated by rapid filtration performed by a Harvester filtermate (PerkineElmer) 
with Filtermat A GF/C filters. After filtering, the filter was washed nine times with filtration buffer 
(50mMTris-HCl and 1 mg/ml BSA, pH 7.4), dried and a melt-on scintillation sheet (MeltilexTM A, 
Perkin Elmer) was melted onto it. Then, radioactivity was quantified by a liquid scintillation 
spectrophotometer (Wallac MicroBeta Trilux, PerkineElmer). Data were analyzed by nonlinear 
regression analysis of sigmoidal dose-response curves using GraphPad Prism 5.01 (GraphPad, San 
Diego, CA). EC50 values are expressed as mean SEM of at least three experiments performed in 
triplicate for each point.
Protocol for CB2 receptors:  
[35S]-GTPγS binding analyses were carried out for compounds 1.33 and 1.41−1.43 using CB2R-
containing membranes (HTS020M2, Eurofins Discovery Services). To this end, membranes (5 
µg/well) were permeabilized by addition of saponin (Sigma-Aldrich), then mixed with 0.3 nM [35S]-
GTPγS (Perkin-Elmer) and 10 μM GDP (Sigma-Aldrich) in 20 mM HEPES (Sigma-Aldrich) buffer 
containing 100 mM NaCl (Merck) and 10 mM MgCl2 (Merck), at pH 7.4. 30 nM CP55,940 (Sigma-
Aldrich) and increasing concentrations of compound 1.33 and 1.41−1.43 (from 10-11 to 10-5 M) were 
added in a final volume of 100 μl and incubated for 30 min at 30 °C. The non-specific signal was 
measured with 10 μM GTPγS (Sigma-Aldrich). All 96-well plates and the tubes necessary for the 
experiment were previously silanized with Sigmacote (Sigma-Aldrich). The reaction was terminated 
by rapid vacuum filtration with a filter mate Harvester apparatus (Perkin-Elmer) through Filtermat 
A GF/C filters. The filters were washed nine times with ice-cold filtration buffer (10 mM sodium 
phosphate, pH 7.4), and bound radioactivity was measured with a 1450 LSC & Luminiscence 
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counter Wallac MicroBeta TriLux (Perkin-Elmer). [35S]-GTPγS binding data were analyzed to 
determine the EC50 and Emax values by using an iterative curve-fitting procedure with the GraphPad 
Prism version 5.02 (GraphPad Software Inc.). EC50 and Emax values are expressed as mean ± SEM of 
at least three experiments performed in triplicate for each point.
Functional activity for CB2 receptors on cultured cells. The functional activity of the new 
compounds for CB2R was evaluated in cultured BV-2 cells, a mouse microglial cell line. Cells were 
plated at a density of 5x105 cells per well in 12-well culture plates previously coated with 15 μg/ml 
Poly-L-ornithine (Sigma), and incubated overnight in Dulbecco’s Modified Eagle’s Medium 
(DMEM, Lonza) supplemented with 10% fetal bovine serum (FBS, Lonza), 2 mM Ultraglutamine 
and antibiotics (Lonza) in a humidified atmosphere of 5% CO2 at 37 ºC. One hour before treatment, 
medium was replaced with DMEM supplemented with 1 % FBS, 2 mM Ultraglutamine and 
antibiotics. Cells were treated for 16 hours with 1 μg/ml  Lipopolysaccharides (LPS from 
Escherichia coli 055:B5, Sigma), alone or in combination with the investigated compound, used at a 
concentration 10-fold the Ki obtained in binding studies. 10 μM WIN55,212-2 (Sigma) and 10 μM 
SR144528 (Santa Cruz Biotechnology) were used as reference compounds because of their 
capabitilily to either activate or block the CB2R, respectively. Media were then removed and used for 
the determination of PGE2 release using the ELISA kit DetectX® Prostaglandin E2 (Arbor Assays).
SPR–biosensor measurements of plasma proteins binding.
Surface plasmon resonance (SPR) experiments were performed at 25 ºC with a Biacore X–100 
apparatus (GE Healthcare, Biacore AB, Uppsala, Sweden).  
Immobilization of human serum albumin (HSA). Essentially fatty acid and globulin free HSA 
(Sigma-Aldrich) was used without further purification. A stock solution was prepared in phosphate 
buffered saline (PBS, pH 7.4) and stored at -20 ºC. Immediately prior to use, this solution was 
diluted to a concentration of 100 μg/mL in 10 mM sodium acetate, pH 5.0. HSA was immobilized 
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on CM5 sensor chips (Biacore) by the use of amine-coupling chemistry. The surface was blocked by 
7-min injection with 1 M ethanolamine, pH 8.0. The immobilization level ranged between 9000 and 
10000 RU.
Immobilization of α1-acid glycoprotein (AGP). AGP (99% purity) was from Sigma-Aldrich 
Sweden AB, Stockholm, Sweden. The protein was modified before immobilization in order to allow 
coupling via thiol groups. PDEA-AGP was synthesized by dissolving 1 mg of AGP and 3 mg of 2-
(2-pyridinyldithio)ethanolamine hydrochloride (PDEA) in 1.0 mL of 0.1 M 2-(4-morpholino)-
ethanesulfonic buffer (MES), pH 5.0. The solution was incubated for 10 min at room temperature 
after addition of 50 µL of 1-ethyl-3-(3-dimethylaminopropyl)carbodiimide hydrochloride (EDC). 
The modified protein was separated from PDEA by applying it to a NAP 10 column (Amersham 
Biosciences, Uppsala, Sweden) and eluting with 1.25 mL of protein with 0.01 M citrate buffer, pH 
3.6, resulting also in an appropriate buffer exchange. The modification reaction was believed to be 
quantitative, resulting in approximately 800 µg/mL final concentration of the modified protein. 
Aliquots of PDEA-AGP were stored at -20 °C and diluted to 270 µg/mL in 0.01 M citrate buffer, 
pH 3.6, immediately before immobilization. Immobilization of the PDEA-modified AGP was 
performed at 25 °C. The carboxymethyl-modified dextrane polymer of the CM5 sensor chip was 
activated with a 2-min injection of a 1:1 mixture of 0.2 M 1-ethyl-3-(3-
dimethylaminopropyl)carbodiimide hydrochloride (EDC) and 0.05 M N-hydroxysuccinimide (NHS). 
Disulfide bridges were introduced on the sensor surface by injection of 40 mM cystamine 
dihydrochloride in 0.1 M sodium borate, pH 8.5, for 3 min. Disulfides were reduced to free thiol 
groups by injection of 0.1 M dithioerythrithol (DTE) in 0.1 M sodium borate, pH 8.5, for 3 min. 
PDEA-modified AGP was then injected for 26 min. Excess reactive groups were deactivated by a 4 
min injection of 20 mM 2-(2-pyridinyldithio)ethanolamine and 1 M NaCl in 0.1 sodium acetate, pH 
4.3 (PDEA-NaCl). The immobilization level achieved varied from 6000-7000 RU.
Ranking experiments. Control drugs (warfarin, dipiramidol, prednisone, phenytoin, and 
sulfanilamide), the well-known cannabinoids SR141617, SR144528, CP55940, HU308, CBD, 2-AG 
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and AEA, and chromenopyrazoles were prepared as 10 mM stock solutions in 100% dimethyl 
sulfoxide (DMSO). The stock solutions were diluted in PBS containing DMSO to reach a final 
concentration of 40 μM in PBS containing 3% DMSO. Binding studies were perfomed at a flow rate 
of 90 μL/min and 40 s association and 60 s dissociation times. Regeneration was not required 
between injections cycles. To clean the flow system, an extra wash with 50% DMSO was performed 
between each injection. Binding responses were corrected for solvent (DMSO bulk differences) by 
using the software available on the Biacore X-100. Several measurements of warfarin binding to 
HSA were carried out over the course of the experiment as a mean of control of the HSA binding 
efficiency throughout the assay. The dose-response curves were obtained by plotting the 
RU/Da*100 against the drug concentrations. At working concentration (40 μM), all of the 
compounds gave measurable responses. For HSA positive controls were used ranking from warfarin 
to prednisone and AGP controls were used ranking from warfarin to dipiramidol. Sulfanilamide was 
used as a negative control for both proteins. 
In silico ADME calculations. 
A set of 34 physico-chemical descriptors was computed using QikProp version 3.5 integrated in 
Maestro (Schrödinger, LLC, New York, USA). The QikProp descriptors are shown in table 5. The 
3D conformations used in the calculation of QikProp descriptors were generated using the program 
Spartan ´08 (Wave function, Inc., Irvine CA) as follows: the structure of each molecule was built 
from the fragment library available in the program. Then, ab initio energy minimizations of each 
structure at the Hartree-Fock 6-31G* level were performed. A conformational search was next 
implemented using Molecular Mechanics (Monte Carlo method) followed by a minimization of the 
energy of each conformer calculated at the Hartree-Fock 6-31G* level. The global minimum energy 
conformer of each compound was used as input for ADME studies with QikProp.
Molecular modeling 
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Amino acid numbering. The numbering scheme for Class A GPCRs suggested by Ballesteros and 
Weinstein200 was employed here. In this numbering system, the label 0.50 is assigned to the most 
highly conserved Class A residue in each transmembrane helix (TMH). This number is preceded by 
the TMH number and followed in parenthesis by the sequence number. All other residues in a TMH 
are numbered relative to this residue. 
Conformational analysis of the compounds. Global minimum energy conformations of 1.4, 1.6b, 
1.17 and 1.41 were determined with Spartan ´08 (Wave function, Inc., Irvine CA) as follows: the 
structure of each molecule was built from the fragment library available in the program. Then, ab 
initio energy minimizations of each structure at the Hartree-Fock 6-31G* level were performed. A 
conformational search was next implemented using Molecular Mechanics (Monte Carlo method) 
followed by a minimization of the energy of each conformer calculated at the Hartree-Fock 6-31G* 
level. For this search, selected bonds were allowed to rotate: C-O bond in the phenolic ring, the first 
two C-C bonds of the dimethylheptyl chain, and the N-C bond in the ethyl substituent of the 
pyrazole. Representative conformers according to their geometry were selected for ab initio energy 
minimization (HF 6-31G*). The global minimum energy conformer of each compound was used as 
input for receptor docking studies.
Electrostatic Potential Map Calculation. The electrostatic potential density surface was calculated 
using Spartan ´08 (Wave function, Inc., Irvine CA). The electrostatic potential energy was calculated 
using the Hartree-Fock method at the 6-31G* level of theory and was mapped on the 0.002 
isodensity surface of each molecule. The surface was color-coded according to the potential, with 
electron rich regions colored red and electron poor regions colored blue. 
CB1* and CB2R* models. The models used for these docking studies were developed by Patricia 
Reggio and coworkers.153 These models are based on the crystal structure of the class A GPCR, 
rhodopsin.201 Complete details on the generation of the activated state models were published and 
properly described by them in the literature.153,154,202,203
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Docking studies. Minimum energy conformers of each ligand were selected for the initial docking. 
Binding site anchoring interactions within the receptor for each ligand were based on earlier 
published docking studies for HU210154 and for AM-841.155,156 Initial steric clashes were removed 
manually with interactive graphics. The energy of the ligand-CBR* TMH bundle complex was 
minimized using the OPLS2005 force field in Macromodel (version 9.1, Schrödinger, LLC, New 
York, NY). An 8.0-Å extended nonbonded cutoff (updated every 10 steps), a 20.0- Å electrostatic 
cutoff, and a 4.0-Å hydrogen bond cutoff were used in each stage of the calculation. All residues 
except D2.50(163), K3.28(192) and D6.58(366) (CB1 model), and D2.50(79), K3.28 (109) and D275 
(CB2 model), were neutralized during the minimization. C alpha atom restraints (100 kcal/mol) for 
all C alpha atoms were applied, and the full bundle was energy minimized until an energy gradient of 
0.1 kcal/mol was reached. The C alpha atom restraints were then reduced in steps to 50 kcal/mol, 
and 0 kcal/mol (no restraints) until an energy gradient of 0.1 kcal/mol was achieved at each step. To 
allow the loops to adjust in their proper environment, atoms of the TMH regions were frozen, and 
the bundle was re-minimized in water solvent to 0.1 kcal/mol gradient with loop residues fully 
charged.
Energy expense assessments for docked ligands. To calculate the energy difference between the 
global minimum energy conformer of each compound and its final conformation after energy 
minimization of the ligand-receptor complex, rotatable bonds in the global minimum energy 
conformation were driven to their corresponding value in the final docked conformation and the 
single point energy of the resultant structure was calculated at the HF 6-31G* level using Jaguar 
(version 9.1, Schrodinger, LLC, New York, NY). 
Assessment of Pairwise Interaction Energies.  After defining the atoms of each ligand as one 
group (group 1) and the atoms corresponding to a residue that lines the binding site in the final 
ligand-CB R* complex as another group (group 2), Macromodel (version 9.1, Schrödinger, LLC, 
New York, NY) was used to output the pairwise interaction energy (coulombic and Van der Waals) 
for a given pair of atoms.  The pairs corresponding to group 1 (ligand) and group 2 (residue of 
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interest) were then summed to yield the interaction energy between the ligand and that residue. Total 
interaction energy for each ligand with the cannabinoid receptor was calculated by summing the 
pairwise interaction energies for all residues in the binding site of that ligand and adding to this sum, 
the conformational energy expense for the ligand. 
Additional Information: 
Pairwise interaction energies for 1.4, 1.6b and 1.41 at CB1R* model. 
Table A. 1.4/CB1R* Complex
Residue VdW (kcal/mol)
Electrostatic 
(kcal/mol) 
Total Energy 
(kcal/mol) 
L2.46 -1.54 -0.02 -1.56
D2.50 -3.04 -2.99 -6.03
G2.53 -0.10 0.01 -0.09
F2.57 -2.44 -0.40 -2.84
F2.64 -0.47 -0.18 -0.65
K3.28 -1.06 -9.96 -11.02
L3.29 -0.86 -0.01 -0.87
G3.31 -0.28 -0.04 -0.32
V3.32 -4.34 -0.06 -4.40
S3.35 -2.87 0.30 -2.57
F3.36 -3.04 0.12 -2.92
A3.38 -0.12 0.04 -0.08
S3.39 -1.06 0.21 -0.85
V3.40 0.00 0.00 0.00
L3.43 -0.08 0.01 -0.07
L6.44 -0.18 0.01 -0.17
C6.47 -0.24 0.04 -0.20
P6.50 -0.39 -0.10 -0.49
L6.51 -2.33 -0.03 -2.36
I6.54 -2.20 0.20 -2.00
M6.55 -0.15 0.04 -0.11
F7.35 0.00 0.00 0.00
C7.38 0.00 0.00 0.00
S7.39 0.87 -11.75 -10.88
M7.40 -0.29 -0.02 -0.31
C7.42 -5.42 -0.80 -6.22
L7.43 -5.32 0.12 -5.20
L7.44 -0.41 -0.06 -0.47
N7.45 -5.01 -0.12 -5.13
S7.46 -1.67 0.32 -1.35
N7.49 -1.44 0.24 -1.20
S7.46 -1.67 0.32 -1.35
N7.49 -1.44 0.24 -1.20
P7.50 -0.07 0.02 -0.05
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Conf Expense 6.51
Grand Total -63.92
Table B. 1.41/CB1R* Complex
Residue VdW (kcal/mol) 
Electrostatic 
(kcal/mol) 
Total Energy 
(kcal/mol) 
C7.42 -5.55 -1.85 -7.39
K3.28 -1.85 -7.74 -9.59
S7.39 -0.78 -3.58 -4.36
V3.32 -4.20 -0.10 -4.30
S7.46 -1.69 0.24 -1.44
F2.57 -1.91 0.05 -1.86
N7.45 -5.12 -0.08 -5.20
S3.39 -0.92 0.05 -0.87
L7.43 -4.69 -0.43 -5.12
L6.51 -2.35 -0.09 -2.44
I6.54 -2.15 0.35 -1.80
F3.36 -3.37 0.14 -3.23
L2.46 -1.14 0.01 -1.13
S3.35 -2.76 0.12 -2.64
N7.49 -1.06 0.13 -0.93
L3.29 -1.38 0.08 -1.30
F2.64 -0.99 -0.45 -1.44
D2.50 -3.04 -1.81 -4.85
P6.50 -0.49 -0.20 -0.69
C6.47 -0.37 0.00 -0.38
F7.35 -0.38 -0.03 -0.41
S2.60 -0.39 0.08 -0.31
L7.44 -0.44 0.00 -0.44
M6.55 -0.18 0.05 -0.12
L6.44 -0.12 -0.01 -0.13
G3.31 -0.26 -0.04 -0.30
C7.38 -0.29 0.03 -0.26
G2.53 -0.09 0.09 -0.01
Conf Expense 2.07
Grand Total -60.87
Table C. 1.6b/CB1R* Complex
Residue VdW (kcal/mol) 
Electrostatic 
(kcal/mol) 
Total Energy 
(kcal/mol) 
S1.39 0.00 0.00 0.00
T1.46 0.00 0.00 0.00
L2.46 -1.23 0.02 -1.21
D2.50 -3.17 -1.53 -4.70
G2.53 -0.11 0.11 0.00
F2.57 -2.24 0.20 -2.04
S2.60 -0.47 -0.06 -0.53
F2.61 0.00 0.00 0.00
F2.64 -1.20 0.11 -1.09
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K3.28 -0.80 -13.54 -14.34
L3.29 -1.34 0.14 -1.20
G3.31 -0.23 -0.07 -0.30
V3.32 -4.56 -0.16 -4.72
S3.35 -2.64 0.09 -2.55
F3.36 -3.37 0.12 -3.25
S3.39 -0.94 0.05 -0.89
L3.43 -0.05 0.01 -0.04
L6.44 -0.14 0.00 -0.14
C6.47 -0.30 0.02 -0.28
P6.50 -0.37 -0.19 -0.56
L6.51 -2.72 -0.19 -2.91
I6.54 -2.11 0.23 -1.88
M6.55 -0.32 0.04 -0.28
D6.58 -0.13 -0.04 -0.17
F7.35 -0.17 0.05 -0.12
C7.38 0.00 0.00 0.00
S7.39 -2.40 -1.16 -3.56
M7.40 0.00 0.00 0.00
C7.42 -4.42 -0.34 -4.76
L7.43 -4.55 -0.58 -5.13
L7.44 -0.44 0.00 -0.44
N7.45 -5.01 -0.18 -5.19
S7.46 -1.57 0.16 -1.41
T7.47 -0.08 0.00 -0.08
N7.49 -1.37 0.14 -1.23
P7.50 -0.06 0.01 -0.05
Conf Expense 5.13
Grand Total -59.92
Pairwise interaction energies for 1.41 and 1.17 at CB2R* model.
Table D. 1.41/CB2R* Complex
Residue VdW (kcal/mol) 
Electrostatic 
(kcal/mol) 
Total Energy 
(kcal/mol) 
S6.58 1.26 -9.10 -7.84
K3.28 -2.31 -8.02 -10.33
V6.51 -2.98 0.08 -2.90
N7.45 -2.29 0.25 -2.04
V3.32 -6.00 -0.26 -6.26
F3.36 -2.53 0.15 -2.38
F7.35 -2.33 -0.29 -2.62
L6.54 -3.08 0.35 -2.74
S7.46 -0.85 0.11 -0.74
L7.43 -3.46 -0.06 -3.52
F2.57 -1.41 0.16 -1.26
S7.39 -4.89 0.10 -4.78
M6.55 -3.24 0.13 -3.11
C7.42 -2.97 -0.16 -3.13
S2.60 -0.91 0.21 -0.70
T3.35 -1.23 0.12 -1.11
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M7.40 -2.36 -0.04 -2.40
F3.25 -1.01 0.12 -0.90
I3.29 -1.85 -0.22 -2.07
T3.33 -0.96 -0.11 -1.08
F2.64 -0.41 0.05 -0.36
D275 -0.95 1.51 0.56
W5.43 -0.25 0.04 -0.21
F2.61 -0.19 0.05 -0.15
I7.44 -0.25 0.00 -0.25
P6.50 -0.16 0.01 -0.14
C7.38 -0.28 -0.07 -0.36
Conf Expense 2.56
Grand Total -60.25
Table E. 1.17/CB2R* Complex
Residue VdW (kcal/mol)
Electrostatic 
(kcal/mol)
Total Energy
(kcal/mol)
S6.58 -1.89 -3.66 -5.55
S2.60 -0.95 0.13 -0.82
V6.51 -2.97 0.06 -2.91
V3.32 -4.16 -0.24 -4.41
I3.29 -1.37 0.11 -1.27
L6.54 -2.48 0.16 -2.32
F7.35 -1.36 0.23 -1.14
K3.28 -3.14 3.27 0.13
N7.45 -2.26 0.13 -2.13
F2.57 -2.15 -0.27 -2.43
F3.25 -1.86 0.07 -1.79
M6.55 -3.10 0.04 -3.07
D275 -1.37 -5.42 -6.79
F3.36 -4.84 -0.01 -4.85
C7.42 -3.68 -0.20 -3.88
S7.39 -5.64 -0.53 -6.17
M7.40 -2.40 0.33 -2.08
L7.43 -1.47 -0.16 -1.62
S3.39 -0.80 -0.01 -0.81
T3.35 -0.65 0.00 -0.65
F2.61 -0.20 -0.04 -0.24
V2.56 -0.42 -0.13 -0.55
S7.46 -0.25 0.05 -0.20
N7.49 -0.07 0.06 -0.01
V3.40 -0.13 0.01 -0.11
A7.36 -0.35 0.13 -0.22
L6.44 -0.13 -0.01 -0.14
T3.33 -0.23 -0.04 -0.28
S274 -0.15 -0.06 -0.21
F2.64 -0.12 0.09 -0.02
A2.53 -0.10 0.09 -0.01
T272 -0.11 0.15 0.04
T6.61 -0.06 -0.04 -0.10
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Conf Expense 2.79
Grand Total -53.82
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Chapter 2
Chromenopyrazolediones: New 
Antitumor Cannabinoid-Quinones
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1. Introduction 
Cancer is one of the most common diseases and a leading cause of death worldwide. Its incidence 
has grown in the past decades, and studies from the World Health Organization point to an 
incessant increase in the coming years.1 Cancer is a complex multifactorial physiopathology that 
triggers dysregulation of diverse cellular systems. The development of new effective and safe 
antitumor treatments that improve the aggressive current therapies remains an unmet clinical need. 
In this scenario, the endocannabinoid system emerges as a promising anticancer target involved in 
the modulation of the main hallmarks of this disease.  
1.1  Cannabinoids and cancer 
So far, studies on cannabinoids as antitumor agents have been mainly focused on understanding the 
mechanism of action of well-known compounds such as Δ9-THC, Δ8-THC or CBD. However, few 
novel cannabinoids with antitumor properties have been reported in the literature. In this section we 
will provide a general biological perspective of the potential of cannabinoids in cancer pathology.  
1.1.1 Palliative effects 
Cannabis has long been known to limit or prevent nausea and vomiting, lack of appetite and pain. 
For this reason, cannabinoids have been successfully used in the treatment of some of the unwanted 
side effects caused by cancer chemotherapy.2
In the middle 1980´s, dronabinol (Marinol®) and nabilone (Cesamet®) were approved for the 
management of chemotherapy-induced nausea and emesis.3 Nowadays, they are only prescribed in 
some countries after conventional anti-emetics fail.4
Even though the best-established palliative effect of cannabinoids in cancer patients is the control of 
nausea and vomiting, these compounds are also appetite stimulants and pain inhibitors. Research 
from different groups demonstrates that THC and other cannabinoids have a stimulatory effect on 
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appetite and increase food intake in animals. Moreover, phase III trials confirmed the orexigenic 
effect of THC in the treatment of cancer anorexia.5–7
The effectiveness of cannabinoids in alleviating pain associated with cancer has been widely 
evidenced. Cannabinoids inhibit pain in animal models of acute and chronic allodynia, hyperalgesia 
or spontaneous pain by inhibiting nociceptive neurotransmission.8,9 Different clinical trials support 
that THC and other synthetic derivatives have similar analgesic potency to codeine, a moderate 
opioid analgesic, emphasizing their relevance in the management of cancer pain.10–12 In several 
countries, Sativex® (Δ9-THC and CBD) is prescribed as an adjunctive analgesic treatment for adult 
patients with advanced cancer.13
Chemotherapy-induced peripheral neuropathies can also be attenuated by treatment with certain 
cannabinoid compounds as demonstrated in different rodent models of neurotoxicity.14 Indeed, 
direct agonists such as WIN55,212, alleviates mechanical and cold allodynia in models of paclitaxel,15
vincristine16 and cisplatin17-evoked neuropathy. Several research groups highlight the role of CB2R 
modulators in the treatment of chemotherapy-induced peripheral neuropathy because of their ability 
to prevent microglial activation.18,19 In addition, CBD has shown ability to protect against 
doxorubicin-induced cardiomyopathy20 and cisplatin-induced nephrotoxicity.21
Cannabinoid palliative effects have been properly validated, nonetheless, further studies are required 
to establish personalized medicine. Distinct treatment approaches are needed for the prevention of 
these undesired cancer-induced effects depending on the patients’ genetic and the types of cancer 
involved. 
1.1.2 Antitumor properties 
Besides their aforementioned palliative potential, cannabinoids have exhibited antitumor effects in 
numerous in vitro and in vivo experimental models of cancer.22–24Antiproliferative properties of 
cannabis compounds were first identified four decades ago. Munson et al.25 demonstrated that oral 
administration of Δ9-THC, Δ8-THC or CBN inhibited the growth of Lewis lung-adenocarcinoma in 
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mice. Despite the importance of these findings, it took more than two decades before the potential 
antitumor properties associated with these molecules were further explored. Since the late 1990s, an 
emerging body of investigation has demonstrated that cannabinoids can reduce tumor growth and 
progression on a wide range of cancer cells in culture and in nude mice tumor xenografts (for 
instance: lung carcinomas, gliomas, thyroid epitheliomas, skin carcinomas and lymphomas).23,26–30
Cannabinoids are able to modulate different cellular signaling pathways implicated in cancer cell 
proliferation, migration or death. The mechanisms through which pharmacological stimulation of 
cannabinoid receptors impact tumor growth are quite complex and the understanding of these 
processes remain incomplete.23 In fact, the signaling pathways implicated in the activation of the 
endocannabinoid system may differ depending on specific cancers and/or experimental models. 
Great efforts are currently being done to further elucidate these anticancer effects.31 Even though 
most studies reveal that cannabinoids promote anti-cancer effects, few reports have proposed that 
under certain conditions, cannabinoid treatment can induce tumor-promoting effects.32,33
Endocannabinoid system upregulation in cancer 
The biological role of the endocannabinoid system in cancer physiopathology is far from being 
completely understood. The ECS is generally upregulated in neoplasms compared with non-tumor 
tissue.23,26,34,35 These observations may be tumor type-specific so further research is needed to 
understand the regulation of cannabinoid receptor expression in cancer.22,34 In distinct types of 
tumors, such as glioblastoma,36 estrogen receptor-negative breast tumors37 and in 91% of ErbB2-
positive breast tumors,38 a remarkable increase of CB2R levels has been detected.  Other specific 
tumors are instead accompanied by overexpression of the CB1R, such as gastric carcinoma39 and 
rhabdomyosarcoma.40 Likewise, increased expression of both receptors has been reported in 
hepatocellular carcinoma,41 mantle cell lymphoma,42 acute myeloid leukemia,43 malignant 
astrocytomas,44 and human pancreatic cancer.45 AEA and 2-AG endocannabinoid tones differ 
significantly between normal cells and several types of tumor.46
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It is clear that dysregulation of the endocannabinoid system plays an important role in the 
physiopathology of cancer.24,26 Few studies have suggested that its over-activation could induce 
tumorigenesis34 and could be related to tumor aggressiveness.47,48 But the majority of them suggest 
that pharmacological activation of the endocannabinoid system induces cell death and reduces 
tumor proliferation.23,29 Bifulco49 suggested a biphasic action on cannabinoid receptors: low 
concentrations of endocannabinoid (nanomolar range) lead to pro-proliferative activity, while, high 
doses (micromolar range) of exogenous cannabinoids contribute to antiproliferative and pro-
apoptotic effects. Another explanation has been suggested by Andradas,50 who proposed that 
GPR55 participates in the proliferative effect of THC on cancer cells as produced by low 
concentrations of the cannabinoid. This putative cannabinoid receptor is also upregulated in a wide 
variety of human cancers conferring a proliferative action on cancer cells from different origins, 
including gliomas, breast adenocarcinoma and squamous skin cell carcinoma, both in vitro and in 
vivo.51–54 Therefore, GPR55 has emerged as a promising therapeutic target in oncology and as a new 
cancer biomarker with possible prognostic value.55  In addition, very recent findings reveal that 
GPR55-CB2R heterodimers are expressed in cancer cells and human tumors which indicates the 
existence of new potential therapeutic approaches.56,57
Albeit further research is required to clarify the complex role of the ECS in this pathology, it is clear 
that cannabinoid-based pharmacotherapies have a remarkable therapeutic potential in the control of 
cancer. 
Potential mechanisms of antitumor action  
The activation of cannabinoid receptors on cancer cells modulates signaling pathways implicated in 
cell proliferation and survival. Even though the underlying mechanisms are not totally unraveled, 
there is significant evidence for the involvement of at least four mechanisms: direct inhibition of 
transformed-cell growth through the suppression of mitogenic signal, induction of apoptosis, 
inhibition of tumor angiogenesis and metastasis (figure 1). 
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Figure 1. Mechanisms of cannabinoid antitumor action: Inhibition of cancer cell proliferation, induction of 
apoptosis, blockade of tumor angiogenesis, metastasization and invasiveness. Figure based on Velasco et al.26
Antiproliferative and pro-apoptotic effects. Cannabinoids impair uncontrolled cancer cell growth 
by inducing cell death through apoptosis and inhibition of cancer cell proliferation. Various signaling 
pathways are associated with these anticancer effects. 
Activation of either CB1R or CB2R induces de novo synthesis of the pro-apoptotic sphingolipid 
ceramide. Synthesis of ceramide occurs via activation of the enzyme ceramide synthase and leads to 
the activation of an extracellular regulated kinase (ERK) signaling cascade. This process promotes 
cell cycle arrest and apoptosis.26,27,45,58,59 In line with this proposal, up-regulation of the stress-
regulated protein p8, an essential mediator of cannabinoid induced-apoptosis, is dependent on de 
novo-synthesized ceramide. This transcriptional regulator, together with several of its downstream 
targets such as the endoplasmic reticulum (ER) stress-related transcription factors ATF4 and 
CHOP, as well as the pseudokinase tribbles-homologue 3 (TRIB3) are implicated in the control of 
tumorigenesis and tumor progression.26 This cascade of events trigger the interaction of TRIB3 with 
the serine-threonine kinase Akt,60 leading to the inhibition of the Akt–mammalian target of 
rapamycin complex 1 (mTORC1) axis, and the subsequent induction of autophagy.61 As acutely 
demonstrated in glioma animal models, the stimulation of autophagy mediates apoptosis after 
cannabinoid treatment.61 Therefore, the ceramide accumulation and the activation of the ER-stress 
related pathway, induce cell death by apoptosis and stimulation of autophagy.62,63 However, 
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additional mechanisms may cooperate with the p8-mediated autophagy pathway to induce cancer 
cell death. It has been suggested that the antiproliferative activity of cannabinoids may involve 
induction of cyclin kinase inhibitor (p27/KIP1) that modulates regulatory molecules of the cell cycle 
(cyclins, cdks) resulting in cell cycle arrest and apoptosis.29,64,65
Up-regulation of the p53 protein is also a factor to take into account in this process. This alteration 
may induce an increase of the pro-apoptotic BCL-2 proteins leading to the activation of caspases, 
which play an essential role in triggering apoptosis.64 Likewise, CB1R ligands have pro-apoptotic 
properties, in part, through inhibition of the Ras protein (p21ras) which is involved in inducing 
DNA synthesis.66 Nonetheless, there are still many unraveled sides on death pathways activated by 
cannabinoids as well as on the different contribution of apoptosis and autophagy in cell death 
depending on the tumor system.  
Figure 2. Schematic representation of the signaling pathways through which cannabinoids impact apoptosis 
and proliferation. Figure based on SEIC´s website.67
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Effects on tumor invasion, metastasis and angiogenesis. Tumors induce blood vessel growth 
by secreting various growth factors that promote capillary development and neoplasm expansion.
This key process in cancer progression, known as angiogenesis, can be blocked by the administration 
of certain cannabinoids.68 The activation of cannabinoid receptors in cancer cells have resulted in the 
suppression of the vascular endothelial growth factor (VEGF) pathway which is an inducer of 
angiogenesis. Different elements of this cascade, such as the main ligand (VEGF) and the active 
forms of its main receptors (VEGFR1 and VEGFR2), are down-regulated after cannabinoid 
treatment of skin carcinomas,69 gliomas59,68 and thyroid carcinomas.70 This inhibition of angiogenesis 
is also associated with a reduced expression of pro-angiogenic cytokine. Besides its anti-angiogenic 
action, cannabinoids may also confer anti-migrative, anti-adhesive, anti-invasive, and anti-metastatic 
properties.71 In animal models of induced and spontaneous metastasis the administration of 
cannabinoids reduced the formation of distant tumor masses. Likewise, cannabinoids can inhibit 
adhesion, migration and invasiveness of lung (Δ9-THC, Met-AEA),72,73 glioma (Δ9-THC),74 cervical
(Δ9-THC, Met-AEA),73 and breast (AEA, JWH-133, WIN-55,212)75,76 cancer cells in culture. These 
effects are due to the modulation of matrix metalloproteinase 2 and its inhibitors. Matrix 
metalloproteinases (MMPs) are a family of proteolytic extracellular enzymes that play a crucial role 
in tumor invasion allowing tissue breakdown and remodeling during angiogenesis and metastasis. 
Tissue inhibitors of MMPs (TIMPs), and in particular TIMP-1, can inhibit the proteolytic activity of 
MMPs and suppress vascular tumor growth and angiogenesis in xenograft animal models.77 For 
instance, in a cervical cancer cell line, Met-AEA as well as Δ9-THC and CBD inhibited the invasive 
properties of these cells via increased expression of TIMP-1.73,78,79 Blázquez et al.74 reported that a 
decrease of MMP-2 expression in glioma cells can lead to inhibition of cell invasion after treatment 
with Δ9-THC. They showed that ceramide biosynthesis and expression of the stress protein p8 are
also involved in this process. Furthermore, THC and CBD have been shown to promote the 
expression of the intercellular adhesion molecule 1 (ICAM-1) on lung cancer cells as part of their 
anti-invasive and antimetastatic action.80
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All these data suggest that cannabinoids are potent inhibitors of both cancer growth and spreading. 
Nonetheless, the potential development of cannabinoids as antitumor drugs has been restricted due 
to their psychoactive properties. 
Towards clinical antitumor application 
Nowadays, cannabinoids are only prescribed for palliative purposes, however, the promising 
preclinical data aforementioned is increasingly raising its potential in the treatment of tumor 
progression itself. Indeed, the anticancer properties of cannabinoids are beginning to be clinically 
evaluated. A few years ago, Guzmán et al.81 developed the first clinical study to investigate the 
antitumor capacity of a cannabinoid receptor agonist on tumor growth activity. In this phase I pilot 
trial, they studied the effects of intratumoral administration of Δ9-THC on nine patients with 
glioblastoma multiforme, who had failed surgical therapy and radiotherapy and exhibited clear 
evidence of tumor progression. The results obtained in this study suggested that cannabinoid 
treatment reduced tumor growth rate. Interestingly, intracranial Δ9-THC administration was found 
to be safe and did not result in obvious psychoactive effects. Furthermore, combinational therapies 
of cannabinoids with other anticancer drugs, such as temozolomide or gemcitabine, are emerging as 
promising antitumor strategies.82,83 Actually, there is an ongoing phase I clinical trial in which 
patients with recurrent glioblastoma are treated with a combination of Sativex® and temozolomide 
(benchmark agent for the management of these brain tumors) to evaluate a possible enhanced 
antitumor activity. Nonetheless, more extensive clinical studies are needed to extract significant 
conclusions that reinforce the potential utility of cannabinoids as anticancer therapeutics.  
1.1.3 A focus on breast and prostate cancer  
In this dissertation, we will focus on the activity of new cannabinoid-quinones in triple negative 
breast cancer and prostate tumors. Therefore, the following section briefly summarizes the current 
knowledge of these two types of cancers in relation to the endocannabinoid system. 
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Triple Negative Breast Cancer (TNBC) 
Breast cancer is the most common malignant disease and the second leading cause of cancer death 
among Western women.84 Despite recent advances in earlier detection and adjuvant systemic 
therapies, mortality rates remain very high due to the emergence of refractory tumors associated 
with multidrug resistance.  
According to immunopathological criteria, there are three main breast cancer subtypes: hormone 
receptor-positive, HER2-positive (human epidermal growth factor receptor 2) and triple-negative 
tumors. Triple-negative breast cancers (TNBC) are defined by the absence of immunohistochemical 
expression of estrogen, progesterone, and HER2 receptors. Although this molecular subtype of 
breast cancer accounts for a low percentage of all breast tumors, it represents a disproportionate 
number of deaths.85 TNBC show aggressive clinical behavior, this fact, along with the lack of 
available targeted therapies leave these patients with a very poor prognosis.85–88 Chemotherapy with 
its well-known side effects is currently used as systemic treatment for this cancer.89 For that reason, 
the discovery of new targets and drugs for the treatment of this disease is an urgent and essential 
clinical challenge. In this context, the therapeutic potential of cannabinoids has been recently 
explored as a new hope for TNBC patients.90,91
Recent evidence suggests that cannabinoid receptors are overexpressed in human breast cancer 
biopsies.35,38,92 Further insights into the endocannabinoid upregulation have demonstrated a 
correlation between CB2R expression and tumor aggressiveness in triple-negative breast cancer 
cells.35 The putative novel cannabinoid receptor GPR55 is also highly expressed in these 
carcinomas.93 Consequently, the ECS represents a promising target for the treatment of TNBC.  
Prostate Cancer
Prostate cancer is the second most common cancer worldwide for males. The rates have increased 
in recent years as its detection has improved in the younger men and as life expectancy is longer.94
Even though most prostate cancers grow slowly, aggressive cases are also detected. These oncogenic 
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cells may metastasize to other parts of the body such as bones and lymph nodes.95 Therefore, there 
are extensive ongoing efforts to develop new therapeutic strategies to treat prostate cancer.96
The basis of medical treatment for advanced prostate cancer is androgen deprivation therapy 
(ADT), intended to lower testosterone levels. However, the reduction of clinical symptoms and 
tumor growth is accompanied by systemic consequences of testosterone deficiency such as 
osteoporosis, gynecomastia, anemia and insulin resistance among others.97,98 Androgen deprivation is 
associated with a gradual transition of prostate cancer cells through a spectrum of androgen 
dependence, androgen sensitivity, and ultimately androgen independence. Too often the appearance 
of hormone refractory cancer cells eventually leads to the recurrence of cancer which turns to a 
hormone-independent state. This type of prostate cancer has a more aggressive phenotype and is 
unresponsive to further hormonal therapy whereby prognosis is very poor. Therefore, to find a 
treatment which could reduce or block both types of prostate cancer would be a very good challenge 
to move forward. 
The expression of cannabinoid receptors has also been studied in prostate cancer tissue. It was 
demonstrated that CB1R expression is upregulated in these neoplasms.99 Indeed, high CB1R 
immunoreactivity score in prostate cancer tissue is associated with prostate cancer severity and 
outcome.100 Moreover, expression of FAAH47 and GPR55101 is demonstrated in some prostate 
carcinoma cell lines. In line with these observations, different endocannabinoids or cannabis-like 
compounds were evaluated exhibiting their ability to inhibit prostate cancer cell proliferation and 
produce apoptosis through cannabinoid receptor mechanisms.102 The dysregulation of this system 
correlates with prostate cancer grade and progression. Therefore, the ECS represents a new 
potential therapeutic target for prostate cancer.103,104
1.2  Antitumor quinones 
Quinones are a class of natural and synthetic compounds that possess numerous physiological and 
therapeutic effects.105 Nowadays cytotoxic quinones represent an important group of antineoplastic 
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drugs. Antitumor properties of quinones have been widely reported and are still the focus of much 
research.106,107 Quinones are formed by a common basic structural pattern: an ortho or a para
substituted dione conjugated either to an aromatic nucleus or to a condensed polycyclic system. 
Their mode of action is related to their structure. Therefore, cytotoxic activity of quinoid derivatives 
can be accounted for their fast redox cycling potential and Michael acceptor properties.108–110 Even 
though their mechanism of action is not completely understood, several mechanisms have been 
suggested. Most investigations propose different combinations of DNA intercalation,111
topoisomerase inhibition,112 DNA alkylation,113,114 and induction of reactive oxygen species (ROS)115
depending on the compound structural features.  
Many of the drugs clinically approved or still in clinical trials against cancer are quinone-related 
compounds (figure 3). The quinoid moiety is present in anthracyclines which are among the most 
used anticancer drugs ever developed.106 Daunorubicin (Cerubidine®) and doxorubicin 
(Adriamycin®), the most prominent members of this class of antitumor agents, are clinically used in 
the therapy of solid cancers as well as hematological malignancies.116 Likewise, mitoxantrone 
(Novantrone®), a dihydroxyanthracenedione, is approved for the treatment of certain types of 
neoplasms such as metastatic breast cancer, acute myeloid leukemia, and non-Hodgkin's 
lymphoma.117 Bioreductive alkylating agents such as mitomycin C and its derivatives also display 
remarkable antitumor effects. Mitomycin C, a potent DNA crosslinker, is a FDA approved drug for 
the treatment of solid tumors.118,119
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Figure 3. Some examples of quinoid compounds with antitumor activity. 
Many other quinoid compounds are currently in advanced clinical phases. For instance, menadione, 
a potential antineoplastic agent for the treatment of prostate cancer.120 This naphthoquinone is a 
prototypical redox cycling molecule that induces death through ROS-mediated pathways.121 β-
lapachone, an ortho naphthoquinone, originally isolated from a tree, is also being evaluated for its 
cancer growth inhibitory properties in diverse tumors.106 Even though in many cases the antitumor 
mechanisms remain uncertain, it is unquestionable that the presence of the quinone moiety is 
exceptionally remarkable in the development of new anticancer drugs.  
Despite the fact that quinones have been extensively studied as antitumor agents, there are only 
three with a cannabinoid-related structure. Few years ago, Kogan et al.122 reported the antitumoral 
activity of quinone derivatives of phytocannabinoid compounds [cannabidiol (HU-331), Δ8-THC 
(HU-336) and cannabinol (HU-345) (figure 4)]. Their biological activity was attributed to their 
quinone structure123,124 independently of their cannabinoid character, since they do not bind to 
cannabinoid receptors.  
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Figure 4. Quinones related to cannabinoids 
The most effective, HU-331, reduced growth of human colon carcinoma HT-29 cells in nude mice. 
The mechanism of action of HU-331 is poorly understood. HU-311 does not promote cell death via 
cell cycle arrest. Recent studies125 indicate that HU-311 inhibits the ATPase function of human 
topoisomerase IIα. The other cannabinoid-structure related quinone, HU-336, inhibits angiogenesis 
by inducing apoptosis of vascular endothelial cells. Consequently, anticancer quinone directly acting 
on the cannabinoid system has not been described so far. 
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2. Aims 
A large diversity of biological signaling-pathways are implicated in the pathogenesis of cancer. 
Appropriate treatment of neoplasms often depends on pharmaceutical intervention at multiple 
pathways using combinations of different drugs. In this context, targeting different anticancer 
modes of action in a single molecule is a significant challenge.126–128 Our interest in cannabinoid 
ligands and antiproliferative agents has prompted us to design molecules which structure includes 
cannabinoid quinone features. Taking into account these targets, we propose structural 
modifications of the chromenopyrazole scaffold, previously described in chapter 1, introducing the 
quinone moiety (figure 5). Subsequently, the specific aims of this chapter are:
- Synthesis of quinones from chromenopyrazoles.a
- Determination of electrochemical parameters of novel compounds.b
- Analysis of in silico drug-like properties of chromenopyrazolediones.a
- Evaluation of their ability to bind to CB1R and CB2R.c
- Assessment of their potential antitumor properties in different human cancer cell lines.d
- Elucidation of their mechanism of action.d
- Appraisal of the antitumor activity in vivo of the best derivatives.d
Figure 5. Proposed structures: chromenopyrazolediones. 
a) Performed by PM at Instituto de Química Médica (CSIC). 
b) Performed in collaboration with Prof. Claudio Olea (Facultad de Ciencias Químicas, Universidad de Chile). 
c) Performed by PM hosted by Prof. Javier Fernández-Ruiz (Facultad de Medicina, UCM). 
d) Breast cancer studies: performed by PM hosted by Prof. Cristina Sánchez (Facultad de Biología, UCM). Prostate cancer 
studies: Performed in collaboration with Prof. Inés Díaz-Laviada (Facultad de Medicina, Universidad de Alcalá de 
Henares).
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3. Results  
3.1 Chemistry  
The initial 7-(1’,1’-dimethylheptyl)-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-ols (1.41.6) were 
synthesized following the procedure described in the previous chapter.129 The regio-controlled 
oxidation of the starting chromenopyrazoles to the corresponding 1,2- or 1,4-quinones was achived 
by reaction under mild conditions with hypervalent iodine reagents.130 Reaction with bis(trifluoro-
acetoxy)iodobenzene (BTIB) yielded the para-quinone derivatives131,132 2.12.3, whereas regiospecific 
oxidation with o-iodoxybenzoic acid (IBX) furnished the ortho analogues 2.42.6. Only few methods 
have been reported for the preparation of ortho-quinones by oxidation of phenols. In 2002, Pettus133
described the use of IBX as a regioselective oxidant of phenols. Since then, IBX-mediated 
oxidations have been extended to polyaromatic ortho-quinones.134,135 Scheme 1 outlines the synthesis 
of the para and ortho chromenopyrazolediones 2.12.6. The 7-(1’,1’-dimethylheptyl)-dihydro-4,4-
dimethylchromeno [4,3-c]pyrazol-6,9 and 8,9-diones 2.12.6 were obtained in moderate to low 
yields.
Scheme 1. Oxidation of chromenopyrazoles to the corresponding quinone derivatives 2.12.6. Reaction 
conditions: (i) [bis(trifluoro-acetoxy)iodo]benzene, MeCN/ H2O (6:1), 15 min, room temperature, 21-
36%; (ii) o-iodoxybenzoic acid, DMF, 30 min, room temperature, 24-30%.
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3.2 Electrochemistry
Since most of the biological functions of quinones are associated with their redox activity, the 
electrochemical properties of 7-(1’,1’-dimethylheptyl)-1,4-dihydro-4,4-dimethylchromen[4,3-
c]pyrazol-6,9-dione (2.1) and 7-(1’,1’-dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethylchromen[4,3-
c]pyrazol-6,9-dione (2.3), as examples, have been studied by cyclic voltammetry. Table 1 lists the 
values of the electrochemical parameters for 2.1 and 2.3. 
Table 1. Cyclic voltammetric parameters of 2.1 and 2.3 vs. saturated calomel electrode at 2.0 V/s
Chromenopyrazolediones 2.1 and 2.3 displayed comparable voltammetric behavior, showing two 
well-defined reduction waves in DMSO. The first wave for both quinones studied corresponded to a 
cuasi-reversible one-electron transfer. The reverse scan showed the anodic counterpart of the 
reduction waves (compound 2.1, figure 6). According to the standard reversibility criteria, this 
couple corresponds to a cuasi-reversible diffusion-controlled one-electron transfer. It is attributable 
to the reduction of quinone to semiquinone that involves a stable anion radical at room temperature.  
The second couple is irreversible over the whole range of sweep rates used (0.1 at 2.0 V/s). We can 
attribute this wave to the production of a hydroquinone derivative. 
Compd Epc I (mV) Epa I (mV) E 1/2 (mV) Ipa/Ipc Epc II (mV)
2.1 -0.512 -0.422 -0.467 0.54 -1.263
2.3 -0.590 -0.527 -0.559 0.65 -1.141
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Figure 6. Cyclic voltammetric curves of 1 mM 2.1 sweep rates ranging from 0.1 to 2 V/s in 100% DMSO 
with 0.1M TBAP. 
Electron spin resonance (ESR) experiments were carried out in order to correlate the cytotoxicity to 
the formation of radicals. The semiquinone free radicals were prepared in situ by electrochemical 
reductions in DMSO, applying a potential corresponding to the first wave for 2.1 or 2.3 obtained 
from the cyclic voltammetric experiments. The interpretation of the ESR spectra by means of a 
simulation process has led to the determination of the coupling constants for all the magnetic nuclei, 
confirmed by theoretical calculations. The ESR spectrum of 2.1 was analyzed and simulated in terms 
of one doublet from hydrogen nuclei of the quinone moiety; the hyperfine constant was 2.635 gauss. 
Figure 7 shows the ESR experimental and simulation spectra. Similar hyperfine pattern was found 
for 2.3 with hydrogen hyperfine constant value of 2.925 gauss. 
Figure 7. ESR experimental and simulated spectrum of 2.1 in DMSO. 
3.3 Cannabinoid binding studies  
The binding affinity of the chromenopyrazolediones 2.12.6 was determined through radioligand 
competition experiments. The ability of compounds 2.12.6 to displace [3H]CP55940 from human 
CB1R or CB2R transfected into HEK293 EBNA cells was assessed. Standard cannabinoid ligand 
WIN55,212 was also tested for appraisal with the new derivatives. Initially, the compounds were 
screened at a concentration of 40 μM. The affinity constant (Ki) of compounds able to displace the 
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radioligand by more than 70% was determined from concentration−effect curves. The experimental 
binding affinities of 2.12.6 and WIN55,212 are reported in table 2. First of all, it is noteworthy that 
chromenopyrazolediones are the first cannabinoid structure-related quinones able to bind to the 
cannabinoid receptors. As already commented in the introduction, quinones related to cannabinoid 
structure reported so far do not have affinity for the cannabinoid receptors.122
Para-chromenopyrazolediones 2.12.3 display affinity for both receptors in the low micromolar 
range. Interestingly, 2.1 showed significant affinity in the nanomolar range for both CB1 and CB2
receptors. Besides, ortho-quinones 2.42.6 are fully selective towards CB2R with affinity in the 
submicromolar range. Their lack of affinity for the CB1R (higher than 40 µM) eliminates any 
psychotropic side effect that would be derived from activation of central CB1R. 
Table 2. Binding affinity of chromenopyrazolediones 2.12.6 and the reference cannabinoid WIN55,212 for 
hCB1R and hCB2R cannabinoid receptors. 
3.4 In silico ADME properties  
Inappropriate absorption, distribution, metabolism, and excretion are among the main determinants 
of drug development failures. Therefore, they should be considered at early stages of the drug 
discovery process. Nowadays, in silico approaches are widely accepted because of their fast and 
precise predictive potential.136,137
Compd CB1R Ki (nM)a CB2R Ki (nM)a
2.1 324 ± 235 134 ± 21
2.2 14180 ± 5638 672 ± 191
2.3 8520 ± 3891 3665 ± 878
2.4 > 40000 398  ± 49
2.5 > 40000 597 ± 77
2.6 > 40000 529 ± 26
WIN55,212 45.6 ± 8.6 3.7 ± 0.2
aValues obtained from competition curves using [3H]CP55940 as radioligand for hCB1R 
and hCB2R and are expressed as the mean ± SEM of at least three experiments.
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Pharmacokinetic properties of compounds 2.1 to 2.6 were predicted using QikProp on each global 
minimum energy conformer. As presented in table 3, chromenopyrazolediones follow Lipinski and 
Jorgensen pharmacokinetics rules.138,139 As highlighted in the previous chapter, due to their lipophilic 
nature, solubility of cannabinoids is a great challenge. Interestingly, the cannabinoid-quinones 
described herein display adequate solubility values. Almost all the predicted properties of the tested 
compounds are within the ranges predicted by QikProp for 95% of known oral drugs (table 3). 
These data indicate that chromenopyrazolediones present a satisfactory druggability profile. 
Table 3. Physicochemical descriptors of compounds 2.12.6 calculated by QikProp 3.5 integrated in Maestro 
(Schrödinger, LLC, New York, USA).  
3.5 Cannabinoid-quinones for TNBC therapy 
As previously mentioned, triple-negative breast neoplasms do not respond to endocrine therapy or 
other available targeted agents. Consequently, there is an evident need to develop effective 
anticancer agents with novel scaffolds or new mechanisms of action for the management of this 
disease. In this context, we decided to evaluate the antiproliferative activity of the novel 
cannabinoid-quinones in models of this highly aggressive breast cancer.  
Compd QPlogSa QlogBBb QPlogHERGc QPPCacod %Human  oral absorption GIe
2.1 -5.15 -1.01 -4.69 666 100
2.2 -5.36 -0.62 -4.90 1701 100
2.3 -5.78 -0.63 -5.23 1985 100
2.4 -5.35 -1.09 -4.90 611 100
2.5 -5.62 -0.69 -5.11 1562 100
2.6 -5.99 -0.65 -5.03 1976 100
aPredicted aqueous solubility [-6.5/0.5]; bPredicted log of the brain/blood partition coefficient [-3.0/1.2]; cHERG K+
Channel Blockage (log IC50) [concern below -5]; dApparent Caco-2 cell permeability in nm/s [<25 poor, >500 
excellent]; eHuman Oral Absorption in GI [<25% is poor]; [range of 95% of drugs].
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3.5.1 Antiproliferative properties in vitro 
The antiproliferative activity of chromenopyrazolediones 2.12.6 was assessed against a human 
derived triple-negative breast cancer cell line, MDA-MB-231. Cell cultures were treated with 
different doses of 2.12.6 for 48 h, and cell viability was analyzed by colorimetric measurements 
using 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT). As shown in figure 8, 
tested cannabinoid-quinones displayed growth inhibitory effects on triple-negative MDA-MB-231 
breast cancer cells, with low micromolar IC50 values (table 4).  
 
Figure 8. Dose-response curves of antiproliferative effect of chromenopyrazolediones 2.12.6 against the 
human breast cancer cell line MDA-MB-231.  
Compounds 2.3 and 2.6 are the most potent inhibitors of cell proliferation with IC50 constants of 
2.5 and 2.8 µM respectively (table 4). Regarding its antiproliferative capacity and its CB2R selective 
profile, compound 2.6 was selected for additional investigations. 
Table 4. Half-maximum inhibitory concentrations (IC50) values for compounds 2.1-2.6.
Compd IC50 (µM)a
2.1 8.2 ± 1.1
2.2 5.8 ± 0.9
2.3 2.5 ± 0.1
2.4 8.5 ± 0.4
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Triple-negative breast cancer is a very heterogeneous disease, not only on the molecular level, but 
also from a clinical point of view.140,141 In fact, at least six different subtypes of this pathology have 
been already identified.142 Therefore, the cytotoxicity of the selected compound 2.6 has been 
evaluated on three additional TNBC cell lines (SUM149, SUM159, and MDA-MB-468). As shown 
on figure 9, these TNBC cell lines were sensitive to compound 2.6, with IC50 values of 4.6, 4.1 and 
17.3 µM respectively.  
Figure 9. Dose-response curves of antiproliferative effect of chromenopyrazoledione 2.6 against the TNBC 
cell lines MDA-MB-231, SUM149, SUM159, and MDA-MB-468.  
Citotoxicity on normal Human Mammary Epithelial.
Selective toxicity for cancer versus non-cancer cells is one of the main challenges of anticancer 
therapies. For that reason, we examined the growth inhibitory activity of compound 2.6 against 
human mammary epithelial cells (HMEC).
2.5 5.0 ± 0.8
2.6 2.8 ± 0.5
aValues are the mean ± SEM of three independent 
experiments performed in triplicate. 
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Figure 10. Effects of compound 2.6 on normal human mammary epithelial cell (HMEC) proliferation. 
HMECs were treated with increasing concentrations of the drug. Cell viability was determined 48 h after 
treatment. Values are the mean ± SEM of three independent experiments performed in duplicate.
At concentrations up to 10 times its IC50 value, chromenopyrazoledione 2.6 did not display 
antiproliferative activity in this non-transformed mammary epithelial cell line (figure 10). Therefore, 
compound 2.6 demonstrates effective inhibition of triple-negative breast cancer cell growth without 
affecting the proliferation of their non-transformed counterparts. This selective toxicity towards 
cancer cells versus non-transformed HMECs was previously observed in phytocannabinoids such as 
9-THC.35,143
In what concerns the selectivity of quinones toward cancer cells, it has been reported that quinones 
affect cancer cells in higher extent than healthy cells.115,144 This selectivity could be explained by the 
fact that cancer cells have increased endogenous ROS levels compared with normal cells due to their 
accelerated metabolism. 
3.5.2 Mechanism of action 
With the aim of further appraising the antitumor mechanism of cannabinoid quinone 2.6, we 
studied the effect of selective inhibitors, alone or in combination with the compound, on cell 
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viability. MDA-MB-231 cells were pre-incubated for 1h with the CB1R antagonist SR141716 (SR1), 
the CB2R antagonist SR144528 (SR2), the GPR55 antagonist CID16020046 (CID), and the 
antioxidant α-tocopherol (Toc). Afterward, these cells were challenged with compound 2.6 for 48 h 
at IC50 concentration (2.8 µM). As presented in figure 11, any of the inhibitors (SR1, SR2, CID, Toc) 
has any effect on MDA-MB-231 cell viability by themselves. Interestingly, SR2 and α-Toc were able 
to significantly prevent the inhibition of cell viability induced by 2.6, indicating that activation of the 
CB2R and generation of reactive oxygen species (ROS) were involved in the antiproliferative action 
of compound 2.6. Conversely, neither SR1 nor CID altered the effect of chromenopyrazoledione
2.6 on cell viability, suggesting that neither CB1R nor GPR55 are targets of this compound. These 
results support our initial design that was the combination of CB2R activity with ROS production in 
a single anticancer agent.
Figure 11. Molecular mechanisms involved in the growth inhibitory activity of compound 2.6. MDA-MB-
231 cell viability was determined by the MTT test. CB1R selective antagonist: SR141716 (SR1); CB2R selective 
antagonist: SR144528 (SR2); GPR55-selective antagonist: CID16020046 (CID); antioxidant: α-tocopherol (α-
Toc). Results represent the mean ± SEM of three different experiments performed in triplicate. Data were 
assessed by two-way analysis of variance followed by the Student-Newman-Keuls (* p < 0.05 and **p < 0.01 
vs vehicle-treated cells; #p < 0.05 versus the compound alone).
In order to evaluate the cellular mechanism underlying this antiproliferative effect, the involvement 
of caspase-3 was assessed in MDA-MB-231 cells. Caspases are crucial mediators of mammalian cell 
death and caspase-3 is an apoptosis related cysteine peptidase responsible for apoptosis execution. 
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Western blots offer an efficient way of detecting caspase-3 activation.145 Thus, western 
immunoblotting analysis was performed following a 48 h treatment of cells with IC50 dose of 2.6. 
Figure 12 illustrates the procaspase-3 cleavage into caspase-3 which confirms the proapoptotic 
effect of cannabinoid-quinone 2.6 on this triple-negative breast cancer cell line. 
Figure 12. Analysis of caspase-3 protein expression. Western blot analysis of caspase 3 after 48 h exposure to 
compound 2.6 at IC50 concentration in MDA-MB-231 cells. The graph represents the densimetric analysis of 
protein levels. The optical density is relative to control cells set as 1. n = 3. Data were assessed by the 
Student’s t-test (*p<0.05 vs vehicle-treated cells).
3.5.3 Antitumor activity in vivo
On the basis of its potent antiproliferative effect and its low toxicity in HMEC cells, compound 2.6 
was selected for in vivo studies. To evaluate its capacity to inhibit TNBC growth, tumor xenografts 
were generated in nude mice by subcutaneous inoculation of MDA-MB-231 human breast 
adenocarcinoma cells. Mice were treated intraperitoneally three times a week during four weeks with 
vehicle or 2 mg/kg of compound 2.6. As shown in figure 13, chromenopyrazoledione 2.6 was able 
to effectively reduce the growth of triple-negative xenografts in this animal model. Volume and 
weight of final tumors was significantly lower in all 2.6-treated mice.  
To assess the in vivo toxicity of compound 2.6, organ histopathology was assessed in tumor-bearing 
mice post-treatment and without treatment (vehicle). Microscopic examination of tissues was 
performed as blind study to the identity of animals. Interestingly, the histopathological analysis of 
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animal organs (liver, spleen, lung, heart, ileum, colon, fundus, antrum, kidney, and duodenum) 
showed no sign of toxicity in these animals (data not shown).
Figure 13. Compound 2.6 reduces tumor growth in vivo. (A) Effect of intraperitoneal administration of 2.6 
on the growth of tumor xenografts generated in nude mice by injection of MDA-MB-231 human breast 
adenocarcinoma cells (mean ± SEM). Images show representative vehicle- and compound 2.6-treated tumors. 
(B) Effect of 2.6 administration on tumor weight. Data were assessed by two-way (with repeated measures) 
analysis of variance followed by the Student-Newman-Keuls (*p<0.05 vs. vehicle-treated tumors). 
In view of these data, we have identified compound 2.6 as a new promising anticancer drug 
candidate with potent antitumor activity in vitro and in vivo in triple-negative breast cancer. 
3.6 Cannabinoid-quinones for prostate cancer treatment 
Experimental evidence shows that the endocannabinoid system is dysregulated in prostate tumors. 
In particular, the level of expression of CB1Rs in prostate cancer cells differs from non-malignant 
cells.103 Thus, due to the significant role of these receptors in prostate cancer,100,146,147 CB1R agonists 
should provide a new therapeutic approach for this type of cancer. Among the series of 
chromenopyrazolediones 2.12.6, the CB1R ligands 2.12.3 were selected for their evaluation in 
androgen-dependent (LNCaP) and androgen-refractory (PC-3) prostate cancer-derived cell lines.  
3.6.1 Antiproliferative properties in vitro 
The antiproliferative effect of chromenopyrazolediones 2.12.3 was evaluated against the cancer cell 
lines LNCaP and PC-3. LNCaP is an androgen-dependent prostate cancer-derived cell line and PC-3 
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is an androgen-refractory prostate cancer-derived cell line. Increasing doses of 2.12.3 were added 
to cell cultures for 48h and cell viability was analyzed by colorimetric measurements using MTT as a 
dye. As showed in figure 14, all the tested cannabinoid-quinones are effective in prostate cancer 
cells, being 2.1 the most potent with an IC50 of 15 µM for prostate cancer LNCaP and PC-3 cells. 
Therefore, the chromenopyrazoledione 2.1 was selected for following investigations in these cancer 
cells. 
Figure 14. Chromenopyrazolediones 2.12.3 decrease human cancer cell viability. Human prostate cancer 
LNCaP (A) and PC-3 (B) cells were incubated for 48 h with increasing doses of the tested compounds. Cell 
viability was determined by MTT. Data are the mean   SD of two different experiments performed in 
triplicate. 
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3.6.2 Mechanism of action 
To study the effect of the chromenopyrazoledione 2.1 on the cell cycle of prostate cells, flow 
cytometry analysis were carried out. Results shown in figure 15 demonstrate that 2.1 increased the 
amount of cells in the sub G0/G1 phase of the cell cycle. This result suggests that 2.1 induces growth 
arrest and cell death.
Figure 15. Chromenopyrazoledione 2.1 induces cell cycle arrest in human prostate cancer cells.  Cell cycle 
analysis of human prostate LNCaP and PC-3 cells treated with the IC50 (15 µM) of 2.1 for 24 h. Cells were 
stained with IP and analyzed by flow cytometry. Figure is representative of other two performed in duplicate. 
In order to quantify the percentage of apoptotic cells after drug treatment, LNCaP and PC-3 cells 
were stained with Annexin V-FITC/PI. Annexin V-FITC is a fluorescent conjugate (fluorescein 
isothiocyanate) of annexin, a protein with high affinity for cell membrane phosphatidyl serine 
located on the surface of cells undergoing apoptosis. Detection was then analysed by flow 
cytometry. Results showed that the rate of late apoptotic cells (figure 16: Annexin V-FITC 
positive/PI positive, upper right quadrant) in 2.1-treated cells was statistically increased compared to 
the control cells. Early apoptotic cells (Annexin V-FITC positive/PI negative) were nearly 6 % in 
Results
166 
LNCaP cells and nearly 4% in PC-3 cells.  These findings indicate that 2.1 induces a significant 
percentage of apoptosis in prostate cancer cells being more efficient in promoting apoptosis in the 
androgen-sensitive LNCaP cell line.
Figure 16. Chromenopyrazoledione 2.1 induces apoptosis in human prostate cancer cells. Evaluation of 
apoptosis by annexin V-FITC/PI staining followed by flow cytometric analysis. Representative plots of 
annexin V-FITC/PI staining of LNCaP or PC-3 cells cultured in the presence of the IC50 (15 µM) of 2.1 for 
24 h are shown. Data showing the percentage of late apoptotic cells (upper right quadrant) are the mean  SD
of three different experiments performed in duplicate.
With the purpose of further studying the underlying molecular mechanism of 2.1-induced prostate 
cell death, cell viability was assayed in presence of cannabinoid antagonists and antioxidant. A 
peroxisome proliferator-activated receptor gamma (PPAR) antagonist was also tested since 
involvement of PPAR receptor in the cannabinoid-induced inhibition of prostate cancer cells 
growth have been suggested.148
The CB1R antagonist SR141716 (SR1, also named rimonabant), the CB2 antagonist SR144528 (SR2), 
the antioxidant N-acetylcysteine (NAC), and the PPAR antagonist GW 9662 were tested against 
LNCaP cells to confirm that they do not have any effect on the cellular viability by themselves.
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Moreover, LNCaP cells pre-treated with SR1, SR2, NAC, or GW 9662 (1h before addition of our 
compound) were challenged with 2.1 (IC50 dose) and incubated for 48h. MTT cell viability assays 
showed that the CB1R antagonist as well as the PPAR antagonist and the antioxidant were able to 
significantly reduce the inhibition of cell viability induced by 2.1 (figure 17). These results indicate 
that chromenopyrazoledione 2.1 inhibits cell viability through a mechanism involving oxidative 
stress, PPAR receptors and partially CB1Rs. It is noteworthy that only SR1 and not SR2 prevent the 
antiproliferative effect of 2.1 in LNCaP cells albeit 2.1 exhibits higher affinity for CB2R than for 
CB1R. This fact might be due to a low expression of CB2R in LNCaP cells as previously observed in 
this type of cancer.146 The antioxidant NAC did not only prevent 2.1-induced cell death but also
slightly increased cell viability. 
Figure 17. Signalling pathways involved in antiproliferative effect produced by compound 2.1. LNCaP cells 
were incubated for 48 h with vehicle (control) or with 2.1 at IC50 dose (15 µM) in presence or not of different 
inhibitors (CB1R antagonist, SR1; CB2R antagonist, SR2; PPAR antagonist, GW9662; and the antioxidant N-
acetylcysteine NAC). Cell viability was determined by MTT. Results represent the mean  SEM of four 
different experiments performed in duplicate. *p 0,05 compared with Student’s test vs NAC treated cells and 
#p 0,05 compared with Student’s test vs the compound alone.
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3.6.3 Antitumor activity in vivo
To investigate the ability of compound 2.1 to inhibit prostate tumor growth in vivo, tumor xenografts 
were generated by subcutaneous inoculation of LNCaP or PC-3 cells in nude mice. Mice were daily 
treated with vehicle (control), or 2 mg/kg of 2.1 intraperitoneally administered for 15 days. As 
shown in figure 18, treatment with 2.1 almost completely blocked the growth of LNCaP tumors 
whereas it inhibited the growth of PC-3 tumors by 40 %. The final tumor volume was smaller in all 
2.1-treated mice. 
Figure 18. In vivo antitumoral effect of compound 2.1. Athymic nude mice were injected s.c. in the right flank 
with either LNCaP (A) or PC-3 (B) cells and four weeks later (day 0) treated during 15 days with vehicle 
(control) or 2 mg/kg of 2.1. Treatments were administered intraperitoneally every day. Tumor growth curves 
are represented in the graph. Results represent the mean  SEM of eight mice in each group. A representative 
dissected tumor after the treatment is shown on the right. 
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4. Discussion and conclusions
Cancer treatment is among the most promising therapeutic uses for cannabinoids.26 Numerous 
pharmacological and biochemical studies exert their antitumor actions in different cell and animal 
models of cancer31,102,149,150 However, as commented in the introduction of this chapter, only a pilot 
clinical trial has been reported so far,81 whereas a few more are presently in progress. 
Since cancer is a complex multifactorial physiopathology triggered by dysregulation of diverse 
cellular systems, successful cancer treatments should involve the modulation of multiple signalling 
pathways using combinations of different agents with different mechanisms of action126,128 Within 
this context, we associated the cytotoxic potential of quinones with the antiproliferative properties 
of cannabinoids in a single molecule. 
Due to the versatility of the chromenopyrazole scaffold for cannabinoid ligands, as previously 
reported in chapter 1, we next explored its quinone derivatives as dual acting anticancer agents. 
Thus, para- and ortho-chromenopyrazolediones (2.12.6) were prepared by regioselective oxidation of 
the corresponding chromenopyrazoles with the appropriate hypervalent iodine reagent. These 
compounds were able to bind to cannabinoid receptors which make them the first quinones related 
to cannabinoid structure as cannabinoid ligands. Indeed, the cannabinoid-quinones reported in the 
literature which derive from oxidation of phytocannabinoids, were not able to modulate CB1R or 
CB2R.122 Moreover, ortho-quinones (2.4-2.6) revealed fully selectivity for the hCB2R. Thus, they are 
devoid of the centrally mediated CB1R effects related to psychotropic activity. This full CB2 receptor 
selectivity represents a high value for potential clinical application. Regarding the para-quinone 
chromenopyrazoles (2.1-2.3), they showed to be mixed CB1R/CB2R ligands with moderate but 
significant affinity for both receptor types. 
To reduce the risk of late-stage failure, in silico approaches136,137 of absorption, distribution, 
metabolism, and excretion (ADME) gave predictive properties of these cannabinoid-quinones. 
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Thus, the physicochemical descriptors calculated for compounds 2.1-2.6 suggest a satisfactory 
druggability profile. 
We focussed the antitumor activity studies on two types of cancer, triple negative breast cancer and 
prostate cancer. In what concerns breast cancer, all the para- and ortho-quinone cannabinoids (2.1-
2.6) displayed potent antiproliferative effects on triple-negative MDA-MB-231 breast cancer cells as 
the same extent than Δ9-THC (IC50 = 5 µM) in the same cell line.35. However, ortho-quinone 
derivatives have the advantage of lacking CB1R-mediated psychotropic effects. It is why we further 
concentrated our studies on the most potent of the ortho-quinone series, compound 2.6. Considering 
that triple negative breast cancer as most of breast cancer types, is heterogeneous, the selected 
compound was tested in other three different triple negative cell lines (SUM149, SUM159 and 
MDA-MB-468) for which it showed antiproliferative profiles.
We next oriented our research on validating the proposed cannabinoid/ROS concept by studying 
the mechanism of action of compound 2.6. Indeed, the antiproliferative effect of 2.6 has been 
shown to be mediated by CB2R activation and through the induction of oxidative stress. We also 
proved that the putative cannabinoid receptor GPR55,93,151,152 highly expressed in the triple-negative 
MDA-MB-231 cell line, was not involved in compound 2.6 antitumor action. 
Two other concerns needed to be taken into consideration as it is done for most of antitumor 
agents: the selectivity for breast cancer cells versus normal breast cells and the cellular mechanism 
underlying this antiproliferative effect. Interestingly, compound 2.6 decreased the viability of breast 
cancer cells and did not affect normal mammary epithelial cell viability. This selectivity could be due 
to the cannabinoid or the ROS nature of the compound. The selective toxicity of cannabinoids 
towards cancer cells versus their non-transformed counterparts was previously observed in 
phytocannabinoids such as 9-THC.35,143 In what concerns the quinone nature of the compound, 
quinones are well-known to act as reactive oxygen species (ROS) and might cause damage to cancer 
cells but also to normal cells. On the one hand, modulation of oxidative stress is considered an 
anticancer strategy. Since the redox status of cancer cells differs from normal cells, tumor cells are 
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more sensitive to oxidative stress than normal cells. On the other hand, high ROS levels might be 
detrimental for normal cells as reviewed recently by Gorrini et al.115 In our system, compound 2.6
proved to be very efficient in reducing the viability of cancer cells in a concentration range that did 
not affect the viability of non-transformed cells.  
The antitumor effect of 2.6 was reproduced in vivo in tumor xenografts (MDA-MB-231) upon 4 
weeks of treatment (2 mg/kg). The lack of toxicity of compound 2.6 observed in cells was further 
confirmed in vivo by histological analysis of different organs such as liver, spleens or heart after 
treatment.
From these data and concerning triple negative breast cancer, we can conclude that cannabinoid-
quinone 2.6 showed encouraging efficacy in this proof-of-concept study.153,154
The other target that we considered for our quinones is prostate cancer. As commented earlier, the 
CB1R plays a major role in prostate cancer process; it is why we selected the mixed CB1R/CB2R
para-chromenopyrazolediones 2.1-2.3 for these studies. In cell viability assays, compounds 2.1-2.3 
exerted antiproliferative effects in androgen-dependent (LNCaP) and androgen-refractory (PC-3) 
prostate cancer cell lines, chromenopyrazole 2.1 displaying the highest efficiency and potency in 
both lines. Compound 2.1 induced cell death through apoptosis as studied by flow cytometry, being
more efficient in the androgen-sensitive LNCaP cell line. At molecular mechanistic level, 
cytotoxicity of 2.1 has been shown to be mediated through cannabinoid receptor TYPE 1 and
oxidative stress. In addition to CB1R and ROS pathways, participation of PPAR receptor in this
underlying mechanism has been explored, since involvement of PPAR receptor in the cannabinoid-
induced inhibition of prostate cancer cells growth has been recently reported.148,155,156 It was then no 
surprising that PPAR receptors had been found to be involved in the mechanism of action of the 
para-quinone cannabinoid 2.1. 
The in vivo studies of the para-quinone cannabinoid 2.1 corroborate the results obtained in vitro. 
Treatment with 2.1 (2 mg/kg) totally inhibited the growth of androgen-dependent prostate cancer 
(LNCaP) tumor compared with control. In relation to androgen-refractory prostate cancer (PC-3), 
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the tumor size decreased significantly after treatment with 2.1. Cytotoxicity has not been evaluated 
on this compound, however concentrations used in our in vivo study are similar to those used with 
cannabidiol derived quinone124 and far from the doses capable to produce toxicity.157 Concerning our 
studies focussed on prostate cancer target, we can conclude that the cannabinoid-quinone 2.1
provides experimental arguments to the cannabinoid/ROS proof-of-concept.158,159
In conclusion, the studies reported in this chapter provide evidence supporting that quinones 
derived from chromenopyrazole exert remarkable antiproliferative properties in vitro and in vivo
through cannabinoid receptor pathway and ROS production. We showed that the selected ortho-
chromenopyrazoledione 2.6 induces triple-negative breast cancer cell death by apoptosis via CB2R
activation and ROS production, and lacks of toxic effects. We also report a potent anticancer agent
(2.1) with in vitro and in vivo activity against hormone-sensitive prostate cancer triggering apoptosis
through a mechanism that involves oxidative stress, CB1R and PPAR.
Both cannabinoid-quinones are good candidates for further development as new anticancer drugs. 
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5. Experimental section 
Chemistry: 
General methods and materials. All commercially available reagents and solvents were used 
without further purification. Products were purified using flash column chromatography (Merck 
Silica gel 60, 230-400 mesh). The purity of the compounds as determined by HPLC-MS and 
elemental analyses is > 95%. HPLC-MS analysis was performed on a Waters 2695 HPLC system 
equipped with a photodiode array 2996 coupled to Micromass ZQ 2000 mass spectrometer (ESI-
MS), using a reverse-phase column SunFireTM (C-18, 4.6 x 50 mm, 3.5 μm) in gradient A: 
CH3CN/0.1% formic acid, B: H2O/0.1% formic acid visualizing at λ = 254 nm. Flow rate was 1 
mL/min. Elemental analyses of the compounds were performed using a LECO CHNS-932 
apparatus. Deviations of the elemental analysis results from the calculated are within ± 0.4%. 1H, 
13C, HSQC and HMBC-NMR spectra were recorded on a Bruker 300 (300 and 75 MHz) at 25 °C. 
Samples were prepared as solutions in deuterated solvent and referenced to internal non-deuterated 
solvent peak. Chemical shifts were expressed in ppm (δ) downfield of tetramethylsilane. Coupling 
constants are given in hertzs (Hz). Melting points were measured on a MP 70 Mettler Toledo 
apparatus. Chromenopyrazoles 1.41.6 were prepared according to procedures described in chapter 
1.
7-(1,1-Dimethylheptyl)-1,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-6,9-dione (2.1). To a 
solution of 7-(1,1-dimethylheptyl)-1,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-ol (1.4) (130 
mg, 0.38 mmol) in MeCN/ H2O (6:1, 2.5 mL) a solution of BTIB (490 mg, 1.14 mmol) in 2 mL of 
MeCN/ H2O (6:1) was added dropwise. The reaction mixture was stirred at room temperature for 
15 min, neutralized with aqueous NaHCO3 satured solution, 
and extracted with diethyl ether. The organic layer was washed 
with H2O, dried over MgSO4 and concentrated. Column 
chromatography on silica gel (hexane/EtOAc, 1:2) afforded the title compound as a red solid (29 
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mg, 21%); mp: 85–86 ºC; 1H-NMR (300 MHz, CDCl3) δ: 8.41 (br s, 1H, NH), 7.40 (s, 1H, 3-H), 
6.69 (s, 1H, 8-H), 1.59–1.57 (br s, 6H, OC(CH3)2), 1.55–1.48 (m, 2H, 2´-H), 1.30 (s, 6H, C(CH3)2), 
1.27–1.23 (m, 6H, 3´-H, 4´-H and 5´-H), 1.19–1.12 (br s, 2H, 6´H), 0.86–0.82 ppm (m, 3H, 7´-H); 
13C-NMR (75 MHz, CDCl3) δ: 184.1 (6-C), 180.9 (9-C), 160.2 (5a-C), 161.2 (7-C), 137.8 (9b-C), 
132.0 (8-C), 130.4 (9a-C), 129.5 (3-C), 113.8 (3a-C), 78.6 (OC(CH3)2), 43.3 (2´-C), 30.9 (1´-C), 29.6, 
28.7 y 27.4 (3´-C, 4´-C and 5´-C); 25.1 (C(CH3)2), 23.2 (OC(CH3)2), 21.8 (6´-C), 14.0 ppm (7´-C); 
HPLC-MS: [A, 70%→100%], tR: 3.37 min (98%), MS (ES+, m/z) 357 [M+H]+; Anal. Calcd. for 
C21H28N2O3: C 70.76%, H 7.92%, found: C 71.03%, H 8.24%.
7-(1,1-Dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-c]pyrazol-6,9-dione (2.2). 
Prepared from 7-(1,1-dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-c]pyrazol-9-ol (1.5b) 
(35 mg, 0.1 mmol) and BTIB (129 mg, 0.3 mmol) by following the procedure described for 2.1. 
Column chromatography on silica gel (hexane/EtOAc, 1:4) 
afforded 2.2 as a red solid (12 mg, 33%); mp: 89–90 ºC; 1H-
NMR (300 MHz, CDCl3) δ: 7.36 (s, 1H, 3-H), 6.61 (s, 1H, 8-
H), 3.95 (s, 3H, NCH3), 1.84 (s, 6H, OC(CH3)2), 1.70–1.65 (br 
s, 2H, 2´-H), 1.33 (s, 6H, C(CH3)2), 1.26–1.20 (br s, 6H, 3´-H, 4´-H and 5´-H), 1.16–1.13 (m, 2H, 
6´H), 0.85 ppm (t, J = 6,9 Hz, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 186.2 (6-C), 181.4 (9-C), 
160.2 (5a-C), 155.0 (7-C), 139.6 (9b-C), 135.4 (8-C), 129.3 (9a-C), 126.9 (3-C), 115.7 (3a-C), 81.5 
(OC(CH3)2), 43.0 (NCH3), 40.9 (2´-C), 31.7 (1´-C), 30.8, 29.3 and 28.1 (3´-C, 4´-C and 5´-C), 27.5 
(C(CH3)2), 23.4 (OC(CH3)2), 22.9 (6´-C), 14.6 ppm (7´-C); HPLC-MS: [A, 80%→100%], tR: 2.43 min 
(99%), MS (ES+, m/z) 371 [M+H]+; Anal. Calcd. for C22H30N2O3: C 71.32%, H 8.16%, found: C 
70.98%, H 8.31%. 
7-(1,1-Dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-6,9-dione 
(2.3). Prepared from 7-(1,1-dimethylheptyl)-2-ethyl-2,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazol-9-ol (1.6b) (61 mg, 0.16 mmol) and BTIB (212 mg, 0.49 mmol) by following the procedure 
described for 2.1. Column chromatography on silica gel (hexane/EtOAc, 2:3) afforded 2.3 as a red 
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solid (22 mg, 36%); mp: 83–84 ºC; 1H-NMR (300 MHz, CDCl3) δ: 7.15 (s, 1H, 3-H), 6.50 (s, 1H, 8-
H), 4.28 (q, J = 7.4 Hz, 2H, NCH2CH3), 1.72 (s, 6H, OC(CH3)2), 1.61–1.52 (m, 2H, 2´-H), 1.49 (t, J
= 7.4 Hz, 3H, NCH2CH3), 1.30 (s, 6H, C(CH3)2), 1.23–1.10 (m, 8H, 3´-H, 4´-H, 5´-H and 6´-H), 
0.89 ppm (t, J = 6.9 Hz, 3H, 7´-H); 13C-NMR (75 MHz, 
CDCl3) δ: 183.4 (6-C), 180.5 (9-C), 152.4 (5a-C), 151.4 (7-C), 
137.2 (9b-C), 133.1 (8-C), 122.1 (3-C), 120.9 (3a-C), 110.6 (9a-
C), 79.9 (OC(CH3)2), 46.6 (NCH2CH3), 39.7 (2´-C), 37.6 (1´-
C), 31.6, 29.7 and 28.7 (3´-C, 4´-C and 5´-C), 26.6 (OC(CH3)2), 24.1 (C(CH3)2), 21.5 (6´-C), 14.6 
(NCH2CH3), 13.0 ppm (7´-C); HPLC-MS: [A, 70%→100%], tR: 3.86 min (96%), MS (ES+, m/z) 385 
[M+H]+; Anal. Calcd. for C23H32N2O3: C 71.84%, H 8.39%, found: C 72.01%, H 8.62%. 
7-(1,1-Dimethylheptyl)-1,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-8,9-dione (2.4). To a 
solution of 7-(1,1-dimethylheptyl)-1,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-9-ol (1.4) (30 
mg, 0.08 mmol) dissolved in DMF (1.5 mL) was added solid IBX (36 mg, 0.13 mmol), and the 
resulting mixture was stirred at room temperature for 30 min. 
The mixture was then extracted with EtOAc, washed with 
water and brine. The solvent was removed under vacuum. The 
resulting residue was purified by chromatography on a silica gel 
column (hexane/EtOAc, 2:1) to furnish the title compound as a red solid (9 mg, 29% yield); mp: 
89–90 ºC; 1H-NMR (300 MHz, CDCl3) δ: 8.03–7.98 (br s, 1H, NH), 7.66 (s, 1H, 3-H), 7.12 (s, 1H, 
6-H), 1.65 (s, 6H, OC(CH3)2), 1.51–1.49 (m, 2H, 2´-H), 1.37 (s, 6H, C(CH3)2), 1.29–1.27 (m, 6H, 3´-
H, 4´-H, 5´-H), 1.21–1.18 (m, 2H, 6´H), 0.84 ppm (t, J = 7.1 Hz, 3H, 7´-H); 13C-NMR (75 MHz,
CDCl3) δ: 180.1 (9-C), 179.6 (8-C), 164.4 (5a-C), 163.8 (7-C), 142.0 (6-C), 138.5 (9b-C), 131.5 (3-C), 
130.3 (3a-C), 110.9 (9a-C), 79.7 (OC(CH3)2), 45.9 (2´-C), 31.2 (1´-C), 30.0, 29.3 y 28.1 (3´-C, 4´-C 
and 5´-C); 25.8 (C(CH3)2), 24.9 (OC(CH3)2), 22.5 (6´-C), 13.6 ppm (7´-C); HPLC-MS: [A, 80% 
→100%], tR: 2.03 min (99%), MS (ES+, m/z) 357 [M+H]+. Anal. Calcd. for C21H28N2O3: C 70.76%, 
H 7.92%, found: C 70.41%, H 7.57%.
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7-(1,1-Dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-c]pyrazol-8,9-dione (2.5).
Prepared from 7-(1,1-dimethylheptyl)-2,4-dihydro-2,4,4-trimethylchromeno[4,3-c]pyrazol-9-ol (1.5b) 
(45 mg, 0.12 mmol) and IBX (53 mg, 0.18 mmol) by following 
the procedure described for 2.4. Column chromatography on 
silica gel (hexane/EtOAc, 1:1) afforded 2.5 as a red solid (11 
mg, 24%); mp: 85–86 ºC; 1H-NMR (300 MHz, CDCl3) δ: 7.28 
(s, 1H, 3-H), 6.73 (s, 1H, 6-H), 3.89 (s, 3H, NCH3), 1.64 (s, 6H, OC(CH3)2), 1.57–1.55 (br s, 2H, 2´-
H), 1.29 (s, 6H, C(CH3)2), 1.22–1.18 (m, 6H, 3´-H, 4´-H, 5´-H), 1.10–1.03 (m, 2H, 6´H), 0.81 ppm (t,
J = 7.0 Hz, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 182.3 (9-C), 180.6 (8-C), 165.1 (5a-C), 160.3 
(7-C), 139.8 (9b-C), 137.0 (6-C), 132.2 (3-C), 129.9 (3a-C), 113.8 (9a-C), 83.0 (OC(CH3)2), 42.3 
(NCH3), 41.0 (2´-C), 33.1 (1´-C), 32.0, 30.9 and 29.6 (3´-C, 4´-C and 5´-C), 28.1 (C(CH3)2), 22.9 
(OC(CH3)2), 21.8 (6´-C), 14.1 ppm (7´-C); HPLC/MS: [A, 80%→100%], tR: 2.07 min (96%), MS 
(ES+, m/z) 371 [M+H]+. Anal. Calcd. For C22H30N2O3: C 71.32%, H 8.16%, found: C 71.19%, H
7.82%.
7-(1,1-Dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazol-8,9-dione 
(2.6). Prepared from 7-(1,1-dimethylheptyl)-1-ethyl-1,4-dihydro-4,4-dimethylchromeno[4,3-
c]pyrazol-9-ol (1.6a) (20 mg, 0.05 mmol) and IBX (22 mg, 0.08 mmol) by following the procedure 
described for 2.4. Column chromatography on silica gel 
(hexanes/EtOAc, 4:1) afforded 2.6 as a red solid (6 mg, 
30%); mp: 94–95 ºC; 1H- NMR (300 MHz, CDCl3) δ: 7.49 
(s, 1H, 3-H), 7.11 (s, 1H, 6-H), 4.04 (q, J = 7.1 Hz, 2H, 
NCH2CH3), 1.49 (s, 6H, OC(CH3)2), 1.35 (t, J = 7.1 Hz, 3H, NCH2CH3), 1.30–1.26 (m, 2H, 2´-H), 
1.22 (s, 6H, C(CH3)2), 1.19–1.16 (m, 6H, 3´-H, 4´-H, 5´-H), 1.03–1.01 (br s, 2H, 6´-H), 0.87 ppm (t, 
J = 6.9 Hz, 3H, 7´-H); 13C-NMR (75 MHz, CDCl3) δ: 182.9 (9-C), 181.0 (8-C), 161.5 (5a-C), 159.3 
(7-C), 138.2 (9b-C), 135.9 (6-C), 131.0 (3-C), 129.7 (3a-C), 112.3 (9a-C), 80.1 (OC(CH3)2), 47.1 
(NCH2CH3), 40.6 (2´-C), 35.3 (1´-C), 31.1, 29.8 and 28.5 (3´-C, 4´-C and 5´-C), 27.0 (OC(CH3)2), 
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25.3 (C(CH3)2), 22.1 (6´-C), 14.9 (NCH2CH3), 13.7 ppm (7´-C); HPLC-MS: [A, 80%→100%], tR: 3.97 
min (98%), MS (ES+, m/z) 385 [M+H]+. Anal. Calcd. for C23H32N2O: C 71.84%, H 8.39%, found: C
71.93%, H 8.06%.
Electrochemistry: 
Cyclic voltammetry. DMSO (spectroscopy grade) was obtained from Aldrich. 
Tetrabuthylammonium perchlorate (TBAP), used as supporting electrolyte, was obtained from 
Fluka. Cyclic voltammetry was carried out using a Metrohm 693 VA instrument with a 694 VA 
Stand convertor and a 693 VA Processor, in DMSO (ca. 1.0×10−3 mol L−1), under a nitrogen 
atmosphere at room temperature, with TBAP (ca. 0.1 mol L−1), using a three-electrode cell. A 
mercury-dropping electrode was used as the working electrode, a platinum wire as the auxiliary 
electrode, and saturated calomel as the reference electrode. 
ESR spectroscopy. ESR spectra were recorded in the X band (9.7 GHz) using a Bruker ECS 106 
spectrometer with a rectangular cavity and 50 kHz field modulation. The nitro radicals were 
generated by electrolytic reduction in situ under the same conditions of temperature, atmosphere and 
concentrations stated at the voltammetric experiment. Simulations of the spectra were made using 
the Simfonia Version 1.25 software. The hyperfine splitting constants were estimated to be accurate 
within 0.05 G. 
In silico ADME calculations: 
A set of 34 physico-chemical descriptors was computed using QikProp version 3.5 integrated in 
Maestro (Schrödinger, LLC, New York, USA). The QikProp descriptors are shown in table 3. The 
3D conformations used in the calculation of QikProp descriptors were generated using the program 
Spartan ´08 (Wave function, Inc., Irvine CA) as follows: the structure of each molecule was built 
from the fragment library available in the program. Then, ab initio energy minimizations of each 
structure at the Hartree-Fock 6-31G* level were performed. A conformational search was next 
implemented using Molecular Mechanics (Monte Carlo method) followed by a minimization of the 
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energy of each conformer calculated at the Hartree-Fock 6-31G* level. The global minimum energy 
conformer of each compound was used as input for ADME studies with QikProp. 
Pharmacological assays: 
Cannabinoid binding experiments. Membranes from transfected cells with human CB1 or CB2
expressed cannabinoid receptors (RBHCB1M400UA and RBXCB2M400UA) were supplied by 
Perkin-Elmer Life and Analytical Sciences (Boston, MA). The protein concentration for the CB1R 
membranes was 8.0 mg/mL, whereas for the CB2R membranes was 4.0 mg/mL or 3.6 mg/mL 
depending on the batch. The commercial membranes were diluted (approximatively 1:20) with the 
binding buffer (50 mM TrisCl, 5 mM MgCl2.H2O, 2.5 mM EDTA, 0.5 mg/mL BSA and pH = 7.4 
for CB1 binding; 50 mM TrisCl, 5 mM MgCl2.H2O, 2.5 mM EGTA, 1 mg/mL BSA and pH = 7.5 
for CB2 binding). The final membrane protein concentration was 0.4 mg/mL of incubation volume 
and 0.2 mg/mL of incubation volume for the CB1R and the CB2R assays, respectively. The 
radioligand used was [3H]-CP55940 (PerkinElmer) at a concentration of membrane KD x 0.8 nm, 
and the final volume was 200 µL for CB1R binding and was 600 µL for CB2R binding. 96-Well plates 
and the tubes necessary for the experiment were previously siliconized with Sigmacote (Sigma). 
Membranes were resuspended in the corresponding buffer and were incubated with the radioligand 
and each compound (10-4-10-11 M) for 90 min at 30 ºC. Non-specific binding was determined with 
10 µM WIN55,212 and 100 % binding of the radioligand to the membrane was determined by its 
incubation with membrane without any compound. Filtration was performed by a Harvester® 
filtermate (Perkin-Elmer) with Filtermat A GF/C filters pretreated with polyethylenimine 0.05%. 
After filtering, the filter was washed nine times with binding buffer, dried and a melt-on scintillation 
sheet (MeltilexTM A, Perkin Elmer) was melted onto it. Then, radioactivity was quantified by a liquid 
scintillation spectrophotometer (Wallac MicroBeta Trilux, Perkin-Elmer). Competition binding data 
were analyzed by using GraphPad Prism program and Ki values are expressed as mean ± SD of at 
least three experiments performed in triplicate for each point.  
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In vitro antiproliferative assays: 
Cell culture and viability. The cell lines used in this work were obtained from the American Type 
Culture Collection (ATCC, Manasas, VA, USA). Prostate LNCaP (ATCC CRL-1740) and PC-3 cells 
(ATCC CRL-1435) (Rockville, MD, USA) were routinely grown in RPMI 1640 supplemented with 
10% fetal calf serum, 100 U/mL penicillin G, 100 g/mL streptomycin, and 0.25 g/mL
amphotericin B (Invitrogen, Paisley, UK). MDA-MB-231 cells were obtained from the American 
Type Culture Collection (ATCC; Manassas, VA) and maintained in DMEM supplemented with 10% 
fetal bovine serum (FBS), 5 units/mL penicillin, and 5 mg/mL streptomycin. SUM149, SUM159, 
and MDA-MD-468 cells were kindly donated by Dr. Moreno-Bueno (Instituto de Investigaciones 
Biomédicas Alberto Sols, Madrid, Spain). SUM149 and SUM159 cells were maintained in Ham’s F-
12 medium with 5% FBS, 5 μg/mL insulin, and 0.5 μg/mL hydrocortisone. MDA-MD-468 was 
maintained in DMEM with 10% FBS. Human mammary epithelial cells (HMEC) were obtained 
from Cambrex and grown in mammary epithelial growth medium (Cambrex, East Rutherford, NJ) 
according to the manufacturer’s instructions. In all cell types, low cell passages (between 10 and 20) 
were used. Experiments were done when cell monolayers were 80% confluent. Cannabinoid ligands 
were prepared in DMSO. Control incubations had the corresponding DMSO content (considered as 
100% of cell viability). Cells were cultured at a density of 5000 cells/cm2 in a 24-well plate. They 
were transferred to a serum-free medium or a 0.5% FBS medium (HMEC) at least 6 h before 
treatment with the compounds at concentrations ranging from 0 to 25 μM (or 0 to 100 μM, 
depending on the experiment) for 48 h. When indicated, cells were pre-incubated with the 
antagonists or the antioxidants for 1 h before treatment with the corresponding cannabinoid-
quinone (at IC50 concentration).  Finally, the MTT reduction assay was carried out to evaluate the 
effects of the different compounds on cell viability and to determine the IC50. Briefly, cells were 
incubated for 2 h at 37ºC with 0.3 mg/mL of 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT, Sigma, St Louis, MO, USA) and then were solubilized with 100 µl isopropanol. 
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Absorbance at 570 nm was measured with a plate spectrophotometer (ELX 800 Bio-Tek 
Instruments, INC).
Western Blot Analysis. MDA-MB-231 human breast cancer cells were treated with DMSO 
(vehicle), or compound 2.1 for two days. Cells were then harvested and lysed. Protein 
concentrations were quantified by the Bradford method with bovine serum albumin as the standard. 
Equal amounts of total cellular protein extract (25 μg) were separated by electrophoresis in 
SDS−polyacrylamide gels (12%) and transferred to PVDF membranes. After blocking with 5% 
nonfat milk, membranes were incubated at 4°C with the desired primary antibodies overnight at the 
following dilutions: anti-caspase-3 (1:500 Cell Signaling), and β-actin (1:5000; Sigma). Subsequently, 
membranes were incubated with appropriate secondary antibodies. Luminograms were obtained 
with an enhanced chemiluminescence detection kit (Amersham Life Sciences, Arlington Heights, IL) 
and densitometric analysis was performed with Quantity One software (Bio-Rad, Hercules, CA, 
USA).
Flow cytometry. Flow cytometry was used to detect apoptotic cells and the distribution of cell 
cycle. After being cultivated with medium alone or medium containing the indicated stimuli, 105 cells 
in 35 mm culture dish were harvested in tripsin, fixed in 70% ethanol and stained with 0.05 mg/mL 
Propidium iodide (PI) plus 0.2 mg/mL RNAse to indicate relative DNA content. The sub-G1 peak 
(DNA content less than 2 N) and cell cycle distribution were measured with FACScan flow 
cytometer (Beckton Dickinson, CA, Costa Rica). To analyze apoptosis by Anexin V staining, the 
cells were washed twice with PBS and incubated in 0.5 mL of Binding Buffer (10 mM HEPES pH 
7.4, 150 mM NaCl, 2.5 mM CaCl2, 1 mM MgCl2, and 4% BSA), with 4 μg/mL Annexin V-FITC for 
15 min. Cells were then washed in PBS and resuspended in Binding Buffer with 0.6 g/mL iodure 
propidium, (Calbiochem, USA). 20000 cells of each sample were analyzed by flow cytometry in a 
FACScan (Beckton Dickinson, CA, Costa Rica). 
In vivo antitumor assays:  
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TNBC xenografts. All procedures involving animals were performed with the approval of the 
Complutense University Animal Experimentation Committee according to European official 
regulations. Tumors were induced in nude mice by subcutaneous injection of 5 x106 MDA-MB-231 
human breast adenocarcinoma cells in PBS. When tumors reached an average size of 200 mm3, 
animals were randomly assigned to different groups. At this point, animals started to receive vehicle 
or compound 2.6 (2 mg/kg/d) in 100 μl of sesame oil thrice a week by intraperitoneal injection. 
Tumors were routinely measured with an external caliper, and volume was calculated as (4π/3) × 
(width/2)2 × (length/2). After 4 weeks of treatment, animals were sacrificed. Tumors were excised, 
weighted and snap frozen for further analysis. Organs (liver, spleen, heart and lungs) were also 
collected and fixed in 4% PFA for histopathological analysis by H&E staining. 
Prostate cancer xenografts. Athymic nude (nu/nu) (BALB/cOlaHsd-Foxn1nu) five week-old male 
mice were obtained from Harlan Iberica Laboratory (Barcelona, Spain) and maintained under 
specific pathogen-free conditions with the approval of the Institutional Ethical Research Committee 
of Alcala University. All animal studies were conducted in accordance with the Spanish institutional 
regulation for the housing, care and use of experimental animals and met the European Community 
directives regulating animal research. Recommendations made by the United Kingdom co-
ordinating Committee on Cancer Research (UKCCCR) have been kept carefully. To study the in vivo
antitumor activity of 2.1, prostate tumors were induced in athymic mice nu/nu (BALB/cOlaHsd-
Foxn1nu). Mice were injected subcutaneously in the right flank with 10 x 106 LNCaP or PC-3 cells in 
0.1 mL of PBS + 0.5% BSA. Two weeks after transplantation, tumors had grown to an average 
volume of 150 mm3. Mice were then divided into different experimental groups of 8 animals each, 
which were treated with 2.0 mg/kg of compound 2.1 intraperitoneally injected. The injection was 
repeated every day and treatment was continued for 15 days. Tumor volumes were monitored every 
day using calliper measurements and were calculated by the formula: (4/3)x (w/2)2x (l/2). At the 
end of the treatment the animals were sacrificed and xenografted tumors were weighted and frozen.
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Targeting GPR55

Introduction
195 
1. Introduction 
CB1 and CB2 receptors have widely been confirmed as cannabinoid targets. However, the complex 
pharmacology of the endocannabinoid system points to the existence of other receptors playing 
important physiological roles. Recently, the G-protein coupled receptor, GPR55, was presented as 
one of the missing cannabinoid subtypes, but the validity of this categorization is being extensively 
discussed.1,2
GPR55 was cloned and identified in 1999 being firstly reported by Sawzdargo et al.3 Few years later, 
screening assays carried out on cannabinoid libraries by AstraZeneca4 and GlaxoSmithKline5
revealed that endogenous, plant-derived and synthetic cannabinoid ligands were able to activate 
GPR55. This is one of the main reasons why GPR55 was proposed as a novel member of the 
endocannabinoid system.  However, the classification of GPR55 is intricate due to its complex 
cellular signaling pathways and biological functions.6 Despite its clear relation with the ECS, the 
International Union of Basic and Clinical Pharmacology (IUPHAR) does not classify GPR55 as a 
cannabinoid receptor so far.7,8  Currently, much research is focused on the determination of its role 
in numerous pathophysiological processes to exhaustively explore the therapeutic potential of such a 
promising target. 
1.1  GPR55 structure 
GPR55 is a seven transmembrane receptor which belongs to the δ group of rhodopsin-like GPCRs 
(Class A). Its human gene maps to chromosome 2q37. This receptor is formed by 319 amino acids 
bearing 67% of homology with its rat homolog.3 The human GPR55 (hGPR55) sequence shares low 
identity with the cannabinoid receptors described so far CB1R and CB2R (13.5% and 14.4% 
respectively). The GPCR proteins disclosing the highest percentages of homology with GPR55 are 
GPR35 (27%), P2Y (29%), GPR23 (30%), CCR4 (23%), LPA4 (30%) and LPA5 (30%).3,9 A 
schematic representation of GPR55 structure is displayed in figure 1.10
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Figure 1. GPR55 structure.10
GPR55 preserves the highly conserved residues in TMH-1, 2, 4 and 5 of other rhodopsin-like 
sequence alignments (N1.50, D2.50, W4.50 and P5.50).  Instead of the conserved E/DRY motif in 
TMH-3 of CBRs, GPR55 contains a DRF conservative substitution. In TMH-6 the conserved 
CWXP of the CBRs and rhodopsin receptors is substituted by SFLP in GPR55. The utmost 
variation appears in TMH-7 where GPR55 incorporates the non-conservative substitution DVFCY 
in place of the highly conserved motif NPXXY. This different sequence produces different 
hydration and local transmembrane flexibility, and consequently, a different conformation in this 
region.10 Another difference with CBRs is the cysteine located on the second extracellular loop (EC-
2) that can potentially form a disulfide bond with C3.25.10,11 There are also changes in the number of 
residues of the EC-1 loop, being shorter in GPR55 (three amino acids versus six) than other 
rhodopsin-like receptors sequences. In contrast, the EC-3 loop is longer (fourteen residues versus 
six) than the Rho and CBRs sequences. 
In what refers to the three-dimensional structure, as most of the GPCRs, no crystallographic data 
has been reported yet. However, homology models based on available GPCR crystal structures have 
been reported and will be discussed later in this chapter.10,12
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1.2  Pharmacology 
The pharmacology of GPR55 has been widely studied in the last years but it is still a very 
controversial issue. Its classification as a third cannabinoid receptor has generated strong debate. On 
the one hand, different cannabinoid ligands are able to stimulate GPR55 effects in several 
assays.6,11,13,14 On the other hand, there is significant inconsistency between studies where 
cannabinoids are presented as agonists or antagonists or to exert no effect depending on the 
pharmacological outcome. In contrast, lysophosphatidylinositol (LPI) has been confirmed as agonist 
in all studies reported so far.6
While CBRs couple to G-proteins of the Gi/0 subfamily, as widely demonstrated in the literature,15,16
GPR55 has been associated with different G-proteins such as Gα13,17 Gαq/11,18 Gαq/Gα1219 or 
Gα12/13.20,17 This G-protein coupling promiscuity depends on the ligand and the cell line. By engaging 
these G proteins, GPR55 activates a range of signaling pathways, including RhoA, MAPK cascades, 
actin filament formation or intracellular calcium release via the activity of phospholipase C (PLC). 
Extracellular signal-regulated kinase (ERK), RhoA activated kinase (ROCK) and 
phosphatidylinositol 3-kinase (PI3K) are ultimately activated in these pathways. Moreover, 
transcription factors such as NFAT or nuclear factor kappa-light-chain-enhancer of activated B cells 
(NFkB), that translocate to the nucleus and modulate the expression of different genes are induced 
following GPR55 activation.17,20
Subsequently, the evaluation of new potential GPR55 ligands has been intensely explored through 
different functional endpoints such as GTPγS binding,1 analysis of intracellular calcium levels,17,19
phosphorylation of ERK1/2,21,22 and the activation of the small GTPase proteins Rac1, RhoA and 
Cdc42.1,17,19 However, to date, GPR55 pharmacological assays have proven to be very problematic 
because of the lack of ligand specificity. Most of them modulate other targets (CBRs, transient 
receptor potential vanilloid channels (TRPVs), or peroxisome proliferator-activated receptors 
(PPARs) among others).20,23 Furthermore, GPR55 discrepancies may rely on intrinsic properties of 
this GPCR such as the presence of different active conformation states,24 the formation of 
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oligomers,25–27 allosterism,28,29 or the possible biased agonism30 as well as the tissue or cell type 
evaluated.8,25,31 These pharmacological inconsistencies have been under discussion in many recent 
reviews demonstrating the growing interest in this field.6,11,13
1.3  Biological relevance of GPR55 
GPR55 is extensively expressed throughout the body; however, its physiological function remains to 
be fully established. GPR55 shows a co-localization with CB1R and CB2R. Indeed, GPR55 mRNA is 
expressed in peripheral tissues including the immune system (spleen, tonsil) as well as in the CNS 
(hippocampus, putamen, caudate, thalamic nuclei).1,3,17,32,33 Recently, the relevance of GPR55 has 
been explored in diverse physiological and pathological processes. 
There is increasing evidence of the implication of GPR55 in the modulation of inflammatory and 
neuropathic pain. GPR55 activation enhances neuronal excitability by increasing intracellular Ca2+
and suppressing the K+ current acting on M-type channels suggesting a pro-nociceptive role of this 
receptor.19 Moreover, Staton et al.34 showed that GPR55 deficient mice did not display hyperalgesia 
upon inflammatory or neuropathic stimuli. Experiments in microglial cells35 and neutrophils36
further supported the role of GPR55 in inflammatory processes.  
The contribution of GPR55 in metabolic regulation and energy homeostasis is now emerging.37–39
For instance, a correlation between body weight and levels of GPR55 expression in visceral adipose 
tissue has been reported. It is clear that GPR55, as well as CB1R, controls food intake, gut motility 
and insulin secretion. 
Due to its expression in vascular endothelial cells, different research groups have studied the 
involvement of GPR55 in the regulation of vascular functions.2,18,40–42
Different indirect evidences indicate that GPR55 plays an important role in cancer physio-
pathology. Increased levels of LPI, the putative GPR55 endogenous ligand, have been found in 
plasma and ascites from patients with this pathology.43,44 Moreover, GPR55 expression is 
significantly increased in tumor tissues compared with their healthy counterparts. This fact 
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demonstrates that GPR55 expression may be used as potential biomarker in oncology associated to 
poor prognosis.45,46 As detailed above, GPR55 signals through Rho GTPases, which control 
cytoskeleton organization, cell polarity and cell migration, are closely related to tumor progression.47–
49 Accordingly, activation of GPR55 triggers a number of signaling cascades that promote cancer cell 
proliferation, migration, and invasion. All these findings support the idea of GPR55 as a new 
potential target in oncology.  
It has been suggested that GPR55 is implicated in bone physiology as well. Whyte et al.50 reported 
that modulation of GPR55 may regulate osteoclast polarization and bone resorption activity. 
Therefore, GPR55 may represent a novel target for osteoporosis and bone loss associated with 
arthritis.
It is worthy to note that GPR55 is not involved in the regulation of CNS development, gross motor 
movement or learned behavior, however, it does play a role in motor coordination.51
The therapeutic potential of GPR55 modulation is schematically summarized in figure 2.  
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Figure 2. Biological relevance of GPR55. Different evidences reported so far suggest the involvement of 
GPR55 in a variety of pathophysiological functions. Adapted from Henstridge et al 2011.52
Even though the implication of GPR55 in the modulation of diverse physiopathological conditions 
has been evidenced, more investigations have to be performed, hopefully with more selective 
ligands, to determine GPR55 functions. 
1.4  GPR55 ligands 
In spite of the potential therapeutic interest of GPR55, the design of potent and selective GPR55 
ligands remains a major challenge for medicinal chemists due to the lack of information on GPR55 
three-dimensional structure and the complexity of the interpretation of GPR55 functionality assays. 
Herein, we categorize the different GPR55 modulators reported so far in the literature. 
1.4.1 Endogenous ligands 
Despite all the contradictory data reported for many GPR55 ligands, the bioactive lipid 
lysophosphatidylinositol has shown to be a GPR55 agonist in all the studies and functional assays 
reported so far.20,32 These data led to propose LPI as an endogenous non-cannabinoid ligand of 
GPR55. Structurally, LPI contains a glycerol backbone esterified with a single fatty acid in sn-1 or 
sn-2 position and a phosphate group substituted with an inositol.14,21 In a recent study performed by 
Oka et al.22 to identify molecular species of LPI in rat brain, the most predominant fatty acyl moiety 
was stearic acid (50.5%) followed by arachidonic acid (22.1%). 2-Arachidonoyl-containing LPI 
species (2-AGPI) displayed the highest potency and efficacy of the LPI species published to date 
(figure 3). Consequently, 2-AGPI has been proposed as the natural LPI ligand for GPR55.22,53
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Figure 3. The structures of lysophosphatidylinositol (LPI) and its 2-arachidonoyl-derivative (2-AGPI).
The ability of LPI to activate GPR55 has been confirmed in various cellular systems and 
pharmacological outcomes. For instance, increase of LPI levels has been detected not only  in 
diverse tumors but also in cancer cell proliferation and tumor progression processes.54–56 In what 
concern the pharmacological outcomes, LPI induces phosphorylation of ERK and elicits a rapid 
Ca2+ transient in GPR55-expressing cells.21 Further reports have supported these findings in 
HEK293 cells expressing GPR55 and in large-diameter DRG neurons19 and endothelial cells.18
Henstridge et al.17 showed that LPI stimulates Ca2+ release that is dependent on Gα13 and RhoA 
activation. In the β-arrestin PathHunterTM assay, LPI also reveals to be a potent agonist.57
1.4.2 Cannabinoid-related GPR55 ligands 
- Endocannabinoids and derivatives
Many endogenous cannabinoid ligands have been identified as GPR55 modulators (figure 4). 
Anandamide, the predominant endocannabinoid, displayed inconsistent results in different GPR55 
assays. This lipid neurotransmitter stimulated [35S]GTPγS binding in the nanomolar range and 
caused calcium mobilization in the micromolar range. Nevertheless, AEA did not affect 
phosphorylation of ERK, β-arrestin signaling and induction of receptor internalization. Another 
important endocannabinoid, 2-arachidonoylglycerol, showed agonist efficacy in [35S]GTPγS binding 
assay but it was ineffective in β-arrestin recruitment and GPR55 internalization. These 
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inconsistencies may be due to the aforementioned discrepancies between functional assays or cell 
systems.8 In accordance with IUPHAR, there is no irrefutable evidence that these eicosanoids are 
GPR55 agonists.  
Other endocannabinoids such as noladin ether, palmitoylethanolamide, virodhamine and 
oleylethanolamide stimulated [35S]GTPγS binding in transiently transfected hGPR55-HEK293 cells, 
with EC50 values of 10, 4, 12 and 440 nM respectively.1 Similar results were previously reported by 
AstraZeneca in the same [35S]GTPγS assay.4 According to those GTPγS studies, anandamide 
activated GPR55 and CBRs with similar potencies while palmitoylethanolamide, virodhamine and 2-
AG displayed selective action through GPR55.  
Figure 4. Endocannabinoids as GPR55 ligands. 
- Phytocannabinoids and related molecules 
Bioactive constituents from the plant Cannabis Sativa and synthetic analogues (figure 5) have also 
shown discrepant data regarding their GPR55 pharmacology. Δ9-THC exhibits activation of GPR55 
in [35S]GTPγS binding, RhoA assays and intracellular calcium mobilization in transiently transfected 
hGPR55-HEK293 cells.1,4,19 However, this phytocannabinoid was unable to stimulate ERK1/2 
phosphorylation or β-arrestin recruitment.21,57 It remains to be determined whether this is a 
consequence of experimental variability, differences in functional readouts or GPR55 intrinsic 
properties. HU210, a synthetic derivative of Δ9-THC, also displayed activity as GPR55 agonist in 
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diverse assays being inactive in others.1,4,57 Abnormal-cannabidiol (Abn-CBD) and its structurally 
related molecule O-1602 have been reported as GPR55 selective agonists in [35S]GTPγS assays with 
EC50 values in the micromolar and nanomolar ranges respectively.1,2,4 Conversely, other research 
groups reported lack of activity through different cellular systems or functional endpoints.22,57
The potent CB1R/CB2R agonist CP55,940 has also shown conflicting data, being GPR55 agonist in 
[35S]GTPγS assays1,4 and GPR55 antagonist17,21,58 in β-arrestin, ERK phosphorylation and calcium 
mobilization tests.
Figure 5. Structure of some phytocannabinoid and synthetic derivatives related to GPR55.
Regarding other compounds such as cannabinol and JWH133, different studies confirmed their 
inactivity towards GPR55.8 However, a recent sensitive ERK assay, developed by Sharon Anavi-
Goffer et al.,28  determined that JWH133 could reduce basal pERK acting as GPR55 inverse agonist. 
From the same GPR55 readout, the phytocannabinoids Δ9-tetrahydrocannabivarin, cannabidivarin 
and cannabigerovarin acted as potent inhibitors of LPI and may be novel GPR55 ligands.  
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CBD, whose cannabinoid mechanism of action has not been fully understood, has also shown 
inconsistent pharmacological data regarding its GPR55 activity. This non-psychoactive 
phytocannabinoid acted as GPR55 antagonist preventing [35S]GTPγS binding and Rho 
activation,1,50,59 but it was inactive in intracellular Ca2+ mobilization assays19 and β-arrestin 
recruitment.57 O-1918, a synthetic derivative of CBD that does not bind to CBRs60 was able to act as 
GPR55 antagonist in the intracellular Ca2+ functional analysis using endothelial cells that express 
GPR55.18
- Synthetic cannabinoid ligands 
Arylpyrazoles
The arylpyrazole scaffold has been widely explored in the cannabinoid system becoming very 
relevant in the design of CB1R or CB2R inverse agonists or antagonists (figure 6). Rimonabant 
(SR141716A), the well-known CB1R arylpyrazole antagonist, has been found to behave as GPR55 
agonist in some assays4,20,57,61 but as GPR55 antagonist in others, 18,19,62 exerting no effect in an 
additional study.21 In contrast, SR144528, a potent CB2R antagonist, is inactive in all the GPR55 
assays reported so far. It did not induce calcium rise in transiently transfected hGPR55-HEK293 
cells nor in β-arrestin binding assays.19,57 The GPR55 pharmacology of AM251 and AM281, CB1R 
antagonists structurally related to SR141716A, was also extensively studied. AM251 behaved as 
GPR55 agonist in different biochemical assays,1,5,17,20,32,57,58,61 whereas AM281 did not interact with 
this GPCR receptor1 or displayed very weak agonist effects.23,35
Figure 6. Arylpyrazoles SR141716A, AM251, AM281 and SR144528.
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As shown by Anavi-Goffer et al.,28 CB1R antagonists (SR141716A, AM281 and AM251) can act as 
agonists by themselves and as inhibitors of LPI inducing activation of ERK phosphorylation under 
the same cellular model. These results may explain the disagreements surrounding GPR55 
pharmacology of several cannabinoid ligands. They suggest that certain arylpyrazole ligands may act 
as bitopic ligands of GPR55.63
In 2010 Daly et al.41 have reported the GPR55 pharmacology of the commercially available 
fluorescent ligand T1117. This molecule, structurally formed by the CB1R ligand AM251 linked to a 
fluorescent tetramethylrhodamine group, showed weak or no affinity towards CB1R but curiously 
activated GPR55 by promoting a characteristic oscillatory Ca2+ response in HEK293 cells stably 
expressing recombinant GPR55.  
Aminoalkylindoles 
The cannabinoid agonist WIN55,212-2 has been extensively used to investigate the 
endocannabinoid system (figure 7). This relevant aminoalkylindole does not display activity towards 
GPR55. Consistent data from various biological assays confirm that this potent CB1R/CB2R ligand 
does not bind GPR55 either as agonist or antagonist.1,4,19 However, JWH015, a WIN55,212-2 
analogue, was able to activate GPR55 in [35S]GTPγS assay with EC50 value in the nanomolar range 
and JWH015 was effective at micromolar concentrations in calcium mobilization assays.19
Figure 7. Synthetic cannabinoid ligands WIN55212,  JWH015 and GW405833 .
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Furthermore, data from an ERK1/2 phosphorylation assay suggest that the CB2R agonist 
GW405833 is bitopic ligand of GPR55. It acts as a partial agonist of GPR55 alone or as an allosteric 
modulator enhancing LPI signaling.28
Coumarins 
The coumarin scaffold has shown a great potential and versatility in the development of highly 
selective and potent CBRs ligands.64 Exploring this scaffold, 3-substituted coumarins have been 
identified as novel GPR55 antagonists through β-arrestin recruitment assays.29 Interaction with 
CBRs require lipophilic moiety in position 7 (PSB-SB-487, figure 8) while the methyl moiety in 
position 8 is favorable for GPR55 antagonism (PSB-SB-489, figure 8). Recently, Deng et al.65 have 
developed computational QSAR models in order to design coumarin derivatives with improved 
potency.  
Figure 8. 3-(2-Hydroxybenzyl)-5-isopropyl-8-methyl-2H-chromen-2-one (PSB-SB-489) and 7-(1,1-
dimethyloctyl)-5-hydroxy-3-(2-hydroxybenzyl)-2H-chromen-2- one (PSB-SB-487) 
Magnolol derivatives 
Magnolol (figure 9) is one of the main bioactive compounds identified in the bark of Magnolia 
officinalis.66  This biphenylic compound and other related lignans are able to interact with cannabinoid 
receptors.67 Magnolol is a partial CB1R/CB2R agonist whereas its major metabolite, 
tetrahydromagnolol, is a potent peripheral CB2R agonist that behaves as a weak antagonist of 
GPR55.68 In a remarkable investigation, Müller et al.69 developed structure-activity relationships of 
new magnolol analogs varying the alkyl chains and the phenolic groups. As a result, they have 
demonstrated that methylation of one of the hydroxyl groups leads to an increase of the antagonistic 
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potency at GPR55 being 5´-hexyl-2´-methoxy-5-propylbiphenyl-2-ol the most potent of this series. 
This structure represents a potential lead compound in the development of new GPR55 antagonists.
Figure 9. Magnolol and analogs. 
1.4.3 Non-cannabinoid related GPR55 ligands 
The growing interest of this therapeutic target has focused extensive research in the identification of 
new selective GPR55 ligands. Within this context, collaborative project between individual 
laboratories and the Sandford-Burnham screening center of the Molecular Libraries Probe 
Production Centers Network (MLPCN)70,71 allowed the identification of  six different GPR55 
chemical scaffolds.70,71 This study consisted in high-throughput screening of a library of compounds 
by β-arrestin assays in U2OS cells permanently expressing HA-GPR55E and βarr2-GFP.58
Phenylpiperazine CID2440433, triazoloquinoline CID1172084 and morpholinesulfonylphenylamide 
CID15945391, represented in figure 10, exemplify the potent GPR55 agonists discovered in this 
study;71 whereas  piperadinyloxadiazolone CID23612552, thienopyrimidine CID1434953 and 
quinoline aryl sulfonamide CID1261822 of figure 10 are representative GPR55 antagonists.70
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Figure 10. Hits of the identified GPR55 agonist scaffolds (CID2440433, CID1172084 and CID15945391) 
and GPR55 antagonist scaffolds (CID23612552, CID1434953 and CID1261822). CID16020046 is another 
GPR55 antagonist recently described by Kargl et al.72
Parallel studies61 developed by the company GlaxoSmithKline in 2011 validated the abovementioned 
benzoylpiperazine as GPR55 agonists in Saccharomyces cerevisiae yeast and in HEK293 cells. 
GSK494581A, the most potent ligand, and GSK575594A, the most selective one, had been 
previously patented as glycine transporter subtype 1 inhibitors (being 60-fold selective for GPR55) 
(figure 11). It is noteworthy that these novel GPR55 selective ligands activate human but not rodent 
GPR55 pointing to differences in the binding pocket of the two orthologs. 
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Figure 11. Benzoylpiperazines previously reported as glycine transporter inhibitors.
In 2013, Kargl et al.72 identified CID16020046 (figure 10) as a selective GPR55 antagonist.72 This 
compound was originated in the same MLSCN screening; however, it was not selected by those 
researchers for further development. This molecule antagonizes agonist-mediated GPR55 activation 
in yeast cells and inhibits GPR55-mediated intracellular Ca2+ release. CID16020046 reduces LPI 
signaling in primary human lung microvascular endothelial cells (HMVEC-L) and in human platelet 
suggesting novel therapeutic applications for GPR55.  
A very recent research has demonstrated that (R,R´)-4´-methoxy-1-naphthylfenoterol (MNF, figure 
12), an analog of (R,R´)-fenoterol (short-acting β2-adrenergic agonist) with a 573-fold greater 
selectivity for β2-AR than β1-AR, is able to reduce GPR55 agonist efficacy.73 The compound exerts 
selective attenuation in GPR55 signaling as demostrated through different biological readouts such 
as ERK phosphorilation and cell motility. (R,R´)-MNF inhibits the pro-oncogenic activity of GPR55 
revealing its therapeutic potential as an antitumor agent.
Figure 12. Naphthylfenoterol (MNF). 
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The analysis of the miscellaneous range of GPR55 scaffolds reported so far may help to deepen in 
the elucidation of the structural motifs involved in the interaction with the receptor. This knowledge 
may contribute to the rational design of new compounds able to selectively bind this promising 
target providing new therapeutic strategies.   
1.5  Molecular modeling studies  
Although no crystal structure is already available for GPR55, Reggio and coworkers10,12,74 have 
developed an homology model based on previously crystallized GPRC structures. This model was 
refined according to sequence differences. It allows exploring the GPR55 ligand binding pocket and 
the key residues involved in the ligand-receptor interaction. However, different mutations on the 
receptor remain to be done in order to fully elucidate these interactions. 
As reported by Reggio10 in the LPI-GPR55* complex the endogenous ligand adopts an inverted-L 
shape conformation where the primary interaction site for LPI involves a salt bridge between its 
phosphate group and the residue K2.60. According to the aforementioned model, LPI inserts its 
fatty acid tail deep within the transmembrane bundle (TMH-2, 3, 5, 6 and 7). Molecular dynamics 
studies of the lipid-derived agonists of GPR55 showed that LPI and 2-AGPI sit much higher in the 
bilayer than anandamide. 2-AGPI and LPI can adopt a tilted head group orientation by hydrogen 
bonding to the phospholipid phosphate group.74 These molecular modeling studies suggest that the 
binding site of the active state of the receptor may accommodate ligands with inverted-L or T 
shapes exposing their most electronegative region in the intersection and positioning their long part 
vertically deep in the receptor. The critical interaction for these agonists may occur between K2.60 
and their highly electronegative moiety.  
Molecular modeling studies of CID1172084, CID2440433 (figure 10) have been accomplished in the 
active GPR55 model described by Kotsikorou et al.10 These agonists fit in the putative binding site of 
the receptor in the region of TMH 2-3-5-6-7 mirroring the bioactive conformation of LPI. Their 
broad head regions occupy a horizontal binding pocket opening near the EC loops. On the other 
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hand, docking studies of the thienopyrimidine derivative CID1434953 and other antagonists were 
performed in the inactive state of the GPR55 model.12 This modeling suggests that GPR55 
antagonists adopt a 7 or T shape with the electronegative region near the end of the central portion 
of the molecule. Their binding pocket is in the extracellular loop region and the top part to the 
transmembrane helixes.  
These studies offer an insight into GPR55 modulation and pharmacophore.  
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2. Aims 
As aforementioned, GPR55 pharmacology reveals serious inconsistencies between studies and 
functional outcomes.6 Therefore, it becomes crucial to focus our efforts in the discovery of novel 
potent and selective GPR55 molecules that may enable the development of adequate research tools 
for the biological study of this putative cannabinoid receptor.  
Within the context of exploring the chromenopyrazole scaffold this chapter includes the following 
specific aims leading to two new series of compounds:  
- Design of novel potential GPR55 ligands.a
- Synthesis of the proposed molecules.a
- Analysis of in silico drug-like properties of the novel structures.a
- Evaluation of GPR55 activity.b
- Study their selectivity vs cannabinoid receptors CB1R and CB2R.c
Figure 13. Proposed potential GPR55 structures. 
a) Performed by PM at Instituto de Química Médica (CSIC). 
b) Performed by PM hosted by Prof. Ruth Ross (School of Medicine, University of Toronto). 
c) Performed by PM hosted by Prof. Javier Fernández-Ruiz (Facultad de Medicina, UCM). 
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3. Results  
3.1 Design 
Potent and selective GPR55 ligands have been unavailable principally because most of the known 
modulators of this receptor were identified from cannabinoid receptor or lipid compound 
libraries.57,61 Recently, the Sanford-Burnham screening center of MLPCN performed a high-
throughput, high-content screening identifying new GPR55 ligands as described in the introduction 
of this chapter.70,71 These new scaffolds served us as a basis to design our novel potential GPR55 
chemotypes. We particularly focused on the structural features highlighted in figure 14.  
Figure 14. GPR55 scaffolds identified in the MLPCN screening. A) Phenylpiperazine B) Triazoquinoline C) 
Thienopyrimidine. Structural features retained for novel GPR55 structures are highlighted. Head region is 
boxed in blue and tail profiles in green.  
Reported SAR studies and molecular modeling of the most potent molecules of these series allowed 
to determine the chemical requirements for GPR55 activity.10,12,70,71 Scaffold A comprises a central 
phenylpiperazine core substituted by a 3-sulfonylphenone. The preferred R1 substituents are 
hydrogen, halogens, methyl or methoxy groups. Other structural modifications such as nitro R1
substituents caused a drastic loss of activity. The triazoloquinoline core of scaffold B accepted 
hydrogen and methoxy groups as R1 and R2 to modulate GPR55. R3 and R4 tolerate hydrogen or 
methyl groups to retain activity. Regarding scaffold C, unsubstituted or methylated thienopyrimidine 
cores were preferred in the active compounds. The acylated piperazine moiety is affected by alkyl R3
substituents whereas furan derivatives were determinant for increased potency.
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Based on these data, we designed novel potential GPR55 chromenopyrazole derivatives. 
Replacement of the triazoloquinoline or thienopyrimidine core by our tricyclic heterocyclic scaffold 
as head region is proposed (figure 15). Phenylpiperazine and acylated piperazine moieties, present in 
scaffolds A and C, were selected as pyrazole substituents. 
Figure 15. Designed chromenopyrazole scaffolds.
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As previously commented, molecular modeling studies10,12 suggested that GPR55 ligands should 
adopt an inverted-L or T shape with the presence of an electronegative region located close to the 
head region or in the central portion of the molecule. To appraise if the minimum energy 
conformers of these prototypes could adopt similar shapes, a conformational analysis of two 
pyrazole isomers from each proposed series was undertaken. The molecular electrostatic potential 
maps were calculated from the global minimum energy. Figure 16 illustrates the minimum energy 
conformer of N1 and N2-substituted chromenopyrazole derivatives. A noteworthy feature resulting 
from this study is the inverted-L shape adopted by the N2-substituted isomers from both series. 
This shape could mimic the bioactive conformation reported by Reggio.10,12 The molecular 
electrostatic potential maps showed a high electronegative region nearby the chromenopyrazole 
head region (series I) and in the central area of the molecule (series II).
Figure 16. A) N1 and N2-(4-(2,3-dimethylphenyl)piperazinyl)acetamidomethyl-chromenopyrazole (Series I)
electrostatic potential maps. B) N1 and N2-(4-(2-thenoyl)piperazinyl)ethyl-chromenopyrazole (Series II)
electrostatic potential maps. . The electrostatic potential scale (in kJ/mol) is provided as a color scale. This 
scale is from blue (most electropositive) to red (most electronegative).
N1-Chromenopyrazole N2-Chromenopyrazole 
A
B
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The different electronegative patterns of these two series along with the possible substitution of the 
pyrazole ring at N1 or N2 position may provide an overview of the scaffold versatility and chemical 
requirements for GPR55 activity.    
3.2 Synthesis 
The chromenopyrazole core of the new derivatives was prepared following the synthetic route 
depicted in scheme 1. 7-Methoxy-2,2-dimethyl-2,3-dihydrochromen-4-one 3.1 was obtained by 
cyclization of 2-hydroxy-4-methoxyacetophenone with acetone. α-Formylation of 3.1 was achieved 
under microwave irradiation conditions as previously described in Chapter 1. 3-
Hydroxymethylenechromen-4-one 3.2 tautomerizes to the corresponding β-keto aldehyde under the 
reaction conditions. Finally, condensation of the β-keto aldehyde with anhydrous hydrazine yielded 
the corresponding 7-methoxy-4,4-dimethyl-1,4-dihydrochromeno[4,3-c]pyrazole (3.3).
Scheme 1. Synthesis of 7-methoxy-4,4-dimethyl-1,4-dihydrochromeno[4,3-c]pyrazole 3.3. Reaction 
conditions: (i) acetone, pyrrolidine, EtOH, 5 h, reflux, 82%; (ii) NaH, THF, MW, 45ºC, 25 min, then 
ethyl formate, THF, MW, 45ºC, 25 min, 52%; (iii) anhydrous hydrazine, EtOH, 2 h, 60ºC, 69%.
Then, arylpiperazines 3.43.7 were synthesized by N-alkylation of the suitable phenylpiperazine with 
2-chloro-N-hydroxymethylacetamide. As displayed in scheme 2, the final compounds 3.8a3.11 
were prepared by alkylation of 7-methoxy-1,4-dihydro-4,4-dimethylchromeno[4,3-c]pyrazole (3.3) 
with the corresponding phenylpiperazine derivative 3.43.7 under refluxing conditions. 
Purification of the N1 and N2 regioisomers resulted difficult in most cases obtaining the desired 
compounds in low yields. Flash column chromatography followed by a semipreparative HPLC was 
required to separate both phenylpiperazinyl-acetamidomethyl chromenopyrazoles isomers. In order 
to improve the yield of this synthetic route, the hydroxyl group of 3.43.7 was mesylated or 
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tosylated with the respective sulfonyl chloride in order to improve the leaving group capacity. 
Unfortunately, the yields of pyrazole alkylation were not significantly enhanced.  
Scheme 2. Synthesis of phenylpiperazinyl-acetamidomethyl chromenopyrazoles 3.8a-3.11 (Series I). 
Reaction conditions: (i) 2-chloro-N-hydroxymethylacetamide, K2CO3, acetonitrile, 2-5 h, reflux (24-63%); 
(ii) compound 3.3, NaH, THF, 12-72 h, reflux (2-14%). 
In view of the difficulties to obtain the phenylpiperazinyl-acetamidomethyl chromenopyrazole 
derivatives, a different strategy was developed for the achievement of the second series of 
compounds. The synthesis of acylpiperazinyl chromenopyrazoles is shown in scheme 3. Alkylation
of compound 3.3 with 1,2-dibromoethane afforded the desired 2-bromoethyl-chromenopyrazoles 
3.12a and 3.12b. In contrast to the above reaction, these regioisomers were easily separated by 
column chromatography. Finally, compounds 3.133.19 were obtained in good yields reacting the 
corresponding bromoethyl-chromenopyrazole with different acyl piperazines under refluxing 
conditions.
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Scheme 3. Synthesis of acylpiperazinyl chromenopyrazoles 3.13-3.19 (Series II). Reaction conditions: (i) 1,2-
dibromoethane, NaH, THF, 4 h, reflux, 21 and 40%; (ii) acyl piperazine, K2CO3, THF, overnight, reflux, 23-
81%. 
 
Most of the reactions were also performed by microwave heating conditions and despite the 
reaction time decrease, the yields were lower and more subproducts were obtained hindering the 
purifications. 
3.3 In silico ADME properties 
So far, the most potent known ligand for GPR55 is LPI. However, LPI is very unstable when 
exposed to air or sunshine; it oxidizes very easily. Due to these particularities, LPI is not suitable as 
therapeutic agent. Therefore, the druggability profile of the new compounds was predicted using a 
set of 34 physicochemical descriptors computed by QikProp. Selected pharmacokinetic properties 
of compounds 3.83.19 and the GPR55 agonist LPI are displayed in table 1. Lipinski rule of five as 
well as Jorgensen rule of three75,76 are followed by all the new chromenopyrazole derivatives whereas 
LPI drug-likeness is quite poor. Several LPI parameters such as bioavailability, aqueous solubility, or 
blood-brain partition coefficient fall outside the optimum range of values for 95% of known drugs 
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showing an overall ADME-compliance score very low. The prediction of solubility, blood-brain 
barrier permeability, human oral absorption, gut-blood barrier permeability and metabolism suggests 
that chromenopyrazole derivatives 3.83.19 can be considered as suitable drug-like candidates. 
Moreover, their predicted parameters suggest a clear ADME improvement compared to LPI.
Table 1. Physicochemical descriptors calculated by QikProp 3.5 integrated in Maestro (Schrödinger, LLC, 
New York, USA)  
3.4 GPR55 assays 
As commented in the introduction of this chapter, the pharmacology of GPR55 is rather puzzling. 
In fact, activity of GPR55 ligands is completely influenced by the assay used to assess receptor-
mediated downstream signaling.20,28,58 Moreover, the paucity of structural data and selective potent 
modulators has also limited the development of accurate pharmacological assays.  
Compd QPlogSa QlogBBb QPlogHERGc QPPCacod %Human  oral absorption GIe
3.8a -4.81 0.11 -5.80 529 100
3.8b -4.75 0.10 -6.06 504 100
3.9a -4.82 0.05 -5.59 529 100
3.9b -4.74 0.04 -5.84 504 100
3.10a -5.50 0.10 -5.54 529 100
3.10b -5.52 0.09 -5.79 504 100
3.11 -4.56 0.06 -5.39 529 100
3.13a -4.11 -0.05 -6.78 559 100
3.13b -4.10 0.08 -7.05 774 100
3.14a -4.73 0.01 -7.07 641 100
3.14b -5.28 0.08 -7.52 796 100
3.15a -4.83 0.12 -6.75 642 100
3.15b -4.92 0.25 -7.08 880 100
3.16 -4.42 0.03 -6.33 589 100
3.17 -2.90 0.13 -5.03 512 89
3.18 -4.67 0.30 -5.13 832 100
3.19 -3.92 0.27 -5.04 750 100
LPI -3.41 -4.84 -4.14 5 11
aPredicted aqueous solubility [-6.5/0.5]; bPredicted log of the brain/blood partition coefficient [-3.0/1.2]; 
cHERG K+ Channel Blockage (log IC50) [concern below -5]; dApparent Caco-2 cell permeability in nm/s 
[<25 poor, >500 excellent]; eHuman Oral Absorption in GI [<25% is poor]; [range of 95% of drugs].
Results
220 
Cellular impedance assay 
The potential GPR55 activity of new chromenopyrazole derivatives was assessed using 
xCELLigence experiments.77,78 This is a label-free methodology based on cellular impedance 
measurements on real time. The integrated readout of GPR55 function allowed by this assay may 
circumvent some of the abovementioned pharmacological problems. The xCELLigence assay has 
been optimized for GPR55 receptors by Ruth Ross´s research group.79 They were able to detect 
agonist or antagonist activity of previously known GPR55 ligands such as LPI, 2-AGPI, or 
CID16020046 among others. These ligands were assessed through other functional assays 
demonstrating similar GPR55 activity profiles. Potency and efficacy differences depend on the 
sensitivity of the technique, assay formats and stable cell lines. 
This assay is based on the detection of cellular morphological changes triggered by ligand-dependent 
GPCR activation and coupling to downstream pathways. These changes modulate the physical 
contact between cell and electrode which is reflected by changes in electrical impedance (converted 
to cell index units by the system). Recent studies have widely validated this impedance-based 
technology for monitoring GPCR activation and signaling in cells.80–82
Figure 17. Schematic representation of microelectrodes and the principle of xCELLigence experiments. Cells 
are plated onto gold microelectrode arrays, which when stimulated with a low voltage generate an electric 
field sensitive to changes in the properties of a cell. The impedance increases as cells attach and spread or 
after cell shape changes induced by GPCR activation. In the absence of cells, the baseline impedance (Z0) 
value is determined by the software. Addition of cells to the sensor microelectrodes leads to changes in 
impedance signal (Zcell) that is directly proportional to the number of cells seeded on the sensors. Figure 
adapted from ACEA Biosciences.83
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Results  
Cellular impedance of increasing concentrations of LPI and chromenopyrazole derivatives 3.83.19 
was monitored in a human embryonic kidney 293 cell line stably overexpressing recombinant human 
GPR55 (hGPR55-HEK293). Cells were seeded one day prior to stimulation with the compounds for 
attachment to the electrodes located in the bottom of the plate. Activation of the receptor by a 
GPR55 ligand causes changes in cellular impedance detected by the system. Agonistic effects of test 
compounds were compared to the activity of the GPR55 agonist LPI (LPI effect at 1 μM is set at 
100%). Dose-response curves were obtained plotting the peak cell index response (five minutes after 
administration of the drugs), versus the logarithm of the concentration for each compound. Cell 
index values were normalized for each well to the time point immediately preceding agonist 
addition. EC50 values and the corresponding Emax of LPI and chromenopyrazole derivatives are 
displayed in table 2. The activity observed for LPI was consistent with published data in all the 
experiments.79
Table 2. Potencies of chromenopyrazole derivatives 3.8-3.19 for GPR55 receptor measured using 
xCELLigence system.  
Compd R Pyrazole Substitution
GPR55
EC50 (nM)a Emax (%)b
3.8a H N1 - NR
3.8b H N2 - NR
3.9b 2-OMe N2 6.36 (0.98-41.52) 51 (36-67)
3.10b 2,3-diMe N2 - NR
3.11 4-OMe N1 - NR
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According to the ability to activate GPR55, there is a clear difference between both series of 
compounds [3.83.11 (series I) and 3.133.19 (series II)]. All the tested acylpiperazinyl 
chromenopyrazoles (series II) exhibited agonistic GPR55 profile except 3.15a. Conversely, excluding 
3.9b which partially activated the receptor, tested phenylpiperazinyl-acetamidomethyl 
chromenopyrazoles (series I) did not show capacity to activate GPR55 in this cell model.  
Compounds 3.9b, 3.13b, 3.14b, 3.15b, 3.16, 3.17, 3.18 and 3.19 displayed partial agonism in GPR55-
HEK293 cells when compared with LPI response. These compounds exhibit good potency with 
EC50 values in the nanomolar range. However, these chromenopyrazole derivatives displayed half of 
the maximal efficacy produced by the putative endogenous modulator LPI. 
Interestingly, in the acylpiperazinyl series (II), the N1- or N2-pyrazole substitution influences the 
ability of the compounds to activate GPR55. Effectively, N2-regioisomers (3.13b, 3.14b, 3.15b, 3.16, 
3.17, 3.18 and 3.19) present the preferred substitution while substitution at N1-position (3.13a and 
3.13a N1 - NR
3.13b N2 0.88 (0.05-14.56) 43 (31-54)
3.14b N2 0.60 (0.12-3.03) 51 (42-60)
3.15a N1 - NR
3.15b N2 0.51 (0.06-4.22) 45 (36-54)
3.16 N2 1.28 (0.20-9.46) 52 (41-63)
3.17 N2 0.40 (0.03-4.61) 51 (40-62)
3.18 N2 8.67 (1.18-63.45) 47 (36-58)
3.19 N2 0.69 (0.06-7.63) 49 (37-62)
LPI - - 2.82 (0.64-12.30) 100 (81-118)
The data is presented as a percentage of the maximal LPI stimulation (at 1 µM, LPI displays off-target activity at 10 
µM). aEC50 values were calculated using nonlinear regression analysis. Data represent the mean of at least four 
experiments performed in duplicate, and 95% confidence intervals (CI) for the EC50 values are given in parentheses. 
bEmax: Maximal agonist effect, determined using nonlinear regression analysis (95% CI). NR: No response at tested 
concentrations (Emax lower that 25% relative to LPI).
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3.15a) exerts a negative impact on GPR55 activation. Figure 18 exemplifies the effects of both 
isomers, N1- (3.13a) and N2-substituted (3.13b), on dose-response curves in hGPR55-HEK293 
cells.
Figure 18. Concentration-response curves of LPI and representative chromenopyrazole derivatives 3.13a and 
3.13b in hGPR55-HEK293 cells. Data points represent the mean ± SEM values of four independent 
experiments, performed in duplicate. The data is presented as a percentage of the maximal LPI stimulation (at 
1 µM, LPI displays off-target activity at 10 µM). 
After analyzing the ability of the compounds to activate GPR55, their potential antagonistic activity 
at the receptor was evaluated. The capacity of 3.8a3.19 to inhibit LPI-mediated GPR55 stimulation 
was assessed at a concentration of 1 μM. Full concentration-response curves for LPI in presence 
and absence of the compounds were determined (table 3). A representative graph is displayed in 
figure 19. These experiments were performed by coincubation of the cells with the tested 
compounds (or vehicle) and different concentrations of the standard agonist LPI.  
Table 3. Potencies and maximal effect of LPI in the presence and absence of chromenopyrazole derivatives 
3.83.19 (1 μM) at GPR55. 
Compd R Pyrazole Substitution
GPR55
EC50 (nM)a Emax (%)b
LPI A+3.8a H N1 27.7 (8.9-86.1) 97 (80-115) 
LPI A+3.8b H N2 31.5 (5.4-83.6) 94 (78-108)
LPI A+3.9b 2-OMe N2 28.4 (4.7-96.1) 90 (71-104)
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As 
showed in table 3, phenylpiperazinyl-acetamidomethyl chromenopyrazoles (series I) were not able to 
significantly inhibit LPI dose-dependent GPR55 activation. Nonetheless, among acylpiperazinyl
chromenopyrazoles (series II), 3.16, 3.17, 3.18 and 3.19 exhibited a significant capacity to antagonize 
LPI effect at 1µM. As previously demonstrated, these compounds are also partial agonist of the 
receptor when administered alone what highlights their interesting pharmacological profile. 
Figure 19. Concentration-response curves of LPI in the presence and absence of chromenopyrazole 
derivative 3.19 in hGPR55-HEK293 cells. Data points represent the mean ± SEM values of at least four 
LPI A+3.10b 2,3-diMe N2 30.4 (10.1-91.5) 102 (90-115)
LPI A+3.11 4-OMe N1 27.3 (1.2-97.5) 80 (60-105)
LPI A+3.13a N1 19.6 (5.9-65.3) 97 (83-111)
LPI B+3.13b N2 19.8 (3.9-76.1) 106 (92-120)
LPI B+3.14b N2 15.5 (3.8-54.6) 105 (96-113)
LPI A+3.15a N1 29.3 (8.4-79.2) 99 (82-116)
LPI B+3.15b N2 8.2 (2.5-26.4) 96 (87-106) 
LPI B+3.16* N2 18.2 (4.6-71.1) 100 (91-115)
LPI B+3.17* N2 24.6 (7.9-66.8) 102 (91-106)
LPI B+3.18* N2 25.4 (6.6-96.7) 99 (90-113)
LPI B+3.19* N2 21.9 (5.5-87.6) 100 (86-114)
LPI A - - 4.1 (1.3-12.1) 104 (91-114)
LPI B - - 1.6 (0.6-4.2) 99 (90-108) 
aEC50 values were calculated using nonlinear regression analysis. Data represent the mean of at least four 
experiments performed in duplicate, and 95% confidence intervals (CI) for the EC50 values are given in 
parentheses. bEmax: Maximal agonist effect, determined using nonlinear regression analysis (95% CI). * 
Significantly different (nonoverlapping confidence intervals) from the corresponding LPI alone. The effect of 
each compound over LPI dose-response is related to their corresponding LPI (A or B) in absence of the 
potential antagonist.
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independent experiments, performed in duplicate. The data is presented as a percentage of the maximal LPI 
stimulation.
Taking into consideration the xCELLigence impedance assays presented so far, the most promising 
results come from series II. Three acylpiperazinyl chromenopyrazoles (3.13b, 3.14b and 3.15b) 
displayed capacity to partially activate GPR55, while 3.16, 3.17, 3.18 and 3.19 displayed both partial 
GPR55 agonism and GPR55 antagonism of LPI response. From series I, only one compound (3.9b) 
showed GPR55 partial agonism.
Selectivity towards GPR55 
The activity of the compounds was evaluated in normal HEK293 cells to study if the response 
detected by cellular impedance was selectively GPR55-mediated. Full dose-response curves of all the 
new compounds and LPI were performed at concentrations from 1 nM to 10 µM in non-transfected 
HEK293 cells. Chromenopyrazoles derivatives 3.83.19 did not exhibit any response at doses up to 
10 µM in normal cells confirming that the effects observed in over-expressed GPR55 cells were 
mediated by this receptor. However, LPI clearly displayed off-target stimulation at high 
concentrations (10 µM). Off-targets effects of LPI at doses over 1 µM have been observed through 
diverse functional endpoints.84,85 Graphs of representative compounds and LPI are shown in figure 
20 comparing their effect in GPR55 transfected and normal HEK293 cells.  
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Figure 
20. Concentration-response curves of LPI and representative chromenopyrazole derivatives in hGPR55-
HEK293 and normal HEK293 cells. Data points represent the mean ± SEM values of four independent 
experiments, performed in duplicate. The data is presented as a percentage of the maximal LPI stimulation.
3.5 Cannabinoid binding studies  
Most of the GPR55 ligands identified so far are also able to modulate CB1 and/or CB2 receptors. 
Indeed, in order to further investigate the selectivity of the new compounds, their capacity to 
interact with CB1R and CB2R was evaluated. The affinities of compounds 3.83.19 were determined 
by radioligand binding studies at human CB1R and CB2R using [3H]CP55940 as cannabinoid 
receptor radioligand. As a source for human CB1R and CB2R, membrane preparations of HEK293 
EBNA cells stably expressing the respective receptor subtype were utilized. Initially the compounds 
were screened at a concentration of 40 μM. In cases where inhibition of radioligand binding was at 
least about 70%, full concentration−effect curves were performed in order to calculate Ki values. 
The experimental binding affinities of 3.83.19 and WIN55,212-2 are reported in table 4. 
As clearly shown by the affinity data, none of the compounds bind to CB1R. From series I, 
chromenopyrazoles 3.93.11 did not bind either to CB2R. However, when the phenyl group was not 
substituted (compounds 3.8a and 3.8b), a moderate CB2R affinity was displayed. From this series, 
compound 9b, which showed to be GPR55 partial agonist, stands out since it did not act on CBRs. 
Regarding series II, chromenopyrazoles 3.133.19 revealed moderate to high affinity towards CB2R
except compound 3.16 which lacked affinity for CBRs.
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In conclusion, 3.16 can be considered a good lead compound for further development considering 
its GPR55 partial agonist/LPI antagonist properties and its GPR55 selectivity versus CBRs. This 
molecule bears a phenoxyacetyl piperazine which is the largest substituent assessed within this series. 
This fact may indicate that smaller substituents are preferred for CB2R affinity.
Interestingly, the GPR55 partial agonist 3.15b, is a selective and potent CB2R agonist with affinity in 
the nanomolar range (GTPγS assays: EC50: 331.0 ± 125.9 nM; Emax: 91.1 ± 7.5%). Even though our 
main purpose is the identification of GPR55 selective ligands, a dual GPR55-CB2 drug may open 
novel therapeutic strategies due to the close relation of both GPCRs in different pathologies.27,26
Table 4. Binding affinity of compounds 3.83.19 and the reference cannabinoid WIN55,212-2 for hCB1R 
and hCB2R. 
Compd R Pyrazole Substitution CB1R Ki (nM)
a CB2R Ki (nM)a
3.8a H N1 >40000 4923 ± 349
3.8b H N2 >40000 1578 ± 461
3.9a 2-OMe N1 >40000 >40000
3.9b 2-OMe N2 >40000 >40000
3.10a 2,3-diMe N1 >40000 >40000
3.10b 2,3-diMe N2 >40000 >40000
3.11 4-OMe N1 >40000 >40000
3.13a N1 >40000 nd
3.13b N2 >40000 698 ± 107
3.14a N1 >40000 nd
3.14b N2 >40000 3604 ± 941
3.15a N1 >40000 nd
3.15b N2 >40000 15.4 ± 7.8
3.16 N2 >40000 >40000
3.17 N2 >40000 1073 ± 238
3.18 N2 >40000 523 ± 144
3.19 N2 >40000 6392 ± 327
WIN55,212-2 - - 45.6 ± 8.6 3.7 ± 0.2
aValues obtained from competition curves using [3H]CP55940 as radioligand for hCB1R and hCB2R
cannabinoid receptors and are expressed as the mean ± SEM of at least three experiments. nd: not 
determined.
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4. Discussion and conclusions
The first selective GPR55 ligands were discovered only a few years ago. Since then, few new 
structures have been reported. Regarding ligand-receptor interactions, there is also little information 
already available. In this context, the study developed in this chapter aims to identify a novel GPR55 
chemotype. The two series presented here have been designed based on the chromenopyrazole 
scaffold and structural features of previously investigated GPR55 ligands. In the first series, the 
chromenopyrazole is N-substituted by a 2-(4-arylpiperazinyl)acetamidomethyl group. In the second 
series, 2-(4-acylpiperazinyl)ethyl group was selected as N-substituent of the same scaffold. The 
synthesis of these compounds showed some difficulties. The preparation of the derivatives of series 
I resulted in poor yields due to purification issues in the last step of the route (scheme 2). 
Nevertheless, the synthesis of the acylpiperazinyl chromenopyrazoles (series II) afforded the desired 
compounds with reasonable yields by a 5 steps synthetic procedure.  
In what concerns the pharmacological evaluation, it is noteworthy to mention that it is the first time 
that a GPR55 screening to discover new ligands was performed by xCELLigence assays. 
Discrepancies reported in the literature regarding GPR55 pharmacology are mainly due to the 
inconsistent outcomes obtained from different functional assays. Therefore, appraisal of GPR55 
activity of the new synthesized compounds was accomplished by using an innovative technology 
based on cell-impedance providing an integrative assessment of the cellular response to GPR55 
stimulation. These assays take into account the different possible signaling pathways circumventing 
the individual functional outcome problems. The use of this novel label-free technology approach 
adds value to the drug discovery process considering the lack of available GPR55 radioligands.  
The functional assays revealed that most chromenopyrazoles of series II showed GPR55-mediated 
effects. Compared to LPI efficacy, they are partial agonist of GPR55, however they have similar 
potency. The only two inactive derivatives correspond to the tested chromenopyrazoles substituted 
in N1-position. This finding highlights the N2-preferred substitution suggested by the electrostatic 
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potential maps studies obtained in the design of the novel potential GPR55 chemotypes. The 
experimental data are in agreement with a possible inversed-L or 7 shape adopted by the N2-
substituted isomers. Upon antagonist treatment, four of these GPR55 partial agonists significantly 
inhibited GPR55-mediated LPI effect (3.16-3.19).  
To ensure that this functionality was GPR55-mediated and considering that the impedance 
measurements are cell-based screening, control experiments with normal HEK293 cells were 
undertaken. It is noteworthy that the new compounds did not show any effect while off-targets 
effects of LPI was observed at 1 µM. 
Since GPR55 was shown to be activated by cannabinoid ligands, it was of interest to evaluate the 
affinity of these novel compounds for CBRs in radioligand binding assays. The first observation 
concerns the lack of CB1R binding for all compounds eliminating the possible psychotropic side-
effects associated with the activation of the central CB1R. One of GPR55 partial 
agonists/antagonists of LPI of series II was also devoid of CB2R affinity. Therefore, this GRP55 
selective compound (3.16) can be considered a good lead candidate for further development. From a 
structural point of view, this chromenopyrazole differs from the others of the series by the presence 
of a phenoxymethyl substituent on the piperazine.  
Compound 3.15b stands out because of its CB2R affinity with EC50 value in the nanomolar range. 
This property, along with its ability to partially activate GPR55 suggests that it could be exploited as 
a dual GPR55-CB2R drug. The recently reported relation of both receptors points to very interesting 
therapeutic opportunities, however, this is beyond the aim of the current work. From series I, we 
identified a partial agonist of GPR55 which lacks of CBRs affinity (3.9). This compound could 
represent a suitable lead structure, however, it would be necessary to look for an easier synthetic 
access to such compounds. 
Despite the potential therapeutic interest of GPR55 agonists and antagonists in the treatment of 
diverse pathologies, it is essential to discover selective and potent ligands to develop adequate 
research tools for its biological study. Although LPI possess good activity and has demonstrated to 
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activate the receptor from different functional readouts, it is still prone to important disadvantages: 
poor “drug-like” properties and lack of selectivity. In this scenario, we have identified a novel 
GPR55 scaffold that may facilitate the characterization of this receptor. The GPR55 selective 
chromenopyrazoles discovered in this project86,87 are potential candidates to generate helpful 
pharmacological tools or potential drugs for novel therapeutic strategies.
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5. Experimental section 
Chemistry. 
General methods and materials. Reagents and solvents were purchased from Sigma-Aldrich Co., 
Fluorochem, Acros Organics, Manchester Organics and Lab-Scan and were used without further 
purification or drying. Microwave assisted organic synthesis was performed using the microwave 
reactor Biotage Initiator. Products were purified using flash column chromatography (Merck Silica 
gel 60, 230-400 mesh) or medium pressure chromatography using Biotage Isolera One with pre-
packed silica gel columns (Biotage SNAP cartridges). Semipreparative HPLC purifications were 
performed on a Waters 2695 HPLC system equipped with a Photodiode Array 2998 coupled to a 
3100 Mass Detector mass spectrometer, using a SunfireTM C18 column (19 mm x 150 mm) and 70 
min gradient A: CH3CN/0.1% formic acid, B: H2O/0.1% formic acid monitoring at λ=254 nm. The 
flow rate was 24 mL/min. The compounds were characterized by combination of NMR 
experiments, HPLC-MS, high resolution mass spectrometry (HRMS) and elemental analysis. HPLC-
MS analysis was performed on a Waters 2695 HPLC system equipped with a photodiode array 2996 
coupled to Micromass ZQ 2000 mass spectrometer (ESI-MS), using a reverse-phase column 
SunFireTM (C-18, 4.6 x 50 mm, 3.5 μm) and 10 min gradient A: CH3CN/0.1% formic acid, B: 
H2O/0.1% formic acid visualizing at λ = 254 nm. Flow rate was 1 mL/min. Elemental analyses of 
the compounds were performed using a LECO CHNS-932 apparatus. Deviations of the elemental 
analysis results from the calculated are within ± 0.4%. The purity of compounds 3.8-3.19 was 
determined by LC coupled to HRMS. The experiments were performed in a LC-MS hybrid 
quadrupole/time of flight (QTOF) analyzer equipped with an Agilent 1100 LC coupled to an 
Agilent 6500 Accurate Mass (1-2 ppm mass accuracy) using electrospray ionization in the positive 
mode (ESI+). 1H, 13C, HSQC and HMBC-NMR spectra were recorded on a Mercury 400 (400 and 
101 MHz) or a Varian 500 (500 and 126 MHz) at 25 °C. Samples were prepared as solutions in 
deuterated solvent and referenced to internal non-deuterated solvent peak. Chemical shifts were 
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expressed in ppm (δ) downfield of tetramethylsilane. Coupling constants are given in hertzs (Hz). 
Melting points were measured on a MP 70 Mettler Toledo apparatus. 
7-Methoxy-2,2-dimethylchroman-4-one (3.1).88
To a solution of 2-hydroxy-4-methoxyacetophenone (3.01 g, 18.05 mmol) in ethanol (30 mL) and 
acetone (13.24 mL, 180.53 mmol), pyrrolidine (4.52 mL, 54.16 mmol) was added in one portion. The 
mixture was refluxed for 6 h. After reaction completion, the solvent was removed under reduced 
pressure. The resultant crude was diluted by EtOAc and washed with aqueous NH4Cl solution and 
brine. The aqueous layer was extracted with EtOAc three times. The combined organic layer was 
dried over anhydrous MgSO4, filtered and the solvent was condensed under vacuum. Column 
chromatography on silica gel (hexane/ EtOAc, 3:1) provided the desired product as a yellow solid 
(3.04 g, 82%); mp: 81–83ºC (82-83ºC);89 1H-NMR (400 MHz, CDCl3) δ: 7.78 (d, J = 8.8 Hz, 1H, 5-
H), 6.52 (dd, J = 8.8, 2.4 Hz, 1H, 6-H), 6.36 (d, J = 2.4 Hz, 1H, 8-H), 3.81 (s, 
3H, OCH3), 2.66 (s, 2H, 3-H), 1.44 ppm (s, 6H, OC(CH3)2); 13C-NMR (101 
MHz, CDCl3) δ: 191.3 (4-C), 166.4 (7-C), 162.2 (8a-C), 128.4 (5-C), 114.3 (4a-
C), 109.5 (8-C), 101.3 (6-C), 79.8 (2-C), 55.8 (OCH3), 48.8 (3-C), 26.9 ppm (OC(CH3)2); HPLC-MS: 
[A, 15→95%], tR: 4.55 min, (99%); MS (ES+, m/z) 207 [M + H]+.
3-(Hydroxymethylene)-7-methoxy-2,2-dimethylchroman-4-one (3.2).90
A solution of 3.1 (2.80 g, 13.59 mmol) in anhydrous THF (15 mL) was added to a vial containing dry 
sodium hydride (1.30 g, 54.36 mmol) under N2 atmosphere. The mixture was 
irradiated under microwave at 45ºC for 25 minutes. Subsequently, ethyl 
formate (5.48 mL, 67.96 mmol) was added to the sealed vial and it was 
irradiated under microwave at 45ºC for 25 minutes. Water was added and the product was extracted 
with EtOAc. The combined organic layers were dried over Mg2SO4 and the solvent was evaporated 
under reduced pressure. The crude was purified by column chromatography on silica gel (hexane/ 
EtOAc, 3:1) to afford the title product 3.2 (1.46 g, 52%) as a light yellow oil: 1H-NMR (400 MHz, 
CDCl3) δ: 7.82 (d, J=8.7 Hz, 1H, 5-H), 7.78 (d, J = 9.0 Hz, 1H, CHOH), 6.49 (dd, J= 8.7, 2.1 Hz, 
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1H, 6-H), 6.26 (d, J = 2.1 Hz, 1H, 8-H), 3.37 (s, 3H, OCH3), 1.45 ppm (s, 6H OC(CH3)2); 13C-NMR 
(101 MHz, CDCl3) δ: 189.6 (4-C), 167.4 (7-C), 164.2 (CHOH), 158.9 (8a-C), 126.8 (5-C), 115.1(4a-
C), 110.3 (8-C), 105.8 (6-C), 87.1 (2-C), 64.5 (OCH3), 50.9 (3-C),  25.8 ppm (OC(CH3)2); HPLC-MS: 
[A, 60→95%], tR: 2.70 min, (98%); MS (ES+, m/z) 235 [M + H]+. 
1,4-Dihydro-7-methoxy-4,4-dimethylchromeno[4,3-c]pyrazole (3.3).91
A solution of 3.2 (1.46 g, 6.27 mmol) and anhydrous hydrazine (0.58 mL, 18.83 mmol) in EtOH (20 
mL) was stirred at 60ºC during 2 h. The solvent was removed under reduced 
pressure, and the crude residue was subjected to silica gel column 
chromatography (hexane/EtOAc, 1:1) to obtain 3.3 as a white solid (0.99 g, 
69%); mp: 158–160ºC (167-169ºC);91 1H-NMR (400 MHz, CDCl3) δ: 7.98-7.96 (br s, 1H, NH), 7.57 
(d, J = 7.8, Hz, 1H, 9-H), 7.33 (s, 1H, 3-H), 6.55 (d, J = 2.5 Hz, 1H, 6-H), 6.52 (dd, J = 7.8, 2.5 Hz, 
1H, 8-H), 3.78 (s, 3H, OCH3), 1.61 ppm (s, 6H, OC(CH3)2); 13C-NMR (101 MHz, CDCl3) δ: 161.3 
(7-C), 154.6 (5a-C), 125.6 (9b-C), 123.7 (3-C), 123.1 (3a-C), 120.2 (9-C), 109.9 (8-C), 108.1 (6-C), 
103.2 (9a-C), 76.2 (OC(CH3)2), 55.5 (OCH3), 29.4 ppm (OC(CH3)2); HPLC-MS: [A, 15→95%], tR: 
4.09 min, (98%); MS (ES+, m/z) 231 [M + H]+.
General procedure for the synthesis of phenylpiperazinyl-acetamides 3.43.7 
To a mixture of the corresponding phenylpiperazine (1 eq) and K2CO3 (1.5 eq) in acetonitrile, a 
solution of 2-chloro-N-hydroxymethylacetamide (2 eq) in acetonitrile was added. The reaction was 
refluxed for 2-5 h. After reaction completion, the solvent was removed under reduced pressure. The 
resultant crude was diluted by EtOAc, washed with water and extracted three times with EtOAc. 
The combined organic layers were dried over MgSO4, filtered and the solvent was evaporated under 
vacuum. The residue was purified by flash column chromatography performed on a Biotage Isolera 
One. The chromatography eluent and yield are indicated below for each reaction. 
N-Hydroxymethyl-2-(4-phenylpiperazinyl)acetamide (3.4). 
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Prepared from 1-phenylpiperazine (0.62 mL, 4.05 mmol) and 2-chloro-
N-(hydroxymethyl)acetamide (0.99 g, 8.11 mmol) and K2CO3 (0.83 g, 
6.08 mmol) by following the above-mentioned procedure. Flash column 
chromatography (EtOAc) furnished 3.4 as a white solid (0.42 g, 41% yield); mp: 112–114ºC; 1H-
NMR (400 MHz, CDCl3) δ: 8.10–8.02 (br s, 1H, NH), 7.39–7.22 (m, 2H, HPh), 7.06–6.85 (m, 3H, 
HPh), 4.82 (s, 2H, CH2OH), 3.28–3.19 (m, 4H, piperazine), 3.13 (s, 2H, COCH2), 2.90–2.57 ppm (m, 
4H, piperazine); 13C-NMR (101 MHz, CDCl3) δ: 173.6 (CO), 151.5 (CPh-N), 129.8, 129.7, 120.5, 
119.3 and 116.7 (CPh), 73.1(CH2OH), 62.0 (COCH2), 54.1, 53.7, 50.9 and 49.8 ppm (piperazine);
HPLC-MS: [A, 2% →95%], tR: 2.46 min (93%), MS (ES+, m/z) 250 [M+H]+; Anal. Calcd. for 
C13H19N3O2: C 62.63%, H 7.68%, found: C 62.41%, H 7.83%.
N-Hydroxymethyl-2-[4-(2-methoxyphenyl)piperazinyl]acetamide (3.5).
Prepared from 1-(2-methoxyphenyl)piperazine (1.17 g, 6.08 
mmol) and 2-chloro-N-hydroxymethylacetamide (1.49 g, 12.18 mmol)
and K2CO3 (1.26 g, 9.12 mmol) by following the general procedure. 
Flash column chromatography (EtOAc) afforded 3.5 as a white solid (1.06 g, 63% yield); mp: 134–
136ºC; 1H-NMR (400 MHz, CDCl3) δ: 8.14–8.11 (br s, 1H, NH), 7.03–6.96 (m, 2H, HPh), 6.89–6.78 
(m, 2H, HPh), 4.79 (s, 2H, CH2OH), 3.94–3.64 (m, 5H, COCH2 and OCH3), 3.17–2.89 (m, 4H, 
piperazine), 2.84–2.66 ppm (m, 4H, piperazine); 13C-NMR (101 MHz, CDCl3) δ: 171.4 (CO), 151.7 
(CPh-N), 140.4 (CPh- OCH3), 122.6, 120.5, 117.6 and 110.8 (CPh), 63.0 (CH2OH), 61.0 (COCH2), 54.8 
(OCH3), 53.6, 53.2, 51.0 and 50.1 ppm (piperazine); HPLC-MS: [A, 2% →95%], tR: 3.24 min (92%), 
MS (ES+, m/z) 280 [M+H]+; Anal. Calcd. for C14H21N3O3: C 60.20%, H 7.58%, found: C 60.31%, H 
7.72%.
2-[4-(2,3-Dimethylphenyl)piperazinyl]-N-hydroxymethylacetamide (3.6). 
Prepared from 1-(2,3-dimethylphenyl)piperazine (0.29 mL, 1.57 mmol) and 2-chloro-N-
hydroxymethylacetamide (0.39 g, 3.15 mmol) and K2CO3 (0.32 g, 2.36 
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mmol) by following the general procedure. Flash column chromatography (EtOAc) yielded 3.6 as a 
white solid (0.11 g, 25% yield); mp: 126–127ºC; 1H-NMR (400 MHz, CDCl3) δ: 8.19–8.14 (br s, 1H, 
NH), 7.07 (t, J = 7.6 Hz, 1H, HPh), 6.98–6.90 (m, 2H, HPh), 5.59–5.57 (br s, 1H, OH), 4.82 (s, 2H,
CH2OH), 3.14 (s, 2H, COCH2), 2.94–2.92 (m, 4H, piperazine), 2.77–2.73 (m, 4H, piperazine), 2.27 
(s, 3H,CH3), 2.21 ppm (s, 3H, CH3); 13C-NMR (101 MHz, CDCl3) δ: 173.8 (CO), 172.0 (CPh-N), 
151.2, 138.0, 131.3, 125.8 and 125.1 (CPh), 74.6 (CH2OH), 67.3 (COCH2), 63.7, 61.5, 54.1 and 52.2 
(piperazine), 20.6 (CH3), 13.9 ppm (CH3); HPLC-MS: [A, 2%→95%], tR: 3.99 min (90%), MS (ES+, 
m/z) 278 [M+H]+; Anal. Calcd. for C15H23N3O2: C 64.96%, H 8.36%, found: C 65.09%, H 8.03%.
N-Hydroxymethyl-2-[4-(4-methoxyphenyl)piperazinyl]acetamide (3.7). 
Prepared from 1-(4-methoxyphenyl)piperazine (0.39 g, 
2.03 mmol) and 2-chloro-N-hydroxymethylacetamide (0.50 g, 
4.05 mmol) and K2CO3 (0.42 mg, 3.04 mmol) by following the 
general procedure. Flash column chromatography (EtOAc) 
provided 3.7 as a white solid (0.14 g, 24% yield); mp: 140–143ºC; 1H-NMR (400 MHz, CDCl3) δ: 
7.09–6.95 (m, 2H, HPh), 6.71–6.54 (m, 2H, HPh), 4.83 (s, 2H, CH2OH), 3.78–3.60 (m, 5H, COCH2
and OCH3), 3.14–3.05 (m, 4H, piperazine), 2.77–2.71 ppm (m, 4H, piperazine); 13C-NMR (101 
MHz, CDCl3) δ: 173.0 (CO), 152.4 (CPh-N), 143.6 (CPh-OCH3), 123.4, 122.1, 118.6 and 112.3 (CPh), 
65.7 (CH2OH), 63.2 (COCH2), 55.1 (OCH3), 54.3, 53.8, 51.8 and 51.2 ppm (piperazine); HPLC-MS: 
[A, 2%→95%], tR: 3.03 min (90%), MS (ES+, m/z) 280 [M+H]+; Anal. Calcd. for C14H21N3O3: C 
60.20%, H 7.58%, found: C 60.56%, H 7.25%.
General procedure for the synthesis of phenylpiperazinyl-acetamidomethyl 
chromenopyrazoles 3.83.11 
A solution of 3.3 (1 eq) in anhydrous THF (2-8 mL) was added dropwise to a precooled suspension 
of NaH (2.5-3 eq) in anhydrous THF (1-4 mL) under nitrogen atmosphere. The resulting mixture 
was stirred for 10 minutes at room temperature. The corresponding phenylpiperazinyl-acetamide (2
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eq) was added and the reaction mixture was refluxed at room temperature 12-72 h. The solvent was 
removed under vacuum and the crude was diluted in EtOAc, washed with water and extracted three 
times with EtOAc. The combined organic layers were dried over MgSO4 and the solvent was 
removed under vacuum. The residue was first purified by flash column chromatography (EtOAc as 
eluent) obtaining a mixture of the N1 and N2 regioisomers which was then purified by 
semipreparative HPLC.
1,4-Dihydro-7-methoxy-4,4-dimethyl-1-[2-(4-phenylpiperazinyl)acetamidomethyl]-
chromeno[4,3-c]pyrazole (3.8a) and 2,4-dihydro-7-methoxy-4,4-dimethyl-2-[2-(4-
phenylpiperazinyl)acetamidomethyl]-chromeno[4,3-c]pyrazole (3.8b).  
The products were prepared according to the above described procedure from 3.3 (95 mg, 0.41 
mmol) N-hydroxymethyl-2-(4-phenylpiperazinyl)acetamide 3.4 (0.21 g, 0.82 mmol) and NaH (24 mg, 
1.03 mmol). Flash column chromatography and subsequent semipreparative HPLC (conditions 
previously indicated) afforded the regioisomers 3.8a and 3.8b. Compound 3.8a was obtained as a 
white solid (25.0 mg, 13% yield); mp: 196–198ºC; 1H-NMR (500 MHz, CDCl3) δ: 8.02–7.97 (br t, J
= 6.3 Hz, 1H, NH), 7.76 (d, J = 8.7 Hz, 1H, 9-H), 7.26 (s, 1H, 3-H), 6.85–
6.74 (m, 2H, Hc and He), 6.55 (dd, J = 8.6, 2.6 Hz, 2H, Hb and Hf), 6.53–6.46 
(m, 2H, 8-H and Hd), 6.45 (d, J = 2.5 Hz, 1H, 6-H), 5.73 (d, J = 6.3 Hz, 2H, 
CH2NH), 3.71 (s, 3H, OCH3), 3.13–3.07 (m, 4H, piperazine), 3.03 (s, 2H, 
COCH2), 2.57–2.48 (m, 4H, piperazine), 1.52 ppm (s, 6H, OC(CH3)2); 13C-
NMR (126 MHz, CDCl3) δ: 170.2 (CO), 165.1 (7-C), 161.0 (5a-C), 154.3 
(Ca), 149.2(9b-C), 133.8 (Cc and Ce), 132.5 (3-C), 129.1 (9-C), 123.3 (3a-C), 
121.4 (Cb and Cf), 120.0 (Cd), 116.2 (9a-C), 107.8 (8-C), 103.85 (6-C), 76.73 
(OC(CH3)2), 61.3 (COCH2), 55.3 (OCH3), 54.32 (CH2NH), 53.4, 49.1 (piperazine), 28.24 ppm 
(OC(CH3)2); HPLC-MS: [A, 15%→40%], tR: 8.01 min (97%), MS (ES+, m/z) 462 [M+H]+; HRMS 
calcd for C26H31N5O3: 461.2426, found: 461.2433.
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Compound 3.8b was obtained as a white gummy solid (10.2 mg, 5% yield); 1H-NMR (500 MHz, 
CD3OD) δ: 8.44–8.40 (br s, 1H, NH), 7.51 (d, J = 8.5, 1H, 9-H), 
7.44 (s, 1H, 3-H), 7.15–7.04 (m, 2H, Hc and He), 6.82 (dd, J = 7.4, 
1.0 Hz, 2H, Hb and Hf), 6.72 (tt, J = 7.4, 1.0 Hz, 1H, Hd), 6.47 (dd, J
= 8.5, 2.4 Hz, 1H, 8-H), 6.39 (d, J = 2.4 Hz, 1H, 6-H), 5.40 (s, 2H, 
CH2NH), 3.69 (s, 3H, OCH3), 3.10-3.07 (m, 4H, piperazine), 3.02 
(s, 2H, COCH2), 2.55-2.49 (m, 4H, piperazine), 1.46 ppm (s, 6H, 
OC(CH3)2); 13C-NMR (126 MHz, CD3OD) δ: 173.7 (CO), 162.7 (7-
C), 156.1 (5a-C), 152.7 (Ca), 144.6 (9b-C), 130.0 (Cc and Ce), 126.6 (3-C), 123.9 (9-C), 122.4 (3a-C), 
121.1 (Cb and Cf), 117.5 (Cd), 111.5 (9a-C), 108.8 (8-C), 104.2 (6-C), 77.6 (OC(CH3)2), 62.1 (COCH2), 
55.8 (OCH3), 55.4 (CH2NH), 54.3, 54.2, 50.5, 50.4 (piperazine), 29.3 ppm (OC(CH3)2); HPLC-MS: 
[A, 15%→40%], tR: 7.71 min (95%), MS (ES+, m/z) 462 [M+H]+; HRMS calcd for C26H31N5O3: 
461.2426, found: 461.2421.
1,4-Dihydro-7-methoxy-1-{2-[4-(2-methoxyphenyl)piperazinyl)acetamidomethyl]}-4,4-
dimethylchromeno[4,3-c]pyrazole (3.9a) and 2,4-dihydro-7-methoxy-2-{2-[4-(2-
methoxyphenyl)piperazinyl]acetamidomethyl}-4,4-dimethylchromeno[4,3-c]pyrazole (3.9b). 
The products were prepared according to the above described procedure 
from 3.3 (50 mg, 0.21 mmol) N-hydroxymethyl-2-[4-(2-
methoxyphenyl)piperazinyl]acetamide 3.5 (0.12 g, 0.43 mmol) and NaH
(15 mg, 0.65 mmol). Flash column chromatography and subsequent 
semipreparative HPLC furnished the regioisomers 3.9a and 3.9b. 
Compound 3.9a was obtained as a white gummy solid (3.4 mg, 3% yield);
1H-NMR (500 MHz, CDCl3) δ: 7.35 (d, J = 8.1 Hz, 1H, 9-H), 7.16 (s, 1H, 
3-H), 6.71–6.59 (m, 4H, Hc, Hd, He and Hf), 6.42 (dd, J = 8.1, 2.4 Hz, 1H, 
8-H), 6.38 (d, J = 2.4 Hz, 1H, 6-H), 5.27 (s, 2H, CH2NH), 3.59 (s, 3H, OCH3), 3.54 (s, 3H, OCH3), 
3.29 (s, 2H, COCH2), 3.10–3.03 (m, 4H, piperazine), 2.98–2.86 (m, 4H, piperazine), 1.69 ppm (s, 
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6H, OC(CH3)2); 13C-NMR (126 MHz, CDCl3) δ: 175.0 (CO), 160.4 (7-C), 155.6 (5a-C), 155.1 (Ca), 
149.5 (Cb), 147.1 (9b-C), 130.2 (3-C), 127.5 (9-C), 124.9 (3a-C), 118.7, 116.9, 116.3, 113.3 (Cc, Cd, Ce
and Cf), 111.4 (9a-C), 106.8 (8-C), 104.2 (6-C), 75.8 (OC(CH3)2), 61.4 (COCH2), 55.9 (OCH3), 55.1 
(OCH3), 54.0 (CH2NH), 53.7, 51.3 (piperazine), 25.9 ppm (OC(CH3)2); HPLC-MS: [A, 15%→40%], 
tR: 7.35 min (93%), MS (ES+, m/z) 492 [M+H]+; HRMS calcd for C27H33N5O4: 491.2532, found: 
491.2528.
Compound 3.9b was obtained as a yellow oil (9.1 mg, 8% yield); 1H-
NMR (500 MHz, CDCl3) δ: 7.04 (d, J = 7.5 Hz, 1H, 9-H), 6.91 (s, 
1H, 3-H), 6.69–6.51 (m, 5H, 8-H, Hc, Hd, He and Hf), 6.42 (d, J = 
2.6 Hz, 1H, 6-H), 5.51 (s, 2H, CH2NH), 3.64 (s, 3H, OCH3), 3.59 (s, 
3H, OCH3), 3.16 (s, 2H, COCH2), 2.92–2.89 (m, 4H, piperazine), 
2.76–2.70 (m, 4H, piperazine), 1.54 ppm (s, 6H, OC(CH3)2); 13C-
NMR (126 MHz, CDCl3) δ: 173.2 (CO), 163.1 (7-C), 156.7 (5a-C), 
153.1 (Ca), 148.1 (Cb), 144.9 (9b-C), 132.6 (3-C), 126.1 (9-C), 125.6 (3a-C), 120.9, 118.2, 117.5, 114.0 
(Cc, Cd, Ce and Cf), 110.6 (9a-C), 109.4 (8-C), 106.0 (6-C), 75.3 (OC(CH3)2), 60.2 (COCH2), 56.8 
(OCH3), 56.1 (OCH3), 54.6 (CH2NH), 52.5, 50.7 (piperazine), 26.4 ppm (OC(CH3)2); HPLC-MS: [A, 
15%→40%], tR: 7.17 min (95%), MS (ES+, m/z) 492 [M+H]+; HRMS calcd for C27H33N5O4: 
491.2532, found: 491.2540.
1-{2-[4-(2,3-Dimethylphenyl)piperazinyl]acetamidomethyl}-1,4-dihydro-7-methoxy-4,4-
dimethylchromeno[4,3-c]pyrazole (3.10a) and 2-{2-[4-(2,3-
dimethylphenyl)piperazinyl]acetamidomethyl}-2,4-dihydro-7-methoxy-4,4-
dimethylchromeno[4,3-c]pyrazole (3.10b). 
The products were prepared according to the above described procedure from 3.3 (90 mg, 0.39 
mmol) N-hydroxymethyl-2-[4-(2,3-dimethylphenyl)piperazinyl]acetamide 3.6 (0.21 g, 0.78 mmol) 
and NaH (23 mg, 0.97 mmol). Flash column chromatography and subsequent semipreparative 
HPLC provided the regioisomers 3.10a and 3.10b. Compound 3.10a was obtained as a yellow oil 
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(3.5 mg, 2% yield); 1H-NMR (500 MHz, CDCl3) δ: 8.08–8.02 (bt, J = 6.4 Hz, 1H, NH), 7.76 (d, J = 
8.1 Hz, 1H, 9-H), 7.50 (s, 1H, 3-H), 6.94 (t, J = 7.5 Hz, 1H, He), 6.85 (d, J = 7.5 Hz, 1H, Hd or Hf), 
6.80 (d, J = 7.7 Hz, 1H, Hd or Hf), 6.61 (dd, J = 8.1, 2.6 Hz, 1H, 8-H), 
6.48 (d, J = 2.6 Hz, 1H, H-6), 5.61 (d, J = 6.4 Hz, 2H, CH2NH), 3.84 (s, 
3H, OCH3), 3.08 (s, 2H, COCH2), 2.77–2.69 (m, 4H, piperazine), 2.64–
2.59 (m, 4H, piperazine), 2.31 (s, 3H, CH3), 2.27 (s, 3H, CH3), 1.48 ppm 
(s, 6H, OC(CH3)2); 13C-NMR (126 MHz, CDCl3) δ: 169.8 (CO), 162.4 (7-
C), 156.0 (5a-C), 151.3 (Ca), 144.2 (9b-C), 140.3 (Cc), 132.5 (3-C), 126.1 
(9-C), 125.0 (Ce), 123.9 (Cd), 123.1 (Cb), 121.8 (3a-C), 117.2 (Cf), 109.8 
(9a-C), 108.4 (8-C), 104.9 (6-C), 75.7 (OC(CH3)2), 61.3 (COCH2), 56.0 
(OCH3), 54.7 (CH2NH), 53.3, 51.9 (piperazine), 28.8 (OC(CH3)2), 19.7 (CH3), 14.1 ppm (CH3); 
HPLC-MS: [A, 15%→40%], tR: 9.47 min (92%), MS (ES+, m/z) 490 [M+H]+; HRMS calcd for 
C28H35N5O3: 489.2739, found: 489.2746.
Compound 3.10b was obtained as a white solid (8.3 mg, 4% yield); mp: 199–201ºC; 1H-NMR (500 
MHz, CDCl3) δ: 8.22–8.17 (br t, J = 6.9 Hz, 1H, NH), 7.62 (d, J = 8.5 Hz, 1H, 9-H), 7.42 (s, 1H, 3-
H), 7.08 (t, J = 7.7 Hz, 1H, He), 6.91 (d, J = 7.7 Hz, 1H, Hd or Hf), 
6.87 (d, J = 7.7 Hz, 1H, Hd or Hf), 6.57 (dd, J = 8.5, 2.5 Hz, 1H, 8-
H), 6.51 (d, J = 2.5 Hz, 1H, H-6), 5.54 (d, J = 6.9 Hz, 2H, CH2NH), 
3.79 (s, 3H, OCH3), 3.11 (s, 2H, COCH2), 2.87 (t, J = 4.8 Hz, 4H, 
piperazine), 2.63 (t, J = 4.8 Hz, 4H, piperazine), 2.25 (s, 3H, CH3), 
2.18 (s, 3H, CH3), 1.58 ppm (s, 6H, OC(CH3)2); 13C-NMR (126 
MHz, CDCl3) δ: 171.5 (CO), 161.0 (7-C), 154.6 (5a-C), 151.1 (Ca), 
143.5 (9b-C), 138.0 (Cc), 131.2 (3-C), 125.8 (9-C), 125.2 (Ce), 124.7 (Cd), 122.8(Cb), 121.5 (3a-C), 
116.6 (Cf), 110.4 (9a-C), 108.0 (8-C), 103.0 (6-C), 76.5 (OC(CH3)2), 61.4 (COCH2), 55.3 (OCH3), 54.2 
(CH2NH), 53.9, 52.0 (piperazine), 29.1 (OC(CH3)2), 20.6 (CH3), 13.8 ppm (CH3); HPLC-MS: [A, 
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15%→40%], tR: 9.11 min (95%), MS (ES+, m/z) 490 [M+H]+; HRMS calcd for C28H35N5O3: 
489.2739, found: 489.2750.
1,4-Dihydro-7-methoxy-1-{2-[4-(4-methoxyphenyl)piperazinyl]acetamidomethyl}-4,4-
dimethylchromeno[4,3-c]pyrazole (3.11).  
The compound was prepared according to the above described procedure from 3.3 (52 mg, 0.22 
mmol) N-(hydroxymethyl)-2-(4-(4-methoxyphenyl)piperazinyl)acetamide 3.7 (0.13 g, 0.45 mmol) 
and NaH (13 mg, 0.56 mmol). Flash column chromatography furnished 
3.11 as a yellow oil (15 mg, 14% yield); 1H-NMR (500 MHz, CDCl3) δ: 
7.50–7.48 (br t, J = 5.1 Hz, 1H, NH), 6.81–6.76 (m, 4H, 9-H, 3-H, Hc and 
He), 6.76–6.68 (m, 2H, Hb and Hf), 6.47 (dd, J = 8.5, 2.5 Hz, 1H, 8-H), 
6.39 (d, J = 2.5 Hz, 1H, 6-H), 5.39 (d, J = 5.1 Hz, 2H, CH2NH), 3.68 (s, 
3H, OCH3), 3.63 (s, 3H, OCH3), 3.01 (s, 2H, COCH2), 2.97–2.94 (m, 4H, 
piperazine), 2.55–2.47 (m, 4H, piperazine), 1.46 ppm (s, 6H, OC(CH3)2); 
13C-NMR (126 MHz, CDCl3) δ: 172.2 (CO), 161.2 (7-C), 154.6 (5a-C), 154.2 (Ca), 145.2 (9b-C), 143.2 
(Cd), 125.1 (3-C), 122.4 (9-C), 120.9 (3a-C), 118.7 (Cb and Cf), 113.8 (Cc and Ce),  110.0 (9a-C), 107.3 
(8-C), 102.7 (6-C), 76.1 (OC(CH3)2), 60.6 (COCH2), 54.4 (OCH3), 54.3 (OCH3), 53.9 (CH2NH), 52.9, 
50.4 (piperazine), 27.8 ppm (OC(CH3)2); HPLC-MS: [A, 15%→40%], tR: 7.35 min (93%), MS (ES+, 
m/z) 492 [M+H]+; HRMS calcd for C27H33N5O4: 491.2532, found: 491.2524.
1-(2-Bromoethyl)-1,4-dihydro-7-methoxy-4,4-dimethylchromeno[4,3-c]pyrazole (3.12a) and 
2-(2-bromoethyl)-2,4-dihydro-7-methoxy-4,4-dimethylchromeno[4,3-c]pyrazole (3.12b). 
A solution of 3.3 (0.23 g, 0.99 mmol) in anhydrous THF (8 mL) was added dropwise to a precooled 
suspension of sodium hydride (28 mg, 1.19 mmol) in anhydrous THF (1 mL) under nitrogen 
atmosphere. The resulting mixture was stirred for 10 minutes at room temperature. 1,2-
Dibromoethane (0.42 mL, 4.97 mmol) was added and the reaction mixture was refluxed for 4 h. The 
solvent was removed under vacuum and the crude was diluted in EtOAc, washed with water and 
extracted three times with EtOAc. The combined organic layers were dried over MgSO4 and the 
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solvent was removed under vacuum. Column chromatography on silica gel (hexane/EtOAc, 1:1) 
afforded the two isomers 3.12a and 3.12b. Compound 3.12a was obtained as a yellow oil (75 mg, 
20%); 1H NMR (400 MHz, CDCl3) δ: 7.34 (d, J = 7.9 Hz, 1H, 9-H), 7.22 (s, 1H, 3-H), 6.50 (dd, J = 
7.9, 2.4 Hz, 1H, 8-H), 6.43 (d, J = 2.4 Hz, 1H, 6-H), 4.61 (t, J = 6.6 Hz, 2H, 1´-H), 4.09 (t, J = 6.6 
Hz, 2H, 2´-H), 3.92 (s, 3H, OCH3), 1.45 ppm (s, 6H, OC(CH3)2); 13C-NMR 
(101 MHz, CDCl3) δ: 161.7 (7-C), 155.3 (5a-C), 144.7 (9b-C), 133.4 (3-C),
123.9 (9-C), 121.9 (3a -C), 108.5 (8-C), 103.4 (6-C), 101.8 (9a-C), 76.7 
(OC(CH3)2), 59.3 (OCH3), 55.8 (1´-C), 29.6 (OC(CH3)2); 28.5 ppm (2´-C); 
HPLC-MS: [A, 30→95%], tR: 4.66 min, (94%); MS (ES+, m/z) 337 [M + H]+; HRMS calcd for 
C15H17BrN2O2: 336.0473, found: 336.0478.
12b was obtained as a yellow oil (0.19 g, 51%); 1H-NMR (400 MHz, CDCl3) δ: 7.68 (d, J = 8.4 Hz, 
1H, 9-H), 7.32 (s, 1H, 3-H), 6.63 (dd, J = 8.4, 2.5 Hz, 1H, 8-H), 6.58 (d, J = 2.5 Hz, 1H, 6-H), 4.54 
(t, J = 6.5 Hz, 2H, 1´-H), 3.86 (s, 3H, OCH3), 3.80 (t, J = 6.5 Hz, 2H, 2´-H), 
1.66 ppm (s, 6H, OC(CH3)2). 13C-NMR (101 MHz, CDCl3) δ: 161.1 (7-C), 
154.7 (5a-C), 143.8 (9b-C), 124.6 (3-C), 123.2 (9-C), 120.9 (3a -C), 110.9 (8-C), 
108.1 (6-C), 103.2 (9a-C), 76.6 (OC(CH3)2), 55.5 (OCH3), 53.8 (1´-C), 30.7 (2´-
C), 29.4 ppm (OC(CH3)2); HPLC-MS: [A, 30→95%], tR: 4.54 min, (96%); MS (ES+, m/z) 337 [M + 
H]+; HRMS calcd for C15H17BrN2O2: 336.0473, found: 336.0470.
General procedure for the synthesis of acylpiperazinyl chromenopyrazoles 3.133.19 
A mixture of the corresponding acyl piperazine (1 eq) and K2CO3 (3 eq) was stirred 10 minutes at 
room temperature in THF (1-3 mL). Then, the corresponding 2-bromoethyl-dihydro-7-methoxy-
4,4-dimethyl-chromeno[4,3-c]pyrazole 3.12a or 3.12b (1 eq) dissolved in THF (1-3 mL) was added. 
The resulting mixture was refluxed overnight. The solvent was evaporated, the crude was dissolved 
in EtOAc, washed with water and extracted three times with EtOAc. The organic layers were 
combined and dried over MgSO4, filtered and the solvent was evaporated under reduced pressure. 
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The residue was purified by flash column chromatography performed on a Biotage Isolera One. The 
chromatography eluents and yields are indicated below for each reaction.
1-{2-[4-(2-Furoyl)piperazinyl]ethyl}-1,4-dihydro-7-methoxy-4,4-dimethylchromeno[4,3-c] 
pyrazole (3.13a). 
Prepared from 3.12a (22 mg, 0.06 mmol), 1-(2-furoyl)piperazine (12 mg, 0.06 mmol) and K2CO3 (27 
mg, 0.19 mmol) by following the general procedure. Flash column 
chromatography (hexane/EtOAc, 1:1) afforded 3.13a as a white oil (7 mg, 
25% yield); 1H-NMR (400 MHz, CDCl3) δ: 7.57 (d, J = 8.5 Hz, 1H, 9-H), 
7.33–7.28 (m, 1H, Hc), 7.11 (s, 1H, 3-H), 6.96–6.92 (m, 1H, He), 6.60 (dd, J
= 8.5, 2.5 Hz, 1H, 8-H), 6.53 (d, J = 2.5 Hz, 1H, 6-H), 6.39–6.36 (m, 1H, 
Hd), 4.22 (t, J = 6.6 Hz, 2H, 1´-H), 3.78 (s, 3H, OCH3), 3.39–3.21 (m, 4H, 
piperazine), 2.83 (t, J = 6.6 Hz, 2H, 2´-H), 2.72-2.64 (m, 4H, piperazine), 
1.52 ppm (s, 6H, OC(CH3)2); 13C-NMR (101 MHz, CDCl3) δ: 162.0 (CO), 155.6 (7-C), 153.1 (5a-C), 
145.3 (9b-C), 142.6 (Ca), 141.8 (Cc), 124.1 (3-C), 123.2 (9-C), 121.3 (3a-C), 117.0, 112.2 (Cd and Ce), 
109.2 (9a -C), 108.4 (8-C), 103.2 (6-C), 76.1 (OC(CH3)2), 57.5 (OCH3), 55.1 (2´-C), 54.1, 50.7 
(piperazine), 49.5 (1´-C), 28.9 ppm (OC(CH3)2); HPLC-MS: [A, 15%→95%], tR: 2.88 min (94%), MS 
(ES+, m/z) 437 [M+H]+; HRMS calcd for C24H28N4O4: 436.2110, found: 436.2107.
2-{2-[4-(2-Furoyl)piperazinyl]ethyl}-2,4-dihydro-7-methoxy-4,4-dimethylchromeno[4,3-c]pyrazole 
(3.13b). 
Prepared from 3.12b (20 mg, 0.06 mmol), 1-(2-furoyl)piperazine (11 
mg, 0.06 mmol) and K2CO3 (25 mg, 0.18 mmol) by following the 
general procedure. Flash column chromatography (EtOAc/MeOH, 
98:2) afforded 3.13b as a pale yellow oil (6 mg, 24 % yield); 1H-
NMR (400 MHz, CDCl3) δ: 7.61 (d, J = 8.4 Hz, 1H, 9-H), 7.48–7.45 
(m, 1H, Hc), 7.18 (s, 1H, 3-H), 7.00–6.94 (m, 1H, He), 6.54 (dd, J = 
8.4, 2.5 Hz, 1H, 8-H), 6.50 (d, J = 2.5 Hz, 1H, 6-H), 6.46–6.44 (m, 1H, Hd), 4.23 (t, J = 6.5 Hz, 2H, 
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1´-H), 3.76–3.62 (br s, 7H, OCH3, piperazine), 2.86 (t, J = 6.5 Hz, 2H, 2´-H), 2.70–2.66 (m, 4H, 
piperazine), 1.58 ppm (s, 6H, OC(CH3)2); 13C-NMR (101 MHz, CDCl3) δ: 160.9 (CO), 159.3 (7-C), 
154.5 (5a-C), 148.0 (9b-C), 143.9 (Ca), 142.9 (Cc), 124.2 (3-C), 123.1 (9-C), 121.0 (3a-C), 116.7, 111.5 
(Cd and Ce), 111.2 (9a -C), 108.0 (8-C), 103.2 (6-C), 76.7 (OC(CH3)2), 58.0 (OCH3), 55.5 (2´-C), 53.6, 
51.3 (piperazine), 50.4 (1´-C), 29.5 ppm (OC(CH3)2); HPLC-MS: [A, 15%→95%], tR: 2.91 min 
(99%), MS (ES+, m/z) 437 [M+H]+; HRMS calcd for C24H28N4O4: 436.2110, found: 436.2121.
1-[2-(4-Benzoylpiperazinyl)ethyl]-1,4-dihydro-7-methoxy-4,4-dimethylchromeno[4,3-c]pyrazole 
(3.14a). 
Prepared from 3.12a (20 mg, 0.06 mmol), 1-benzoylpiperazine (11 mg, 0.06 mmol) and K2CO3 (25 
mg, 0.18 mmol) by following the general procedure. Flash column 
chromatography (hexane/EtOAc, 1:1) yielded 3.14a as a yellow gummy solid 
(8 mg, 30 % yield); 1H-RMN (400 MHz, CDCl3) δ: 7.55 (d, J = 8.4 Hz, 1H, 
9-H), 7.38–7.29 (m, 5H, Hb, Hc, Hd, He and Hf), 7.13 (s, 1H, 3-H), 6.49 (dd, J
= 8.4, 2.5 Hz, 1H, 8-H), 6.44 (d, J = 2.5 Hz, 1H, 6-H), 4.41 (t, J = 6.7 Hz, 
2H, 1´-H), 3.73 (s, 3H, OCH3), 3.41–3.26 (m, 4H, piperazine), 2.81 (t, J = 6.7 
Hz, 2H, 2´-H), 2.59–2.37 (m, 4H, piperazine), 1.52 ppm (s, 6H, OC(CH3)2); 
13C-NMR (101 MHz, CDCl3) δ: 170.3 (CO), 165.1 (7-C), 160.7 (5a-C), 154.3 (9b-C), 130.2 (Ca), 129.7 
(Cd), 128.5, 127.1 (Cb, Cc, , Ce and Cf), 124.4 (3-C), 123.9 (9-C), 122.8 (3a-C), 107.9 (9a -C), 107.6 (8-
C), 103.0 (6-C), 76.4 (OC(CH3)2), 57.8 (OCH3), 55.4 (2´-C), 55.3, 53.6 (piperazine), 50.1 (1´-C), 29.2.
ppm (OC(CH3)2); HPLC-MS: [A, 15%→95%], tR: 3.05 min (97%), MS (ES+, m/z) 447 [M+H]+; 
HRMS calcd for C26H30N4O3: 446.2317, found: 446.2324.
2-[2-(4-Benzoyl-piperazinyl)ethyl]-2,4-dihydro-7-methoxy-4,4-dimethylchromeno[4,3-c]pyrazole 
(3.14b). 
Prepared from 3.12b (28 mg, 0.08 mmol), 1-benzoylpiperazine (16 mg, 0.08 mmol) and K2CO3 (34 
mg, 0.25 mmol) by following the general procedure. Flash column chromatography 
(EtOAc/MeOH, 95:5) furnished 3.14b as a yellow solid (30 mg, 81 % yield); mp: 161–162ºC; 1H-
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NMR (400 MHz, CDCl3) δ: 7.62 (d, J = 8.4 Hz, 1H, 9-H), 7.46–7.32 (m, 5H, Hb, Hc, Hd, He and Hf), 
7.17 (s, 1H, 3-H), 6.55 (dd, J = 8.4, 2.5 Hz, 1H, 8-H), 6.50 (d, J = 
2.5 Hz, 1H, 6-H), 4.23 (t, J = 6.6 Hz, 2H, 1´-H), 3.79 (s, 3H, 
OCH3), 3.41–3.20 (m, 4H, piperazine), 2.87 (t, J = 6.6 Hz, 2H, 2´-
H), 2.73–2.60 (m, 4H, piperazine), 1.58 ppm (s, 6H, OC(CH3)2); 
13C-NMR (101 MHz, CDCl3) δ: 170.4 (CO), 160.8 (7-C), 154.5 
(5a-C), 142.9 (9b-C), 135.8 (Ca), 129.9 (Cd), 128.6, 127.1 (Cb, Cc, 
Ce and Cf), 124.1 (3-C), 123.0 (9-C), 120.9 (3a-C), 111.1 (9a -C), 107.9 (8-C), 103.1 (6-C), 76.6 
(OC(CH3)2), 57.9 (OCH3), 55.4 (2´-C), 53.7, 50.2 (piperazine), 47.9 (1´-C), 29.4 ppm (OC(CH3)2);
HPLC-MS: [A, 15%→95%], tR: 3.08 min (100%), MS (ES+, m/z) 447 [M+H]+; HRMS calcd for 
C26H30N4O3: 446.2317, found: 446.2311. 
1,4-Dihydro-7-methoxy-4,4-dimethyl-1-{2-[4-(2-thenoyl)piperazinyl]ethyl}-chromeno[4,3-
c]pyrazole (3.15a). 
Prepared from 3.12a (20 mg, 0.06 mmol), 1-(2-thenoyl)piperazine trifluoroacetate (18 mg, 0.06 
mmol) and K2CO3 (25 mg, 0.18 mmol) by following the general procedure. 
Flash column chromatography (hexane/EtOAc, 1:9) yielded 3.15a as a yellow 
gummy solid (6 mg, 23 % yield); 1H-NMR (400 MHz, CDCl3) δ: 7.49 (d, J = 
8.8 Hz, 1H, 9-H), 7.44 (dd, J = 5.0, 1.2 Hz, 1H, Hc), 7.28 (s, 1H, 3-H), 7.23-
7.21 (m, 1H, He), 7.03 (dd, J = 5.0, 3.6 Hz, 1H, Hd), 6.61–6.58 (m, 1H, 8-H), 
6.57 (d, J = 2.6 Hz, 1H, 6-H), 4.54 (t, J = 7.1 Hz, 2H, 1´-H), 3.82 (s, 3H, 
OCH3), 3.77–3.64 (m, 4H, piperazine), 2.93–2.87 (m, 2H, 2´-H), 2.67–2.43 (m, 4H, piperazine), 1.58 
ppm (s, 6H, OC(CH3)2); 13C-NMR (101 MHz, CDCl3) δ: 163.7 (CO), 161.0 (7-C), 154.6 (5a-C), 150.3 
(9b-C), 137.1 (Ca), 132.8, 129.1, 128.9 (Cc, Cd and Ce), 126.9 (3-C), 122.7 (9-C), 121.4 (3a-C), 109.1 
(9a -C), 107.9 (8-C), 104.1 (6-C), 76.4 (OC(CH3)2), 57.4 (OCH3), 55.6 (2´-C), 53.6, 51.3 (piperazine), 
49.5 (1´-C), 28.6 ppm (OC(CH3)2); HPLC-MS: [A, 15%→95%], tR: 3.22 min (97%), MS (ES+, m/z) 
453 [M+H]+; HRMS calcd for C24H28N4O3S: 452.1882, found: 452.1891.
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2,4-Dihydro-7-methoxy-4,4-dimethyl-2-{2-[4-(2-thenoyl)piperazinyl]ethyl}-chromeno[4,3-
c]pyrazole (3.15b). 
Prepared from 3.12b (30 mg, 0.09 mmol), 1-(2-thenoyl)piperazine trifluoroacetate (28 mg, 0.09 
mmol) and K2CO3 (37 mg, 0.27 mmol) by following the general 
procedure. Flash column chromatography (EtOAc/MeOH, 98:2) 
afforded 3.15b as a yellow solid (22 mg, 55 % yield); mp: 163–165ºC;
1H-NMR (400 MHz, CDCl3) δ: 7.62 (d, J = 8.4 Hz, 1H, 9-H), 7.44 (dd, 
J = 5.0, 1.2 Hz, 1H, Hc), 7.25–7.23 (m, 1H, He), 7.20 (s, 1H, 3-H), 7.03 
(dd, J = 5.0, 3.6 Hz, 1H, Hd), 6.55 (dd, J = 8.4, 2.5 Hz, 1H, 8-H), 6.51 
(d, J = 2.5 Hz, 1H, 6-H), 4.27 (t, J = 6.5 Hz, 2H, 1´-H), 3.79 (s, 3H, OCH3), 3.78–3.72 (m, 4H, 
piperazine), 3.01–2.91 (m, 2H, 2´-H), 2.63–2.43 (m, 4H, piperazine), 1.59 ppm (s, 6H, OC(CH3)2); 
13C-NMR (101 MHz, CDCl3) δ: 163.8 (CO), 161.0 (7-C), 154.6 (5a-C), 143.1 (9b-C), 137.0 (Ca), 
129.1, 128.9, 126.9 (Cc, Cd and Ce), 124.3 (3-C), 123.1 (9-C), 121.0 (3a-C), 111.1 (9a -C), 108.0 (8-C), 
103.2 (6-C), 76.7 (OC(CH3)2), 57.9 (OCH3), 55.5 (2´-C), 53.5, 50.2 (piperazine), 46.1 (1´-C), 29.5 
ppm (OC(CH3)2); HPLC-MS: [A, 15%→95%], tR: 3.03 min (100%), MS (ES+, m/z) 453 [M+H]+; 
HRMS calcd for C24H28N4O3S: 452.1882, found: 452.1889.
2,4-Dihydro-7-methoxy-4,4-dimethyl-2-[2-(4-phenoxyacetylpiperazinyl)ethyl]-chromeno[4,3-
c]pyrazole (3.16). 
Prepared from 3.12b (30 mg, 0.09 mmol), 1-(phenoxyacetyl)piperazine (20 mg, 0.09 mmol) and 
K2CO3 (37 mg, 0.27 mmol) by following the general procedure. 
Flash column chromatography (EtOAc/MeOH, 95:5) afforded 
3.16 as an orange solid (16 mg, 38 % yield); mp: 177–179ºC;
1H-NMR (500 MHz, CD3OD) δ: 7.56 (d, J = 8.5 Hz, 1H, 9-H), 
7.52 (s, 1H, 3-H), 7.31–7.21 (m, 2H, Hc and He), 7.00–6.90 (m, 
3H, Hb, Hd and Hf), 6.56 (dd, J = 8.5, 2.5 Hz, 1H, 8-H), 6.48 (d, J = 2.5 Hz, 1H, 6-H), 4.76 (s, 2H, 
OCH2), 4.26 (t, J = 6.4 Hz, 2H, 1´-H), 3.77 (s, 3H, OCH3), 3.63-3.50 (m, 4H, piperazine), 2.84 (t, J = 
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6.4 Hz, 2H, 2´-H), 2.56-2.46 (m, 4H, piperazine), 1.56 ppm (s, 6H, OC(CH3)2); 13C-NMR (126 MHz, 
CD3OD) δ: 167.4 (CO), 161.1 (7-C), 158.0 (Ca), 154.5 (5a-C), 142.5 (9b-C), 129.1 (Cc and Ce), 125.4 
(3-C), 122.3 (9-C), 121.1 (Cd), 120.5 (9-C), 114.3 (Cb and Cf), 110.4 (9a-C), 107.2 (8-C), 102.8 (6-C), 
76.2 (OC(CH3)2), 66.1 (OCH2), 57.2 (OCH3), 54.3 (2´-C), 52.8, 52.3 (piperazine), 49.1 (1´-C), 44.7, 
43.7 (piperazine), 28.0 ppm (OC(CH3)2); HPLC-MS: [A, 15%→95%], tR: 3.24 min (100%), MS (ES+, 
m/z) 477 [M+H]+; HRMS calcd for C27H32N4O4: 476.2423, found: 476.2427.
2,4-Dihydro-7-methoxy-4,4-dimethyl-2-{2-[4-(2-tetrahydrofuroyl)piperazinyl]ethyl}-chromeno[4,3-
c]pyrazole (3.17). 
Prepared from 3.12b (30 mg, 0.09 mmol), 1-(2-tetrahydrofuroyl)piperazine (16 mg, 0.09 mmol) and 
K2CO3 (37 mg, 0.27 mmol) by following the general procedure. Flash column chromatography 
(EtOAc/MeOH, 98:2) furnished 3.17 as a yellow solid (14 mg, 36 % yield); mp: 158–160ºC; 1H-
NMR (500 MHz, CD3OD) δ: 7.46 (d, J = 8.5 Hz, 1H, 9-H), 7.43 (s, 
1H, 3-H), 6.46 (dd, J = 8.5, 2.5 Hz, 1H, 8-H), 6.38 (d, J = 2.5 Hz, 1H, 
6-H), 4.67–4.54 (m, 1H, Ha), 4.17 (t, J = 6.5 Hz, 2H, 1´-H), 3.83–3.81
(m, 1H, Hc), 3.76–3.70 (m, 1H, Hc´), 3.68 (s, 3H, OCH3), 3.55–3.39 
(m, 4H, piperazine), 2.76 (t, J = 6.5 Hz, 2H, 2´-H), 2.46–2.33 (m, 4H, 
piperazine), 2.12–1.99 (m, 1H, He), 1.95–1.86 (m, 1H, He´), 1.85–1.75 (m, 2H, Hd and Hd´), 1.47 ppm 
(s, 6H, OC(CH3)2); 13C-NMR (126 MHz, CD3OD) δ: 171.3 (CO), 161.1 (7-C), 154.5 (5a-C), 142.5 
(9b-C), 125.4 (3-C), 122.3 (9-C), 120.5 (3a-C), 110.4 (9a-C), 107.2 (8-C), 102.8 (6-C), 76.2 (Ca), 75.2 
(OC(CH3)2), 68.7 (Cc), 57.2 (OCH3), 54.3 (2´-C), 52.9, 52.3 (piperazine), 47.5 (1´-C), 44.9, 43.7 
(piperazine), 28.8 (Ce), 28.0 (OC(CH3)2), 25.1 ppm (Cd); HPLC-MS: [A, 15%→95%], tR: 2.98 min 
(95%), MS (ES+, m/z) 441 [M+H]+; HRMS calcd for C24H32N4O4: 440.2423, found: 440.2436.
2-[2-(4-Cyclohexylcarbonylpiperazinyl)ethyl]-2,4-dihydro-7-methoxy-4,4-
dimethylchromeno[4,3-c]pyrazole (3.18). 
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 Prepared from 3.12b (30 mg, 0.09 mmol), 1-(cyclohexylcarbonyl)piperazine (17 mg, 0.09 mmol) and 
K2CO3 (37 mg, 0.27 mmol) by following the general procedure. Flash column chromatography 
(EtOAc/MeOH, 95:5) yielded 3.18 as a yellow solid (25 mg, 62 % 
yield); mp: 151–152ºC; 1H-NMR (400 MHz, CDCl3) δ: 7.63 (d, J = 8.5 
Hz, 1H, 9-H), 7.18 (s, 1H, 3-H), 6.56 (dd, J = 8.5, 2.5 Hz, 1H, 8-H), 
6.51 (d, J = 2.4 Hz, 1H, 6-H), 4.23 (t, J = 6.6 Hz, 2H, 1´-H), 3.79 (s, 
3H, OCH3), 3.66–3.39 (m, 4H, piperazine), 2.85 (t, J = 6.6 Hz, 2H, 2´-
H), 2.54–2.35 (m, 4H, piperazine), 1.82–1.75 (m, 1H, Ha), 1.73–1.61 
(m, 4H, Hb and Hf), 1.59 (s, 6H, OC(CH3)2), 1.57–1.42 ppm (m, 6H, Hc, Hd and He); 13C-NMR (101 
MHz, CDCl3) δ: 174.8 (CO), 160.9 (7-C), 154.6 (5a-C), 143.0 (9b-C), 124.2 (3-C), 123.1 (9-C), 121.0 
(3a-C), 111.2 (9a -C), 108.0 (8-C), 103.2 (6-C), 76.7 (OC(CH3)2), 58.0 (OCH3), 55.5 (2´-C), 53.2, 50.3 
(piperazine), 45.6 (1´-C), 41.7 (Ca), 30.6 (Cb and Cf), 29.6 (OC(CH3)2), 26.1 ppm (Cc, Cd and Ce); 
HPLC-MS: [A, 15%→95%], tR: 3.19 min (100%), MS (ES+, m/z) 453 [M+H]+; HRMS calcd for 
C26H36N4O3: 452.2787, found: 452.2773. 
2,4-Dihydro-7-methoxy-4,4-dimethyl-2-[2-(4-pivaloyl-piperazinyl)ethyl]-chromeno[4,3-
c]pyrazole (3.19). 
 Prepared from 3.12b (20 mg, 0.06 mmol), 1-(pivaloyl)piperazine (10 mg, 0.09 mmol) and K2CO3 (25 
mg, 0.18 mmol) by following the general procedure. Flash column 
chromatography (EtOAc/MeOH, 95:5) gave 3.19 as a yellow gummy 
solid (8 mg, 32 % yield); 1H-NMR (400 MHz, CDCl3) δ: 7.62 (d, J = 
8.4 Hz, 1H, 9-H), 7.18 (s, 1H, 3-H), 6.55 (dd, J = 8.4, 2.5 Hz, 1H, 8-
H), 6.51 (d, J = 2.5 Hz, 1H, 6-H), 4.23 (t, J = 6.6 Hz, 2H, 1´-H), 3.79 
(s, 3H, OCH3), 3.63 (t, J = 5.0 Hz, 4H, piperazine), 2.84 (t, J = 6.6 Hz, 
2H, 2´-H), 2.46 (t, J = 5.0 Hz, 4H, piperazine), 1.59 (s, 6H, OC(CH3)2), 1.26 ppm (s, 9H, C(CH3)3); 
13C-NMR (101 MHz, CDCl3) δ: 176.5 (CO), 160.9 (7-C), 154.6 (5a-C), 142.9 (9b-C), 124.2 (3-C), 
123.1 (9-C), 121.0 (3a-C), 111.2 (9a -C), 108.0 (8-C), 103.2 (6-C), 76.7 (OC(CH3)2), 58.0 (OCH3), 
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55.5 (2´-C), 53.6, 50.2 (piperazine), 45.3 (1´-C), 38.8 (C(CH3)3), 29.5 (OC(CH3)2), 28.6 ppm 
(C(CH3)3); HPLC-MS: [A, 15%→95%], tR: 2.99 min (99%), MS (ES+, m/z) 427 [M+H]+; HRMS 
calcd for C24H34N4O3: 426.2630, found: 426.2618.
Conformational analysis and electrostatic potential map calculation. Global minimum energy 
analysis of the compounds was performed using ab initio Hartree-Fock (HF) calculations at the 6-
31G* level, within the Spartan ’08 (Wave function, Inc., Irvine, CA). A conformational search was 
next implemented using Molecular Mechanics (Monte Carlo method). Local energy minima was 
identified by rotation of a subject torsion angle through 360 in 60 increments (6-fold search), 
followed by HF 6-31G* energy minimization of each rotamer generated. The electrostatic potential 
of the global minimum energy conformer was calculated using the Hatree-Fock method at the 6-
31G* level of theory and was mapped on the 0.002 isodensity surface of each molecule. The surface 
was color-coded according to the potential, with electron rich regions colored red and electron poor 
regions colored blue. 
In silico ADME calculations.  A set of 34 physico-chemical descriptors was computed using 
QikProp version 3.5 integrated in Maestro (Schrödinger, LLC, New York, USA). The QikProp 
descriptors are shown in table 1. The 3D conformations used in the calculation of QikProp
descriptors were generated using the program Spartan ´08 (Wave function, Inc., Irvine CA) as 
follows: the structure of each molecule was built from the fragment library available in the program. 
Then, ab initio energy minimizations of each structure at the Hartree-Fock 6-31G* level were 
performed. A conformational search was next implemented using Molecular Mechanics (Monte 
Carlo method) followed by a minimization of the energy of each conformer calculated at the 
Hartree-Fock 6-31G* level. The global minimum energy conformer of each compound was used as 
input for ADME studies with QikProp.
Pharmacological assays. 
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Cannabinoid binding experiments. Membranes from transfected cells with human CB1 or CB2
expressed cannabinoid receptors (RBHCB1M400UA and RBXCB2M400UA) were supplied by 
Perkin-Elmer Life and Analytical Sciences (Boston, MA). The protein concentration for the CB1R 
membranes was 8.0 mg/mL, whereas for the CB2R membranes was 4.0 mg/mL or 3.6 mg/mL 
depending on the batch. The commercial membranes were diluted (approximatively 1:20) with the 
binding buffer (50 mM TrisCl, 5 mM MgCl2.H2O, 2.5 mM EDTA, 0.5 mg/mL BSA and pH = 7.4 
for CB1 binding; 50 mM TrisCl, 5 mM MgCl2.H2O, 2.5 mM EGTA, 1 mg/mL BSA and pH = 7.5 
for CB2 binding). The final membrane protein concentration was 0.4 mg/mL of incubation volume 
and 0.2 mg/mL of incubation volume for the CB1R and the CB2R assays, respectively. The 
radioligand used was [3H]-CP55940 (PerkinElmer) at a concentration of membrane KD x 0.8 nm, 
and the final volume was 200 µL for CB1 binding and was 600 µL for CB2R binding. 96-Well plates 
and the tubes necessary for the experiment were previously siliconized with Sigmacote (Sigma). 
Membranes were resuspended in the corresponding buffer and were incubated with the radioligand 
and each compound (10-4-10-11 M) for 90 min at 30ºC. Non-specific binding was determined with 10 
µM WIN55212-2 and 100 % binding of the radioligand to the membrane was determined by its 
incubation with membrane without any compound. Filtration was performed by a Harvester® 
filtermate (Perkin-Elmer) with Filtermat A GF/C filters pretreated with polyethylenimine 0.05%. 
After filtering, the filter was washed nine times with binding buffer, dried and a melt-on scintillation 
sheet (MeltilexTM A, Perkin Elmer) was melted onto it. Then, radioactivity was quantified by a liquid 
scintillation spectrophotometer (Wallac MicroBeta Trilux, Perkin-Elmer). Competition binding data 
were analyzed by using GraphPad Prism program and Ki values are expressed as mean ± SD of at 
least three experiments performed in triplicate for each point.  
[35S]-GTPγS Binding analysis. [35S]-GTPγS binding analysis of compound 3.15b was performed 
using CB2R-containing membranes (HTS020M2, Eurofins Discovery Services). For this purpose, 
membranes (5 µg/well) were permeabilized by addition of saponin (Sigma-Aldrich), then mixed with 
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0.3 nM [35S]-GTPγS (Perkin-Elmer) and 10 μM GDP (Sigma-Aldrich) in 20 mM HEPES (Sigma-
Aldrich) buffer containing 100 mM NaCl (Merck) and 10 mM MgCl2 (Merck), at pH 7.4. 30 nM 
CP55,940 (Sigma-Aldrich) and increasing concentrations of compound 3.15b  (from 10-11 to 10-4 M) 
were added in a final volume of 100 μl and incubated for 30 min at 30 °C. The non-specific signal 
was measured with 10 μM GTPγS (Sigma-Aldrich). All 96-well plates and the tubes necessary for the 
experiment were previously silanized with Sigmacote (Sigma-Aldrich). The reaction was terminated 
by rapid vacuum filtration with a filtermate Harvester apparatus (Perkin-Elmer) through Filtermat A 
GF/C filters. The filters were rinsed nine times with washing buffer (10 mM sodium phosphate, pH 
7.4), and left to dry, and melt-on scintillation pads (Meltilex A, Perkin Elmer) were melted onto 
them. The bound radioactivity was quantified by liquid scintillation spectrophotometer (Wallac 
MicroBeta Trilux, PerkinElmer). Data were analyzed by nonlinear regression analysis of sigmoidal 
dose- response curves using GraphPad Prism 5.02 (GraphPad, San Diego, CA). EC50 and Emax
values are expressed as mean ± SEM of at least three independent experiments performed in 
triplicate.
GPR55 functionality: xCELLigence assays. Untransfected HEK293 and hGPR55-HEK29317
cells were maintained at 37 °C with 5% CO2 in -MEM supplemented with 10% FBS, 100 IU/mL 
Penicillin, 100ug/mL Streptomycin and 2 mM Glutamine. The xCELLigence RTCA instrument 
(ACEA Biosciences; San Diego, CA) is housed within the incubator at all times allowing all 
experiments to be performed at 37 °C with 5% CO2. E-plates (ACEA Biosciences; San Diego, CA) 
with microelectrodes integrated into the bottom of the wells to allow measurement of impedance at 
the electrode-cell interface, were used. In preparation for the experiment, cells were grown to 80% 
confluence in flasks, harvested by trypsinisation and then seeded into 96 well E-plates at a density of 
5x104 cells per well in duplicate. Before the addition of cells to the plate, a background reading was 
obtained by adding 100 µl of serum free media to each well in order to adjust for any discrepancies 
between wells (wells with a cell index reading above or below 0.01 were not used for experiments). 
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Cellular impedance was measured every 30 minutes overnight in order to monitor cell attachment 
and subsequent proliferation. The following day the cells were switched to serum free media (100 µl 
-MEM without FBS) for 5 hours, the time taken for cellular impedance to re-stabilise in HEK293 
and GPR55-HEK293 cells. All ligands were prepared in serum free media with a final concentration 
of DMSO at 0.1% (agonist studies) or 0.2% (antagonist studies). Compounds were tested at 
concentrations from 1 nM to 10 µM. The experiment is started immediately after the addition of test 
compounds to the wells (10 µl per well). To ensure consistency within the analysis, all experiments 
were normalised to the point directly before the addition of test compounds. Once normalised, the 
minimum cell index (dose dependant decrease found to be 5 minutes for all the compounds) was 
obtained and converted to a percentage decrease in cellular impedance. Dose response curves were 
generated using GraphPad PRISM software in order to calculate EC50 and Emax values. Full 
concentration−response curves for LPI in presence and absence of the compounds were 
determined by coadministration of the test compounds at 1 µM (or vehicle) and different 
concentrations of the standard agonist. 
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General conclusions 
In this dissertation several drug discovery approaches targeting the ECS have been developed. For 
that purpose, the chromenopyrazole scaffold was intensively explored by following different 
strategies. Structural modifications have been performed on the tricyclic core mainly focusing on the 
pyrazole and the phenol moieties leading to novel compounds able to modulate the cannabinoid 
receptors or/and the putative cannabinoid receptor GPR55. 
The results obtained in this dissertation allow us to conclude that:   
Chapter 1  
The design and the synthesis of alcoxychromeno-pyrazoles and -isoxazoles led to selective CB2 
cannabinoid receptor ligands in agreement with molecular modeling data. These new lead 
compounds could afford a great therapeutic opportunity in various disease states where CB2
cannabinoid receptors are physiologically relevant. 
The bivalent ligand approach targeting CB2R dimers provided bisalcoxychromenopyrazoles as 
the first CB2R fully selective homobivalent ligands. Since dimerization plays an essential role in 
the regulation of receptor processing and trafficking, these new ligands are considered attractive 
tools for selective targeting of CB2R dimers. 
Chapter 2  
The reported chromenopyrazolediones, designed by merging the cannabinoid scaffold with a 
quinone feature, resulted in multifunctional agents for cancer therapy as tested in vitro and in vivo. 
Selected compounds reduced prostate tumor through activation of the cannabinoid receptor 
CB1, PPAR receptors and through oxidative stress. Other compounds were active against 
triple-negative breast cancer through a mechanism involving the cannabinoid receptor CB2 and 
redox properties. Another additional fact that needs to be taken into consideration for these new 
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antitumor agents is their lack of cytotoxicity confirmed in vitro and in vivo.  Therefore, the use of 
both types of chromenopyrazolediones represents a promising canabinoid-quinone anticancer 
approach. The CB2R acting antitumor agents would have the advantage of lacking psychotropic 
effects giving them high potential for further preclinical development in the management of 
neoplasms. 
Chapter 3 
Targeting the new potential drug target GPR55, acylpiperazinyl chromenopyrazoles have been 
identified as partial agonists and antagonists of this putative cannabinoid receptor. The novelty 
in this area lies on i) the selectivity of some of these compounds vs cannabinoid receptor CB1R 
and CB2R activity, ii) the use of an innovative label-free cell impedance assay that resolved the 
problems resulting from the complex signaling pathways generated by GPR55 modulation, iii) 
the improved druggable properties of the new compounds compared to the endogenous ligand 
LPI. Therefore, these compounds can serve as pharmacological tools for mechanistic studies of 
GPR55 as well as radioligands for binding screening assays.  
In summary, the results reported in this dissertation uncover the chromenopyrazole as a privileged 
scaffold in drug discovery and especially in the cannabinoid field.  
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Conclusiones generales 
A lo largo de esta tesis se han desarrollado distintas estrategias para la obtención de nuevos 
moduladores del sistema endocannabinoide. Para ello, se ha profundizado en la estructura del 
esqueleto de cromenopirazol realizando diversas modificaciones sobre el fenol y el pirazol que 
constituyen en esqueleto tricíclico central. Estos cambios estructurales han sido diseñados en base a 
distintas aproximaciones farmacológicas que han permitido desglosar este trabajo de investigación 
en tres capítulos. Concretamente, los resultados obtenidos en esta tesis doctoral nos permiten 
obtener las siguientes conclusiones:   
Capítulo 1  
El diseño y síntesis de una serie de alcoxicromenopirazoles y alcoxicromenoisoxazoles dio lugar a 
la identificación de ligandos potentes y selectivos para el receptor CB2. Dada la relevancia 
terapéutica de este receptor en procesos patológicos, estos nuevos compuestos presentan un gran 
potencial para el tratamiento de numerosas enfermedades. 
A continuación, con el fin de profundizar en la homodimerización del receptor CB2, se sintetizó 
una serie de bis-alcoxicromenopirazoles que resultaron ser los primeros ligandos bivalentes CB2
selectivos. Puesto que los procesos de dimerización juegan un papel esencial en la regulación 
funcional de los receptores acoplados a proteínas G, estas nuevas moléculas podrían constituir 
interesantes herramientas para el estudio de homodímeros CB2.  
Capítulo 2  
Las cromenopirazoldionas descritas en el segundo capítulo de esta tesis resultaron ser 
prometedores agentes multifuncionales con propiedades antitumorales in vitro e in vivo. 
Determinados compuestos de esta serie fueron capaces de reducir el crecimiento de tumores de 
próstata mediante la activación de receptores CB1 y PPAR y mediante la inducción de estrés 
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oxidativo. Otras cromenopirazoldionas mostraron propiedades antitumorales en modelos de 
cáncer de mama triple negativo generando apoptosis mediante la activación de receptores CB2 e 
induciendo estrés oxidativo. Ensayos in vitro e in vivo, demostraron que estas nuevas moléculas no 
generan cititoxicidad en células normales. Por tanto, las cromenopirazoldionas representan una 
prometedora aproximación antitumoral quinona-cannabinoide con potencial aplicación para el 
tratamiento del cáncer de mama triple negativo y el cáncer de próstata. Los compuestos CB2
selectivos presentan la ventaja de carecer de propiedades psicoactivas teniendo por ende un 
mayor potencial para el desarrollo preclínico de estos compuestos en el tratamiento de neoplasias. 
Capítulo 3  
Con el fin de desarrollar nuevas moléculas capaces de unirse al receptor GPR55, se diseñó y 
sintetizó una serie de acilpiperazinil cromenopirazoles. Entre estos derivados se identificaron 
agonistas parciales y antagonistas de GPR55. Dentro de este trabajo de investigación cabe 
destacar los siguientes aportes novedosos: i) el descubrimiento de compuestos selectivos por el 
receptor GPR55 frente a CB1 y CB2; ii) el empleo de una novedosa técnica para la evaluación de 
la actividad GPR55 mediante el análisis de la impedancia celular en tiempo real; iii) el perfil 
fisicoquímico y farmacocinético mejorado de los nuevos compuestos con respecto al agonista 
endógeno LPI. Por tanto, estos compuestos tienen potencial para el desarrollo de herramientas 
farmacológicas que permitan continuar con la caracterización funcional de GPR55.  
En resumen, los resultados obtenidos en esa tesis doctoral ponen de manifiesto el potencial de la 
estructura de cromenopirazol siendo un esqueleto privilegiado y versátil para el desarrollo de 
moduladores del sistema endocannabinoide.  
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Introduction 
Cancer is a multifactorial disease that involves numerous pathological processes. Therefore, the 
combination of different therapies represents a promising strategy in the treatment of malignant 
neoplams. In this scenario, photodynamic therapy (PDT) appears as a minimally invasive 
alternative.1,2 PDT has already been clinically approved for the treatment of various types of 
malignant disorders such as bladder, lung or esophageal cancer.3 This technique involves the 
administration of a tumor localizing photosensitizer (PS) followed by its activation with irradiation at 
a wavelength corresponding to an absorbance band of the PS (figure 1). In the presence of tissue 
oxygen, the photoactive sensitizer triggers a series of photochemical processes that lead to direct 
cancer cell death and tumor microvascular damage.4 Different cell death pathways such as apoptosis, 
necrosis and autophagy may be evoked by PDT.5 Furthermore, the preferential accumulation of the 
photosensitizer by malignant cells and the focused light delivery confer to this procedure certain 
selectivity toward cancer cells.6
Figure 1. PDT destroys neoplastic lesions with reactive oxygen species (ROS), which are produced by using 
light of specific wavelengths to irradiate the PS. In the first step of PDT for cancer treatment, the PS is 
injected into the bloodstream. The agent is absorbed by cells all over the body but stays in cancer cells longer 
than in normal cells. 
Porphyrin-based photosensitizers  
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The critical step in PDT is the election of an appropriate photosensitizer. The efficacy of this agent 
depends on its efficient insertion into cellular membranes and specific delivery into tumor cells. An 
optimal photosensitizing agent should have a high absorption peak between 600 and 800 nm (red to 
deep red) in order to form a substantial yield of reactive oxygen species upon irradiation. Higher is 
the wavelength deeper is the penetration in tissues. Consequently, agents with strong absorbance like 
porphycenes, porphyrin derivatives, chlorins, and phthalocyanines are suitable for PDT.7 Most of 
the photosensitizers used in cancer therapy are based on a tetrapyrrole structure, similar to that of 
the protoporphyrin contained in hemoglobin. 
Porphyrins can localize in tumor tissue and have been widely investigated as sensitizing drugs for 
application in PDT.8 In fact, the first PS to be clinically employed for cancer treatment was a water-
soluble mixture of porphyrins called hematoporphyrin derivative (HpD).9,10 A partial purification of 
this mixture later became the commercial product porfimer sodium known as Photofrin®, which was 
approved in several countries in the 1990s. Even though Photofrin® still is the most widely used 
photosensitizer, it has some disadvantages including a long-lasting skin photosensitivity. 
The second generation photosensitizer 5-aminolevulanic acid (ALA, (Levulan®), a biosynthetic 
precursor of protoporphyrin IX, offers different advantages such as rapid clearance along with oral 
or topical administration. It is approved in certain countries for the treatment of actinic keratosis 
and basal cell carcinoma.11 Many research efforts are currently focused on the development of 
improved porphyrin-based photosensitizers with less normal tissue photosensitivity and with better 
tumor specificity.
Porphyrins conjugated to biomolecules
In spite of the promising results obtained in the cancer treatment using PDT, most current 
phototherapy agents have serious side effects as they damage healthy tissue.12 To overcome these 
limitations novel strategies are emerging.13 These last years, it has increased the development of 
studies in which porphyrins are conjugated to molecules showing preferential accumulation on 
Appendix 2
287 
specific tumors.3 Most intensive efforts have been generated for the use of carriers such as 
nanoparticles,14–16 liposomes,17 polymers,18 translocator protein,19 glycoproteins,20 antibodies,21 or 
cyclodextrins22 to enhance the efficiency of the photosensitizers. Another challenging strategy is the 
conjugation of a therapeutic drug to a porphyrin that could conduce to two different approaches: 
combining a photosensitizer with a chemotherapy agent or using porphyrins as carriers due to their 
ability to accumulate in cancer tissues as compared to normal tissues.23 For instance, the 
photosensitizer temoporfin has been conjugated to non-steroidal anti-inflammatory compounds to 
improve the post-PDT treatment tumor regrowth.24 The cytotoxic agent trilobolide, a sesquiterpene 
lactone inductor of nitroxic oxide, has been lately conjugated to porphyrin to increase its taking up 
by cancer cells.25 The use of porphyrins as translocation vectors has also been examined with the 
anticancer agent doxorubicin that has been conjugated to porphyrazine through an acid-labile oxime 
linker.26
Aims and background 
One of the challenges going forward in our research27,28 is to design an antitumor agent selectively 
delivered. Since porphyrins possess selectivity toward tumor tissues, conjugating such macrocycles 
with CB1 or CB2 cannabinoids could be a strategy for specific drug delivery to tumor cells. Another 
therapeutic approach could be the use of combined PDT and cannabinoid therapies in a single 
entity. 
Many types of cannabinoid receptors positive cancers are superficial or can be reached by 
endoscopy, consequently, cannabinoids have great potential for target-selective phototherapy. The 
aim of the current study is to develop a novel cannabinoid photosensitizer based on porphyrin-
chromenopyrazoledione conjugation as displayed in figure 2. During the course of this research, Bai 
et al. reported the first CB2R-targeted photosensitizer (IR700DX-mbc94).29 Phototherapy treatment 
using IR700DX-mbc94 greatly inhibited the growth of CB2 positive tumors but not CB2 negative 
tumors.30,31
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Figure 2. Schematic design of the porphyrin-chromenopyrazoledione conjugate. 
Tetraphenylporphyrin (TPP), an intense chromophore with strong Soret band and medium Q-band 
absorption, has been chosen as the photosensitizer of our novel conjugates. As other porphyrin 
photosensitizers, it generates effectively singlet-oxygen upon excitation with a far-red irradiation 
(650 nm).32
Furthermore, chromenopyrazoledione 2.1 described in Chapter 2 was selected for this study because 
of biological and chemical reasons. On the one hand, this compound exhibited promising 
antiproliferative effects in prostate cancer mediated by generation of ROS and CB1 receptors.28 This 
cannabinoid-quinone displays affinity towards both cannabinoid receptors in the submicromolar 
range. On the other hand, its non-substituted pyrazole moiety enables different organic reactions 
that may ease the synthesis of the conjugate. 
Results  
Synthesis 
Preparation of the porphyrin moiety started from the commercially available meso-
tetraphenylporphyrin which was regioselectively para-nitrated to 5-(p-nitrophenyl)-10,15,20-
triphenylporphyrin (1). The mononitro functionality was introduced using 1.8 equiv of sodium 
nitrite in the presence of TFA. This regiospecific mild procedure for electrophilic nitration at the 
para position of the phenyl groups in TPP was previously reported by Kevin Smith and coworkers.33
This approach provides selective control in the number of phenyl groups nitrated by varying the 
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amount of sodium nitrite and the duration of the reaction. Nitroporphyrin 1 was then easily reduced 
with tin (II) chloride to obtain 5-(p-aminophenyl)-10,15,20-triphenylporphyrin 2 (scheme 1).  
The conversion of the amino group of porphyrin 2 to the carboxylic acid 3, was achieved by 
reaction with diglycolic anhydride in DMF.34 Unfortunately, the coupling of porphyrin 3 with 
chromenopyrazoledione 2.1 that was attempted through diverse procedures was not achieved in our 
hands. 
Scheme 1: Synthesis of porphyrin derivatives. Reaction conditions: (i) NaNO2 (1.8 equiv), TFA, 25 °C, 3 min 
(49%); (ii) SnCl2, conc. HCl, 65 °C, 1 h (99%); (iii) Diglycolic anhydride, DMF, rt, 24 h (89%).
Conversion of the carboxylic acid 3 to the corresponding acid chloride reacting with thionyl chloride 
followed by reaction with 2.1 failed to give the desired amide. Similarly, different coupling reagents 
such as carbodiimides [carbonyldiimidazole (CDI)] or more potent coupling reagents such as 
phosphonium-[(benzotriazol-1-yloxy)-tris[pyrrolidino] phosphonium hexafluorophosphate 
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(PyBOP)] or uronium salts [hexafluorophosphate salt of the O-(7-azabenzotriazolyl)tetra-methyl 
uranium (HATU)] in the presence of a base and dry DMF as solvent were unsuccessfully employed 
in independent reactions.  
In some of these reactions, intramolecular cyclation of the (amino-2-oxoethoxy)-acetic acid group of 
compound 3 to the corresponding morpholine-3,5-dione porphyrin 4 was observed. Curiously, this 
porphyrin has never been described so far in the literature.  
To avoid this intramolecular cyclation, the same synthetic approach was followed using the malonyl 
derivative 6 prepared by reaction of aminoporphyrin 2 with malonyl chloride and hydrolyzing with 
sodium hydroxide afterwards. However, the desired final coupling did not afford the expected 
conjugate (scheme 2). 
Scheme 2: Synthesis of porphyrin derivatives. Reaction conditions: (i) Malonyl chloride, Et3N, DCM, rt, 1 h 
(74%); (ii) NaOH, rt, 4 h (91%).
After these synthetic failures, we decided to use the piperazine derivative 7 as starting material for 
the coupling with the chromenopyrazoles. This porphyrin (7) was previously decribed by Masson 
and colleagues35 to tether tetraphenylporphyrin to glucosamines. Following their procedure, in order 
to convert aminoporphyrin 2 into a more potent nucleophile, the photosensitizer derivative was 
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firstly acylated using bromoacetyl bromide to give 5-(4α-bromoacetylamidophenyl)-10,15,20-
triphenylporphyrin (7). Then, a nucleophilic substitution with piperazine afforded the nucleophilic 
porphyrin intermediate 5-(4α-piperazineacetylamidophenyl)-10,15,20-triphenylporphyrin (8) (scheme 
3). Interestingly, the piperazine moiety is an appropriate linker because of its low toxicity and 
biotransformation that involves several well-known metabolic reactions.36
Scheme 3: Synthesis of the porphyrin-piperazine intermediate. Reaction conditions: (i) Bromoacetyl 
bromide, Et3N, CH2Cl2, 25 °C, 1 h (31%); (ii) Piperazine, CH2Cl2, 25 °C, 45 min (96%). 
Finally, the porphyrin-cannabinoid conjugate 10 was achieved as depicted in scheme 4. Acylation of 
chromenopyrazoledione 2.1 using bromoacetyl bromide afforded the substituted chromenopyrazole 
9 that was then allowed to alkylate the piperazine intermediate 8.
Scheme 4: Synthesis of the porphyrin-chromenopyrazoledione conjugate. Reaction conditions: (i)
Bromoacetyl bromide, Et3N, CH2Cl2, 25 °C, 1 h (58 %); (ii) Porphyrin8, Et3N, CH2Cl2, 25 °C, 24 h (7 %).
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It is interesting to note that attempts to directly link the aminoporphyrin 2 to compound 9 did not 
give the porphyrin-chromenopyrazoledione conjugate in our experiments. This fact may be due to 
the weak nucleophilicity of the aminoporphyrin.37
Conformational analysis of the porphyrin-chromenopyrazoledione conjugate 
A complete conformational analysis of the novel conjugate (10) was performed using ab initio Hartre-
Fock calculations at the 6-31G* level as encoded in Spartan ´08 (Wave function, Inc., Irvine CA). As 
displayed in figure 2 the global minimum energy conformer of conjugate 10 adopts an expanded 
spatial conformation whereas folded conformers (Figure 2B) exert higher relative energy values.
Nonetheless, these theoretical values are calculated for vacuum conditions, the polarity of the 
solvent should determine the lowest energy conformer in solution. Under physiological conditions 
the aggregation of porphyrins should influence their conformation.
Figure 2. A) Global minimum energy conformer of compound 10 (E: -0.11 Kcal/mol). B) Higher energy 
conformer of compound 10 showed for comparison (E: 4.55 Kcal/mol). 
Photophysicochemical properties 
The UV−vis spectra of the porphyrin-chromenopyrazoledione conjugate 10 and the free meso-
tetraphenylporphyrin were recorded. A Soret band with absorption maxima near 420 nm and 
medium Q-bands at 500-700 nm were observed for both porphyrins (figure 3). Even though the 
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shape of the absorption spectrum of 10 is quite similar to that of TPP in water/DMSO, slight 
bathochromic shifts are displayed. As clearly depicted in figure 3, compound 10 shows stronger 
absorption intensity relative to free TPP in both Soret and Q-bands exhibiting higher molecular 
extinction coefficients (table 2). In what concerns organic solvents, the Soret peak of 10 became 
gradually sharper and slightly shifted in dioxane and dichloromethane being broader in water 
solution. This fact could be due to either porphyrin–solvent interactions or self-aggregation of the 
TPP moiety. In conclusion, the molecular extinction coefficients of the new conjugate 10 are higher 
from those of TPP what highlights its appropriate absorption pattern. Absorption maxima and 
molecular extinction coefficients are summarized in table 2. 
Figure 3. UV−vis absorption spectra of 10 and tetraphenylporphyrin (TPP) at constant concentration (0.1 mM) in 
different solvents at room temperature. 
Table 2. Absorption maxima and molecular extinction coefficients of 10 and tetraphenylporphyrin (TPP) in 
different solvents at room temperature. 
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TPP (water/DMSO) Compd 10 (water/DMSO) Compd 10 (dioxane) Compd 10 (DCM)
Absorption 
Band max (nm) M−1cm−1) max (nm) M−1cm−1) max (nm) M−1cm−1) max (nm) M−1cm−1)
Soret Band 418 17763.2 423 69244.8 418 201449.6 418 173102.4
Q-Band
517 1984.0 518 6985.6 514 10276.6 515 7721.6
552 968.1 553 3979.2 549 5752.0 550 3782.4
591 688.0 592 2417.6 591 3564.8 590 2300.8
648 479.9 648 1731.2 647 2809.6 646 1795.2
A suitable PS should absorb light in the red or far-red wavelengths in order to penetrate tissue. 
Absorption bands at shorter wavelengths have less tissue penetration and are more likely to trigger 
skin photosensitivity. Consequently, these absorption studies qualify the novel cannabinoid-TPP 
conjugate 10 as a potential photosensitizer with applicability to PDT.  
At the same concentration, the fluorescence intensity of the TPP or compound 10 in aqueous 
solution showed practically no emission (fluorescence is almost fully quenched). This absence of 
fluorescence may be caused by porphyrin–solvent interactions promoting non-radiative decay or 
self-aggregation of porphyrin molecules. Excitation of compound dissolved in DCM at 418 nm 
resulted in the fluorescence spectrum displayed in figure 4. 
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Figure 4. Fluorescence spectrum of compd 9 under excitation with light of 418 nm in dichloromethane (slit width: 
15−15 nm, and 1 cm path length). 
Cannabinoid receptors affinity 
The cannabinoid binding affinity of the porphyrin-chromenopyrazoledione conjugate 10 was 
determined through radioligand competition experiments. The porphyrin-piperazine intermediate 8
was also appraised in order to check if the potential affinity is due to interaction of the receptors 
with the TPP or the piperazine moieties. As depicted in table 1, the new conjugate did not retain the 
affinity of its chromenopyrazole precursor 2.1. Compound 10 did not bind to CB1 receptors but 
displayed moderate affinity towards CB2 in the micromolar range. The TPP intermediate did not 
show binding affinity for these targets. 
Table 1. Binding affinity of the porphyrin-chromenopyrazoledione conjugate 10, the porphyrin intermediate 
8 and the reference cannabinoid WIN55,212-2 for hCB1 and hCB2 cannabinoid receptors.  
The tetraphenylporphyrin macrocycle may difficult the entrance of the molecule in the receptor and 
therefore, its binding to CB1 or CB2 receptors. The synthesized conjugate is probably too bulky to fit 
into the binding site. Likewise, the physicochemical properties of the conjugate have been 
completely modified compared to the chromenopyrazoldione contributing to the drastic loss of 
affinity.  
Compd CB1 Ki (µM)a CB2 Ki (µM)a
2.1 0.32 ± 0.23 0.13 ± 0.02
8 > 40 > 40
10 > 40 13.79 ± 0.20
WIN55,212-2 0.04 ± 0.08 0.003 ± 0.002
aValues obtained from competition curves using [3H]CP55940 as radioligand for hCB1 and 
hCB2 cannabinoid receptors and are expressed as the mean ± SEM of at least three 
experiments.
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Conclusions and future perspectives 
With the purpose of developing an improved antitumor agent, chromenopyrazoledione 2.1 was 
conjugated to a tetraphenylporphyrin derivative. This macrocycle may confer to our cannabinoid a 
more specific tumor tissue delivery and may enable the development of target-selective 
phototherapy approaches.  
The novel conjugate 10 binds moderately but selectively to CB2R. Further antiproliferative 
experiments will be performed on tumor cell lines to appraise its antitumor capacity. 
Photophysicochemical properties of the new chromenopyrazoledione conjugate 10 are consistent 
with those of well-known porphyrins and therefore, completely appropriate for the development of 
near-infrared photosensitizers. In view of that, antiproliferative experiments will be also performed 
under light exposure conditions regarding the possibility of combining antitumor cannabinoid 
effects with PDT. Another aspect that needs to be taking into account is the metabolism process of 
this porphyrin-chromenopyrazoledione. Therefore, metabolism assays will be carried out to check if 
the conjugate is stable under physiological conditions or if it acts as a prodrug. 
The results presented in this appendix are very preliminary, for that reason, optimization of the 
ligand, the linker, and the macrocycle will be further explored.  
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